<SEC-DOCUMENT>0001179929-21-000086.txt : 20210429
<SEC-HEADER>0001179929-21-000086.hdr.sgml : 20210429
<ACCEPTANCE-DATETIME>20210429110735
ACCESSION NUMBER:		0001179929-21-000086
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210429
DATE AS OF CHANGE:		20210429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		21868137

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOLINA HEALTHCARE INC
		DATE OF NAME CHANGE:	20020812
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>moh-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:1bf58a98-2aa7-4eef-bb6c-f5c42b4c24b2,g:53e813d1-18be-4855-aac7-c0269cc6b95f,d:b3ee4b8182cb4a97b16d7a57b13a8868--><html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:moh="http://www.molinahealthcare.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>moh-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV8zLTEtMS0xLTA_295acb2a-0a88-429d-a79d-11bf039722ab">0001179929</ix:nonNumeric><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV80LTEtMS0xLTA_ef9a3e8d-a325-42db-82d7-63e73961c183">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV81LTEtMS0xLTA_8524025f-6260-417e-be91-792c0c6e9e26">2021</ix:nonNumeric><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV82LTEtMS0xLTA_03b01ead-cf32-43ec-a102-57feb33db796">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV83LTEtMS0xLTA_d4ca7b95-5a7a-44b8-9330-10874df273f3">false</ix:nonNumeric><ix:nonNumeric contextRef="ib2f6d5bf02f946d797a178b2243023d2_D20210101-20210331" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMyOA_8b240c5c-ac85-4fc4-b548-e90f16414f04">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="moh-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4e071f24a77d46dfba2cb28cb63b9814_I20210423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4cb5b33923d44d48d6582373ff531da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3cf6223852e470887ad11579c175927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa001ce9f4904c2cb8455fe03b80f1a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b15a9bdcdf4106965f1b2a88548c51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cd7e619ba24682912dc1fadfbab673_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8589aefa8f474c159c7cbd51cc1dc98d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2976206aa3ad4285b3d0c9437c99451d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031215c830df4ab98eaef20814b485e1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c24e92034d4912a1dc6ad0b7a49302_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b49845196634f1eb09dc0789aad5d88_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bfeb6ebf43e495da6988002aa92c4e4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c912df2a854b3083036cd0dcf70baf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b8ea1f43854547ba8cbbd4c725d620_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17551bd8c156404499e937e8c5664e40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609e20519d204f7e8a1f149974d04ee8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0394e14e2ddb48f081b7cc6c9f6df17d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba871cbc2264413b2e0bb8f269203ea_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95adf552e2d049cbb4f27501f9a4dbad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691ed4ca23c74d7e8b19e0fc8b00560c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86edd17ebbb94db398c8c9bf6325ad1e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcdc345193e4adcb86cd7488aa5651e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb5b5c80f1a4b3988c0ec8e5cf119cc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2edda39d39945aa83dab49b96ac9571_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7250e43387d044659d3061f2be2719fd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="member"><xbrli:measure>moh:member</xbrli:measure></xbrli:unit><xbrli:context id="if6be335f460e4209851cdbd1a986fddb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f6d5bf02f946d797a178b2243023d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3024a8346b4e4de8a8f90f83f027c364_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia27ea1622e334357a45a3002d5876949_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:HidalgoTarrantAndNortheastServiceAreasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e9ad87a1c5a48a78489b9938d8eae4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:HidalgoServiceAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4236126773456e8b7ccaac00eaead1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba56960a4e954002902a215411511282_D20210422-20210422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-22</xbrli:startDate><xbrli:endDate>2021-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85aa51d656a149329969f88cf738f0a2_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf57704a9f64502924a6c99e4e92834_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb11d0cba77b4ec99ba52541a7506b5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1535abc2ae740d5bf9944b12b802296_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfa8c0b58cc4e4f8075fdbc4b67b24c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eddaa9fd8a147b7949ef2c683c7f322_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14923db8e82452ead1cb8577da709c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3e8a05c22746188f8006f0cc466248_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68770710aff54e859f753302935e9a33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060bbae192754af18735ff173a812ff9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:CompleteCareReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f348898f464752bc2bb4d15a2e7e2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:CompleteCareReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if812ef76536b438e99d9bdfc430cff90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0497f33d5bf4e7187e8f9c8f6fb4d3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:StructuredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e7332f8532480b940cc14c82d5a66c_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf47769cb2064e43baa8252d52471732_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be9ab0685c342fdb10ce4970ddf28c6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a91a1b851c5460ea799477e1d8ffea0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d894df64afc4b708465d180e9e4d828_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34971f76fea54413af66394067162aa4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ea329b6ce44f08b01706088442cd3d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia72442a16d054cf6b2add623661e1309_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c2c65749b7345faafdfba7c882cf15c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idffa9f6c7ef243a0945eb16b52a45524_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89eff6b8e212434c80c97106458c80f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8486b4460641688370ab5c52704984_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fffabe708ad4e94ba5b0636c6518d9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd148c06afc46d29d9896ffc0517005_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e957ac778a7477899bb650c9835d5d2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c53b5850b44aea95b55cac2de8f94a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96c7085c6d14448b5deab7fd704714d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if612cc865e074f888043131a4ddf811f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i367c629760754439af0a0d0519f9eccd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90962768e25e4a079c9fa088d378e436_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e2bb0b925543119143aeb28e57dfb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i776889e2aac941f6b8777a276968f455_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c4d02fdb08d40358bf0167b7e447156_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2484837902cc473abe31b5f45b8b5d5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81450857ab248f39dd4d14ca25f6884_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624191553621462ab6d620e9fa29afe5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66bdf91f7c54e64ae93432279b0c7d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc3f4d81df942ecbe0f17b7684f3a38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i544ceef696034b4e8335a1bbb52a445a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8626edaea2f544f68b7eeffc9cdc5c74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ffff4e3ba0343a2861c235a54ba7686_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb78d77ebc514051a2802fae9ffa2745_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89766e1120fe4cfdbf2765441a571fcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4908d014efa1485e92e9f298580b4e47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b9ad1f540c43b5b9d22ae02827f3b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bde201c232c4a07b85ad5ea4c855816_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i573d0b621da54b35beb8a4b399d05e90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b1d89062504208983df2df1d02c5ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9348c98a684882a89a1791746cd066_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i999e7c8caf5d4a449709bfcf9071b5d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cfb1e5f1124f08a113456fed9b0aba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a3d683acc0407d9bc0027bd95e5c34_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifabcec5c78a74e89969fc2325fe4e83f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d77563cade44be7befb74c969a2dd4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd7f1592daf42cfa111ef9d3525f7dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59b0cf8fcf28410b85ca7ccc1bd5028e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed421117c6f422a9b4454963e89aaa4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4316903bcdcb421181b02d8d89f68ed1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c23e80da0749b18fdf5572eeccf013_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d58211ae65042729ae93bc766bb2f03_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7598a3a1ef3e4c72915a1f6a9b3e0870_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64eb88418e44ccdaa7c1b45b0e9c179_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10b590b22514a43a3f12d61a7d8768a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if379c70eb4bc4cb89f39dd8542e38baa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1fea16fef42471dba019c040233981e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8074103f41e04c56b96df5ea82a9c412_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if451e23108a3485e917d50dbd51706d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1936ea8520f42d384dec241609293d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>moh:position</xbrli:measure></xbrli:unit><xbrli:context id="i54983f52f1db4e76b731097292942bb3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba24de5e17564671afe22ec89f5f3acf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i340f4a8c71a1410b99e342dbbe44f76c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09ae954893b4c35919a0f83d0592f6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9981d0011a794884b2a7987b32480b6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad67715684f94d79a4e970a446c35348_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd4b30c10a94ae093780ce38d46a370_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e72d808dd54b4097d93c8105045161_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i250ad4b68c834c7ab7f008a13f28fed5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03cf9b99099a418cbff01db407d511cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0363d1d407c43858260eb498134562a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e8a21df22c49dea82dcb63e4eff8cb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087cf67012d04ba0bbee3ed77b869dbd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if445e6aa2f2a404c9c2cae784a9d3c67_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4790b3dd8c914707b7598d0687f23cf3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6b03e1fc3e49bdbe024dcf4fec7e6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25bb3713e7dc4ce8aff3b343553d1d5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5537a3735a44efbf12ff851ff5fb61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddefd20760394cda9704c051843be4a0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d78eaf9f7854f45a976f7a9c34f0b2e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33bc647cc4d341da839b637a42b74f25_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f1ddd5eada4525b9899833bd42aa9e_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d95ca3899b4bbf91022aa523d90b4a_D20210101-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdb8495a786463fb1d63d538dedadd6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74eb9bfff592416381c1931711db9989_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d574edc32f4858b10a9e95a7043b62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4af07d6f77c412fa6fc30634723476c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a8212f4d97436f86b773388a97609f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica7f1fd63c014e4598191fc6de8562ec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930068e669b4450986374f16ef76a5d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib75fd2e45f3d4d8982e9fdaef11c065a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1114f0eae5487fa865b3bccaf5b9bd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e52755e7437453ea2f981a32951d999_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6918db6cf1846b8806408b26be49e6a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7187b436a3ea4d1da6a4704097325340_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d19f8b5724c4f88b4fa8f61f0b315f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1ddd3ae7e349248f4a8de4b08df629_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1dad7a9e5040f9af2c8f17dc219501_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5586721f5cb7493dab355f7ba8acf352_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ce0ea0bd4a41f486cf13d1a3ecc8cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304f43ebe4b34d7b9ce83118a0cac64b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ac1d580f1145538873140cefeff994_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:385.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE2_7bb23a00-d1c6-44f0-a977-d5cc6c21750f">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:506.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6YmM1ZDM2NTViY2JkNGM5M2FkYTQ2MjVlZWMxMjgwZGYvdGFibGVyYW5nZTpiYzVkMzY1NWJjYmQ0YzkzYWRhNDYyNWVlYzEyODBkZl8wLTAtMS0xLTA_588c6492-deee-461c-b786-043f7fbc6a8e">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8xNDA_1b7925e3-b311-4779-b7fc-50a92e72ad12">March 31, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6NmYyOGQ3YmYyMjAxNDBkN2IyYTA0MjZjNGQ0NTUxYTUvdGFibGVyYW5nZTo2ZjI4ZDdiZjIyMDE0MGQ3YjJhMDQyNmM0ZDQ1NTFhNV8wLTAtMS0xLTA_79c3279f-09ff-4ed9-8b98-8e178545a47b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ________&#160;to&#160;________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTEy_e33fae4b-f483-4e49-b657-62074fb89133">001-31719</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="moh-20210331_g1.jpg" alt="moh-20210331_g1.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE3_307ef2f4-ad84-4145-8cf3-4cca2d4bcd16">MOLINA HEALTHCARE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8wLTAtMS0xLTA_0bf576d5-b3b7-48c9-a9d2-40220910a241">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8wLTMtMS0xLTA_f72e494f-6012-4411-80c0-66d1eccaffe1">13-4204626</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDNhZjM3YjQ0MzU0ODJjOGExMWEzYTNmZTE3NjY1ZV84Nzk2MDkzMDIyMjQ5_200d38db-c73b-4fae-8f42-4a2f64df492a">200 Oceangate</ix:nonNumeric>, <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDNhZjM3YjQ0MzU0ODJjOGExMWEzYTNmZTE3NjY1ZV84Nzk2MDkzMDIyMjYx_6a83d136-917d-4408-8cec-b7b1ca5e6ba0">Suite 100</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF80LTAtMS0xLTA_925c13d3-1102-42d6-9d6a-826582a05392">Long Beach,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF80LTEtMS0xLTA_b7d85eaf-e223-4a3a-8902-f68b9fb5bd6d">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF80LTMtMS0xLTA_5262c07b-c934-42fb-8a62-b4ec56c87d00">90802</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTEz_5231f563-b8a9-4802-b8e1-6750b8715166">562</ix:nonNumeric>) <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE4_773dcf3d-ef22-4e1f-8c4c-1bc1c7277245">435-3666</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6M2EzNmMzNzdjOTg2NGY0N2I4ZDM2YjM0NmRkZjExMDYvdGFibGVyYW5nZTozYTM2YzM3N2M5ODY0ZjQ3YjhkMzZiMzQ2ZGRmMTEwNl8xLTAtMS0xLTA_9a745e7e-33f8-47fa-b180-516185651f9b">Common Stock, $0.001 Par Value</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6M2EzNmMzNzdjOTg2NGY0N2I4ZDM2YjM0NmRkZjExMDYvdGFibGVyYW5nZTozYTM2YzM3N2M5ODY0ZjQ3YjhkMzZiMzQ2ZGRmMTEwNl8xLTEtMS0xLTA_cd9b3c30-004d-4b3c-8a68-28f45fc7230a">MOH</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6M2EzNmMzNzdjOTg2NGY0N2I4ZDM2YjM0NmRkZjExMDYvdGFibGVyYW5nZTozYTM2YzM3N2M5ODY0ZjQ3YjhkMzZiMzQ2ZGRmMTEwNl8xLTItMS0xLTA_372e4b06-aa63-4712-bc03-6ea950d25445">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE5_9a4e2efc-1749-4cd6-bb36-637b94909c76">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTIw_6f12a460-dc74-4dbd-b4dc-19f214e9a1c3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTIx_542f3484-3521-41f6-83f2-92f94778e1d3" continuedAt="ic1b2cb6326a24872958752a126847fc2">L</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ic1b2cb6326a24872958752a126847fc2">arge Accelerated Filer</ix:continuation> &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTIy_1a56c6c8-4f5e-406e-b211-d188f781a51a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE0_54c9467a-681a-413d-a806-6402345f622e">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   &#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;   Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE1_349f2872-284f-4852-871a-1304f9602020">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.001 par value, outstanding as of April&#160;23, 2021, was approximately <ix:nonFraction unitRef="shares" contextRef="i4e071f24a77d46dfba2cb28cb63b9814_I20210423" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTEw_526fb36b-38c9-4509-8909-4f0b21bbc2c1">58,400,000</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MOLINA HEALTHCARE, INC. FORM 10-Q</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 </span></div><div><span><br/></span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ITEM NUMBER</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_10">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_76">20</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_118">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_118">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_121">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_121">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_124">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_127">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_130">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_133">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_136">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_13"></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNS04LTEtMS0xODU2_344a384f-03f9-4e55-b12b-35614d6a0a15">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNS0xMC0xLTEtMTg1OQ_a2eb8934-a643-42ba-878f-6f28ec0d95f3">4,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNi04LTEtMS0xODU2_3e199a45-2150-4f7c-a3b3-27a1a50edb02">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNi0xMC0xLTEtMTg1OQ_dd253ca3-adc2-459d-a1f4-43d1fb1d0b3b">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees reimbursed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNy04LTEtMS0xODU2_3fc23379-13ab-4207-8c27-cc8f00b5529f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNy0xMC0xLTEtMTg1OQ_22232187-bafa-46fc-abe8-cd03e9581aff">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfOS04LTEtMS0xODU2_208eac34-e9a3-4d9e-b486-b572e0c3befb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfOS0xMC0xLTEtMTg1OQ_ee43813e-e238-43ce-87a6-0ef098c2c134">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTAtOC0xLTEtMTg1Ng_f0c2122a-e3cd-49c2-91fa-79a726d9f3c7">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTAtMTAtMS0xLTE4NTk_1dc6c42e-c5d3-4a84-8aa7-e07e989470ab">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTEtOC0xLTEtMTg1Ng_58b59b68-01d2-4538-a654-a825dd6817b5">6,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTEtMTAtMS0xLTE4NTk_7b87f64c-961e-4605-bc30-879e99a17e63">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical care costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTMtOC0xLTEtMTg1Ng_b70550d1-7f5b-4b87-931d-d0408b955fc5">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTMtMTAtMS0xLTE4NTk_6da693fd-7dc2-4b04-a6fd-63f6b82dfed4">3,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTQtOC0xLTEtMTg1Ng_18d30fbb-29f4-471f-8f3a-06f73449b0e9">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTQtMTAtMS0xLTE4NTk_4e4246e7-33e1-4475-be53-94f33dc0041f">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTUtOC0xLTEtMTg1Ng_1011f82d-3012-4343-980e-5363d6eb9198">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTUtMTAtMS0xLTE4NTk_d270ac78-99fd-4da8-83a8-9b4461b8e257">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTYtOC0xLTEtMTg1Ng_d29714c3-1288-42b5-81df-b416a36e647d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTYtMTAtMS0xLTE4NTk_d1c1f9d5-96e7-4668-b9ef-4aeeeff41b81">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTctOC0xLTEtMTg1Ng_124f838f-aac7-470e-8577-02d8fb82cc45">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTctMTAtMS0xLTE4NTk_aedb9725-819e-46a8-9533-224879e9acde">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTgtOC0xLTEtMTg1Ng_26a601b5-4892-499b-8726-2de7deb82112">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTgtMTAtMS0xLTE4NTk_6cc13fe4-ba49-4f0d-b295-80cf2e377158">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTktOC0xLTEtMTg1Ng_77bf27fb-0596-4371-a069-b7efe871b63a">6,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTktMTAtMS0xLTE4NTk_1a2e16b2-8298-4f1e-8c03-e064df53a5ab">4,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjAtOC0xLTEtMTg1Ng_172a45b6-43e7-4d44-9fba-9606b579f09c">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjAtMTAtMS0xLTE4NTk_43589c7e-ad99-47bf-8aa8-9f0813ae2f34">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjItOC0xLTEtMTg1Ng_6efadf1d-d2b7-42c5-9791-697899aa89d7">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjItMTAtMS0xLTE4NTk_710c87ba-39b7-48d2-80d8-4c032cc078e1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjQtOC0xLTEtMTg1Ng_1cf75a0f-841b-4f9e-a075-5a63fe53accc">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjQtMTAtMS0xLTE4NTk_51648753-c621-41e4-ac71-753ab2b53237">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjUtOC0xLTEtMTg1Ng_63499ccc-7eca-40cc-8b8f-64f55c52d184">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjUtMTAtMS0xLTE4NTk_d0a88908-1e16-449a-b1bd-80f058c28903">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjYtOC0xLTEtMTg1Ng_10699b6f-a2dd-449b-9fce-b2a88a9299fd">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjYtMTAtMS0xLTE4NTk_7dda60af-2242-40b7-a8fd-340af887c509">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjctOC0xLTEtMTg1Ng_ae4207af-c20a-4e9a-a1f6-a42f95fea351">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjctMTAtMS0xLTE4NTk_85d3ac97-61bb-4413-a09b-f808616fb4f3">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjktOC0xLTEtMTg2OQ_e54ce7ad-6164-427f-a3dc-d1b44f37337c">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjktMTAtMS0xLTE4NzI_a628f128-a902-4e7c-8642-b3a9987ee657">2.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMzAtOC0xLTEtMTg2OQ_eb4e7516-b13b-4dea-aeda-8bc267d36f1a">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMzAtMTAtMS0xLTE4NzI_a3b268cf-3c9e-479a-a6b9-1d4d368a83f1">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNC04LTEtMS0yOTcz_55fa31c4-d955-4425-af71-3191dae8a8fa">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNC0xMC0xLTEtMjk3Ng_d4af7f74-eff2-451c-a4b1-98c4879987c2">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNi04LTEtMS0yOTcz_6c0e37cc-5907-4ab0-b45f-23e4d8fc8a7e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNi0xMC0xLTEtMjk3Ng_7001372b-73bf-4780-a5eb-5f1868aef889">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNy04LTEtMS0yOTcz_5732463d-2083-45db-a93f-b189434b4476">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNy0xMC0xLTEtMjk3Ng_b4759254-c162-41bf-add2-4eef36fff157">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOC04LTEtMS0yOTcz_8d488d67-8e4d-4c16-a445-baa336de85bd">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOC0xMC0xLTEtMjk3Ng_46b089f8-5cc3-49fc-9c38-c166dec66a70">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOS04LTEtMS0yOTcz_fb85fbb3-5abf-4282-b0d8-d6944f2f0e51">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOS0xMC0xLTEtMjk3Ng_e6dde489-5260-4c75-8abe-ab23925187e0">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 3</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions,<br/>except per-share amounts)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNi0xLTEtMS0w_10508d2e-8d77-4649-9c42-d482c8c85cbb">4,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNi0zLTEtMS0w_a8445fea-96c8-40bf-8a83-9670597a7dec">4,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNy0xLTEtMS0w_82cf7060-0872-49e2-b2d7-e1c6af8a32d1">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNy0zLTEtMS0w_5d5fa7be-b5f8-4078-a614-9646e877938c">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOC0xLTEtMS0w_66f956ca-7bec-4a21-9bcf-c6828bff09f6">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOC0zLTEtMS0w_54d9fc73-04e9-439b-818c-cd39e8d24086">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOS0xLTEtMS0w_12bf418e-81a5-4934-83ac-f409d7fd350b">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOS0zLTEtMS0w_0f2326b1-461f-4e99-a6a8-1b981c9966a5">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTAtMS0xLTEtMA_31aab5fd-1b4e-4805-a937-bfda236d7c4d">8,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTAtMy0xLTEtMA_e60496d1-8ce4-4a61-b7ce-44c9eadd4df4">7,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTEtMS0xLTEtMA_b071c9b2-a5c8-4f06-a9c1-791b9d0e1d12">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTEtMy0xLTEtMA_2b1e9796-0ba3-4868-b9ff-279bb78555cc">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill, and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTItMS0xLTEtMA_06b0a521-ac56-402c-90f3-fe0eccb59bda">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTItMy0xLTEtMA_b4478a75-0234-49df-82b4-24bf834724bf">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTMtMS0xLTEtMA_e4c01580-f913-4839-b8d2-84769be2191e">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTMtMy0xLTEtMA_a5aeb881-bb64-4f09-ac34-966f63101305">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTQtMS0xLTEtMA_7a3cd57b-f86c-4fa2-8654-1b3b24bf8341">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTQtMy0xLTEtMA_370a85a8-f978-4630-a299-a43b9f55d8fd">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTUtMS0xLTEtMA_6d9c1710-de60-44cf-a208-94f53f740da3">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTUtMy0xLTEtMA_950414f1-cba2-40ac-a2fd-32894d2d7d24">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTYtMS0xLTEtMA_5a9bfa69-cbbf-4f28-b404-e0bbfb2b1d68">9,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTYtMy0xLTEtMA_8c3aee7f-39fa-412a-b6f0-88aa99f9d366">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjAtMS0xLTEtMA_a510deaf-e140-45f4-8484-29e7bb53ec52">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjAtMy0xLTEtMA_5e10bbfd-fedc-4074-ab48-2b2325a50a60">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjEtMS0xLTEtMA_12c3b629-ad31-4cc5-a12a-5a9f5f755ae9">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjEtMy0xLTEtMA_11f8a7ef-295e-4563-932c-438f40744bac">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjItMS0xLTEtMA_6f6b7446-e5a3-416b-9159-d8f98615a54e">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjItMy0xLTEtMA_3048f089-92d9-432d-bc41-97cc688f2925">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjMtMS0xLTEtMA_600da553-1cb8-4cdd-ba8d-daf3b86d7999">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjMtMy0xLTEtMA_c9cee950-99ba-41f4-b330-b6b7b8b9421b">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjQtMS0xLTEtMA_5f6f02dd-90a7-46aa-8160-952475fffd3c">5,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjQtMy0xLTEtMA_d3b1a926-683c-483a-8be5-a0eaf5c373e9">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjUtMS0xLTEtMA_238147f8-25a9-42d7-a789-335d02412c7f">2,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjUtMy0xLTEtMA_f291cc29-de7d-47c7-b52e-52933f1d95ab">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjYtMS0xLTEtMA_8d2596fe-fa30-4f8a-86c1-e5c6f1a4b703">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjYtMy0xLTEtMA_e5e7edfd-9092-4ae2-9d25-cf971c487d6b">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjctMS0xLTEtMA_c57169ab-fe28-4eeb-ae62-58f11140fb7b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjctMy0xLTEtMA_1290b5ba-9c6a-4a33-8a52-d33f5693106b">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjgtMS0xLTEtMA_de40d593-45ec-47cb-a988-3863376f9d36">7,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjgtMy0xLTEtMA_3317f1f1-ac30-487a-b799-16f4db65ebf3">7,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzE5_24acdebb-27b2-4398-97cb-f81e6d264ecc"><ix:nonFraction unitRef="usdPerShare" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzE5_2b5ee931-3257-49a6-a749-9d7bbfaa67bb">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzMz_5b5ed99f-42be-492f-9347-19ea5c8fdec2"><ix:nonFraction unitRef="shares" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzMz_e62d7772-5157-41ce-b374-173ee0373507">150</ix:nonFraction></ix:nonFraction> million shares authorized; outstanding: <ix:nonFraction unitRef="shares" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzY4_cf40f925-b62c-463d-9b64-94f59cef70e3">58</ix:nonFraction> million shares at March&#160;31, 2021, and <ix:nonFraction unitRef="shares" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3Xzg5_0d316b69-a542-4913-ac1d-25f0d989d971">59</ix:nonFraction> million shares at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMS0xLTEtMA_0cdfa854-696f-4949-8158-111b5c2b8837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMy0xLTEtMA_c418f3ce-ad5f-4413-8f9f-0e08247d331f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzIy_02a278e6-5cc3-4764-8116-6bf290ee2ee3"><ix:nonFraction unitRef="usdPerShare" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzIy_296db74a-8fb1-4780-bbe9-075d049d006b">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzM2_04c9bdca-8297-4db6-aeac-b8c6c2a3facf"><ix:nonFraction unitRef="shares" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzM2_a3145584-c460-471f-a1c4-5322e2876c9f">20</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="shares" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_5cd60690-a097-4cb8-a6dd-b0dd4fea049d"><ix:nonFraction unitRef="shares" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_7e4ca020-8b7d-4757-bc04-e6d81cf5ba01"><ix:nonFraction unitRef="shares" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_c052085e-0a11-448a-b6ef-bb85b9c469a8"><ix:nonFraction unitRef="shares" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_e516fb3a-ce65-44d1-8597-6e340f2a8fbd">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMS0xLTEtMA_fb9e02dd-cdc3-40ed-82e4-3e8db73c91ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMy0xLTEtMA_412d2960-c19d-4907-b236-c7979be499e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzItMS0xLTEtMA_9ece06bd-6fdf-4090-a35c-6cbd3026c002">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzItMy0xLTEtMA_9c3399b1-c36a-4d65-9fe7-a65aa9f67bae">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzMtMS0xLTEtMA_53d89917-80c7-40e8-bcac-b961c6c6fab3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzMtMy0xLTEtMA_3af6d45a-20fb-454d-a414-101cb132fb08">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzQtMS0xLTEtMA_8cd07697-d2bc-41d4-8f2e-c0ae5cfd5d8f">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzQtMy0xLTEtMA_517f77b4-ee2f-4304-9ff8-f6c045bca7d1">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzUtMS0xLTEtMA_f9b12bca-706e-487a-9a74-362e6ba9d8c2">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzUtMy0xLTEtMA_5ad1b69c-c93f-42c2-8d8b-0290b10ede4d">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzYtMS0xLTEtMA_5639d2d4-4ea7-4013-8352-ccb41d0df496">9,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzYtMy0xLTEtMA_2c4fe667-5044-470d-9839-0f0fe67da343">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 4</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4cb5b33923d44d48d6582373ff531da_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS0xLTEtMS0w_7427341f-ed0b-47bf-b244-8ab82fc25afd">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cb5b33923d44d48d6582373ff531da_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS0zLTEtMS0w_8d592142-fa77-4afc-981c-ce9072120cee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cf6223852e470887ad11579c175927_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS01LTEtMS0w_f47d9e4b-7421-45af-b98e-d82af3ae9a8c">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa001ce9f4904c2cb8455fe03b80f1a3_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS03LTEtMS0w_85ba4b1e-8c92-4235-b8cb-b8e7841b3b60">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b15a9bdcdf4106965f1b2a88548c51_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS05LTEtMS0w_c3ab30ac-6c23-407a-a38f-a2df991bf4ce">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS0xMS0xLTEtMA_fa11510c-0b75-4100-be19-8491dd26f6c6">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cd7e619ba24682912dc1fadfbab673_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNi05LTEtMS0w_1aa2f16e-0b3b-4d2f-9d94-35be35d0168f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNi0xMS0xLTEtMA_e012182b-9b3c-424e-b6e0-11fa1a6a0ac8">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8589aefa8f474c159c7cbd51cc1dc98d_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy0xLTEtMS0w_f23c0172-b444-4a72-8399-d677bad20d6e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2976206aa3ad4285b3d0c9437c99451d_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy01LTEtMS0w_15eba16c-7ca3-4c86-81d3-cde51cf09f94">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cd7e619ba24682912dc1fadfbab673_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy05LTEtMS0w_f5e9b7b1-ef83-4804-8103-6f2f09009f78">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy0xMS0xLTEtMA_6cc58f56-71ca-4ac4-bd67-f0319972c671">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i031215c830df4ab98eaef20814b485e1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfOS03LTEtMS0w_4362feca-e811-497c-85c5-6f79edf5faf6">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfOS0xMS0xLTEtMA_b1d651ce-d902-47c7-a20f-6eef3aedffd0">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2976206aa3ad4285b3d0c9437c99451d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTAtNS0xLTEtMA_37568cc9-2dd6-4573-bb3c-79802d7993ed">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTAtMTEtMS0xLTA_a1907f08-5294-4e36-b0bf-d0443c46acb7">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32c24e92034d4912a1dc6ad0b7a49302_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtMS0xLTEtMA_58bd3f6e-d127-426e-bcd8-98a4f0f43bf6">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c24e92034d4912a1dc6ad0b7a49302_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtMy0xLTEtMA_5c955dfc-4136-4afc-b0fa-a841d1e0c77d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b49845196634f1eb09dc0789aad5d88_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtNS0xLTEtMA_447bcd6f-0953-4a72-ac2d-dec12e61fae5">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfeb6ebf43e495da6988002aa92c4e4_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtNy0xLTEtMA_8d9f5b32-ef69-40af-907c-873c66f23d02">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c912df2a854b3083036cd0dcf70baf_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtOS0xLTEtMA_8bce10e4-01e4-401a-9933-728b3f3e8ee7"><ix:nonFraction unitRef="usd" contextRef="ib3c912df2a854b3083036cd0dcf70baf_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtOS0xLTEtMA_e308bd13-f87f-411b-bdc4-30534d567029">1,968</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtMTEtMS0xLTA_f3c56ba1-b20a-4819-bf89-c7197dbffa89">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8b8ea1f43854547ba8cbbd4c725d620_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS0xLTEtMS0w_6a6911c3-85d8-46f1-af16-5bab023d4f57">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b8ea1f43854547ba8cbbd4c725d620_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS0zLTEtMS0w_d3e7d46f-290c-417e-899e-6947fc953576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17551bd8c156404499e937e8c5664e40_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS01LTEtMS0w_691a7458-dd24-4691-a0f5-612616971312">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609e20519d204f7e8a1f149974d04ee8_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS03LTEtMS0w_98d8e194-ccf2-4b8f-9088-24baa531b12d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0394e14e2ddb48f081b7cc6c9f6df17d_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS05LTEtMS0w_7304b0fc-8b25-4026-80aa-e1a5460ce10b">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS0xMS0xLTEtMA_c40f0f42-f1a2-4382-84a6-3da50eb205a4">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba871cbc2264413b2e0bb8f269203ea_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNi05LTEtMS0w_10f13df0-5d2b-4319-a406-bf3e4da2a54b">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNi0xMS0xLTEtMA_9fd7d40c-38b3-4584-a582-6ee90308364f">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i95adf552e2d049cbb4f27501f9a4dbad_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy0xLTEtMS0w_ba5f46c8-817a-42ac-885f-f15ae916727c">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy01LTEtMS0w_053edb65-f65d-4fd5-bbaf-fb000c80f098">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ba871cbc2264413b2e0bb8f269203ea_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy05LTEtMS0w_62287dbe-a950-48d6-ba04-fd74ef9cf6c1">437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy0xMS0xLTEtMA_fa628680-c830-40c6-81ce-5204e06f3387">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOC01LTEtMS0w_9c53b5ea-0bdf-4c81-8512-9880b7e623f0">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOC0xMS0xLTEtMA_9a00885e-529e-4223-b068-f667b87146a6">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i691ed4ca23c74d7e8b19e0fc8b00560c_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOS03LTEtMS0w_e506a7ef-f4a9-427f-8533-a749fff31617">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOS0xMS0xLTEtMA_52083204-2f0e-462a-892f-6a35271662ab">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTAtNS0xLTEtMA_25c3ec07-fb99-45ef-b162-e0746681822d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTAtMTEtMS0xLTA_f6437097-b915-4adb-842f-907c4c8c1aa5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86edd17ebbb94db398c8c9bf6325ad1e_I20200331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtMS0xLTEtMA_6df313cf-4c41-4423-bd68-0be62d8255f8">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86edd17ebbb94db398c8c9bf6325ad1e_I20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtMy0xLTEtMA_10a8e8a7-31b1-4c3a-a2cf-ce1a5b560d53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcdc345193e4adcb86cd7488aa5651e_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtNS0xLTEtMA_48bca466-6355-4a43-9668-cd1acab292e7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fb5b5c80f1a4b3988c0ec8e5cf119cc_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtNy0xLTEtMA_939dcea5-d79a-4301-812f-f58f2c1b5b4e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2edda39d39945aa83dab49b96ac9571_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtOS0xLTEtMA_6487d581-02b2-4bb9-b8b7-cb378b71b784">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtMTEtMS0xLTA_fd8c0e3c-b411-47db-8a8e-da67ca223f8f">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 5</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNS0xLTEtMS0yNTA5_eccd8c5d-06c5-4a25-b876-3fccff5977b1">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNS0zLTEtMS0yNTA5_7ea02b7e-f748-46b0-8745-9d66ea7546e9">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNy0xLTEtMS0w_d20a1580-d533-4453-a119-03ccab6a8695">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNy0zLTEtMS0w_812ead68-8a84-44f8-9a49-696e2fb04983">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOC0xLTEtMS0w_3ee44193-668c-48ff-8110-9b1e6b1df82d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOC0zLTEtMS0w_d1a0c1ac-bec2-415a-83af-b037eb22a121">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOS0xLTEtMS0w_d684e816-0173-4e8b-9f22-5faf2163fe5f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOS0zLTEtMS0w_c638b88e-e0f2-4345-8868-c091b332b8e4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTQtMS0xLTEtMA_a9d4ccc3-6f0a-40e9-bf47-518a27ad38ce">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTQtMy0xLTEtMA_5c56dc67-3348-4974-b7e7-ee4553273664">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTYtMS0xLTEtMA_53257c43-a00d-4c92-a011-d9a7247cad7b">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTYtMy0xLTEtMA_9ed8208b-fb35-4dc1-a44f-3ba0eb7f00bf">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTctMS0xLTEtMA_167c8cf8-5e80-4dde-a761-0f820139705b">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTctMy0xLTEtMA_2b5c8e57-a30b-4d9b-97f5-0d74e4355426">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTgtMS0xLTEtMA_a4132c26-cd8a-45f4-97fd-db3a1b30c39c">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTgtMy0xLTEtMA_3ae0d186-4ade-4cee-94b3-00f14bc13f83">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTktMS0xLTEtMA_8a230975-f776-4701-bb1e-4d93a00c69f3">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTktMy0xLTEtMA_3314d588-f530-4541-9f58-a65a5f2014bf">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjAtMS0xLTEtMA_9c0d7784-b035-45c4-8a39-b5891624d37a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjAtMy0xLTEtMA_767e6577-f45c-41a4-8ade-a561e223b666">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjEtMS0xLTEtMA_47f4804e-e4a0-40e2-85c4-f2ca83b24dfc">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjEtMy0xLTEtMA_7c33ad79-c7cf-49ac-a30a-74ae9955e150">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjItMS0xLTEtMA_7feed9ec-dc84-487a-8419-0770e96acacd">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjItMy0xLTEtMA_cd05056b-281b-4d38-a3a2-5f57851c8f04">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjMtMS0xLTEtMA_5b5442d5-a7ef-49a8-af2b-c7e244c535d0">568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjMtMy0xLTEtMA_961710e3-2811-4219-b989-988aaf83d53b">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjUtMS0xLTEtMA_1f0416f1-c0cc-47d8-9f4e-a8503a797acb">388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjUtMy0xLTEtMA_d1f8ba84-ca34-42f2-9746-a3aba4ba8fc0">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjYtMS0xLTEtMA_5f72d73b-abe8-490a-a88a-619d2143cb66">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjYtMy0xLTEtMA_af1cb2ba-3c62-402e-804c-e426e01f9792">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjgtMS0xLTEtMA_c2f839fd-0638-4caf-8bfd-ad7f42d95a3f">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjgtMy0xLTEtMA_b92c478c-b3b2-4d3c-bf77-d44d1600a3ca">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjktMS0xLTEtMA_d40a15ac-b893-4232-b745-c9178012451c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjktMy0xLTEtMA_7b7ffca6-8a7c-47d9-9e56-2c9e1f937b6e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzAtMS0xLTEtMA_60b052fc-f58e-4ab3-9b48-56b0b8775d45">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzAtMy0xLTEtMA_b9fae753-c082-423c-a3e1-64d6b81bb0fb">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzQtMS0xLTEtMA_4825f70a-9f56-4f0e-a6ae-7cc4a9e2c96d">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzQtMy0xLTEtMA_1f184528-f103-47f6-95c1-e096fbc7df1c">453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMS0xLTEtMTAyOTg_ab3c49ec-1661-4c21-8c99-9b12d5b947fe">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMy0xLTEtMTAyOTA_d268e4c2-afb2-499f-946c-31f4263eef7f">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMS0xLTEtODMzMA_9a26e309-2316-428d-ad5f-206b37f59fd5">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMy0xLTEtODMzMA_8c6469ff-cbab-4fa8-b709-a8584bdc03a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzUtMS0xLTEtMA_5de52ac4-e541-4b75-9d23-742703645d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzUtMy0xLTEtMA_31f5d303-478b-46c6-b8b5-369005d97e20">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDAtMS0xLTEtMA_af24c385-8fde-4e52-b4c6-b820fc1aae77">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDAtMy0xLTEtMA_dcb6fd1b-ad3d-42af-86c9-d2103fc34b2c">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDEtMS0xLTEtMA_5b71beda-1439-4504-aa87-c978d3b55805">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDEtMy0xLTEtMA_1d81e226-f7bd-4d36-9a3b-7ca067d87ef0">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDItMS0xLTEtMA_bb511081-8c06-4914-a4b0-3c0d059d817f">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDItMy0xLTEtMA_545e0d22-9eb2-4afa-8527-6f3ac04b2957">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDMtMS0xLTEtMA_e976ecf1-c896-424f-bf7f-56dcbc762a0e">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDMtMy0xLTEtMA_6766e04a-9a53-4907-b853-e2c2877e98a8">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDQtMS0xLTEtMA_b9639b88-bfd6-443d-b8a7-ee199292c678">4,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDQtMy0xLTEtMA_130f0a98-de8a-461f-9506-7105037f9455">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 6</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">MARCH&#160;31, 2021 </span></div><div><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_34"></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">1. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfNzMwMw_73f477cc-4398-4c72-a285-a143a5d3cf5d" continuedAt="ibe32764f189e4710b2196345d541db6f" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="ibe32764f189e4710b2196345d541db6f" continuedAt="i225355df947249dbafc40ba262455cd7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. For further information, refer to Note 10, &#8220;Segments.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we served approximately <ix:nonFraction unitRef="member" contextRef="if6be335f460e4209851cdbd1a986fddb_I20210331" decimals="-5" format="ixt:numdotdecimal" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMzI5ODUzNDg5NTA4Ng_906efdb3-4fdb-4172-bea6-932f5439d346">4.6</ix:nonFraction>&#160;million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMyOA_8b240c5c-ac85-4fc4-b548-e90f16414f04">three</span>&#160;to&#160;<ix:nonNumeric contextRef="i3024a8346b4e4de8a8f90f83f027c364_D20210101-20210331" format="ixt-sec:durwordsen" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMzMg_ea3e4e9c-0a96-4302-b5d9-39f7fef604a4">five years</ix:nonNumeric>, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately <ix:nonFraction unitRef="member" contextRef="ia27ea1622e334357a45a3002d5876949_I20201231" decimals="-3" format="ixt:numdotdecimal" name="moh:NumberOfMembersCovered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI5MQ_b117deb7-0b0a-44e2-a055-a5f1ecd9a55f">48,000</ix:nonFraction> members in the Texas ABD program, also known as &#8220;STAR+PLUS,&#8221; in the Hidalgo, Tarrant and Northeast service areas, and approximately <ix:nonFraction unitRef="member" contextRef="i5e9ad87a1c5a48a78489b9938d8eae4b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="moh:NumberOfMembersCovered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI5OQ_ca4ea5c4-13b4-485e-8668-3f327f80a3ec">2,000</ix:nonFraction> MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="ibf4236126773456e8b7ccaac00eaead1_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI2NA_06c09f92-1f94-41f0-a007-12af64b4a995">1.0</ix:nonFraction>&#160;billion. The purchase price for the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="iba56960a4e954002902a215411511282_D20210422-20210422" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI3OA_57ddd305-3e8e-48e1-8baf-063c4d893a1d">60</ix:nonFraction>&#160;million, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals and satisfaction of other customary closing conditions. We currently expect the transaction to close in the second half of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin in early 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio&#8217;s Covered Family and Children, Expansion, and ABD programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="i85aa51d656a149329969f88cf738f0a2_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTk4Mg_26ccf6f9-6115-410b-a9d7-504b7a259463">380</ix:nonFraction>&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close in the third quarter of 2021.</span></div><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfNzMxMg_ffd4b328-0497-47a5-b69b-f96e45c2c997" continuedAt="i93f15f9b39764e8f92a9013f76e20bb3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the first quarter of 2021 are not necessarily indicative of the results for the entire year ending December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2020, audited consolidated financial statements have been omitted. These </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i225355df947249dbafc40ba262455cd7" continuedAt="i279afb78e21545559d9c7871baa9e501"><ix:continuation id="i93f15f9b39764e8f92a9013f76e20bb3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; and Note 10, &#8220;Segments,&#8221; have been recast to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the three months ended March&#160;31, 2020, have been reclassified to conform to the current year presentation.</span></div></ix:continuation><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfNzMyMQ_4bbaafbb-6f28-47aa-9ce2-d2c909e1a646" continuedAt="if392f67c300e4ad98fce7909ed6596bc" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets;&#160;and</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i279afb78e21545559d9c7871baa9e501" continuedAt="ibd19131fac654524af87bb47c847113d"><ix:continuation id="if392f67c300e4ad98fce7909ed6596bc" continuedAt="i89968c627d4742bb81d149c31d1e70f5">&#8226;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:continuation id="ibd19131fac654524af87bb47c847113d"><ix:continuation id="i89968c627d4742bb81d149c31d1e70f5">The determination of unrecognized tax benefits.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2Njc_d3be8dea-3fbd-4ba8-8541-4ceb8ce370e5" continuedAt="ib515089fa9314dc48aaa0a7cc45a7c07" escape="true">Significant Accounting Policies</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="ib515089fa9314dc48aaa0a7cc45a7c07" continuedAt="iba801d4b3f704fffa78cebf8ffa947d3"> </ix:continuation></span></div><ix:continuation id="iba801d4b3f704fffa78cebf8ffa947d3" continuedAt="i4f050986e5de4c05986477ee6db4f280"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NDA_306f75c6-bb76-4bf5-bcf7-1796a3dd3805" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NzI_36dc6a26-4873-4856-b098-b3ad13c3fdb7" continuedAt="i47f6bf94d31343f4b1d1f47555bca80e" escape="true"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2ODY_dc8782d7-3f04-4835-a85a-58c253559677" continuedAt="i6108cae55f094bedb0353a2f26aa9f29" escape="true">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i47f6bf94d31343f4b1d1f47555bca80e"><ix:continuation id="i6108cae55f094bedb0353a2f26aa9f29"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNC0xLTEtMS0zODgx_8f147375-fa78-4946-9a80-5b94f6f81995">4,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNC0zLTEtMS0zODg0_8005dc1d-6c71-43d5-8a9e-2f68febb8ee1">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNS0xLTEtMS0zODgx_e50964f3-6f71-4d13-9b44-4f75100561ed">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNS0zLTEtMS0zODg0_bd760e44-d999-49f4-9f1d-1e98212da0bf">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNi0xLTEtMS0zODgx_f42889a3-9a32-4bd3-8b86-ad897486c8ef">4,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNi0zLTEtMS0zODg0_8c4af0b8-9c23-4c4e-8f50-d53bbd5ccf2c">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTA0NDUzNjA0OTQ2MzY_cb23a6a7-f4b8-4981-bb9c-f9178df2b29b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTA0NDUzNjA0OTQ2Mzg_d49706e2-8dfb-44c1-a8f4-9138115ae8b3" continuedAt="ieb8dbe95c24f46be9d02a089ed1f8dc3" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i4f050986e5de4c05986477ee6db4f280" continuedAt="ie980d288bf3d43ff8ceec0ee436f8ec8"><div style="margin-top:6pt"><ix:continuation id="ieb8dbe95c24f46be9d02a089ed1f8dc3"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf57704a9f64502924a6c99e4e92834_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfMy0xLTEtMS0zODc1_029e9665-9c35-4edb-957e-d8ef79d7d25e">1,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb11d0cba77b4ec99ba52541a7506b5d_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfMy0zLTEtMS0zODc1_adcc9f77-49c7-49b6-8818-1fa2d385b9a7">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1535abc2ae740d5bf9944b12b802296_I20210331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNC0xLTEtMS0zODc1_51abadc2-c795-49a9-9ede-cdf6e878c3f1">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfa8c0b58cc4e4f8075fdbc4b67b24c_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNC0zLTEtMS0zODc1_59698139-9ec8-4d37-822d-b19cef1f709f">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eddaa9fd8a147b7949ef2c683c7f322_I20210331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNS0xLTEtMS0zODc1_b045625e-a552-44f1-9705-0e92af00cdbd">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if14923db8e82452ead1cb8577da709c5_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNS0zLTEtMS0zODc1_a1b7b629-7c35-40af-97b6-2c9334ea0efe">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3e8a05c22746188f8006f0cc466248_I20210331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNi0xLTEtMS0zODc1_b5d5324b-1595-4365-9ea1-c793f69633ac">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68770710aff54e859f753302935e9a33_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNi0zLTEtMS0zODc1_ff5c7366-d036-4dc2-889c-8054eef64464">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060bbae192754af18735ff173a812ff9_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNy0xLTEtMS0zODc1_92fbf36e-f7cb-4cd4-8bdd-8bc7def02347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f348898f464752bc2bb4d15a2e7e2a_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNy0zLTEtMS0zODc1_5193a200-56a7-4b7c-9015-49386be7c214">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfOC0xLTEtMS0zODc1_16d32841-45f5-4c3b-b8b6-c7d6c0e622ce">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfOC0zLTEtMS0zODc1_e5a19c82-bfad-47ca-be17-89817a27b5b5">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NjY_9f00f3dc-5c22-453c-a5a8-780ee31a363c" continuedAt="i41c512e2f1f04e4894ef53b0ad7275a2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41c512e2f1f04e4894ef53b0ad7275a2" continuedAt="iaa665934ae2b42c38a46ba5ecc089910">Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions.</ix:continuation> <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ReservesReportedToOtherAgenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc3MTg_df7d3bc8-9ad5-4ff4-9b27-0f546d4edbec" continuedAt="i27b5b355f9d64ef1b9f9d7545a7e9b35" escape="true">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i27b5b355f9d64ef1b9f9d7545a7e9b35"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNC00LTEtMS0zOTA3_fcdbaa98-6e03-4522-b72e-3b6aa87c8fc5">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNC02LTEtMS0zOTA3_dc23afba-34d3-43ce-84fa-f0ce6ffb6eb2">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNS00LTEtMS0zOTA3_ffe612ce-639e-43bd-a8d8-34cb8370393e">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNS02LTEtMS0zOTA3_5db87c37-e0d9-487b-a93b-2a7c1722503e">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0xLTEtMS04Nzcz_4a2f5d98-32d5-42c2-8cd8-cd2353cef632">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0zLTEtMS04Nzcz_4e9a9fcd-79de-45e3-8bf2-c32753658972">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0xLTEtMS04Nzcz_3caf1608-de2b-4eb5-8060-12cf34f55cb7">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0zLTEtMS04Nzcz_28546cc9-0a35-4965-b36f-15bf88e61f58">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0xLTEtMS04Nzcz_91c40b30-981e-498b-a9bd-a7f71d536c62">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0zLTEtMS04Nzcz_be252afa-d434-43cc-86ea-58ad5b16b3fd">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0xLTEtMS03OTg2_df0385db-c274-43b2-8c8d-55c88a58e988">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0zLTEtMS03OTg2_d66715e6-a64c-46d0-8b2d-e7354eb9a46d">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0xLTEtMS03OTg2_12a91bb1-4b62-487d-95ae-564b00862fd4">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0zLTEtMS03OTg2_caeebcda-99b5-4c5b-8a96-e81b2b6f3f1f">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0xLTEtMS03OTg2_4bb0403b-7a99-4deb-95ce-7936a326bda3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0zLTEtMS03OTg2_0457bf8c-73ad-4ec1-a862-ef1173593035">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:zerodash" name="moh:AmountsDueToGovernmentAgenciesBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTQtNC0xLTEtMzkwNw_29099548-fe49-40e6-bad6-656768be9b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTQtNi0xLTEtMzkwNw_e6cdb9ef-f31b-4bdb-9c11-724dbbe3a50d">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTUtNC0xLTEtMzkwNw_e5db1d70-2ddf-48cc-8d45-731b864ab563">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTUtNi0xLTEtMzkwNw_eb405931-3061-4614-98e8-fec95863fa78">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation></div><ix:continuation id="iaa665934ae2b42c38a46ba5ecc089910" continuedAt="ic0a048258af3435b83c11f5d15e28a34"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, through March 31, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="ie980d288bf3d43ff8ceec0ee436f8ec8" continuedAt="id0fe0be047f8455ebbacaeeae8732574"><ix:continuation id="ic0a048258af3435b83c11f5d15e28a34" continuedAt="i0a6e2dc71c1747af98918a72d73141e3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In the first quarter of 2021, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="if812ef76536b438e99d9bdfc430cff90_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfNTMzNw_973c2940-937e-4018-8e4f-6027f38fe4d9">110</ix:nonFraction>&#160;million related to such risk corridors, primarily in the Medicaid segment.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i0a6e2dc71c1747af98918a72d73141e3" continuedAt="iaa8104f9dd3144b499afd36207b51ab4">Risk Adjustment.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa8104f9dd3144b499afd36207b51ab4"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</ix:continuation> As of March&#160;31, 2021, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODg5Ng_d13f0a3b-997e-4e97-bdc5-6198d270b0b2">520</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODkzNQ_de2fc4b5-4485-4055-ace3-1c23abaee89d">20</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODk2MA_6c61708c-a063-4f8c-a286-4ddd29cdc13e">500</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODk5NA_c24cdbf3-2397-495b-acb6-8a301224494a">211</ix:nonFraction>&#160;million related to 2021, and $<ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTAzMQ_144bd3b4-2326-49f5-bfd3-d847c254a244">289</ix:nonFraction> million related primarily to 2020. As of December&#160;31, 2020, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTEzNg_b6488fdb-4305-4e7d-bb3e-3ed716104e2a">326</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTE3NQ_1bc87946-e6b5-4145-af35-d26219bcb6d2">20</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTIwMA_563e83e1-6f1a-4443-ba23-0a37882a4004">306</ix:nonFraction> million. </span></div><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NjA_08cd9754-45d8-4fc4-80f8-e39f3b5af419" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" format="ixt-sec:duryear" name="moh:InvestmentsMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTMwMTI_78586759-719e-4fa0-ad66-21d709e50640">10</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="id0497f33d5bf4e7187e8f9c8f6fb4d3c_D20210101-20210331" format="ixt-sec:duryear" name="moh:InvestmentsAverageMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMjc0ODc3OTA5ODY5Mw_be2114a1-a005-4e57-bfb8-dbdb1e88c990">10</ix:nonNumeric> years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2MzA_40bc199d-ddf2-4066-bc94-2e1ddaa078f3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc3MDM_3695a9f5-e4db-4f24-bd90-3811827e9ae8" continuedAt="ia0719a61879541c38da68a4ad4708226" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0fe0be047f8455ebbacaeeae8732574"><ix:continuation id="ia0719a61879541c38da68a4ad4708226">Various recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements</ix:continuation></ix:continuation>.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 10</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">3. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RleHRyZWdpb246YmFjMjFmNjBmNTNmNGY1YWJhNjAzYzg0NTkwNDg4NjhfNDQx_38de5bea-25fc-49de-8140-32ba7caa2138" continuedAt="i6279b9f3fa4e4245b01482b765dcc45a" escape="true">Net Income per Share </ix:nonNumeric></span></div><ix:continuation id="i6279b9f3fa4e4245b01482b765dcc45a"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RleHRyZWdpb246YmFjMjFmNjBmNTNmNGY1YWJhNjAzYzg0NTkwNDg4NjhfNDI2_ad0fe6ef-6bf8-46ad-b5db-797f91e422cb" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNS0xLTEtMS00MDA3_730d58ae-7538-41d3-bb98-d529428c504d">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNS0zLTEtMS00MDEw_47339b01-7dda-430a-af0a-0ba71e665513">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNy0xLTEtMS00MDA3_31c7abd9-a939-458b-8c9f-9006dca9c76d">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNy0zLTEtMS00MDEw_10e49b83-fec3-44ff-8c65-9df78f24f47c">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfOS0xLTEtMS00MDA3_6b3acf50-45ce-4d2a-988a-4537b3bff9d2">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfOS0zLTEtMS00MDEw_77dc7b18-b9ab-40b6-a403-bfba16cf57de">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTAtMS0xLTEtNDAwNw_31db2d63-1011-4524-9f1b-76c23dfe5ffb">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTAtMy0xLTEtNDAxMA_4a8fe8eb-64fe-42a5-878d-6fe2c562867a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTEtMS0xLTEtNDAwNw_0c16ba52-ea12-4ede-97fa-e1cade2d8924">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTEtMy0xLTEtNDAxMA_9b83259e-9ed4-4889-8737-be60287df550">60.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMS0xLTEtNzY2OQ_b7a71c8d-b838-4a46-8654-1743ecf2fc86">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMy0xLTEtNzY2OQ_19dc715f-28ee-4876-b820-116887bdeefc">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMS0xLTEtNDAwNw_f623e8e9-41e2-458a-872a-785d157145e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMy0xLTEtNDAxMA_a2ef19a5-f125-4ea7-a17a-b41035181ebf">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTUtMS0xLTEtNDAwNw_22872f44-32d7-451b-92ed-8b4c2c51616d">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTUtMy0xLTEtNDAxMA_9b58f356-6697-49bd-a034-4626b93a11d5">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTctMS0xLTEtMjU2Nw_3fffcf8b-aafe-4720-8140-765832a3ee55">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTctMy0xLTEtMjU2Nw_641257f4-7085-4867-bb11-32b22ae45e7f">2.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTgtMS0xLTEtMjU2Nw_b1e2fefc-c6ad-4a11-a683-04c341347e04">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTgtMy0xLTEtMjU2Nw_f2320684-c8d0-4109-b5dd-72e882f4ca5a">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">4. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMzIwNQ_cbd92b8f-cc5b-4ead-8d75-dae98f3f17bf" continuedAt="ia7809198d76b491c947f87c65f96d139" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="ia7809198d76b491c947f87c65f96d139"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, we closed on our acquisition of <ix:nonFraction unitRef="number" contextRef="i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA0NDUzNjA0NzE5Mzk_4a99d24d-5098-4522-9ad7-255d29c72d30">100</ix:nonFraction>% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc., for total purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i89e7332f8532480b940cc14c82d5a66c_D20201231-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMjc0ODc3OTA3NzM5MQ_2319b954-be3d-4d3b-9277-68513712ac02">1,037</ix:nonFraction>&#160;million. In the first quarter of 2021, we recorded various measurement period adjustments, including an increase of $<ix:nonFraction unitRef="usd" contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE1Nw_d8291174-ecc3-43c4-ae69-4c378ee52e41">6</ix:nonFraction>&#160;million to &#8220;Receivables,&#8221; a decrease of $<ix:nonFraction unitRef="usd" contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE4Mg_dc2d9073-3bb1-48da-b48c-3bf1dae4adbf">25</ix:nonFraction>&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $<ix:nonFraction unitRef="usd" contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE2OQ_9af3d4ca-32ce-4e9e-bee6-68297f9c44d7">33</ix:nonFraction>&#160;million to &#8220;Amounts due government agencies.&#8221; In the aggregate, we recorded a net decrease of $<ix:nonFraction unitRef="usd" contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE5NQ_ecdc044b-1ccc-4e1e-8561-6748040808fe">6</ix:nonFraction>&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, &#8220;Segments&#8221; for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">5. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMjk4Mg_30866604-0492-493b-b445-a1bd3aeff99b" continuedAt="i81604663de324288be3fd441ecbdb7c3" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i81604663de324288be3fd441ecbdb7c3" continuedAt="i7ac5d07d8aad4bab8963a3b29e60331b">We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2020 Annual Report on Form 10-K, Note 5, &#8220;Fair Value Measurements.&#8221;</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i7ac5d07d8aad4bab8963a3b29e60331b" continuedAt="i4c1e0fea4d8741d9943be306e7844645"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMjk3MQ_da4e4a05-0270-498e-bcbf-cfe65d8315b0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC0xLTEtMS00MjA2_f9757bb7-a0d8-4bee-bd08-973e6b030941">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be9ab0685c342fdb10ce4970ddf28c6_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC0zLTEtMS00MjA2_3abc9e1b-5bf3-4819-adea-81656b7717cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a91a1b851c5460ea799477e1d8ffea0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC01LTEtMS00MjA2_70da7e6a-6a13-491f-9d43-6a64ee7de15e">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d894df64afc4b708465d180e9e4d828_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC03LTEtMS00MjA2_980b64eb-830c-4491-b48e-066ae3979065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS0xLTEtMS00MjA2_d0b7d4b5-6903-45a1-a9cb-651d0b6ab7ee">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34971f76fea54413af66394067162aa4_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS0zLTEtMS00MjA2_7e46c360-3332-410b-80cd-491d3362dbd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ea329b6ce44f08b01706088442cd3d_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS01LTEtMS00MjA2_8e65b626-952e-4b95-9998-aa7c9f35e3ea">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72442a16d054cf6b2add623661e1309_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS03LTEtMS00MjA2_085d4a10-5e3b-4404-8c9b-c2ca444664d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi0xLTEtMS00MjA2_c3516f95-6396-4b10-b138-0d67e945b8de">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffa9f6c7ef243a0945eb16b52a45524_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi0zLTEtMS00MjA2_e6cb9f79-5d65-4144-be17-76527500e288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89eff6b8e212434c80c97106458c80f9_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi01LTEtMS00MjA2_1102c18d-9d08-4144-97d1-3d8089d3af57">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8486b4460641688370ab5c52704984_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi03LTEtMS00MjA2_f4b298db-0588-4f93-839e-948b2ee2398b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy0xLTEtMS00MjA2_6a2e64c9-a3f4-4d10-80e1-ed16d0b101d3">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fffabe708ad4e94ba5b0636c6518d9f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy0zLTEtMS00MjA2_2ffd1aff-8104-424d-9f51-f06e9f073587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd148c06afc46d29d9896ffc0517005_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy01LTEtMS00MjA2_92308aa8-9f92-4e47-9b86-c3bcacc9ca0b">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e957ac778a7477899bb650c9835d5d2_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy03LTEtMS00MjA2_68acfb80-bb65-499f-9185-845a27b2e25e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC0xLTEtMS00MjA2_cf0358be-617e-4734-90e3-fc405c7fa366">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c53b5850b44aea95b55cac2de8f94a_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC0zLTEtMS00MjA2_39a293ea-726f-4708-ae1c-d4769d6f3a6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96c7085c6d14448b5deab7fd704714d_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC01LTEtMS00MjA2_f57970ca-fa90-4ab6-8053-11f5a00e99ae">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if612cc865e074f888043131a4ddf811f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC03LTEtMS00MjA2_de2da6b0-7d66-4afb-a6bc-71103c533ed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItMS0xLTEtNDIwNg_33917e7f-c4dc-4adc-9025-b75183b8c36b">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367c629760754439af0a0d0519f9eccd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItMy0xLTEtNDIwNg_5024c619-b14a-4de2-ba55-719d1c5322bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90962768e25e4a079c9fa088d378e436_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItNS0xLTEtNDIwNg_8b414069-d46d-4a64-898a-99af4de61d2a">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItNy0xLTEtNDIwNg_1712f898-f7c2-484c-b556-7c058d14918e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtMS0xLTEtNDIyNA_34489ecc-67dd-4e6f-b39b-2e18f41fc70e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367c629760754439af0a0d0519f9eccd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtMy0xLTEtNDIyNA_825ed9f9-1c9a-4e3a-b56b-36a7eeabdac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90962768e25e4a079c9fa088d378e436_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtNS0xLTEtNDIyNA_b1ea61de-849e-41a3-9f5f-16e189ce5c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtNy0xLTEtNDIyNA_9bebb1c9-e29b-4063-b121-6da98092afe7">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtMS0xLTEtNDIyNA_d5de784c-fa0f-4931-84db-19bb17977be6">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367c629760754439af0a0d0519f9eccd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtMy0xLTEtNDIyNA_e8637b47-0948-4b01-b80c-00610f274e2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90962768e25e4a079c9fa088d378e436_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtNS0xLTEtNDIyNA_859082a4-00ff-476f-92a9-5db736b50197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtNy0xLTEtNDIyNA_7753e9f3-0344-44cf-85cc-d88141006673">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2020, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC0xLTEtMS0w_20c4c84f-041b-43b7-8736-9b7c88037f9e">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776889e2aac941f6b8777a276968f455_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC0zLTEtMS0w_99387a7f-fd2b-40b1-8776-3ba6aacebbb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c4d02fdb08d40358bf0167b7e447156_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC01LTEtMS0w_89b322b3-4626-4574-84a8-625589f73a2a">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2484837902cc473abe31b5f45b8b5d5c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC03LTEtMS0w_fd32291f-05e2-43f3-af7f-18134794a923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS0xLTEtMS0w_81846d72-0d4f-4aef-99f4-6fba01f456b3">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624191553621462ab6d620e9fa29afe5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS0zLTEtMS0w_3194d0f0-8032-4c30-ad80-62eb6da2c7b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66bdf91f7c54e64ae93432279b0c7d9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS01LTEtMS0w_84634cd5-b93a-42c2-848e-2f794abb91e8">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc3f4d81df942ecbe0f17b7684f3a38_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS03LTEtMS0w_7be492d0-9d7f-4d89-b718-2f56a300517f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0xLTEtMS00MDYx_ab302cda-9940-4dbc-aff4-d04d29671288">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8626edaea2f544f68b7eeffc9cdc5c74_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0zLTEtMS00MDYx_2d3d8624-64c0-43a6-b900-9d00696a86fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffff4e3ba0343a2861c235a54ba7686_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi01LTEtMS00MDYx_39301114-3ee3-460d-a435-114aea96bbb5">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb78d77ebc514051a2802fae9ffa2745_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi03LTEtMS00MDYx_4d5f6ba2-0d4b-4557-87e4-3c8958eaef61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0xLTEtMS0w_202b24f8-bc28-4f37-932e-b266ce587caf">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4908d014efa1485e92e9f298580b4e47_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0zLTEtMS0w_060a3aa8-ee91-4f4e-9b1a-813344afa408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b9ad1f540c43b5b9d22ae02827f3b2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi01LTEtMS0w_7fb99cd8-6eb2-4bf9-a827-e4059425a026">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bde201c232c4a07b85ad5ea4c855816_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi03LTEtMS0w_56ccc375-76ce-4fdc-99eb-7d5f2745339c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC0xLTEtMS0w_01d169f6-6477-4db3-89c5-46d99be244b6">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b1d89062504208983df2df1d02c5ba_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC0zLTEtMS0w_3db7d378-61cd-4ad0-9959-3b3b6400fcbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9348c98a684882a89a1791746cd066_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC01LTEtMS0w_34163192-51d3-4454-acaa-6a61fb87c818">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999e7c8caf5d4a449709bfcf9071b5d8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC03LTEtMS0w_e9dab5c0-1755-4e60-9b34-44c6c03fe72f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItMS0xLTEtNDExNw_eedb11e2-fcd1-4b64-b5e9-96eb4d4b346c">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfb1e5f1124f08a113456fed9b0aba_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItMy0xLTEtNDExNw_45de794e-183e-4f20-a807-25fa2885c55e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItNS0xLTEtNDExNw_267f01e6-98e9-492f-bb1c-dbbe780ba28a">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItNy0xLTEtNDExNw_d7b1f20d-f3ad-4a36-bd62-47d1dbdba1cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtMS0xLTEtMA_8b91b5b0-5837-40f6-8c01-9cb83d4e2a63">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfb1e5f1124f08a113456fed9b0aba_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtMy0xLTEtMA_85f91b29-4a94-440d-8fb3-73e544fe50b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtNS0xLTEtMA_20b2d580-48e7-417c-a9d3-bd3849adc0be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtNy0xLTEtMA_8c61bf79-bf8e-45fa-bf0e-fb1dc7b04cca">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctMS0xLTEtMA_e164e840-3e77-46db-875d-2bbe8a36ba1e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfb1e5f1124f08a113456fed9b0aba_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctMy0xLTEtMA_78def395-28b5-4427-8ccd-5293621f7511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctNS0xLTEtMA_db68b615-39c6-464e-a4d5-4933ae6e48a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctNy0xLTEtMA_42558ba3-5dd1-434f-b123-08ede2e93aaf">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the first quarter of 2021, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfNDM5ODA0NjUyNDY3Nw_9ed7d919-bd61-438c-b2b5-6f4310850cde">8</ix:nonFraction>&#160;million for the increase in the fair value of the contingent consideration liabilities described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $<ix:nonFraction unitRef="usd" contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfNDM5ODA0NjUyNDk1NQ_9bebb1c9-e29b-4063-b121-6da98092afe7">31</ix:nonFraction> million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. In the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMTA0NDUzNjA0Nzg0ODA_77a6e3d8-5c9b-47ae-86fe-1a57f04dd7c3">23</ix:nonFraction>&#160;million, was paid to the seller. We expect to pay the remaining balance of the liabilities, reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets, later in 2021 and in the first quarter of 2022. The portion of the contingent purchase consideration paid in the first quarter 2021 has been presented primarily in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i4c1e0fea4d8741d9943be306e7844645"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMjk5Mw_2f698cc4-7de9-4947-bec0-646766e38175" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy0wLTEtMS0xNjcvdGV4dHJlZ2lvbjo2ZjUyYjZlNmE5YWI0YTUwOGRjYzY5YTYyYTBkMzgwMl8yNzQ4Nzc5MDY5NDUz_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee">4.375</ix:nonFraction>% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a3d683acc0407d9bc0027bd95e5c34_I20210331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy0xLTEtMS0xNjc_1d0c8cfd-f40f-40c9-b8b5-b0a6cc9f8d97">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabcec5c78a74e89969fc2325fe4e83f_I20210331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy0zLTEtMS0xNjc_1cf4137c-1afb-4438-b083-744e2dbb4e4b">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d77563cade44be7befb74c969a2dd4d_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy01LTEtMS0zOTk_a75a081c-8aad-4d43-b7a6-e6d88603bb04">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd7f1592daf42cfa111ef9d3525f7dd_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy03LTEtMS0zOTk_2abcb772-065a-47f4-9044-8b68ed4e9870">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC0wLTEtMS0xNjcvdGV4dHJlZ2lvbjpmM2I3ZjczOWFlYzQ0ZWQ0OWRkMGUxYzE1M2FkNzBiN18yNzQ4Nzc5MDY5NDU0_8a0c0854-4886-4d9b-8a59-f87640c3c730">5.375</ix:nonFraction>% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59b0cf8fcf28410b85ca7ccc1bd5028e_I20210331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC0xLTEtMS0xNjc_bb833d98-d6af-4cf8-a92d-8cc9c8cb51dc">697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed421117c6f422a9b4454963e89aaa4_I20210331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC0zLTEtMS0xNjc_6b6c7977-b1b5-4718-8fbd-bddb8b7d5c60">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4316903bcdcb421181b02d8d89f68ed1_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC01LTEtMS0xNjc_afc9a6fd-e312-4ff1-8e31-f6f433c3542d">697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c23e80da0749b18fdf5572eeccf013_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC03LTEtMS0xNjc_188373bb-11bb-48b0-95b8-d338e692c199">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS0wLTEtMS0xNjcvdGV4dHJlZ2lvbjo0ZmQ4NzgyZTRiYWM0MTg3ODhmOWZmOGQ2NmRjMmIxZV8yNzQ4Nzc5MDY5NDUz_e5b68285-40c8-462e-a4ec-2c6158818115">3.875</ix:nonFraction>% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7598a3a1ef3e4c72915a1f6a9b3e0870_I20210331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS0xLTEtMS0xNjc_8ab4c297-d3bd-494b-b9b1-d83f2060d1ee">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64eb88418e44ccdaa7c1b45b0e9c179_I20210331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS0zLTEtMS0xNjc_30ac6f47-5f81-42dd-9d88-b56a48bfcb57">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10b590b22514a43a3f12d61a7d8768a_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS01LTEtMS00MDM_e2f95f09-dd81-42c1-9e80-9ba0bc3004cd">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if379c70eb4bc4cb89f39dd8542e38baa_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS03LTEtMS00MDM_2a3f4340-e7f4-40ad-aab8-d83589aedc72">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fea16fef42471dba019c040233981e_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS0xLTEtMS0xNjc_ed467274-4713-4447-8761-d0cf783c1018">2,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8074103f41e04c56b96df5ea82a9c412_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS0zLTEtMS0xNjc_dc631186-5d3e-4e20-b58e-029042d07524">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if451e23108a3485e917d50dbd51706d3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS01LTEtMS0xNjc_3e4df0fe-da27-46df-a660-456e9b2f5ad8">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1936ea8520f42d384dec241609293d7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS03LTEtMS0xNjc_2b58f165-6e2f-474c-9d54-bfb1821f64a6">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_49"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">6. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMjY0Nw_1077ae8d-a8e3-4d60-915f-527a3738c392" continuedAt="i4d10d738ee5c43c8be7ee1c40fc6b809" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="i4d10d738ee5c43c8be7ee1c40fc6b809" continuedAt="ia852ad10d79546fc818fbbbac7ee62b2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all our investments classified as current assets to be available-for-sale. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMjY2Mg_8a22cd1f-0f7a-4b4b-9114-9d31968ec378" continuedAt="i3e727a0a4f0f40b4a51b10fa6bbabe97" escape="true">The following tables summarize our investments as of the dates indicated:</ix:nonNumeric></span></div><ix:continuation id="i3e727a0a4f0f40b4a51b10fa6bbabe97"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS0xLTEtMS0w_d7f1b885-e99a-44e7-8318-88e28ece7997">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS0zLTEtMS0w_5ba8c950-8867-4044-88f5-5c0515ffbf16">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS01LTEtMS0w_babfa135-35fa-4c75-8cdb-89aa81abf5e4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS03LTEtMS0w_ecbebc86-e1b0-4989-b03d-dfb80391ba9f">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi0xLTEtMS0w_d666669b-d061-4d71-8aaf-e23f2c8a148c">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi0zLTEtMS0w_1d11b662-290b-42fd-b214-a2f373298ba8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi01LTEtMS0w_76b626d1-bdb0-4dfb-84a0-cb09844623dd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi03LTEtMS0w_8c0c5072-b35e-4f32-b9ed-92a6f24bd778">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy0xLTEtMS0w_a4c7b815-8a01-4766-94ae-3e4639d7fd98">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy0zLTEtMS0w_c741529e-44b1-450e-a86f-66833f5b5175">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy01LTEtMS0w_eda8ccde-f49c-430e-9b98-e658374a94f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy03LTEtMS0w_22589246-806d-4173-8b22-1fe93df8f125">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC0xLTEtMS0w_cd3d7ca1-2171-4007-b3da-1744e9b46968">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC0zLTEtMS0w_7031d286-5bf9-456b-b58b-0bf4d66b1ee1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC01LTEtMS0w_36eb2ef9-82f9-451e-a68a-53b0057c2d75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC03LTEtMS0w_959b0ba4-f1d7-4887-b0ab-0302a66b06f4">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS0xLTEtMS00Mjgw_b7c09b1f-0dda-4de5-8766-c56486a12317">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS0zLTEtMS00Mjgw_752e2ad9-4186-449f-b890-c5511a472245">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS01LTEtMS00Mjgw_f7e83283-011f-44c0-b1af-ece39d25420b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS03LTEtMS00Mjgw_fe7deb9c-03ec-4fbe-87c2-266d4a459418">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtMS0xLTEtMA_31261421-526f-4e89-9098-bfa013876bc4">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtMy0xLTEtMA_fb94b009-f762-473d-906f-2e5ca7131da8">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtNS0xLTEtMA_10fcd9bb-2d4c-41ab-9c8a-67e808cd2363">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtNy0xLTEtMA_ef027950-735f-451f-b493-bd3d0e7128cc">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS0xLTEtMS0w_53109880-beaf-4e33-9947-4a8d954d957d">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS0zLTEtMS0w_e22e5d8f-78a5-46d2-a0bc-636f40e22588">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS01LTEtMS0w_a6e97feb-c935-4c5c-ac13-00a8afe9e55e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS03LTEtMS0w_0934631c-e2a7-4bae-8649-57181827ce84">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi0xLTEtMS0w_c8ce4b13-8008-4f90-b1f1-087de843a9e2">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi0zLTEtMS0w_37819a7e-7e3d-455d-861b-74d7f0a63353">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi01LTEtMS0w_294f4155-1ab0-41f5-b69e-c8e73ba17d4e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi03LTEtMS0w_8f176922-7e2d-4ba8-9e94-68c5d691f6b2">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy0xLTEtMS0w_300ca947-11ca-4e11-b4bc-7b31d9ef43b3">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy0zLTEtMS0w_954fc726-c604-465c-9878-f79da3c6a496">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy01LTEtMS0w_57e4a1c0-aa7f-4a1b-b98d-2be14ff42b96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy03LTEtMS0w_ead956ee-7cf5-4c33-8ccb-3221dbafe912">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC0xLTEtMS0w_d2d2d673-2fb8-46cf-9db6-aa495efc9818">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC0zLTEtMS0w_587b043f-41ba-42b1-8b73-3bafc3d480b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC01LTEtMS0w_0a61398b-2faa-49bb-9475-6b3e1b94f789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC03LTEtMS0w_326d5ca6-66f3-4446-8b47-d81683c0747c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS0xLTEtMS00Mjc1_2f0ba28f-f551-4698-9675-dcd929b4a0d5">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS0zLTEtMS00Mjc1_b9949f3e-915b-44ae-babd-eaaa8ddcd2c8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS01LTEtMS00Mjc1_0872785d-f37f-454c-913b-57b38e49174a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS03LTEtMS00Mjc1_ff7affa1-dd7e-406d-9b24-1674aa20012a">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtMS0xLTEtMA_6c4ce8b6-c91a-4093-8a8d-77c16343457d">1,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtMy0xLTEtMA_4283b4bd-57a5-4398-ae77-d6a9ca8a1c44">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtNS0xLTEtMA_9ebd676b-7654-46e9-bb43-b58c2a5a4c37">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtNy0xLTEtMA_a522a32b-0d42-44a7-b780-93085ab6391f">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="ia852ad10d79546fc818fbbbac7ee62b2" continuedAt="i7ba5b884929640c39cc892a61835d927"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMjY0Ng_35ed7416-26fb-453e-b3e9-76091844d313" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of March&#160;31, 2021 are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfMy0xLTEtMS0w_8c780853-1c1e-4a69-b7e7-0f756cee9c32">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfMy0zLTEtMS0w_06a4aeec-4026-4e3a-b949-d5b3605c12e3">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNC0xLTEtMS0w_20f4b78a-0f0d-4231-a044-2b13ca7dbef9">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNC0zLTEtMS0w_5e34a51d-cca5-48f7-932e-c5cf3e0dddbd">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNS0xLTEtMS0w_968d71c9-baad-4b5d-9dab-12b14d8bab17">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNS0zLTEtMS0w_6422285c-1037-4958-bdc8-1d7118d7c909">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNi0xLTEtMS0w_8f9c70da-2f95-4fed-b6c0-c0f90891705e">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNi0zLTEtMS0w_d0d43198-053c-4a7d-b4fe-f1cdf6740259">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNy0xLTEtMS0w_6c1d785a-a537-47f1-b8a0-74b8b664d517">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNy0zLTEtMS0w_0510ca9b-78a8-498e-9335-9e882a26c939">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant in the three months ended March 31, 2021, and amounted to $<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMTY0OTI2NzQ0NDUwMw_136f0c9a-4d1c-41a1-802c-48c42d45c6de">5</ix:nonFraction>&#160;million in the three months ended March 31, 2020. Gross realized investment losses were insignificant in the three months ended March 31, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at March&#160;31, 2021, and December&#160;31, 2020, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div></ix:continuation><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_1172"></div><ix:continuation id="i7ba5b884929640c39cc892a61835d927" continuedAt="i3637585f98214cd0ab79effb22b27522"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGV4dHJlZ2lvbjpkODQ0OTViMzNiZGE0ODRjODY4MmQxYTFkM2NjMjViMV8xMDQ0NTM2MDQ2NDE2Nw_cc05d83c-be5d-4e14-8266-dee8e6e7ba40" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2021, and December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTEtMS0xLTU1NTc_c4670c4b-ac28-4925-9337-3c1ce2098f1c">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTMtMS0xLTU1NTc_434900c9-9749-448c-b229-3d8db5e9fdf0"><ix:nonFraction unitRef="usd" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTMtMS0xLTU1NTc_72edbdf9-5f3a-4127-bc3f-dd63175a3c79">1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="iaf47769cb2064e43baa8252d52471732_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTUtMS0xLTU1NTc_cd73002d-55a3-4f11-97e7-0eef369cf326">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTctMS0xLTU1NTc_ba6e1bb4-86ff-448b-9f09-4ab8fff31935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTktMS0xLTU1NTc_23a59682-a8c3-4e69-ace4-b4de6c801c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTExLTEtMS01NTU3_fe0a08b1-39b6-4ba4-bce4-eb75b034da83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTEtMS0xLTU1NTc_b71b540a-b7be-47fc-a88a-3abb16f52e07">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTMtMS0xLTU1NTc_455f0ed4-a4ba-4c42-a2dc-b47988e1697c"><ix:nonFraction unitRef="usd" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTMtMS0xLTU1NTc_ea6fc609-9ae3-4419-bb5c-eac17e0117aa">1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTUtMS0xLTU1NTc_1e4e702c-e564-4462-8b53-bebf6d94ab92">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTctMS0xLTU1NTc_413481cb-5d6a-43ce-8ba7-cae6b9b612fe">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTktMS0xLTU1NTc_81fa310f-1abf-4458-937e-1cc4ffdfc80f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTExLTEtMS01NTU3_6adbd347-2d5d-471c-a52d-84e3161c53bf">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0xLTEtMS01NTU3_befc5b35-9a0c-4153-a0f7-bd9308509fe0">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0zLTEtMS01NTc3_a7f430b8-2215-4ec1-9ce2-81d3ce70690c"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0zLTEtMS01NTc3_f406bf3c-65d6-418b-82d5-fdff53ae676f">2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi01LTEtMS01NTc3_3be15ffb-7c93-4bdb-afa0-5a5b07e02dd1">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi03LTEtMS01NTU3_18dedc86-1c12-459f-bb5d-b49bd3b5af3b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi05LTEtMS01NTU3_181cce03-1249-4c7c-a063-cad4243f19ad">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0xMS0xLTEtNTU1Nw_a80a02d1-ef86-4896-91b3-4575372256de">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_1165"></div><ix:continuation id="i3637585f98214cd0ab79effb22b27522"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTY1L2ZyYWc6ZGE1ZDdhZmJmYWVkNGQ4Mzg5NGYwZjBhMWQ5ZWU3NTkvdGV4dHJlZ2lvbjpkYTVkN2FmYmZhZWQ0ZDgzODk0ZjBmMGExZDllZTc1OV8yNzQ4Nzc5MDcwNDMx_b0270c2e-ced0-4a43-8841-13707ce1dd9d">138</ix:nonFraction> million at March&#160;31, 2021, of which $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTY1L2ZyYWc6ZGE1ZDdhZmJmYWVkNGQ4Mzg5NGYwZjBhMWQ5ZWU3NTkvdGV4dHJlZ2lvbjpkYTVkN2FmYmZhZWQ0ZDgzODk0ZjBmMGExZDllZTc1OV8yNzQ4Nzc5MDcwNDUy_3bdb01c5-e6f9-4e4a-b2ab-5f96848a3ec8">122</ix:nonFraction> million will mature in one year or less, and $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTY1L2ZyYWc6ZGE1ZDdhZmJmYWVkNGQ4Mzg5NGYwZjBhMWQ5ZWU3NTkvdGV4dHJlZ2lvbjpkYTVkN2FmYmZhZWQ0ZDgzODk0ZjBmMGExZDllZTc1OV8yNzQ4Nzc5MDcwNDkz_7c8dfb6f-099e-436e-9155-4f7499e6d408">16</ix:nonFraction> million will mature in after one through five years.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 14</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">7. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="moh:MedicalClaimsAndBenefitsPayableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTkwNA_a231f369-3f78-4fa3-8c28-d12794711063" continuedAt="ie524daf482044b7ca857b6af70fcca90" escape="true">Medical Claims and Benefits Payable</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="ie524daf482044b7ca857b6af70fcca90" continuedAt="i0574c9860b824a28ad77f9055f084dfa"> </ix:continuation></span></div><ix:continuation id="i0574c9860b824a28ad77f9055f084dfa" continuedAt="i156dd402d74a40ee96ac13756b3d5df9"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTkwNw_6944357d-5ad7-4c10-9f37-6813f54da3e9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfMy0xLTEtMS0w_44258058-d0f1-403a-b505-992bdd8dc6c9">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfMy0zLTEtMS0w_3b03289e-c6d5-4501-b136-d29ace20ce44">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNC0xLTEtMS0w_e9c87ff1-09e7-4f4e-8d3d-d4ef5b8e6898">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNC0zLTEtMS0w_9bd0b110-5d97-4898-95da-192d35019561">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNS0xLTEtMS0w_0dd8cc5d-1468-493b-bdfe-de1be0127d5a">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNS0zLTEtMS0w_0a2cecf3-a859-4693-aa1c-71299ef2647f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0xLTEtMS0xNjA5_2c93a9ac-c1e8-4b06-82b0-45e509393672">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0zLTEtMS0xNjAx_6174cb1c-32ca-42f6-8693-9f90a35b7156">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54983f52f1db4e76b731097292942bb3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0xLTEtMS0w_1ec6c78d-b22c-4b5b-b1a8-24512f861b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0zLTEtMS0w_a40b7fa6-a18b-4512-9131-a1df6772ecb3">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNy0xLTEtMS0w_4ac4c686-66b9-4f32-95ff-beb017b39f2f">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNy0zLTEtMS0w_a5177061-5b9e-485a-b20b-4f6d0710ea94">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalClaimsAndBenefitsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfNDQ1_f361a5ea-7d0a-4bd6-985f-015e0a1d81d6">222</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalClaimsAndBenefitsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfNDUy_28992d97-6384-4205-af27-37bd769cc6fe">235</ix:nonFraction> million as of March&#160;31, 2021, and December&#160;31, 2020, respectively.</span></div><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTkxNw_e40f18c1-2354-4021-a01b-c0e235ca88cd" continuedAt="i93cf93bd0fb14ec2bd19703229014009" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba24de5e17564671afe22ec89f5f3acf_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC0xLTEtMS04MTYw_b661b8e3-7b36-477a-9954-48b6c49ddaeb">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340f4a8c71a1410b99e342dbbe44f76c_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC0zLTEtMS04MTY0_7b3ee3ec-6b52-4158-a840-949a52c88c13">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09ae954893b4c35919a0f83d0592f6d_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC01LTEtMS04MTY3_dd93118a-4fd3-458d-b4c2-b6b2e3d97f46">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC0zLTEtMS0w_b29d8867-0d7d-4399-978d-e5a0da9a4ec4">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi0xLTEtMS04MTYw_d4c41124-49d9-4428-95c0-a2b9805f0805">4,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi0zLTEtMS04MTY0_e4411fd8-dcb5-484c-b974-d3dc9244ebb2">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi01LTEtMS04MTY3_80f67d7a-da47-4248-83d3-379acd8fe5e8">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi0zLTEtMS0w_e81eeb34-66dd-4b0f-b836-a7a7ec572333">5,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy0xLTEtMS04MTYw_8e25e560-b094-4c6b-90e3-f766219465cc">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy0zLTEtMS04MTY0_adb23702-0fc1-40e0-ac2d-3ed84b57a6d8">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy01LTEtMS04MTY3_cf73c938-9f03-4b0b-b69b-160e3116f75b">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy0zLTEtMS0w_0e7616c7-177d-40fc-81f0-ed4a0148ce99">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC0xLTEtMS04MTYw_a7550f2d-3ae9-4094-ab1f-6908c6e08a12">4,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC0zLTEtMS04MTY0_29e0d62e-77da-4984-bcfd-aac5e73b0e14">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC01LTEtMS04MTY3_c14f46ac-c170-47d0-8c9b-e2201b9f2b56">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC0zLTEtMS0w_4862753d-5de4-4f3a-81e3-eeea7186185d">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTAtMS0xLTEtODE2MA_ca2b24a6-3abc-4a81-8077-9d818ce0dfa5">2,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTAtMy0xLTEtODE2NA_25f00978-181a-4224-bf26-503e64dad157">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTAtNS0xLTEtODE2Nw_c01ac37c-543e-4363-b61d-c7e4ef334bcc">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtMy0xLTEtMA_2ae171b9-2b3b-480c-96ae-831b2269376e">3,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtMS0xLTEtODE2MA_35c877fb-af27-4458-afbe-c653fa95cd92">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtMy0xLTEtODE2NA_e835f019-3cdb-4afd-97ea-ff977b987b92">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtNS0xLTEtODE2Nw_1d0d8d9c-3d0d-4a31-9096-c272d876ce7c">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItMy0xLTEtMA_5277c884-4fed-44f2-bf2f-a6200baaf356">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItMS0xLTEtODE2MA_ea6dcf40-c8a2-448a-9d59-af0b9ad03408">4,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItMy0xLTEtODE2NA_46a23f6b-a6d6-404e-858d-ea82e20af33d">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItNS0xLTEtODE2Nw_0cc42530-998a-46cd-872b-ae4ee1a42779">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTMtMy0xLTEtMA_1ab5bf4f-6ede-4d52-b6e2-c0992c5d2ad5">5,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in acquired balances </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" name="moh:ChangeInAcquiredBalances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtMS0xLTEtODE2MA_131be792-6141-475b-bfec-1f7203f58052">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" sign="-" name="moh:ChangeInAcquiredBalances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtMy0xLTEtODE2NA_84c073bd-ef44-4752-a860-e3119d2092ff">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="moh:ChangeInAcquiredBalances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtNS0xLTEtODE2Nw_3e64472c-257c-49ce-89a6-c99baab47723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="moh:ChangeInAcquiredBalances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTMtMy0xLTEtMjE2NQ_3e9996e9-4bcc-47b2-9989-68917726adb4">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtMS0xLTEtODE2MA_42fbf646-7750-4aca-add3-fe675ce1d4c4">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtMy0xLTEtODE2NA_8864e7bb-e55e-4329-b935-9df262aa6c3c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtNS0xLTEtODE2Nw_ea3025c5-1c78-4824-93be-771c95177a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtMy0xLTEtOTY0_68359c31-db0d-4073-8ded-0f1b8c6e7792">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9981d0011a794884b2a7987b32480b6b_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTYtMS0xLTEtODE2MA_1a0decd4-370a-45b9-9506-60d09257e07a">2,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad67715684f94d79a4e970a446c35348_I20210331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTYtMy0xLTEtODE2NA_58294473-7378-4114-b7e4-2891dbc7e9fd">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd4b30c10a94ae093780ce38d46a370_I20210331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTYtNS0xLTEtODE2Nw_c9eb2680-c658-440e-bec5-e02c905aec01">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtMy0xLTEtMA_582cfd58-f688-4e4c-8cc3-9817b42bf88f">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i156dd402d74a40ee96ac13756b3d5df9"><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i93cf93bd0fb14ec2bd19703229014009"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e72d808dd54b4097d93c8105045161_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC0xLTEtMS04MTc2_169f7b52-1fab-448e-9c2a-25998620708d">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250ad4b68c834c7ab7f008a13f28fed5_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC0zLTEtMS04MTgz_fd714b2b-b60e-46d3-a0aa-1ec51ff36357">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03cf9b99099a418cbff01db407d511cf_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC01LTEtMS04ODc0_a2ec5a67-23c8-4e6e-922b-236e5a701918">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC03LTEtMS03ODc4_0b7f4ddf-8e9f-41a7-b9dc-5ed35de4ef5f">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi0xLTEtMS04MTc2_4490956e-cf98-4120-8c82-5ee61dd126ad">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi0zLTEtMS04MTgz_d3dcf832-689e-4750-b1c6-ae81099b095b">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi01LTEtMS04ODc0_144cd3a7-0b38-48ba-8be3-69bbfd8bf562">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi03LTEtMS03ODc4_39d2dbd2-2f89-4faa-b903-e10c5b873b77">3,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy0xLTEtMS04MTc2_fcb22a8f-c309-4901-98f3-823f56f672ca">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy0zLTEtMS04MTgz_41c743f8-1394-4099-8da8-3ccf90bfba28">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy01LTEtMS04ODc0_73ad1fd2-6fce-44a0-91ae-efbf87ca26bb">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy03LTEtMS03ODc4_647c827f-060e-4f28-8113-c4821f96b4f2">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC0xLTEtMS04MTc2_defc3632-d816-4ddf-af91-26b4aa3dbe96">2,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC0zLTEtMS04MTgz_4be6da2a-bce1-4145-96cc-80ca99f531bf">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC01LTEtMS04ODc0_eb7291f8-e7d8-445d-9297-c500debd659c">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC03LTEtMS03ODc4_e717248e-db5f-48c2-91ec-4d182007d26e">3,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtMS0xLTEtODE3Ng_4accca7b-50bc-4c70-b226-e23a000c5f1e">1,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtMy0xLTEtODE4Mw_f8c75d3d-0c94-4501-b66b-c44ec31bb8f4">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtNS0xLTEtODg3NA_a863b114-5cc3-414d-be6d-fc5937c28935">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtNy0xLTEtNzg3OA_4a9a3f7b-15cd-4a3e-81f9-381c92ef2703">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtMS0xLTEtODE3Ng_edf162cc-7ff0-4beb-81d0-cb5565ef64d8">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtMy0xLTEtODE4Mw_8190fabe-7dd7-4072-9571-6e2757dfa487">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtNS0xLTEtODg3NA_f1d6d306-8c74-4794-90a6-b330add231c8">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtNy0xLTEtNzg3OA_c2257e3b-2915-4d18-b682-fa5b3ca8d2dc">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItMS0xLTEtODE3Ng_568edc66-1b46-4d5b-8d5e-7ac11af0458b">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItMy0xLTEtODE4Mw_7d789f36-0b35-4abc-b836-063bc86b073c">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItNS0xLTEtODg3NA_7408c968-5763-4189-b76c-f4843bf3c231">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItNy0xLTEtNzg3OA_912ff859-38c9-4123-8c5e-ff4c220e083e">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTMtMS0xLTEtODE4MA_7ad51c34-7a04-4d00-ad77-6ba71b7cbdaf">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTMtMy0xLTEtODE4OQ_da7ad554-1f92-46f7-998e-243d7e62a51a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTMtNS0xLTEtODg3NA_ddaafb7f-c483-47cc-b149-326da5c2dd82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtNy0xLTEtNzg3OA_d7eda5b3-c0ea-4f71-94dd-03f3f0daa4e5">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e8a21df22c49dea82dcb63e4eff8cb_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtMS0xLTEtODE4MA_3604afb1-0ceb-4119-a894-d11edb3f4299">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087cf67012d04ba0bbee3ed77b869dbd_I20200331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtMy0xLTEtODE4OQ_ab872fb0-8cb3-47be-817c-12bd1b31941c">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if445e6aa2f2a404c9c2cae784a9d3c67_I20200331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtNS0xLTEtODg3NA_4c414610-3d4d-4de8-a5c8-2de2b7e84f30">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7250e43387d044659d3061f2be2719fd_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTUtNy0xLTEtNzg3OA_5aa35098-8cfd-41a5-84c2-f7786142f052">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2020, and 2019 developed favorably by approximately $<ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTEwNg_0e7616c7-177d-40fc-81f0-ed4a0148ce99">194</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTExMw_647c827f-060e-4f28-8113-c4821f96b4f2">101</ix:nonFraction> million as of March&#160;31, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior period development recognized in the first quarter of 2021 was primarily due to lower than expected utilization of medical services by our Medicaid members and improved operating performance. Consequently, the ultimate costs recognized in 2021, as claims payments were processed, were lower than our original estimates in 2020.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">8. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfNDI3MQ_2347fbb5-fb9d-4bf0-ae0d-be2c948ad349" continuedAt="ie0422551cd7041988bc6efbef9a9099f" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="ie0422551cd7041988bc6efbef9a9099f" continuedAt="i45381afa702a4bf483fbd77ee2bdece6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-term debt is held at the parent, which is reported in the Other segment. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfNDI3Mw_3fc7cafd-3ef4-42e7-b2a9-85001c529516" continuedAt="ib9b5a162ad0e4013895eb6aebbc9e47c" escape="true">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ib9b5a162ad0e4013895eb6aebbc9e47c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOC0wLTEtMS0wL3RleHRyZWdpb246YWVjMTE3NTkxM2YzNDg3Zjg1YWJiYWQ3NGY1YmI5MTZfMjc0ODc3OTA2OTQ2Mg_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOC0xLTEtMS0w_72d2b256-fe3d-4c57-9220-416e216beb5e">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4790b3dd8c914707b7598d0687f23cf3_I20201231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOC0zLTEtMS0w_0070dc7c-eef5-4d93-8758-a5b4a9110cfd">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOS0wLTEtMS0wL3RleHRyZWdpb246MTViZDFjZDdjNzJiNGZhMDkyMTQ2YWJhMGVkYzZmZjNfMjc0ODc3OTA2OTQ2Mg_8a0c0854-4886-4d9b-8a59-f87640c3c730">5.375</ix:nonFraction>% Notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOS0xLTEtMS0w_33c36253-cd7b-43e7-961b-bc4b881ef1db">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6b03e1fc3e49bdbe024dcf4fec7e6d_I20201231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOS0zLTEtMS0w_ed77be51-8921-406a-be78-ac2c548ae5f6">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTAtMC0xLTEtNDUzNS90ZXh0cmVnaW9uOjIwMDcxMWRiOTdhMjQyNDc5ZjhkMTAyZmQ1MzZjOTliXzI3NDg3NzkwNjk0NzI_e5b68285-40c8-462e-a4ec-2c6158818115">3.875</ix:nonFraction>% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTAtMS0xLTEtOTQ4_34351841-cce0-4c13-b5b4-d0749284e46c">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bb3713e7dc4ce8aff3b343553d1d5a_I20201231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTAtMy0xLTEtOTQ4_7d6fc5ae-4e1f-41ab-8630-ffc9f6f563d3">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTItMS0xLTEtMA_e86d7a2d-4577-4271-9497-fc725dc3c706">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTItMy0xLTEtMA_6db37f94-a2e8-4247-829d-1ebb5457f64e">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTMtMS0xLTEtMA_6cf614f2-5b94-4125-ad79-2d7fc86f2ae1">2,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTMtMy0xLTEtMA_e90f64cc-ce9b-4a80-8b95-39b07122e846">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (&#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="iee5537a3735a44efbf12ff851ff5fb61_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfNzIw_d2359952-f53f-4e45-91d3-d5c283f45b41">1.0</ix:nonFraction> billion, among other provisions. The Credit Agreement has a term of <ix:nonNumeric contextRef="iddefd20760394cda9704c051843be4a0_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMTMyNw_334c8ec2-a70e-4fcf-8773-5e224d5d23ad">five years</ix:nonNumeric>, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of March&#160;31, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of March&#160;31, 2021, <ix:nonFraction unitRef="usd" contextRef="iee5537a3735a44efbf12ff851ff5fb61_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMTk1OQ_c6df7de7-8b54-4687-9d0a-d9d2898e73c8">no</ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">High-Yield Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina Healthcare, and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i45381afa702a4bf483fbd77ee2bdece6" continuedAt="i152336475e934ac29a900c7970e05093"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjY3Ng_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee">4.375</ix:nonFraction>% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0OQ_69e105d4-7b37-497a-b94f-bfc971818848">800</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjgwMQ_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee">4.375</ix:nonFraction>% Notes&#8221;) outstanding as of March&#160;31, 2021, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjk3OQ_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee">4.375</ix:nonFraction>% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzM3Nw_8a0c0854-4886-4d9b-8a59-f87640c3c730">5.375</ix:nonFraction>% Notes due 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzQwMw_ebfa4331-ed4c-4e6f-a5f6-29a0f1218cf4">700</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzQ1NQ_8a0c0854-4886-4d9b-8a59-f87640c3c730">5.375</ix:nonFraction>% Notes&#8221;) outstanding as of March&#160;31, 2021, which are due November&#160;15,&#160;2022, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzU2OQ_8a0c0854-4886-4d9b-8a59-f87640c3c730">5.375</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i152336475e934ac29a900c7970e05093" continuedAt="i3632308463294e7d9aa2b73c5a447ac1"><ix:nonFraction unitRef="number" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU4MA_e5b68285-40c8-462e-a4ec-2c6158818115">3.875</ix:nonFraction>% Notes due 2030. </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3632308463294e7d9aa2b73c5a447ac1">We had $<ix:nonFraction unitRef="usd" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU5Mg_0247298a-d03a-4ec7-9e94-f26cf69ce455">650</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU4NA_e5b68285-40c8-462e-a4ec-2c6158818115">3.875</ix:nonFraction>% Notes&#8221;) outstanding as of March&#160;31, 2021, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU4OA_e5b68285-40c8-462e-a4ec-2c6158818115">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15 of each year, commencing on May 15, 2021.</ix:continuation> </span></div><div><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">9. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMjc0MQ_359ac18f-f0b5-4b51-b7b3-343abc7759b0" continuedAt="ia4ba954d82fa448f961ba0e5636de60e" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4ba954d82fa448f961ba0e5636de60e">In September 2020, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i9d78eaf9f7854f45a976f7a9c34f0b2e_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTEy_a9ea7490-3199-444c-8a56-769a62fc3280">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This program is funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="i33bc647cc4d341da839b637a42b74f25_D20210101-20210131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjA3Mg_b8c3781c-e319-4091-a852-d17ba1e2d05c">577,000</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i05f1ddd5eada4525b9899833bd42aa9e_D20210201-20210228" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjA4OA_1c8d4af2-490c-4565-ae89-404d9aeff40e">122</ix:nonFraction> million in January and February 2021 (average cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib7d95ca3899b4bbf91022aa523d90b4a_D20210101-20210228" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjA5OQ_3b662e7c-cda5-4823-b7c1-d9a3855c436d">211.65</ix:nonFraction>). In the first quarter of 2021, we also paid $<ix:nonFraction unitRef="usd" contextRef="i8589aefa8f474c159c7cbd51cc1dc98d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjExMg_25a02c27-df92-4bf0-afc5-2f38e8cbcbdd">6</ix:nonFraction> million to settle shares purchased in late December 2020.</ix:continuation></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">10. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RleHRyZWdpb246OThkMDczOWYxM2E5NGVjY2E3N2FiYjQwNjdiYzVkZDdfMTM0Mw_934a4892-ac35-45ef-8647-f706407ab3ee" continuedAt="i36984b9f65a44c1680908f015b9b61f6" escape="true">Segments </ix:nonNumeric></span></div><ix:continuation id="i36984b9f65a44c1680908f015b9b61f6" continuedAt="i2a5ff0c1020a4703b247e22530e59963"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><ix:continuation id="i2a5ff0c1020a4703b247e22530e59963"><ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RleHRyZWdpb246OThkMDczOWYxM2E5NGVjY2E3N2FiYjQwNjdiYzVkZDdfMTMzNg_fe8b2609-d114-4a51-b1e2-53df5aa61cd7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdb8495a786463fb1d63d538dedadd6_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNS0xLTEtMS01MTE1_c87251ec-ee79-461f-9a9c-f1e17569bb91">5,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74eb9bfff592416381c1931711db9989_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNS0zLTEtMS01MTE3_68a83ccd-e4fc-4b62-bd57-071f6d3c051f">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0xLTEtMS04NjY1_4e64dbe5-9d2b-4d62-b8fb-404967731457">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0zLTEtMS04NjY1_798f687c-fadf-44e9-80ba-ed2c8fc2545f">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0xLTEtMS04MDQ0_ae50f322-d1c4-4b73-a786-a49b4e78c5fa">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0zLTEtMS04MDQ0_93935404-67fa-4069-925b-e417f54e9d8e">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d574edc32f4858b10a9e95a7043b62_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOC0xLTEtMS01MTE1_63dca098-1dc8-4b17-ab89-910181f74fde">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4af07d6f77c412fa6fc30634723476c_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOC0zLTEtMS01MTE3_9a4ddd8c-c524-4330-88a4-833d8fd356f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOS0xLTEtMS01MTE1_8ae2ef47-0db5-422e-97d2-46973269d08f">6,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOS0zLTEtMS01MTE3_9805032c-c3f4-4906-82eb-0aa481a3f605">4,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December&#160;31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6be335f460e4209851cdbd1a986fddb_I20210331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNS0xLTEtMS02MzUz_095e00dd-bc2c-4468-a4b9-6af59a7ad8bd">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a8212f4d97436f86b773388a97609f_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNS0zLTEtMS02MzUz_a4a62548-0332-42f8-a3b2-7c9a2c6b43b4">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad67715684f94d79a4e970a446c35348_I20210331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNi0xLTEtMS02MzUz_5a07a4c6-4d74-49eb-9ec9-d9127356251b">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340f4a8c71a1410b99e342dbbe44f76c_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNi0zLTEtMS02MzUz_de432a95-f930-48ff-8b30-11be97ab819b">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7f1fd63c014e4598191fc6de8562ec_I20210331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOC0xLTEtMS02MzUz_22c145e3-cf7d-4ec3-a369-7e652a24624c">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930068e669b4450986374f16ef76a5d1_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOC0zLTEtMS02MzUz_1469e309-e5b8-4eaf-b5f7-5ff6f8ba1e47">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles assets, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6be335f460e4209851cdbd1a986fddb_I20210331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0xLTEtMS03NjEx_2a467dd8-0305-40fd-a2f6-5955d75b0e25">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a8212f4d97436f86b773388a97609f_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0zLTEtMS03NjEz_a1cf8bc2-f7dd-4063-bccd-d734409d11d8">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad67715684f94d79a4e970a446c35348_I20210331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTAtMS0xLTEtNzYxMQ_0302727b-d9da-45dc-b4bd-9ac897689ccf">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340f4a8c71a1410b99e342dbbe44f76c_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTAtMy0xLTEtNzYxMw_31e7d113-2ca3-4612-ba57-9457e830b847">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7f1fd63c014e4598191fc6de8562ec_I20210331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0xLTEtMS02MzUz_44fa4cb7-6d99-46f2-894e-c91496188d6c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930068e669b4450986374f16ef76a5d1_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0zLTEtMS02MzUz_64b08208-36d2-44c4-aab4-52d5f9cb7ea6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTItMS0xLTEtNzYxMQ_b666fc3b-95ee-4a31-b14a-c3c0c5ab5233">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTItMy0xLTEtNzYxMw_723736b1-36c7-4b4c-abaa-e06e8db26a9b">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib75fd2e45f3d4d8982e9fdaef11c065a_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNS0xLTEtMS01MTM1_0643e52b-48b1-45f7-a451-a2bf9e6b9487">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1114f0eae5487fa865b3bccaf5b9bd_D20200101-20200331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNS0zLTEtMS01MTM3_44e6c1e5-6ec7-477e-a5f8-76ac421c5785">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e52755e7437453ea2f981a32951d999_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0xLTEtMS04NzA2_a841122e-e0c8-4609-a647-39bb1a1371ba">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6918db6cf1846b8806408b26be49e6a_D20200101-20200331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0zLTEtMS04NzA2_b64b5c3b-1b47-49c9-947a-96fbbdd52bef">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7187b436a3ea4d1da6a4704097325340_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0xLTEtMS04MDU0_85f5d69a-088e-4f84-be27-afd8d5818ae1">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d19f8b5724c4f88b4fa8f61f0b315f6_D20200101-20200331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0zLTEtMS04MDU0_9b6f5855-609a-4edf-bf9f-0eec24d5f3bd">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1ddd3ae7e349248f4a8de4b08df629_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOC0xLTEtMS01MTM1_4d34dedd-0e8d-4363-abcf-db4cc7feb9ce">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1dad7a9e5040f9af2c8f17dc219501_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOC0zLTEtMS01MTM3_e5f8925c-c780-4406-bb0d-3d6c054af75a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5586721f5cb7493dab355f7ba8acf352_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOS0xLTEtMS01MTM1_acf55971-9845-4b1d-8042-f99d9f71b408">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ce0ea0bd4a41f486cf13d1a3ecc8cf_D20200101-20200331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOS0zLTEtMS01MTM3_e4a6e314-5215-4244-946b-a1f3c336adea">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304f43ebe4b34d7b9ce83118a0cac64b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTAtMS0xLTEtNTEzNQ_14cdb152-8c97-457c-8916-712e9a2463f5">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ac1d580f1145538873140cefeff994_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTAtMy0xLTEtNTEzNw_54ce6053-6764-4049-96c8-c31e750e2062">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i304f43ebe4b34d7b9ce83118a0cac64b_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTEtMS0xLTEtNTEzNQ_274c93b2-4fe6-4e65-a8d0-1553999701df">700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9ac1d580f1145538873140cefeff994_D20200101-20200331" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTEtMy0xLTEtNTEzNw_08ebc383-360e-4c72-9ad6-e75d62452fce">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTItMS0xLTEtNTEzNQ_f7df9b1d-68bf-4545-a9d2-2b11b6359818">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTItMy0xLTEtNTEzNw_5bd9c79a-b412-4b79-88ca-6532a6450a9a">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTMtMS0xLTEtNTEzNQ_360e756d-6a9a-431d-a440-008a365042c4">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTMtMy0xLTEtNTEzNw_292e54d6-7330-441d-ad37-b129b76f6fab">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTQtMS0xLTEtNTEzNQ_7bc0164c-73bc-4ad3-aca8-d48663913fa5">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTQtMy0xLTEtNTEzNw_1fc28d62-614a-412e-84eb-79bcb716b46d">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_70"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">11. <ix:nonNumeric contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF83MC9mcmFnOjU1NGViY2E0NGY2ZjQ4YzliMjcyNDk4OGFjOTY4OTMxL3RleHRyZWdpb246NTU0ZWJjYTQ0ZjZmNDhjOWIyNzI0OTg4YWM5Njg5MzFfMTI2MQ_a0029df7-a9b0-4fdc-9c3e-9e36ffd4002e" continuedAt="i64b2bac3e4504af0b9b24a82fd7fea80" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i64b2bac3e4504af0b9b24a82fd7fea80"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the winning bidder health plans, including Molina Healthcare of Kentucky, Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the court issued a temporary injunction directing that open enrollment for 2021 proceed with six health plans, including both Molina Healthcare and Anthem. The new Medicaid contracts commenced on January 1, 2021. On March 2, 2021, the court heard oral argument on multiple motions for partial summary judgment filed by all parties in the consolidated action. On April 28, 2021, the court issued its Opinion and Order. Under the Order, the court granted Molina&#8217;s motion for partial summary judgment, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina&#8217;s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the court ordered a new RFP, with the status quo of six health plans to continue in the interim. This matter remains subject to potential additional legal proceedings, and no assurances can be given regarding the ultimate outcome. Under the court&#8217;s April 28, 2021 Order, Molina Healthcare of Kentucky will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 19</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (&#8220;MD&amp;A&#8221;)</span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_79"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section&#160;27A of the Securities Act of 1933, or Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or Securities Exchange Act. Many of the forward-looking statements are located under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as &#8220;guidance,&#8221; &#8220;future,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;growth,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company&#8217;s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled &#8220;Risk Factors&#8221; in our 2020 Annual Report on Form 10-K, including without limitation the following:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic and its associated or indirect effects on our business, operations, and financial results;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the &#8220;ACA&#8221;), including the ultimate outcome of the California et al. v Texas et al. matter currently pending for decision before the United States Supreme Court;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">significant budget pressures on state governments from diminished tax revenues incidental to the COVID-19 pandemic and their efforts to reduce rates or limit rate increases, to impose profit caps or risk corridors, or to recoup previously paid premium amounts on a retroactive basis; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the market dynamics surrounding the ACA Marketplaces, including issues impacting enrollment, risk adjustment estimates and results, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the legal proceedings in Kentucky with regard to the Medicaid contract award to our Kentucky health plan and our acquisition of certain assets of Passport;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to retain existing or awarded government contracts, and the success of any bid submissions in response to requests for proposal, including our contracts in California and Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consummate, integrate, and realize benefits from acquisitions, including the completed acquisitions of Magellan Complete Care and Passport, and announced acquisitions of Affinity and of the Medicaid assets of Cigna in Texas;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">effective management of our medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with COVID-19; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">cyber-attacks, ransomware attacks, or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected information;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success and renewal of our Medicare-Medicaid Plan (&#8220;MMP&#8221;) programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the accurate estimation of incurred but not reported or paid medical costs across our health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">efforts by states to recoup previously paid and recognized premium amounts;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our annual effective tax rate, due to federal and/or state legislation, or changes in our mix of earnings and other factors;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">complications, member confusion, eligibility redeterminations, or enrollment backlogs related to the renewal of Medicaid coverage;   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">fraud, waste and abuse matters, government audits or reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, corrective action plan, monitoring program, or premium recovery that may result therefrom;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our exit from Puerto Rico, including the payment in full of our outstanding accounts receivable, the effective run-out of claims, and the return of our capital;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes with respect to our provider contracts and the loss of providers; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">approval by state regulators of dividends and distributions by our health plan subsidiaries;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">high dollar claims related to catastrophic illness; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the favorable resolution of litigation, arbitration, or administrative proceedings;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to comply with the financial or other covenants in the Credit Agreement or the indentures governing our outstanding notes;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of a state in which we operate to renew its federal Medicaid waiver;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes generally affecting the managed care industry; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increases in government surcharges, taxes, and assessments;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the unexpected loss of the leadership of one or more of our senior executives; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increasing competition and consolidation in the Medicaid industry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms &#8220;Molina Healthcare, Inc.&#8221; &#8220;Molina Healthcare,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us,&#8221; as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Readers should refer to the section entitled &#8220;Risk Factors&#8221; in our 2020 Annual Report on Form 10-K, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management&#8217;s Discussion and Analysis appearing in our 2020 Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 21</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). Through our locally operated health plans, we served approximately 4.6&#160;million members as of March&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FIRST QUARTER 2021 HIGHLIGHTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net income per diluted share of $3.89 for the first quarter of 2021, with net income of $228 million, which included the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Membership increase of 1.2 million, or 35%, compared with March&#160;31, 2020.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Premium revenue of $6.3 billion, which increased 47% compared with the first quarter of 2020, reflecting increased membership consistent with our expectations in Medicaid and Medicare, and exceeding our expectations in Marketplace;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated medical care ratio (&#8220;MCR&#8221;) of 86.8%, which increased compared with 86.3% for the first quarter of 2020, but demonstrated strong fundamentals of cost management, particularly in light of the various pressure points caused by the COVID-19 pandemic, and was consistent with our expectations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expense (&#8220;G&amp;A&#8221;) ratio of 7.3%, which increased compared with 7.0% in the first quarter of 2020, but was consistent with our expectations; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After-tax margin of 3.5%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We note the following factors impacting first quarter of 2021 financial results:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The net effect of COVID had a negligible impact on the first quarter of 2021, as the COVID-related utilization curtailment was offset by the states&#8217; COVID-related risk corridors and direct COVID medical costs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">While the net effect of COVID was in-line with our expectations and net negligible to the quarter in total, the impacts were varied by segment; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We experienced higher than expected membership increases in Marketplace, due to strong open enrollment. This improvement resulted from several factors, including strong product design and competitive pricing, better than expected natural attrition rates, and the extended open enrollment period, as described in further detail below in &#8220;Trends and Uncertainties.&#8221;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL SUMMARY</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MCR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees reimbursed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">G&amp;A ratio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Statistics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After-tax margin </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;MCR represents medical care costs as a percentage of premium revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;G&amp;A ratio represents general and administrative expenses as a percentage of total revenue. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;After-tax margin represents net income as a percentage of total revenue.</span></div><div><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_85"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED RESULTS</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">NET INCOME AND OPERATING INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income in the first quarter of 2021 amounted to $228 million, or $3.89 per diluted share, compared with $178 million, or $2.92 per diluted share, in the first quarter of 2020. Operating income of $335 million in the first quarter of 2021, was higher compared with $274 million in the first quarter of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The improvement in operating income was mainly due to membership growth and higher premium revenues in Medicaid and Marketplace, partially offset by increases in the Medicare and Marketplace MCRs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share in the first quarter of 2021 was favorably impacted by the reduction in common shares outstanding as a result of our share repurchases in late 2020 and early 2021. See further discussion in &#8220;Liquidity and Financial Condition,&#8221; below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">PREMIUM REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue increased $2 billion in the first quarter of 2021, when compared with the first quarter of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, membership increased by 1.2 million compared with the first quarter of 2020, which mainly reflected increases in the Medicaid and Marketplace segments and included the impact from the Magellan Complete Care and other acquisitions that closed in the second half of 2020. The increase in premium revenue was net of COVID-related risk corridors that have been enacted in several states beginning in the second quarter of 2020.</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">MEDICAL CARE RATIO</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated MCR in the first quarter of 2021 was 86.8%, compared with 86.3% in the first quarter of 2020. Our overall medical margin performance and MCR were consistent with expectations. The net effect of COVID had a negligible impact on the first quarter of 2021; however, the impacts were varied by segment. The Medicaid MCR benefited from lower utilization due to modest COVID-related curtailment, severe winter weather in several states, and the absence of a typical flu season, which was mostly offset by COVID-related risk corridors enacted in several states. The Medicare and Marketplace MCRs both increased compared with the first quarter of 2020, as both segments experienced a disproportionately negative impact from the net effect of COVID. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year reserve development in the first quarter of 2021 was modestly favorable, but its impact on earnings was absorbed by the COVID-related risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">PREMIUM TAX REVENUE AND EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was 2.9% and 3.4% for the first quarter of 2021 and 2020, respectively. The current year ratio decrease was mainly due to changes in business mix resulting from the Magellan Complete Care and other acquisitions closed in the second half of 2020.</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">INVESTMENT INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income decreased to $9 million in the first quarter of 2021, compared with $25 million in the first quarter of 2020, due to the continued low interest rate environment and a temporarily higher allocation in shorter-term invested assets during the COVID-19 pandemic, which has been rescinded effective for the second quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue increased to $20 million in the first quarter of 2021, compared with $4 million in the first quarter of 2020. Beginning in the first quarter of 2021, other revenue includes service revenue associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of our Magellan Complete Care acquisition. Such service revenue amounted to $17 million in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">G&amp;A EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G&amp;A expense ratio increased to 7.3% in the first quarter of 2021, compared with 7.0% in the first quarter of 2020, mainly reflecting integration and other costs associated with the Magellan Complete Care and other acquisitions closed in the second half of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">HEALTH INSURER FEES (&#8220;HIF&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no HIF fees incurred or reimbursed in 2021, because the HIF was repealed effective for years after 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEPRECIATION AND AMORTIZATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization increased to $33 million in the first quarter of 2021, compared with $20 million in the first quarter of 2020, due primarily to amortization associated with acquisitions completed in the second half of 2020. Refer to Notes to Consolidated Financial Statements, Note 10, &#8220;Segments,&#8221; for further information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OTHER OPERATING EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased to $20 million in the first quarter of 2021, compared with $4 million in the first quarter of 2020. Beginning in the first quarter of 2021, other operating expenses included service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as noted above. Such service costs amounted to $13 million in the first quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">INTEREST EXPENSE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased to $30 million in the first quarter of 2021, compared with $21 million in the first quarter of 2020, mainly due to the issuance of $650 million principal amount of 3.875% Notes issued in the fourth quarter of 2020. See further details of our financing transactions in Notes to Consolidated Financial Statements, Note 8, &#8220;Debt,&#8221; and below in &#8220;Liquidity and Financial Condition.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">INCOME TAXES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense amounted to $77 million in the first quarter of 2021, or 25.2% of pretax income, compared with income tax expense of $75 million, or 29.8% of pretax income in the first quarter of 2020. The effective tax rate was lower in 2021 mainly because the nondeductible HIF was repealed for years after 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_1113"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">TRENDS AND UNCERTAINTIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">COVID-19 PANDEMIC</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, its ongoing impact to our business, results of operations, financial condition, and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our Medicaid, Medicare, and Marketplace segments follow. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Economic Stabilization and Other Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to various programs enacted in 2020 and described in our 2020 Annual Report on Form 10-K, the $1.9 trillion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Rescue Plan Act of 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was enacted on March 11, 2021. This legislation includes several components to assist in COVID-19 vaccine testing and deployment, as well as provisions relating to the opening of schools; direct immediate relief to working families; and additional support for communities struggling the most in the wake of the pandemic. Among its specific provisions:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$350 billion in state and local funding;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Funding for Medicaid and CHIP COVID-19 vaccines and treatment to be matched at 100% of the federal medical assistance percentage (&#8220;FMAP&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incentives for states that have not expanded Medicaid to do so;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State flexibility to extend Medicaid eligibility to women for 12 months postpartum; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A temporary 10% FMAP increase for states to improve Medicaid home- and community-based services for one year; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase to the ACA Marketplace premium subsidies for 2021 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Biden Administration has extended the COVID-19 related Public Health Emergency Declaration (&#8220;PHE&#8221;). The Biden Administration has indicated the PHE will likely remain in place throughout 2021, and that states will receive 60 days&#8217; notice before the end of the PHE to prepare for the end of emergency authorities and the resumption of pre-PHE rules. This extension of the PHE will continue the suspension in state Medicaid eligibility redeterminations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, President Biden&#8217;s January 2021 executive order providing for a three-month Marketplace special enrollment period from February 15, 2021, to May 15, 2021, was extended through August 15, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty as to the duration and breadth of the pandemic, we are unable to reasonably estimate the ultimate impact of the economic stabilization and other programs to our business, financial condition, and operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enrollment and Premium Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding acquisitions and our exit from Puerto Rico, we have added nearly 500,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, through the end of the third quarter of 2021. We estimate that for each month the PHE is extended, it could increase our full-year revenue estimate by $150 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketplace revenue growth is now expected to be over 50% in 2021, and we expect to end 2021 with slightly more than 500,000 members.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current rate environment is stable and rational. We continue to believe that the risk-sharing corridors previously introduced are related to the declared PHE and will likely be eliminated as the COVID pandemic subsides. However, the risk corridors continue to contribute an added level of variability to our results of operations. In the first quarter of 2021, we recognized approximately $110&#160;million for the impact of risk corridors enacted in several states beginning in the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Care Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect continued uncertainty regarding utilization trends as the pandemic continues. The speed and extent to which utilization rebounds will be greatly impacted by the economy and consumer behavior, provider capacity, and the potential resurgence of COVID-19 infection rates. We believe that some portion of the utilization curtailment experienced in the first quarter of 2021 is likely the result of service deferrals, and so these services will likely be provided to members over the remainder of the year.   </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capital and Financial Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future. Refer to &#8220;Liquidity and Financial Condition&#8221; below for further discussion of our capital and financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">AFFORDABLE CARE ACT</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, in a case brought by the state of Texas and nineteen other states, a federal judge in Texas held that the individual mandate of the ACA is unconstitutional. He further held that since the individual mandate is inseverable from the entire body of the ACA, the entire ACA is unconstitutional. The effect of his ruling was stayed pending the appeal of the ruling to the Fifth Circuit Court of Appeals. In December 2019, a three-judge panel of the Fifth Circuit Court of Appeal, in a two to one decision, affirmed the District Court&#8217;s ruling that the individual mandate is unconstitutional, but remanded the case back to the District Court for further consideration of the severability issue. The intervenor defendant states led by California subsequently appealed the case to the U.S. Supreme Court, which heard oral arguments in the case on November 10, 2020. The Supreme Court&#8217;s decision is expected by June 2021. If the Supreme Court were to rule that the individual mandate is unconstitutional, and that the individual mandate is not severable from the balance of the ACA, or that the entirety of the ACA is unconstitutional, that ruling could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we served a significant number of members enrolled in programs created by the ACA, including approximately 990,000 Medicaid Expansion members and 620,000 Marketplace members. In the first quarter of 2021, premium revenue associated with these members amounted to $2.1 billion, and contributed medical margin of $374&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OTHER RECENT DEVELOPMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as &#8220;STAR+PLUS,&#8221; in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0&#160;billion. The purchase price for the transaction is approximately $60&#160;million, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals and satisfaction of other customary closing conditions. We currently expect the transaction to close in the second half of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin in early 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio&#8217;s Covered Family and Children, Expansion, and ABD programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional segment trends, uncertainties and other developments, refer to our 2020 Annual Report on Form 10-K, &#8220;Item 1. Business&#8212;Our Business,&#8221; and &#8220;&#8212;Legislative and Political Environment.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_1119"></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">REPORTABLE SEGMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we served approximately 4.6 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">HOW WE ASSESS PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of the change in medical margin is discussed below under &#8220;Segment Financial Performance.&#8221; For more information, see Notes to Consolidated Financial Statements, Note 10, &#8220;Segments.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">SEGMENT MEMBERSHIP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our membership by segment as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,859,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,599,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,970,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,605,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,032,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,404,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.62pt">Approximately 200,000 members, from the Magellan Complete Care acquisition that closed on December 31, 2020, are included in the totals as of March&#160;31, 2021, but not in prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">SEGMENT FINANCIAL PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes premium revenue, medical margin, and MCR by segment for the periods indicated (dollars in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid premium revenue increased $1,554 million in the first quarter of 2021, when compared with the first quarter of 2020. The increase was mainly due to membership growth and the impact from the Magellan Complete Care and other acquisitions closed in the second half of 2020. Excluding the acquisitions, the membership growth was across several states and was mainly driven by the extension of the PHE period and the associated suspension of membership redeterminations due to COVID-19. The overall increase was partially offset by state risk corridors stemming from COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above in &#8220;Trends and Uncertainties,&#8221; we recognized approximately $110&#160;million in the first quarter of 2021, for the impact of risk corridors enacted in several states beginning in the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical margin in our Medicaid program increased $239 million, or 65%, in the first quarter of 2021 when compared with the first quarter of 2020. The increase was driven by increased premium revenues and margin associated with the membership growth discussed above, and from a reduction in the MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total Medicaid MCR decreased to 87.5% in the first quarter of 2021, from 88.9% in the first quarter of 2020, or 140 basis points. The improvement was mainly attributable to lower than expected utilization, resulting from the combined effects of a modest level of COVID-related utilization curtailment, severe winter weather in several states, and the absence of a typical flu season. Performance in utilization management and payment integrity also favorably impacted the MCR. The improvement was partially offset by the impact of the various COVID-related risk corridors enacted by several states, as discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare premium revenue increased $165&#160;million in the first quarter of 2021, primarily due to the impact from the Magellan Complete Care acquisition, including higher membership and higher premium revenue PMPM. The increase was partially offset by risk corridors, mainly in MMP, enacted in response to the lower utilization of medical services stemming from COVID-19.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The medical margin for Medicare decreased $40&#160;million, in the first quarter of 2021, when compared with the first quarter of 2020, mainly due to an increase in the MCR, partially offset by the increase in revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare MCR increased to 90.3% in the first quarter of 2021, from 81.7% in the first quarter of 2020, or 860 basis points. The increase was primarily driven by higher direct COVID medical costs, and risk scores that do not fully reflect the acuity of our membership. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketplace premium revenue increased $283&#160;million in the first quarter of 2021, mainly due to increased membership, partially offset by a decrease in premium revenue PMPM. Our Marketplace membership as of March&#160;31, 2021, amounted to 620,000 members, representing growth of 302,000 members sequentially, and substantially exceeding our previous beginning of the year expectation of approximately 500,000 members. This improvement resulted from several factors, including strong product design and competitive pricing, better than expected natural attrition rates, and the extended open enrollment period. The decrease in premium revenue PMPM was mainly driven by changes in business mix, with an increase of members in the bronze metal tier.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Marketplace medical margin increased $45 million in the first quarter of 2021, when compared with the first quarter of 2020, primarily due to the increase in membership and premiums, partially offset by an increase in the MCR compared to 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace MCR increased to 77.3% in the first quarter of 2021, from 72.3% in the first quarter of 2020, or 500 basis points. The increase resulted from higher direct COVID medical costs, as the COVID infection rate resurged in many of our Marketplace geographies.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other segment includes service revenues and costs associated with the long-term services and supports consultative services we now provide in Wisconsin, and also includes certain corporate amounts not allocated to the Medicaid, Medicare, or Marketplace segments. Such amounts were immaterial to our consolidated results of operations in the first quarters of 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_100"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">LIQUIDITY AND FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity. In the first quarter of 2021, we did not experience noticeable delays of, or changes in, the timing and level of premium receipts as a result of the COVID-19 pandemic, but there can be no assurances that we will not experience such delays in the future. See further discussion below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Uses&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for general corporate purposes. In the first quarter of 2021, the parent received $74&#160;million in dividends from the regulated health plan subsidiaries. See further discussion of dividends below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company may also contribute capital to the regulated health plan subsidiaries to satisfy minimum statutory net worth requirements, including funding for newer health plans with growing enrollment. In the first quarter of 2021, the parent contributed capital of $52&#160;million to the regulated health plan subsidiaries. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments at the parent company amounted to $436&#160;million and $644&#160;million as of March&#160;31, 2021, and December&#160;31, 2020, respectively. The decrease as of March&#160;31, 2021, was mainly due to our share repurchase program. In the first quarter of 2021, we purchased an aggregate of approximately 577,000 shares for $122 million, at an average cost of $211.65 per share.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio remains strong and is rated AA. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating the current volatility in the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets. </span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month&#8217;s premium payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations for the first quarter of 2021 was $568 million, compared with $143 million in the first quarter of 2020. The $425 million increase in cash flow was due to the growth in operations and the net impact of timing differences in government receivables and payables.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $87 million in the first quarter of 2021, compared with $103 million in the first quarter of 2020, an increase in cash flow of $16 million. This increase was primarily due to decreased purchases of investments in the first quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $207 million in the first quarter of 2021, compared with $125 million in the first quarter of 2020, a decrease in cash flow of $82 million. In the first quarter of 2021, financing cash outflows included common stock purchases of $128 million, $51 million for common stock withheld to settle employee tax obligations, and $20 million paid to settle contingent consideration liabilities relating to our Kentucky Passport acquisition in 2020. In the first quarter of 2020, net cash paid for the common stock purchases amounted to $453 million, partially offset by proceeds of $380 million borrowed under the term loan facility.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 30</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash resources, borrowing capacity available under the Credit Agreement as discussed further below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources,&#8221; and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, at March&#160;31, 2021, our working capital was $3.0 billion, compared with $2.9 billion at December&#160;31, 2020. At March&#160;31, 2021, our cash and investments amounted to $6.5 billion, compared with $6.2 billion at December&#160;31, 2020. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital and Dividend Restrictions </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our regulated, wholly owned subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement for these subsidiaries was estimated to be approximately $1.7 billion at March&#160;31, 2021, compared with $1.5 billion at December&#160;31, 2020. The aggregate capital and surplus of our wholly owned subsidiaries was in excess of these minimum capital requirements as of both dates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable regulatory requirements, the amount of dividends that may be paid by our wholly owned subsidiaries without prior approval by regulatory authorities as of March&#160;31, 2021, was approximately $30 million in the aggregate. The subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash and investments balances as of March&#160;31, 2021, management believes that its regulated wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Ratings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our high-yield senior notes is rated &#8220;BB-&#8221; by Standard &amp; Poor&#8217;s, and &#8220;Ba3&#8221; by Moody&#8217;s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our borrowing costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Covenants</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the indentures governing each of our outstanding high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of March&#160;31, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt.</span></div><div><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_109"></div><div style="margin-bottom:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FUTURE SOURCES AND USES OF LIQUIDITY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Excluding acquisitions and our exit from Puerto Rico, we have added nearly 500,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, through the end of the third quarter of 2021. We estimate that for each month the PHE is extended, it could increase our full-year revenue estimate by $150 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends from Subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which would reduce the liquidity of the parent company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement Borrowing Capacity. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had available borrowing capacity of $1.0&#160;billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500&#160;million, plus an unlimited amount of such term loans as long as our consolidated net leverage ratio is not greater than a defined maximum. See further discussion in the Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Uses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Purchases. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program is funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of April&#160;29, 2021, approximately $219 million remained available to purchase our common stock under this program through December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as &#8220;STAR+PLUS,&#8221; in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0&#160;billion. The purchase price for the transaction is approximately $60&#160;million, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals and satisfaction of other customary closing conditions. We currently expect the transaction to close in the second half of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close in the third quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain assets of Passport Health Plan, Inc. in 2020, in the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $23&#160;million, was paid to the seller. We expect to pay the remaining balance of the liabilities, reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets, later in 2021 and in the first quarter of 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outcome of ACA Constitutionality Court Case</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described above in &#8220;Trends and Uncertainties,&#8221; the Supreme Court&#8217;s decision is expected by June 2021. If the Supreme Court were to rule that the individual mandate is unconstitutional, and that the individual mandate is not severable from the balance of the ACA, or that the entirety of the ACA is unconstitutional, that ruling could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described above in &#8220;Trends and Uncertainties,&#8221; we have been subject to Medicaid risk corridors as a result of the pandemic. Beginning in 2020, through March 31, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In the first quarter of 2021, we recognized approximately $110&#160;million related to such risk corridors, primarily in the Medicaid segment.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Capital Requirements and Dividend Restrictions.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 32</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of future obligations under our various contractual obligations and commitments as of December&#160;31, 2020, was disclosed in our 2020 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our contractual obligations and commitments outside the ordinary course of business during the first quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_115"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medical claims and benefits payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Notes to Consolidated Financial Statements, Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, in the first quarter of 2021 there have been no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2020 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may adjust or limit revenue or profit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the first quarter of 2021, there have been no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2020 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business combinations, goodwill, and intangible assets, net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Such reportable operating segments also now constitute our reporting units in the annual assessment of goodwill impairment. Refer to Notes to Consolidated Financial Statements, Note 10, &#8220;Segments,&#8221; for a presentation of goodwill, and intangibles assets, net, by reportable segment, and &#8220;Critical Accounting Estimates,&#8221; in our 2020 Annual Report on Form 10-K, for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_118"></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at March&#160;31, 2021, the fair value of our fixed income investments would decrease by approximately $44 million.&#160;Declines in interest rates over time will reduce our investment income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 33</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management, with the participation of our chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There has been no change in our internal control over financial reporting during the fiscal quarter ended March&#160;31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 11, &#8220;Commitments and Contingencies.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_127"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain risks may have a material adverse effect on our business, financial condition, cash flows, results of operations, or stock price, and you should carefully consider them before making an investment decision with respect to our securities. In addition to the other information set forth in this report, you should carefully consider the risk factors discussed under the caption &#8220;Risk Factors,&#8221; in our 2020 Annual Report on Form 10&#8209;K. The risk factors described in our 2020 Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, results of operations, or stock price. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_130"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of common stock made by us, or on our behalf during the first quarter of 2021, including shares withheld by us to satisfy our employees&#8217; income tax obligations, are set forth below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchased&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly&#160;<br/>Announced&#160;<br/>Plans or <br/>Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dollar&#160;Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares that May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1 - January 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1 - February 28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1 - March 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">During the first quarter of 2021, we withheld approximately 228,000 shares of common stock, to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For further information on our stock repurchase program, refer to Note 9, &#8220;Stockholders' Equity.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 34</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh1q21_ex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 302 Certification of Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh1q21_ex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 302 Certification of Chief Financial Officer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh1q21_ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh1q21_ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 35</span></div></div></div><div id="ib3ee4b8182cb4a97b16d7a57b13a8868_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib3ee4b8182cb4a97b16d7a57b13a8868_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MOLINA HEALTHCARE, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 29, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JOSEPH M. ZUBRETSKY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 29, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ MARK L. KEIM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mark L. Keim</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2021 Form 10-Q | 36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>moh1q21_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2c7a703d9472427398374749740dab3c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph M. Zubretsky, certify that&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended March&#160;31, 2021, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 29, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>moh1q21_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id4bb46b0b674487fa7ed50b8fbfa3d13_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark L. Keim, certify that&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended March&#160;31, 2021, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 29, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>moh1q21_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i131f494685054b8e88303f8c853b306a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2021 (the &#8220;Report&#8221;), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 29, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>moh1q21_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iadbecf1d8a314d19ba87c21dbc3e6bb5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2021 (the &#8220;Report&#8221;), I, Mark L. Keim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 29, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>moh-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1bf58a98-2aa7-4eef-bb6c-f5c42b4c24b2,g:53e813d1-18be-4855-aac7-c0269cc6b95f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:moh="http://www.molinahealthcare.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.molinahealthcare.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.molinahealthcare.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReceivablesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails">
        <link:definition>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeperShare" roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare">
        <link:definition>2110103 - Disclosure - Net Income per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeperShareTables" roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables">
        <link:definition>2311302 - Disclosure - Net Income per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeperShareDetails" roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails">
        <link:definition>2412406 - Disclosure - Net Income per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.molinahealthcare.com/role/BusinessCombinations">
        <link:definition>2113104 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>2414407 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements">
        <link:definition>2115105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.molinahealthcare.com/role/Investments">
        <link:definition>2120106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.molinahealthcare.com/role/InvestmentsTables">
        <link:definition>2321304 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails">
        <link:definition>2422411 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails">
        <link:definition>2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails">
        <link:definition>2424413 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails">
        <link:definition>2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayable" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable">
        <link:definition>2126107 - Disclosure - Medical Claims and Benefits Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableTables" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables">
        <link:definition>2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails">
        <link:definition>2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.molinahealthcare.com/role/Debt">
        <link:definition>2131108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.molinahealthcare.com/role/DebtTables">
        <link:definition>2332306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails">
        <link:definition>2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails">
        <link:definition>2434419 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.molinahealthcare.com/role/StockholdersEquity">
        <link:definition>2135109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2436420 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.molinahealthcare.com/role/Segments">
        <link:definition>2137110 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.molinahealthcare.com/role/SegmentsTables">
        <link:definition>2338307 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
        <link:definition>2439421 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies">
        <link:definition>2140111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="moh_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidOther" abstract="false" name="AmountsDueToGovernmentAgenciesMedicaidOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CommonStockWithheldToSettleEmployeeTaxObligations" abstract="false" name="CommonStockWithheldToSettleEmployeeTaxObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PharmacyRebateReceivablesMember" abstract="true" name="PharmacyRebateReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" abstract="false" name="ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_HealthInsurerFeeReimbursementReceivablesMember" abstract="true" name="HealthInsurerFeeReimbursementReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AffinityHealthPlanMember" abstract="true" name="AffinityHealthPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" abstract="false" name="BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" abstract="false" name="MedicalPremiumsLiabilityMedicalCareCostsThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" abstract="true" name="CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_GovernmentReceivablesMember" abstract="true" name="GovernmentReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ThreePointEightSevenFivePercentSeniorNotesMember" abstract="true" name="ThreePointEightSevenFivePercentSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_A4375SeniorNotesMember" abstract="true" name="A4375SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlansMember" abstract="true" name="HealthPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_CapitationClaimsPayable" abstract="false" name="CapitationClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicareProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableTextBlock" abstract="false" name="MedicalClaimsAndBenefitsPayableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" abstract="false" name="MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicalPremiumLiabilityDueToAgency" abstract="false" name="MedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" abstract="false" name="LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" abstract="false" name="IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_HidalgoTarrantAndNortheastServiceAreasMember" abstract="true" name="HidalgoTarrantAndNortheastServiceAreasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moh_ComponentsOfMedicalCareCostsAbstract" abstract="true" name="ComponentsOfMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayable" abstract="false" name="MedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PremiumTaxExpenses" abstract="false" name="PremiumTaxExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CompleteCareReceivablesMember" abstract="true" name="CompleteCareReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_InvestmentsAverageMaturityPeriod" abstract="false" name="InvestmentsAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_HidalgoServiceAreaMember" abstract="true" name="HidalgoServiceAreaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_NumberOfMembersCovered" abstract="false" name="NumberOfMembersCovered" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_OtherClaimsPayable" abstract="false" name="OtherClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthCareOrganizationInsurerFeeRevenue" abstract="false" name="HealthCareOrganizationInsurerFeeRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MunicipalSecuritiesMember" abstract="true" name="MunicipalSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_OtherMedicareProgram" abstract="false" name="OtherMedicareProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_PharmacyClaimsPayable" abstract="false" name="PharmacyClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherReceivablesMember" abstract="true" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_StructuredSecuritiesMember" abstract="true" name="StructuredSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_HealthCareOrganizationInsurerFeeExpense" abstract="false" name="HealthCareOrganizationInsurerFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_SeniorNotesDue2022Member" abstract="true" name="SeniorNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_InvestmentsMaturityPeriod" abstract="false" name="InvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_MarketplaceMember" abstract="true" name="MarketplaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesOther" abstract="false" name="AmountsDuetoGovernmentAgenciesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_WeightedAverageNumberofSharesShareBasedCompensation" abstract="false" name="WeightedAverageNumberofSharesShareBasedCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" abstract="false" name="AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MagellanCompleteCareMember" abstract="true" name="MagellanCompleteCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_HealthPlanContractTerm" abstract="false" name="HealthPlanContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_ChangeInAcquiredBalances" abstract="false" name="ChangeInAcquiredBalances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" abstract="false" name="AmountsDuetoGovernmentAgenciesRiskAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesBusinessCombination" abstract="false" name="AmountsDueToGovernmentAgenciesBusinessCombination" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthCareOrganizationPremiumTaxRevenue" abstract="false" name="HealthCareOrganizationPremiumTaxRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>moh-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1bf58a98-2aa7-4eef-bb6c-f5c42b4c24b2,g:53e813d1-18be-4855-aac7-c0269cc6b95f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6c88e467-8bb8-48d1-8a78-edd8e5e1842d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_83185500-540b-4af9-9468-f80f2061af25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6c88e467-8bb8-48d1-8a78-edd8e5e1842d" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_83185500-540b-4af9-9468-f80f2061af25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_64be2a90-385a-4e92-8918-c0685983954c" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6c88e467-8bb8-48d1-8a78-edd8e5e1842d" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_64be2a90-385a-4e92-8918-c0685983954c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_8b6a5ca8-11b4-4cd5-a094-864a141921eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6c88e467-8bb8-48d1-8a78-edd8e5e1842d" xlink:to="loc_us-gaap_NetInvestmentIncome_8b6a5ca8-11b4-4cd5-a094-864a141921eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_00d288b6-791c-4842-b906-514ee5ced609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6c88e467-8bb8-48d1-8a78-edd8e5e1842d" xlink:to="loc_us-gaap_PremiumsEarnedNet_00d288b6-791c-4842-b906-514ee5ced609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue_d9127b8c-a832-4436-9117-b97a8db78908" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6c88e467-8bb8-48d1-8a78-edd8e5e1842d" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeRevenue_d9127b8c-a832-4436-9117-b97a8db78908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_de09f787-1f70-42e8-a45b-bd542e9c365e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2943ebea-5c8f-4e2f-a807-b3bc50b8cdd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_de09f787-1f70-42e8-a45b-bd542e9c365e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2943ebea-5c8f-4e2f-a807-b3bc50b8cdd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_56a0ef93-e033-46c3-b015-ec1f4452d371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_de09f787-1f70-42e8-a45b-bd542e9c365e" xlink:to="loc_us-gaap_OperatingIncomeLoss_56a0ef93-e033-46c3-b015-ec1f4452d371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e5f018e9-2e4d-4e64-ba9c-455cea4452bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_20a4f390-0dbb-4339-b6bb-c33042ba552a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e5f018e9-2e4d-4e64-ba9c-455cea4452bc" xlink:to="loc_us-gaap_Revenues_20a4f390-0dbb-4339-b6bb-c33042ba552a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_42c782eb-d16f-4139-9401-4b92b0a71215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e5f018e9-2e4d-4e64-ba9c-455cea4452bc" xlink:to="loc_us-gaap_CostsAndExpenses_42c782eb-d16f-4139-9401-4b92b0a71215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ef422d6c-45e8-4ce8-98f2-e458ae6a5db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cbbefd72-c43e-442c-bf9b-5185967be652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ef422d6c-45e8-4ce8-98f2-e458ae6a5db5" xlink:to="loc_us-gaap_InterestExpense_cbbefd72-c43e-442c-bf9b-5185967be652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5965f448-1692-4a1d-816b-cb22c40dbd44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5965f448-1692-4a1d-816b-cb22c40dbd44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d3aefd59-8522-4328-a8fd-71702faab507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d3aefd59-8522-4328-a8fd-71702faab507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_3941417c-b163-40bc-83d4-14575f5fae3d" xlink:href="moh-20210331.xsd#moh_PremiumTaxExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:to="loc_moh_PremiumTaxExpenses_3941417c-b163-40bc-83d4-14575f5fae3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense_699a0abd-891d-4d9d-94de-65e3113cc89d" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeExpense_699a0abd-891d-4d9d-94de-65e3113cc89d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9caa7bbb-7b21-47e9-a8d0-46dc86cff269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:to="loc_us-gaap_DepreciationAndAmortization_9caa7bbb-7b21-47e9-a8d0-46dc86cff269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_b3d0ec0b-e603-4ea7-bf27-ff631b53708c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d7c03d6b-a12b-4804-8a82-d8294d07399c" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_b3d0ec0b-e603-4ea7-bf27-ff631b53708c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_601840ef-5227-4f64-95ae-236f9048d3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2f9093e8-a078-4725-9c42-7f6f6c31b202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_601840ef-5227-4f64-95ae-236f9048d3db" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2f9093e8-a078-4725-9c42-7f6f6c31b202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8885bdb9-5882-49de-a6df-fadea817b412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_601840ef-5227-4f64-95ae-236f9048d3db" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8885bdb9-5882-49de-a6df-fadea817b412" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_19f56e77-7c8b-4517-b5c2-7ea7a19543f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9a1d455f-db07-4422-93e7-8a6575e26447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_19f56e77-7c8b-4517-b5c2-7ea7a19543f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9a1d455f-db07-4422-93e7-8a6575e26447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_accc043b-b050-4880-a4a9-c7e98bc0fc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_19f56e77-7c8b-4517-b5c2-7ea7a19543f1" xlink:to="loc_us-gaap_NetIncomeLoss_accc043b-b050-4880-a4a9-c7e98bc0fc32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e43025b5-da31-4585-9ad3-8f6742e35c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ba2e1f89-c7fb-4754-aaca-4c348b44ab19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e43025b5-da31-4585-9ad3-8f6742e35c15" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ba2e1f89-c7fb-4754-aaca-4c348b44ab19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_d8df7131-601e-4676-b41d-911ae947099a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e43025b5-da31-4585-9ad3-8f6742e35c15" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_d8df7131-601e-4676-b41d-911ae947099a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8cd3714b-e931-4da5-95f9-e406dbd918d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b1307742-e7e9-4e3e-8e4b-6e61ee4215ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cd3714b-e931-4da5-95f9-e406dbd918d8" xlink:to="loc_us-gaap_LiabilitiesCurrent_b1307742-e7e9-4e3e-8e4b-6e61ee4215ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d229e993-a2fc-469f-b987-4469ee28e142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cd3714b-e931-4da5-95f9-e406dbd918d8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d229e993-a2fc-469f-b987-4469ee28e142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f758d6b4-800f-4edb-baf2-a1a4045d1f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cd3714b-e931-4da5-95f9-e406dbd918d8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f758d6b4-800f-4edb-baf2-a1a4045d1f45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f1e5e7f7-45db-4c54-8ce4-20ab6a32b118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cd3714b-e931-4da5-95f9-e406dbd918d8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f1e5e7f7-45db-4c54-8ce4-20ab6a32b118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ced86b84-e62a-49f4-8cb0-381dca83799b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:to="loc_us-gaap_AssetsCurrent_ced86b84-e62a-49f4-8cb0-381dca83799b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_cf67a1cd-68c6-484a-b63b-257e94b92f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_cf67a1cd-68c6-484a-b63b-257e94b92f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_f04e803f-8369-4b8d-8e55-bce5ab519ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_f04e803f-8369-4b8d-8e55-bce5ab519ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_1f994e45-b3ea-435c-a60a-4e1afd282ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_1f994e45-b3ea-435c-a60a-4e1afd282ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9c20e5ad-9da5-44a2-9dd2-d5badb28e1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9c20e5ad-9da5-44a2-9dd2-d5badb28e1a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4b0412a9-6623-4231-b1d1-9be7fb3230f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dbb2d092-63d3-4dd5-a0f5-4a95aeb663cc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4b0412a9-6623-4231-b1d1-9be7fb3230f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_573bf365-006b-4410-9f88-2a5f7b64e2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_2b164b50-5bc4-438a-84ca-b9cde6c89972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573bf365-006b-4410-9f88-2a5f7b64e2d2" xlink:to="loc_us-gaap_CommonStockValueOutstanding_2b164b50-5bc4-438a-84ca-b9cde6c89972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_006ff293-b358-46bf-bb8a-919a6e5f71a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573bf365-006b-4410-9f88-2a5f7b64e2d2" xlink:to="loc_us-gaap_PreferredStockValue_006ff293-b358-46bf-bb8a-919a6e5f71a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e92493ec-460f-4fef-afe3-f0a6006174ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573bf365-006b-4410-9f88-2a5f7b64e2d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e92493ec-460f-4fef-afe3-f0a6006174ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_245599f3-5758-413d-a729-e0db54b95122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573bf365-006b-4410-9f88-2a5f7b64e2d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_245599f3-5758-413d-a729-e0db54b95122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e61a7a46-1591-4c3f-9fb3-e3dea2efc9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_573bf365-006b-4410-9f88-2a5f7b64e2d2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e61a7a46-1591-4c3f-9fb3-e3dea2efc9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3a96065d-1af5-4c10-8b18-d5e0dfd0aa19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_249b567c-6363-4120-ad97-9b641f0eb3ff" xlink:href="moh-20210331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a96065d-1af5-4c10-8b18-d5e0dfd0aa19" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_249b567c-6363-4120-ad97-9b641f0eb3ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_580f92ad-31ae-4201-83ac-dff04e42bae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a96065d-1af5-4c10-8b18-d5e0dfd0aa19" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_580f92ad-31ae-4201-83ac-dff04e42bae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9afb557d-9972-46d2-b64f-164c23f37b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a96065d-1af5-4c10-8b18-d5e0dfd0aa19" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9afb557d-9972-46d2-b64f-164c23f37b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4eba5a99-97ca-4033-80ff-28fe893b5862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a96065d-1af5-4c10-8b18-d5e0dfd0aa19" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4eba5a99-97ca-4033-80ff-28fe893b5862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ebd193c9-2714-4e03-b5f6-4bd549e89a49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_4b7e32f6-2b64-4ac6-bf31-73480d00926b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd193c9-2714-4e03-b5f6-4bd549e89a49" xlink:to="loc_us-gaap_ReceivablesNetCurrent_4b7e32f6-2b64-4ac6-bf31-73480d00926b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_edeebc9e-713f-4f34-9e1f-50fb23717b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd193c9-2714-4e03-b5f6-4bd549e89a49" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_edeebc9e-713f-4f34-9e1f-50fb23717b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_41a83b75-4201-480e-bb4f-7263b13c2c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd193c9-2714-4e03-b5f6-4bd549e89a49" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_41a83b75-4201-480e-bb4f-7263b13c2c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_333b77f2-dea0-407a-aa2d-b924d1588dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ebd193c9-2714-4e03-b5f6-4bd549e89a49" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_333b77f2-dea0-407a-aa2d-b924d1588dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1b9d5a4-86bf-47f4-bc30-8c423856df85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cbce9704-4b95-404c-9406-67666c1fbebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1b9d5a4-86bf-47f4-bc30-8c423856df85" xlink:to="loc_us-gaap_Liabilities_cbce9704-4b95-404c-9406-67666c1fbebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b4e57fd-2e69-479b-97b0-e310e9f7cdda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1b9d5a4-86bf-47f4-bc30-8c423856df85" xlink:to="loc_us-gaap_StockholdersEquity_9b4e57fd-2e69-479b-97b0-e310e9f7cdda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_febe70ee-b056-462f-a01c-6e6fe52cede5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09b7f70b-f634-46f6-9976-c5291adad95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_febe70ee-b056-462f-a01c-6e6fe52cede5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09b7f70b-f634-46f6-9976-c5291adad95a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b4cf008-d9fb-4154-9076-83f5fa76b18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_febe70ee-b056-462f-a01c-6e6fe52cede5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b4cf008-d9fb-4154-9076-83f5fa76b18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a436cdb8-f67a-4fa7-8eb7-b1dcf604031f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_febe70ee-b056-462f-a01c-6e6fe52cede5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a436cdb8-f67a-4fa7-8eb7-b1dcf604031f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0f7c54fa-6de7-4980-8bce-4dc2edf1244e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0f7c54fa-6de7-4980-8bce-4dc2edf1244e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4baa6a0e-d573-43c5-a4ec-b7a500057465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4baa6a0e-d573-43c5-a4ec-b7a500057465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_480832bb-359c-47bd-b06c-0497c020c4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_ShareBasedCompensation_480832bb-359c-47bd-b06c-0497c020c4e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d264350d-2659-4a7b-9713-3c1ef6f792d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d264350d-2659-4a7b-9713-3c1ef6f792d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_5733de31-7c93-4bea-9df5-b178a9d4fadd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_5733de31-7c93-4bea-9df5-b178a9d4fadd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6b5ff17b-40cb-434a-9fc8-d5fd6ec80612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6b5ff17b-40cb-434a-9fc8-d5fd6ec80612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_dee258b3-5137-469a-a629-d224fc69b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_dee258b3-5137-469a-a629-d224fc69b10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_76489cc6-e0aa-449a-98bf-cf0d17cbd3ca" xlink:href="moh-20210331.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_76489cc6-e0aa-449a-98bf-cf0d17cbd3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_59b41df9-396b-426f-9622-ae9dbb80d7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_59b41df9-396b-426f-9622-ae9dbb80d7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_eccc17ff-7bc2-400a-9f4c-17920e9775f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_eccc17ff-7bc2-400a-9f4c-17920e9775f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8d355436-2618-4761-999d-f680f8bfa2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_8d355436-2618-4761-999d-f680f8bfa2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01c08e9c-42e5-437e-b6c4-2a70300b0a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5950d0fe-d508-4459-893f-ac179d8d5561" xlink:to="loc_us-gaap_NetIncomeLoss_01c08e9c-42e5-437e-b6c4-2a70300b0a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9807a749-030b-4436-a311-d7075d456eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dc005cf7-ef34-4cc2-afc9-9c4869df3af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9807a749-030b-4436-a311-d7075d456eb1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dc005cf7-ef34-4cc2-afc9-9c4869df3af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_82646e12-889d-4425-abcf-943157c4e355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9807a749-030b-4436-a311-d7075d456eb1" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_82646e12-889d-4425-abcf-943157c4e355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b958a132-3cf7-4fb6-97e7-d937be105e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9807a749-030b-4436-a311-d7075d456eb1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b958a132-3cf7-4fb6-97e7-d937be105e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8260e328-d423-46ad-98c4-c49a34b9b013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9807a749-030b-4436-a311-d7075d456eb1" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8260e328-d423-46ad-98c4-c49a34b9b013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_4ce1880c-886e-404b-ad75-04d924281aa3" xlink:href="moh-20210331.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9807a749-030b-4436-a311-d7075d456eb1" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_4ce1880c-886e-404b-ad75-04d924281aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfa94bfe-e882-4809-b5ff-df8120610c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_20777010-c669-460e-825f-66b621047d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfa94bfe-e882-4809-b5ff-df8120610c4d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_20777010-c669-460e-825f-66b621047d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_df9cb26d-ff4f-41b5-a424-898d20f3b8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfa94bfe-e882-4809-b5ff-df8120610c4d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_df9cb26d-ff4f-41b5-a424-898d20f3b8e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_88c5c6ca-809e-4c33-9e29-61b0af191798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfa94bfe-e882-4809-b5ff-df8120610c4d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_88c5c6ca-809e-4c33-9e29-61b0af191798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2fcf5064-43e8-48b6-81fc-2f7975bac72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfa94bfe-e882-4809-b5ff-df8120610c4d" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2fcf5064-43e8-48b6-81fc-2f7975bac72f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71e98778-6946-4207-a17f-930c7d1fd439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3f28f693-fda1-47e5-8091-5521677d6068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71e98778-6946-4207-a17f-930c7d1fd439" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3f28f693-fda1-47e5-8091-5521677d6068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_53ed660e-1031-44aa-9002-312a25d727e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71e98778-6946-4207-a17f-930c7d1fd439" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_53ed660e-1031-44aa-9002-312a25d727e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:href="moh-20210331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_25dbd940-38ff-4997-a440-088086f5f638" xlink:href="moh-20210331.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_25dbd940-38ff-4997-a440-088086f5f638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_7ba83db9-f771-42d0-801f-ad7f011d4f2d" xlink:href="moh-20210331.xsd#moh_OtherMedicareProgram"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_OtherMedicareProgram_7ba83db9-f771-42d0-801f-ad7f011d4f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_5d6df04f-c42e-44da-a004-f1c18678fa4b" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_5d6df04f-c42e-44da-a004-f1c18678fa4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesBusinessCombination_c3a744f9-68e5-407e-bb04-213b39b753f4" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesBusinessCombination"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesBusinessCombination_c3a744f9-68e5-407e-bb04-213b39b753f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_50493b14-47c7-43e3-8228-e57356cc2c33" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_50493b14-47c7-43e3-8228-e57356cc2c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_26e8865a-7850-47c3-883a-212f4591ea8c" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_26e8865a-7850-47c3-883a-212f4591ea8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_6a79b952-7769-43c6-b2f9-ddac322f0b09" xlink:href="moh-20210331.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_6a79b952-7769-43c6-b2f9-ddac322f0b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_f3992603-58ea-411b-b203-168d6a9e7f6a" xlink:href="moh-20210331.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_f3992603-58ea-411b-b203-168d6a9e7f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_a4a46d08-c447-4e85-bf1f-eda86a594c73" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_638cb4ba-3c71-473e-805b-d3188e91049a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_a4a46d08-c447-4e85-bf1f-eda86a594c73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShare"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShareTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShareDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e244bec-46d7-4950-8117-c74bf75f574c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a824f6c-ce1d-45db-9ac8-c6a3b1649b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e244bec-46d7-4950-8117-c74bf75f574c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a824f6c-ce1d-45db-9ac8-c6a3b1649b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_e3a580c9-670f-4e95-8221-4b2d36c27c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e244bec-46d7-4950-8117-c74bf75f574c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_e3a580c9-670f-4e95-8221-4b2d36c27c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_982ece14-6ccc-4ff7-beb6-503b905bfb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e244bec-46d7-4950-8117-c74bf75f574c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_982ece14-6ccc-4ff7-beb6-503b905bfb3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20210331.xsd#BusinessCombinations"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e5c45f88-49be-4c37-b2d6-efa0b992f1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2dd852e3-72f9-45f1-bb03-ce1a969aeff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e5c45f88-49be-4c37-b2d6-efa0b992f1a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2dd852e3-72f9-45f1-bb03-ce1a969aeff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_de6b422c-f0ed-4968-b135-02673f0b2722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3d89079f-b143-4325-8583-de794055eaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_de6b422c-f0ed-4968-b135-02673f0b2722" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3d89079f-b143-4325-8583-de794055eaf2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20210331.xsd#Investments"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_844fe58e-d381-4152-afa1-cc7b8968b77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_af8ad685-3f53-4715-b255-1c80acb3a741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_844fe58e-d381-4152-afa1-cc7b8968b77a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_af8ad685-3f53-4715-b255-1c80acb3a741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_067c2f8b-b92f-4e9e-bbc1-fe9fdf7b3612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_844fe58e-d381-4152-afa1-cc7b8968b77a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_067c2f8b-b92f-4e9e-bbc1-fe9fdf7b3612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7db20482-12a4-4ef8-92d8-0a9a9d3b6693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_844fe58e-d381-4152-afa1-cc7b8968b77a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7db20482-12a4-4ef8-92d8-0a9a9d3b6693" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_f4a57b9d-48b6-4f8b-ad71-ae9183ec5fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_da4b9952-24f1-40f8-b55d-4648c441ffbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_f4a57b9d-48b6-4f8b-ad71-ae9183ec5fbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_da4b9952-24f1-40f8-b55d-4648c441ffbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d10d39a-c11d-4c47-884b-afdb9265b71b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_f4a57b9d-48b6-4f8b-ad71-ae9183ec5fbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d10d39a-c11d-4c47-884b-afdb9265b71b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_305f99af-1a39-48a2-9306-48e573caa717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_f4a57b9d-48b6-4f8b-ad71-ae9183ec5fbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_305f99af-1a39-48a2-9306-48e573caa717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_de63fc14-7067-4381-a112-0d0a4cff74a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_f4a57b9d-48b6-4f8b-ad71-ae9183ec5fbb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_de63fc14-7067-4381-a112-0d0a4cff74a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4544db8e-1080-495e-9d04-1af7cc817002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2e65cea3-a718-4f6c-856c-5b59bacd5247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4544db8e-1080-495e-9d04-1af7cc817002" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2e65cea3-a718-4f6c-856c-5b59bacd5247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a2c6b568-12a7-46ca-bde5-9c398e5b1879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4544db8e-1080-495e-9d04-1af7cc817002" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a2c6b568-12a7-46ca-bde5-9c398e5b1879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_df0abac0-13b2-40d5-b1fa-daa6a2f35ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4544db8e-1080-495e-9d04-1af7cc817002" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_df0abac0-13b2-40d5-b1fa-daa6a2f35ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_1e1d96de-8174-4b5c-ba2a-0c1dc33acd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4544db8e-1080-495e-9d04-1af7cc817002" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_1e1d96de-8174-4b5c-ba2a-0c1dc33acd3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_28e6a1a1-2086-48e7-a966-11cabb8b1f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_681e6459-e0b6-4078-bf65-52ed5ebbdfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_28e6a1a1-2086-48e7-a966-11cabb8b1f67" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_681e6459-e0b6-4078-bf65-52ed5ebbdfd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8a1c0f73-bcff-4672-b3b3-df20786919ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_28e6a1a1-2086-48e7-a966-11cabb8b1f67" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8a1c0f73-bcff-4672-b3b3-df20786919ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_23fe4119-42a7-41c7-b2af-aff1a36dc959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0702e98c-a413-451f-9776-75392e8cabf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_23fe4119-42a7-41c7-b2af-aff1a36dc959" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0702e98c-a413-451f-9776-75392e8cabf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_1e95657d-6b73-44e8-aec1-21f4036073d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_23fe4119-42a7-41c7-b2af-aff1a36dc959" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_1e95657d-6b73-44e8-aec1-21f4036073d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20210331.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b61e28e7-e181-4c01-802e-daa76240c7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_eb0da5ac-fe42-492a-82ba-fcdd1581e09c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_b61e28e7-e181-4c01-802e-daa76240c7fc" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_eb0da5ac-fe42-492a-82ba-fcdd1581e09c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_8be8d5d3-1467-4c84-83bc-13e0f4564af6" xlink:href="moh-20210331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_b61e28e7-e181-4c01-802e-daa76240c7fc" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_8be8d5d3-1467-4c84-83bc-13e0f4564af6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20210331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20210331.xsd#Segments"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#SegmentsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c228e8ee-b7e8-496e-8257-b7ae98f05169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4c867d10-0fb2-489c-b908-d99573cfb90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c228e8ee-b7e8-496e-8257-b7ae98f05169" xlink:to="loc_us-gaap_Goodwill_4c867d10-0fb2-489c-b908-d99573cfb90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d3c93b33-021d-451f-a046-c4956eea15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c228e8ee-b7e8-496e-8257-b7ae98f05169" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d3c93b33-021d-451f-a046-c4956eea15e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f4bb8180-9f71-4230-bdb0-dd0bd367dce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f33a7dd6-1a31-434f-b584-de9adfebc9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f4bb8180-9f71-4230-bdb0-dd0bd367dce5" xlink:to="loc_us-gaap_GrossProfit_f33a7dd6-1a31-434f-b584-de9adfebc9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1b3176d0-6743-4e39-9c4a-d6ce624936d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f4bb8180-9f71-4230-bdb0-dd0bd367dce5" xlink:to="loc_us-gaap_Revenues_1b3176d0-6743-4e39-9c4a-d6ce624936d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a56e16a9-174a-4ea4-b7df-ae5f61a120f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f4bb8180-9f71-4230-bdb0-dd0bd367dce5" xlink:to="loc_us-gaap_CostsAndExpenses_a56e16a9-174a-4ea4-b7df-ae5f61a120f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>moh-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1bf58a98-2aa7-4eef-bb6c-f5c42b4c24b2,g:53e813d1-18be-4855-aac7-c0269cc6b95f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended" id="ica8f80e1e19b404d9b11b4a5851632d7_CoverPage"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="i959440a8cf2c4efd9aac856be0b812fc_CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended" id="id0873507d3f14353b8bd11855fc073dc_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i64a08d055cd44ba99b66e76fc5c2cfb7_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i45a7ded2093b40efa2c93f8af8057b10_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ie26679f9a2484bcca39381491adda554_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b07c0874-6dfe-4d57-b7c7-c0aa0c8f48e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b07c0874-6dfe-4d57-b7c7-c0aa0c8f48e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bc4d1281-ef16-497a-8892-e5391e2b6fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_SharesOutstanding_bc4d1281-ef16-497a-8892-e5391e2b6fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e62c4d6-f8b9-437c-8625-75bb579303b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e62c4d6-f8b9-437c-8625-75bb579303b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_697e2609-aa50-4669-ac10-060a6da786da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_NetIncomeLoss_697e2609-aa50-4669-ac10-060a6da786da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_798c31e8-20d1-439f-b5e4-2bdab96b20eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_798c31e8-20d1-439f-b5e4-2bdab96b20eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_19021abe-b337-468d-833f-3ccc5e7ccaa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_19021abe-b337-468d-833f-3ccc5e7ccaa6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0952a895-888c-4e71-b208-3dd796219764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0952a895-888c-4e71-b208-3dd796219764" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee21610c-3361-4a44-b2ca-62eccf1218cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee21610c-3361-4a44-b2ca-62eccf1218cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_05e83ddb-621e-47ef-8c2e-d4070c3761c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_05e83ddb-621e-47ef-8c2e-d4070c3761c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0e1c3210-6070-4364-a0be-cf739aeee1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d72ebe6d-29e2-42ef-a801-2ab40aba0d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b07c0874-6dfe-4d57-b7c7-c0aa0c8f48e7" xlink:to="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2bf05f4a-707b-48c3-9446-fc49a3e0fe74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:to="loc_us-gaap_EquityComponentDomain_2bf05f4a-707b-48c3-9446-fc49a3e0fe74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:to="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_382a62ef-f5f9-48c4-912f-1b88c371985b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_CommonStockMember_382a62ef-f5f9-48c4-912f-1b88c371985b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6242a7c7-e674-40b1-aa11-16cf98d30bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6242a7c7-e674-40b1-aa11-16cf98d30bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5b24e48-b85e-4590-9273-6f9ee32d3517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5b24e48-b85e-4590-9273-6f9ee32d3517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_70eb1b44-ed6d-4e76-b6ee-027356ebe774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_RetainedEarningsMember_70eb1b44-ed6d-4e76-b6ee-027356ebe774" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i4e6cee19d9e6416b99246ed4e7049568_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="ia3af55cdfe3149eebe3992b4cac8dbb6_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="ib421d06225a44d6ab329047e3b7175a6_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_4b7d5631-dd93-494a-949d-563bf29385cc" xlink:href="moh-20210331.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_4b7d5631-dd93-494a-949d-563bf29385cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_e10dceef-89c8-4c2b-8c25-4d9de9c890b2" xlink:href="moh-20210331.xsd#moh_HealthPlanContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_moh_HealthPlanContractTerm_e10dceef-89c8-4c2b-8c25-4d9de9c890b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfMembersCovered_546a7cd4-e296-4c1c-b809-6de0faf74848" xlink:href="moh-20210331.xsd#moh_NumberOfMembersCovered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_moh_NumberOfMembersCovered_546a7cd4-e296-4c1c-b809-6de0faf74848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_0c44542c-14f4-4ee5-a6d3-eef50cf02305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_PremiumsEarnedNet_0c44542c-14f4-4ee5-a6d3-eef50cf02305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_05c662fc-e5c5-454f-8ffa-48a2ae7df0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_05c662fc-e5c5-454f-8ffa-48a2ae7df0ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5f8daf2b-9450-421b-8a9d-3552b932ff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5f8daf2b-9450-421b-8a9d-3552b932ff20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:to="loc_srt_RangeMember_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:to="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c09b1c2-ff9d-4291-9566-c3b059a72eb6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:to="loc_srt_MinimumMember_1c09b1c2-ff9d-4291-9566-c3b059a72eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37689b3d-ec15-4e02-91cc-f4206221fb99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:to="loc_srt_MaximumMember_37689b3d-ec15-4e02-91cc-f4206221fb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:to="loc_us-gaap_SegmentDomain_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d1075ca-1df1-48bf-a308-f443d9af5a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:to="loc_us-gaap_SegmentDomain_2d1075ca-1df1-48bf-a308-f443d9af5a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_493b3a36-b686-4ac2-b990-25fd47b364fd" xlink:href="moh-20210331.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2d1075ca-1df1-48bf-a308-f443d9af5a83" xlink:to="loc_moh_HealthPlansMember_493b3a36-b686-4ac2-b990-25fd47b364fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e15eca8-349a-4b69-8e39-07ce06b0a600_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e15eca8-349a-4b69-8e39-07ce06b0a600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_bee1295f-f3e6-48de-a62b-8ba652b73f5d" xlink:href="moh-20210331.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_bee1295f-f3e6-48de-a62b-8ba652b73f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanMember_0aeb89b2-13dd-470d-9244-9c1ef76948f0" xlink:href="moh-20210331.xsd#moh_AffinityHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:to="loc_moh_AffinityHealthPlanMember_0aeb89b2-13dd-470d-9244-9c1ef76948f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d597e330-a705-4b71-b0a1-492decf8e0d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d597e330-a705-4b71-b0a1-492decf8e0d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7a5ebda-3305-4480-acc3-dcc40bc409cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7a5ebda-3305-4480-acc3-dcc40bc409cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_be13c4f3-2169-471f-80fc-886c467e9511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7a5ebda-3305-4480-acc3-dcc40bc409cb" xlink:to="loc_us-gaap_SubsequentEventMember_be13c4f3-2169-471f-80fc-886c467e9511" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a469b565-83e1-42b0-addb-1a01a3288a46_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:to="loc_dei_EntityDomain_a469b565-83e1-42b0-addb-1a01a3288a46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_409b33d6-7911-4a1b-9e7c-25571f80f067" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:to="loc_dei_EntityDomain_409b33d6-7911-4a1b-9e7c-25571f80f067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_821917f4-fe9e-43ff-8129-8a24b398f26b" xlink:href="moh-20210331.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_409b33d6-7911-4a1b-9e7c-25571f80f067" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_821917f4-fe9e-43ff-8129-8a24b398f26b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_91a4e8ac-05e1-4b42-80ad-f985e296d3a3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:to="loc_srt_SegmentGeographicalDomain_91a4e8ac-05e1-4b42-80ad-f985e296d3a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:to="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HidalgoTarrantAndNortheastServiceAreasMember_6c23b148-091c-4cb9-abb0-4027280a0223" xlink:href="moh-20210331.xsd#moh_HidalgoTarrantAndNortheastServiceAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:to="loc_moh_HidalgoTarrantAndNortheastServiceAreasMember_6c23b148-091c-4cb9-abb0-4027280a0223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HidalgoServiceAreaMember_de81ce5e-d600-4e1b-9d1f-0129a28b6acc" xlink:href="moh-20210331.xsd#moh_HidalgoServiceAreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:to="loc_moh_HidalgoServiceAreaMember_de81ce5e-d600-4e1b-9d1f-0129a28b6acc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended" id="ia27dbde0fdde44eaa51a9fc95970d24e_SignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i9dd6302f020f49d2aa7e9f3101b1a318_SignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" id="i1ea6a4f9f71b41fb9917551715c800cc_SignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i6d735680d8b4409eb335df89ba523559_SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended" id="i5c65cea59c694fe9b35d1958b5e98888_SignificantAccountingPoliciesReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_40fcbbca-230d-4818-87c0-72318a3f568f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_b1d4a4ab-763b-4d6e-a199-758e9a714650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_40fcbbca-230d-4818-87c0-72318a3f568f" xlink:to="loc_us-gaap_ReceivablesNetCurrent_b1d4a4ab-763b-4d6e-a199-758e9a714650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_40fcbbca-230d-4818-87c0-72318a3f568f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4f47fd52-d93a-4575-8cc9-feeffc048a93_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:to="loc_us-gaap_ReceivableTypeDomain_4f47fd52-d93a-4575-8cc9-feeffc048a93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:to="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_95a95a8a-e144-40dc-a8f8-f3857b81b318" xlink:href="moh-20210331.xsd#moh_GovernmentReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_GovernmentReceivablesMember_95a95a8a-e144-40dc-a8f8-f3857b81b318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_eea9ce67-7be3-4e82-a030-760791f8bd66" xlink:href="moh-20210331.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_PharmacyRebateReceivablesMember_eea9ce67-7be3-4e82-a030-760791f8bd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_3f55a151-d684-495a-b170-985310ce3b91" xlink:href="moh-20210331.xsd#moh_HealthInsurerFeeReimbursementReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_3f55a151-d684-495a-b170-985310ce3b91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_858b4971-c63e-4c12-bbf3-6cb341da0484" xlink:href="moh-20210331.xsd#moh_OtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_OtherReceivablesMember_858b4971-c63e-4c12-bbf3-6cb341da0484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CompleteCareReceivablesMember_ad39e7af-b4b6-46e0-a1b8-425dbceaa98b" xlink:href="moh-20210331.xsd#moh_CompleteCareReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_CompleteCareReceivablesMember_ad39e7af-b4b6-46e0-a1b8-425dbceaa98b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended" id="i1bec3f14248148ca8ca25e811f61e871_SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ic9487c6607c2458db7bf2fbbe431dec5_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:href="moh-20210331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc518592-7b07-4fd3-9616-47d7736b496c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc518592-7b07-4fd3-9616-47d7736b496c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_016fb336-8c89-40be-a2fb-e9c7a8f2f325" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_016fb336-8c89-40be-a2fb-e9c7a8f2f325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b54a633f-cb3f-45b6-be14-8ee2a2ee5b6b" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b54a633f-cb3f-45b6-be14-8ee2a2ee5b6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_ce995b64-468f-46d1-92fe-03b83fd47fd5" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_ce995b64-468f-46d1-92fe-03b83fd47fd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_8e373a13-ae3a-4a9b-b53e-3d90c0a6483f" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_8e373a13-ae3a-4a9b-b53e-3d90c0a6483f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_54a65dfb-07c2-4854-a759-885965420099" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_54a65dfb-07c2-4854-a759-885965420099" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_5e612d05-0550-4a98-814a-74c6e480218d" xlink:href="moh-20210331.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_InvestmentsMaturityPeriod_5e612d05-0550-4a98-814a-74c6e480218d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_d06d09a6-42c1-4e29-8280-8139a46b8364" xlink:href="moh-20210331.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_d06d09a6-42c1-4e29-8280-8139a46b8364" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:href="moh-20210331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_c54feb4d-3171-43d7-a278-79bd221a8efe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_c54feb4d-3171-43d7-a278-79bd221a8efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_69f17e68-ad81-459e-ba73-a638194d58a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_69f17e68-ad81-459e-ba73-a638194d58a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_77112f6f-bd4a-4af1-98d7-d0557affb25a" xlink:href="moh-20210331.xsd#moh_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_69f17e68-ad81-459e-ba73-a638194d58a4" xlink:to="loc_moh_COVID19Member_77112f6f-bd4a-4af1-98d7-d0557affb25a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d18514b-1223-40e7-9812-cf116ebde17a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d18514b-1223-40e7-9812-cf116ebde17a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c220124-1405-4fe8-bc39-5dbdca8f039b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c220124-1405-4fe8-bc39-5dbdca8f039b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember_04ba98f3-3f1a-4cc3-a420-8e698359924c" xlink:href="moh-20210331.xsd#moh_StructuredSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c220124-1405-4fe8-bc39-5dbdca8f039b" xlink:to="loc_moh_StructuredSecuritiesMember_04ba98f3-3f1a-4cc3-a420-8e698359924c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShare"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="extended" id="iaf3280dfeea04e61a8239e7b184a7379_NetIncomeperShare"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShareTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="extended" id="i195c9f28e4de4dd0b9096c9a6177ba9f_NetIncomeperShareTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShareDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="extended" id="i7d7a4cd865894017aba02037133c87a7_NetIncomeperShareDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20210331.xsd#BusinessCombinations"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended" id="i04b245a5c35c4ee2b716828ccb0d18ba_BusinessCombinations"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="ife2940831d3440dfb9199062da086a54_BusinessCombinationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_10d03d22-6f1a-482c-8d29-a2b5be8d7e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_10d03d22-6f1a-482c-8d29-a2b5be8d7e96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_61908a20-3788-498d-bf90-cdb52a19e038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_61908a20-3788-498d-bf90-cdb52a19e038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_74d5598d-95f6-4c28-a148-c962a3aa3302" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_74d5598d-95f6-4c28-a148-c962a3aa3302" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_f4287b43-6d82-481b-92fe-40bf44ee09b0" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_f4287b43-6d82-481b-92fe-40bf44ee09b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_0c1d7c74-c8d6-4647-bd6f-a19944846cc0" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_0c1d7c74-c8d6-4647-bd6f-a19944846cc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b417884b-e5b2-456b-ab99-da2fa0efa89b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b417884b-e5b2-456b-ab99-da2fa0efa89b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c89c75a-ab0c-42be-b628-60ca5c02852f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c89c75a-ab0c-42be-b628-60ca5c02852f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6059f8a0-f1cd-45c8-89b9-a98760af6162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6059f8a0-f1cd-45c8-89b9-a98760af6162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_708895b7-9c3e-4e8e-b3b8-b00c0dc12e3e" xlink:href="moh-20210331.xsd#moh_MagellanCompleteCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6059f8a0-f1cd-45c8-89b9-a98760af6162" xlink:to="loc_moh_MagellanCompleteCareMember_708895b7-9c3e-4e8e-b3b8-b00c0dc12e3e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended" id="i862e8db523e343c5b1c31970a0e85388_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i33c40536ff6c475aa4b27cd3c119fa08_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended" id="i8d784437bfa04079b28ad2d7459fbee4_FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_651eac06-b695-4eb2-91ff-5bfec51f5d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_651eac06-b695-4eb2-91ff-5bfec51f5d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e48719cc-02c5-4e1d-9d51-e6d81bd81b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e48719cc-02c5-4e1d-9d51-e6d81bd81b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc53abca-a2ce-4284-935f-8cf05bda025c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc53abca-a2ce-4284-935f-8cf05bda025c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_274abb13-f3d6-46e9-b38f-6ca1a4a00c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_274abb13-f3d6-46e9-b38f-6ca1a4a00c97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6aa5c030-d686-433a-a50d-b332ac5582cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6aa5c030-d686-433a-a50d-b332ac5582cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b925d023-704c-4b40-ade9-3bdc64d5c52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b925d023-704c-4b40-ade9-3bdc64d5c52b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bfc1da9b-df30-4e01-987b-57ef39840e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bfc1da9b-df30-4e01-987b-57ef39840e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e30385f7-d36a-4041-9ee7-2ef8e699fa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e30385f7-d36a-4041-9ee7-2ef8e699fa98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac62adc9-0a62-43f5-82ca-032e4cac12f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac62adc9-0a62-43f5-82ca-032e4cac12f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5be1db28-ac3b-4b46-b9c0-999c220ecfed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5be1db28-ac3b-4b46-b9c0-999c220ecfed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b5f8f32d-4dc5-484f-8210-862644f5528d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b5f8f32d-4dc5-484f-8210-862644f5528d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_1a933831-77bb-4158-a007-0541fd82b566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_1a933831-77bb-4158-a007-0541fd82b566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_d6270d61-775e-4fee-9adf-c1e98bbfdd81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_d6270d61-775e-4fee-9adf-c1e98bbfdd81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_a49b3acb-9680-41c8-b108-a1b2192923fc" xlink:href="moh-20210331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_moh_MunicipalSecuritiesMember_a49b3acb-9680-41c8-b108-a1b2192923fc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="iadf1f2d80f8946c5b7532a1da80289e9_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ecefd01f-e292-41d9-bdd2-856f6c1fc266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ecefd01f-e292-41d9-bdd2-856f6c1fc266" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_20142ff1-7d6e-4a6a-b5a7-3fbbbccd7da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_20142ff1-7d6e-4a6a-b5a7-3fbbbccd7da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_271b55f6-9c2a-4b03-9fa9-d450f686ad5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_271b55f6-9c2a-4b03-9fa9-d450f686ad5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6ee7cec-d030-4281-8067-35bfe6e23a0b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6ee7cec-d030-4281-8067-35bfe6e23a0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eda56772-ee60-4ec8-b1ef-cf5aebf7d2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eda56772-ee60-4ec8-b1ef-cf5aebf7d2da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_29eba0fd-d3cf-4201-b8a3-2de9b8600f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eda56772-ee60-4ec8-b1ef-cf5aebf7d2da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_29eba0fd-d3cf-4201-b8a3-2de9b8600f5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended" id="iab681d43382b408fad58d973e4980a2a_FairValueMeasurementsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89c09cf6-5730-4c9c-8d6d-8b4f9784997e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89c09cf6-5730-4c9c-8d6d-8b4f9784997e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f7c776a5-db80-4f36-86e9-f770feaf228a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f7c776a5-db80-4f36-86e9-f770feaf228a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c70e31e5-600c-433a-b7c5-8dda83ec34ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c70e31e5-600c-433a-b7c5-8dda83ec34ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ee34bb68-e937-47cd-9d1d-c4cd298bacd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ee34bb68-e937-47cd-9d1d-c4cd298bacd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fca96e69-71ff-4cc9-9c19-a853be17980f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ee34bb68-e937-47cd-9d1d-c4cd298bacd1" xlink:to="loc_us-gaap_SeniorNotesMember_fca96e69-71ff-4cc9-9c19-a853be17980f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_d98df1a5-9213-4886-b599-a65b0374fa10" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:to="loc_moh_A4375SeniorNotesMember_d98df1a5-9213-4886-b599-a65b0374fa10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_cd894a90-3e03-4011-a378-d8bd68d24bea" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:to="loc_moh_SeniorNotesDue2022Member_cd894a90-3e03-4011-a378-d8bd68d24bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_62e7d270-1fdc-4208-a738-1f978911c326" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_62e7d270-1fdc-4208-a738-1f978911c326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f69b3f0e-76ca-4e61-82d7-fb021d716a35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f69b3f0e-76ca-4e61-82d7-fb021d716a35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_982ded08-c689-44be-98ae-2c427761885c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_982ded08-c689-44be-98ae-2c427761885c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e630406a-9657-4c25-99bf-61ecffa21341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e630406a-9657-4c25-99bf-61ecffa21341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9d42c418-931b-4d51-b793-87d2fc8bda8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9d42c418-931b-4d51-b793-87d2fc8bda8b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20210331.xsd#Investments"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended" id="id53d73cc5f3b49bab93a1f5420ad0d71_Investments"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended" id="ic329cecb288140b1af0356c5f196863f_InvestmentsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended" id="ia178284885cf431d8c7f2ac23bbdc4e4_InvestmentsSummaryofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ace0bdec-4397-4353-9a15-90eba5cb4837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ace0bdec-4397-4353-9a15-90eba5cb4837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fbf39e3-999e-4911-8f7d-3f0d4403e735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fbf39e3-999e-4911-8f7d-3f0d4403e735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_047daa87-776c-429a-b746-6e5aa7db674e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_047daa87-776c-429a-b746-6e5aa7db674e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a6e3aa8-7fa9-4205-ad8e-ec845359084f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a6e3aa8-7fa9-4205-ad8e-ec845359084f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8037cc2-72b3-4c9c-86fb-48811282c98e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8037cc2-72b3-4c9c-86fb-48811282c98e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_902a1d3c-66bd-4bdc-9e2f-8bb540a1c994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_902a1d3c-66bd-4bdc-9e2f-8bb540a1c994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_d8aeb19c-aba0-4190-8716-a446f9efdfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_d8aeb19c-aba0-4190-8716-a446f9efdfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ecae7ef7-050a-400a-9310-472e3a509ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ecae7ef7-050a-400a-9310-472e3a509ff1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_c778dd58-8e19-4e05-8c27-888fa8f5ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_c778dd58-8e19-4e05-8c27-888fa8f5ed62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_fec39517-d8c4-4b1f-9bb6-aa2687a42180" xlink:href="moh-20210331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_moh_MunicipalSecuritiesMember_fec39517-d8c4-4b1f-9bb6-aa2687a42180" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended" id="i8827062cf986479393e89f9f66900bba_InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="i86ef324256954bab9c0f9f204b9a9abf_InvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended" id="ifc1a43671c164648aa6ba612c33913ec_InvestmentsAvailableforSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_670b3472-a898-4b0d-b57d-5cf90facb1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_670b3472-a898-4b0d-b57d-5cf90facb1ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c7b81bc6-d2ae-4708-bd99-5df92596fc72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c7b81bc6-d2ae-4708-bd99-5df92596fc72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_ef3cc167-168c-46ba-951e-984d20a88f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_ef3cc167-168c-46ba-951e-984d20a88f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:to="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_230f5ca9-c372-4e9b-ba35-d9648d01b2d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_230f5ca9-c372-4e9b-ba35-d9648d01b2d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_656e75a7-93e4-4d93-87ad-b75f3b6f177c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_656e75a7-93e4-4d93-87ad-b75f3b6f177c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_8b84c504-96eb-4b4c-a86d-3c51e06676f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_8b84c504-96eb-4b4c-a86d-3c51e06676f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended" id="i23bbba8aba5347cea77da9e3755ed34a_MedicalClaimsandBenefitsPayable"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended" id="i15ffdf86d75b46759916aea41e1ba437_MedicalClaimsandBenefitsPayableTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended" id="ia317bcef5a374652acd913741ee39a88_MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_73a52f79-0aa6-459f-8efb-3879111b5d9c" xlink:href="moh-20210331.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_73a52f79-0aa6-459f-8efb-3879111b5d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_d996bf58-468f-43a2-bfbf-b99e7078137c" xlink:href="moh-20210331.xsd#moh_PharmacyClaimsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_PharmacyClaimsPayable_d996bf58-468f-43a2-bfbf-b99e7078137c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_f21da673-632c-44ae-8083-847969a18722" xlink:href="moh-20210331.xsd#moh_CapitationClaimsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_CapitationClaimsPayable_f21da673-632c-44ae-8083-847969a18722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_8f96992d-365a-4b8d-8894-a70293a440ba" xlink:href="moh-20210331.xsd#moh_OtherClaimsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_OtherClaimsPayable_8f96992d-365a-4b8d-8894-a70293a440ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2a87774d-3347-4bef-a835-4353e6ff6a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2a87774d-3347-4bef-a835-4353e6ff6a85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec71db64-f152-49ee-aeea-02c6de869b96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec71db64-f152-49ee-aeea-02c6de869b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27b0af88-d828-43d9-8e64-4b9e5e2b4f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27b0af88-d828-43d9-8e64-4b9e5e2b4f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_3585c386-87eb-48ba-9b00-26e9e92c77db" xlink:href="moh-20210331.xsd#moh_MagellanCompleteCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27b0af88-d828-43d9-8e64-4b9e5e2b4f3e" xlink:to="loc_moh_MagellanCompleteCareMember_3585c386-87eb-48ba-9b00-26e9e92c77db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended" id="ia11e7297c1994e2bb5341793ac67aad2_MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended" id="i199db4a30ddb4cd1b2b384c5bfba8380_MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_8de661a9-77ba-44be-aa4d-9b14af4fcc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_8de661a9-77ba-44be-aa4d-9b14af4fcc00" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4f39f347-6fcd-4fee-825e-2203f41f3d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4f39f347-6fcd-4fee-825e-2203f41f3d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:href="moh-20210331.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2dc97ffb-7edf-4cca-a23a-295a55016bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2dc97ffb-7edf-4cca-a23a-295a55016bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_908c30dc-ff8e-4346-942f-2dbeacbc3a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_908c30dc-ff8e-4346-942f-2dbeacbc3a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_7152b5ef-ebd3-42aa-8ec9-ffda7b4a6aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_7152b5ef-ebd3-42aa-8ec9-ffda7b4a6aa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:href="moh-20210331.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1fc13136-79e6-45b4-9647-e75cf272ec7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1fc13136-79e6-45b4-9647-e75cf272ec7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_bcaff3d4-6327-4d7a-9629-bf04cdcbf209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_bcaff3d4-6327-4d7a-9629-bf04cdcbf209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_da08f452-92b8-4feb-8efc-396890f7b1fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_da08f452-92b8-4feb-8efc-396890f7b1fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ChangeInAcquiredBalances_108cde1f-708d-4a50-909d-1833bcc4f68d" xlink:href="moh-20210331.xsd#moh_ChangeInAcquiredBalances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_ChangeInAcquiredBalances_108cde1f-708d-4a50-909d-1833bcc4f68d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_cdb02eee-c3f7-484a-9218-c10bea3f4af3" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_cdb02eee-c3f7-484a-9218-c10bea3f4af3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_39d6e16a-f68c-4a72-9f7f-0e81436ddeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_8de661a9-77ba-44be-aa4d-9b14af4fcc00" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1de7a25e-0503-4df6-a0c7-835df1da1dca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:to="loc_us-gaap_SegmentDomain_1de7a25e-0503-4df6-a0c7-835df1da1dca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:to="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_eeff9bf3-296d-4238-94ae-3d473095fc80" xlink:href="moh-20210331.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:to="loc_moh_MedicaidMember_eeff9bf3-296d-4238-94ae-3d473095fc80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_ec288328-4c91-4c97-85c0-720fc4464ee2" xlink:href="moh-20210331.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:to="loc_moh_MedicareMember_ec288328-4c91-4c97-85c0-720fc4464ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_a0fc49ae-851e-4998-a284-20571ae8bf51" xlink:href="moh-20210331.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:to="loc_moh_MarketplaceMember_a0fc49ae-851e-4998-a284-20571ae8bf51" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20210331.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended" id="i90f408c50797423c8aef31540ffa512c_Debt"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended" id="i9ca76268aa904496a135d481e0ebac3a_DebtTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended" id="ie69c45a81be84eb9992bfcfe89be9415_DebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3c6d764-a141-4fa1-a748-1cf8bc8e7b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3c6d764-a141-4fa1-a748-1cf8bc8e7b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_fe15fca9-15db-4aa2-b34c-a8a94f221ae8" xlink:href="moh-20210331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_fe15fca9-15db-4aa2-b34c-a8a94f221ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8dcc8212-007d-43ef-9534-aa70349579b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8dcc8212-007d-43ef-9534-aa70349579b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_17bac1f7-10df-44be-9adc-b42f699fe224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_17bac1f7-10df-44be-9adc-b42f699fe224" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c8ae5cd1-c78b-4aef-97e7-369bd05cd7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c8ae5cd1-c78b-4aef-97e7-369bd05cd7c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_15a90a03-81f1-45a5-9a99-ae44b296b164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c8ae5cd1-c78b-4aef-97e7-369bd05cd7c7" xlink:to="loc_us-gaap_SeniorNotesMember_15a90a03-81f1-45a5-9a99-ae44b296b164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:to="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f24d62a-78d7-4bc2-bf74-057fd8bf2378_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f24d62a-78d7-4bc2-bf74-057fd8bf2378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_f9bb57c0-feb9-4388-aa77-5f363ab1e902" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:to="loc_moh_A4375SeniorNotesMember_f9bb57c0-feb9-4388-aa77-5f363ab1e902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_5a5f9149-976e-417c-acc7-accd35939b99" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:to="loc_moh_SeniorNotesDue2022Member_5a5f9149-976e-417c-acc7-accd35939b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f02f6ee3-dec6-42c9-857f-32f821238c0f" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f02f6ee3-dec6-42c9-857f-32f821238c0f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended" id="i5b933fba83a24efa9614da06c0580d7e_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_92dec33d-765b-4845-94db-75dbb7bc9e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_92dec33d-765b-4845-94db-75dbb7bc9e52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_44323a6f-35dc-45ce-8e3c-4b30d1c7a4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentTerm_44323a6f-35dc-45ce-8e3c-4b30d1c7a4f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_58fed6cd-5da2-4a7e-9430-1d527cbf49d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_LineOfCredit_58fed6cd-5da2-4a7e-9430-1d527cbf49d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6586e0a1-49c9-44bb-a4e4-4a78f883fda2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6586e0a1-49c9-44bb-a4e4-4a78f883fda2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cbc0b576-6a7a-4827-a3a3-5943e7302e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cbc0b576-6a7a-4827-a3a3-5943e7302e8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_314e9088-84fa-413b-ab30-986ce7bdc296_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_314e9088-84fa-413b-ab30-986ce7bdc296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_69bf5e54-962d-4bdc-aee8-be9060956b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:to="loc_us-gaap_LineOfCreditMember_69bf5e54-962d-4bdc-aee8-be9060956b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4c00124a-1be5-4d1e-b5c0-65aca50974a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:to="loc_us-gaap_SeniorNotesMember_4c00124a-1be5-4d1e-b5c0-65aca50974a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e1858ea6-c934-486b-a524-e1330f876898_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:to="loc_us-gaap_CreditFacilityDomain_e1858ea6-c934-486b-a524-e1330f876898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_98fb694e-faec-4781-88cb-5fdf818e26e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:to="loc_us-gaap_CreditFacilityDomain_98fb694e-faec-4781-88cb-5fdf818e26e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_64c90014-dbca-4121-a2de-ccfe89fee705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_98fb694e-faec-4781-88cb-5fdf818e26e4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_64c90014-dbca-4121-a2de-ccfe89fee705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65d9e868-1f27-47b2-b60e-21c9774827a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65d9e868-1f27-47b2-b60e-21c9774827a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_27a2f32c-0fe8-425e-b9e0-1c57555a75cd" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:to="loc_moh_A4375SeniorNotesMember_27a2f32c-0fe8-425e-b9e0-1c57555a75cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_17383720-4625-4b0f-b7c3-b6b90f7022e5" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:to="loc_moh_SeniorNotesDue2022Member_17383720-4625-4b0f-b7c3-b6b90f7022e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_26b63ab3-28d0-4726-b61a-6f0b12c097cc" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_26b63ab3-28d0-4726-b61a-6f0b12c097cc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20210331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended" id="i5cbe6fa6aafb41e88e472a71e5cff777_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="if7364fccaefb462ab751fa15603f6cf6_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bd37e953-a1b4-42fe-9e07-cfa14dcdf11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bd37e953-a1b4-42fe-9e07-cfa14dcdf11a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_59595789-7a65-4b03-90a4-766a2b984911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_59595789-7a65-4b03-90a4-766a2b984911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_18d6815e-2575-4078-875e-ce0a2eaafd56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_18d6815e-2575-4078-875e-ce0a2eaafd56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20ee847c-e61c-42d7-a7eb-2292f7f60f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20ee847c-e61c-42d7-a7eb-2292f7f60f9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_31b0d66d-34a8-4f16-9729-4636f52c57e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_ShareBasedCompensation_31b0d66d-34a8-4f16-9729-4636f52c57e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4f9d98e-3aba-4394-b773-3b6450cd2774_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:to="loc_us-gaap_EquityComponentDomain_c4f9d98e-3aba-4394-b773-3b6450cd2774_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afc53e76-552b-441d-9622-a574a786581f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:to="loc_us-gaap_EquityComponentDomain_afc53e76-552b-441d-9622-a574a786581f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f956e196-627a-4402-a2d5-eb419fc5005e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afc53e76-552b-441d-9622-a574a786581f" xlink:to="loc_us-gaap_CommonStockMember_f956e196-627a-4402-a2d5-eb419fc5005e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20210331.xsd#Segments"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended" id="i437688ca1c04482d93a416e2cf519ba1_Segments"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#SegmentsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended" id="i33d241075d2947dd988489eb105595bf_SegmentsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended" id="i48a108ef2e654ad3ad06c56381dfeca1_SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad66b102-d487-4a03-989b-2fd47366e776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_Revenues_ad66b102-d487-4a03-989b-2fd47366e776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b603c765-e2e1-461f-b3d0-22805c8eddd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_Goodwill_b603c765-e2e1-461f-b3d0-22805c8eddd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a78183c4-d52e-4466-8f01-216941e3e006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a78183c4-d52e-4466-8f01-216941e3e006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_d0e3f295-e347-49d8-bccf-90b5317f88f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_d0e3f295-e347-49d8-bccf-90b5317f88f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8cfa4daf-fcb8-4207-abf7-3f6216fa13f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_GrossProfit_8cfa4daf-fcb8-4207-abf7-3f6216fa13f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f30ae921-9fc6-4fe5-865e-ba71daaaa2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_CostsAndExpenses_f30ae921-9fc6-4fe5-865e-ba71daaaa2b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39ef5915-a5e0-4a3d-8dd2-8aa1018b4e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_OperatingIncomeLoss_39ef5915-a5e0-4a3d-8dd2-8aa1018b4e42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_111a9201-8e2d-4c26-aa83-020b7a21a362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_111a9201-8e2d-4c26-aa83-020b7a21a362" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6bc66dd3-5917-488a-83a5-8d997210bb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6bc66dd3-5917-488a-83a5-8d997210bb38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:to="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9c35f704-5207-4a2b-b680-d9494b57a908_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:to="loc_srt_ConsolidationItemsDomain_9c35f704-5207-4a2b-b680-d9494b57a908_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:to="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e5c3f694-ceba-4e49-87e6-2ca5d0577d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:to="loc_us-gaap_OperatingSegmentsMember_e5c3f694-ceba-4e49-87e6-2ca5d0577d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_4204b19c-289c-468e-88b7-36f7dc0c8b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_4204b19c-289c-468e-88b7-36f7dc0c8b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_83143910-7ea0-497c-b344-114b3c13476a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:to="loc_us-gaap_SegmentDomain_83143910-7ea0-497c-b344-114b3c13476a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:to="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_3717428e-b2c1-4a48-99f9-3a2f0b498673" xlink:href="moh-20210331.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_moh_HealthPlansMember_3717428e-b2c1-4a48-99f9-3a2f0b498673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_a42cbb9d-1c04-46fc-aeb5-1decf6a68450" xlink:href="moh-20210331.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_moh_MedicareMember_a42cbb9d-1c04-46fc-aeb5-1decf6a68450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_bcc23f90-ebd3-4467-830b-56600915e99f" xlink:href="moh-20210331.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_moh_MarketplaceMember_bcc23f90-ebd3-4467-830b-56600915e99f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_71047fb6-fc29-4f9c-9328-1b5764d3f737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_us-gaap_AllOtherSegmentsMember_71047fb6-fc29-4f9c-9328-1b5764d3f737" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended" id="ia50bb43c5e344161a8a3a10985a334a9_CommitmentsandContingencies"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>moh-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1bf58a98-2aa7-4eef-bb6c-f5c42b4c24b2,g:53e813d1-18be-4855-aac7-c0269cc6b95f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_b09973ff-4ea5-4d07-a22d-dfeffd8329f4_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fees</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_label_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Expense</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationInsurerFeeExpense" xlink:to="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d29ae471-42ab-4f24-84a0-47aad9149ea6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fe0d7291-e69f-4b63-a9f6-63a00147c70a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_40e24167-49f4-4393-ae57-78a4dfb1654b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0cdc295e-be1a-4003-b36a-86da41a992bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_fa433d3f-b13d-4fdc-9c25-43e698711e0a_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable, prior year</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ad8ee9a0-d2b7-47a6-a8af-93f6f3f8751e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_4c1d065a-9994-4683-9246-ed04a6df08ab_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_b4d0cfa4-ddad-478d-bb82-dd79412f2f5a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffinityHealthPlanMember_a236420e-5b76-4d36-bef6-27fd19aeb750_terseLabel_en-US" xlink:label="lab_moh_AffinityHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity health plan</link:label>
    <link:label id="lab_moh_AffinityHealthPlanMember_label_en-US" xlink:label="lab_moh_AffinityHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan [Member]</link:label>
    <link:label id="lab_moh_AffinityHealthPlanMember_documentation_en-US" xlink:label="lab_moh_AffinityHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanMember" xlink:href="moh-20210331.xsd#moh_AffinityHealthPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffinityHealthPlanMember" xlink:to="lab_moh_AffinityHealthPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_66008269-28b8-4b52-acc3-dc016c912cbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f8b8e245-ff03-43a6-9f14-69a68b89377f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_533e762b-cd72-4b34-bb10-11805fbc4889_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_beed9579-abea-4cca-9a50-81460deb7309_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_20285e92-b771-4ca1-a05b-6924bf4613ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_09edfe00-5858-4c40-8e8e-84aed7711dc5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical care costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d04694e-be0f-488a-bd84-01f58f5e7d43_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ebc98ef-964b-4268-9af6-b8336f6c8a8d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherClaimsPayable_285f7d42-60bc-4096-94f4-5406cafd77fe_terseLabel_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_label_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_documentation_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable" xlink:href="moh-20210331.xsd#moh_OtherClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherClaimsPayable" xlink:to="lab_moh_OtherClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d20e14be-e4a9-457c-83ed-e52c2fdd51f8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_7ee76bd1-1821-4e2f-98ed-975458545944_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a5065b10-3813-462a-bebb-ccefc24f45c4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_3584a5dd-ea51-40c9-ab87-c30bcc1cf771_negatedLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: other operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_2ed4c08b-fff9-41fe-bdf9-6d8b2e1d76e6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5a81345a-4ee2-4128-8614-7d4947975ff9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6fb4a78b-2308-485a-95d3-6364ffa001c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MagellanCompleteCareMember_f9fd5d36-0db7-425f-a5be-23936236eea2_terseLabel_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan complete care</link:label>
    <link:label id="lab_moh_MagellanCompleteCareMember_label_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care [Member]</link:label>
    <link:label id="lab_moh_MagellanCompleteCareMember_documentation_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember" xlink:href="moh-20210331.xsd#moh_MagellanCompleteCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MagellanCompleteCareMember" xlink:to="lab_moh_MagellanCompleteCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_9083f1ef-135d-4934-8228-1c29b014b01a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e1fd57c0-906a-4ede-a416-dcc0c3e49c6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_59010546-a0bb-4974-a8b0-f24ba14056c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3d4ba38e-d84e-41c0-b79f-55b6720e6dbf_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_31130171-8c84-4c74-aaa6-536f7195c90e_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_e6fbd4f6-d388-49ee-85a2-28928acf0744_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7f8c5890-568b-47d3-99a8-26c4a5ce6924_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_1b3f92d8-43e1-47e9-81f2-1c11dfa2b55e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f89d3d0f-b7f2-4115-989f-ef5314bdabb5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0642f0b3-69c6-4ee2-9ffe-e9f4c62e22ea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_31f3023a-4453-4787-87ac-5965c802ca39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e230e637-dd87-4f83-8b13-5179edf73912_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5b978d3b-5861-442f-8966-324633932ac3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_111e7082-d22b-4be7-8c08-44dd70481962_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_4a29dfe1-8788-4814-80d4-dca6980508c4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_8fdd2e94-8eb3-4e43-84b8-3a938f505123_terseLabel_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to government agencies</link:label>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves Reported to Other Agencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:to="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5b794251-89b4-4877-b986-0b659c1846c5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_e10e05d8-3b74-4971-ac77-7955e43ea56e_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6bf56e39-4ae5-4283-aaef-916202dc8d71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_fbff5d30-98ca-4f75-b252-2232746927f3_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_a5e67ee8-89a7-4703-9d6b-1df947585e48_totalLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:href="moh-20210331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b0e7f8a7-9fda-48ca-8734-97268dc037af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fdff6c21-f0ec-4190-b3ae-02c2d9eba477_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2f6458d8-c173-4da2-b17f-78f6b973cafc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5dcdadb8-5be8-433a-9a10-ac3efb8b76ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5661a498-4062-4017-a67a-ee417398bbb2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1e240404-2b92-4bb9-b2f1-d8fdea96155b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_bbc2023a-f372-44ab-b9be-75053499c898_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_656c5a49-0728-4fb6-8463-d0787f0a7d1f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_87734676-3bb3-4f7a-9bce-8b6a5917edb9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_d5be97fb-b15e-4ea8-b438-4fa600e055bd_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_87b9aa9c-a0f8-49f3-b221-07612bb21a50_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_549ead28-cd55-4a0c-9ff1-92119ed52abb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_4c2ddce4-73af-423e-a773-b87b46f55fdd_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f04cc870-9059-46fc-8ead-66fa1308cd8c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_dd096d2a-5d2f-4301-812f-843165a80f12_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_3bb4f051-b50a-47d1-8b9c-29ead3434d9e_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Due one year through five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_089c9ed5-91ab-4853-ab86-b3e64cf6dfd9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b7fcb065-b75b-4161-85a0-830ba3d43098_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_310ab6df-dc48-4f03-a916-574c6eb9e5e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_94c8483e-6fc7-4c0a-a458-3cce1df1aacf_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_1453b6c3-6f3b-4ff3-a80d-2d48716cba5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_18bccc67-dd58-48f7-98c1-c436d6e81d25_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1f3ca9ec-d7a5-4856-b666-c4139edc807a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1099fe7c-effb-411c-830e-178ea5e5711f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_76f857c4-1b86-41c8-a729-4c0c28286305_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e4eb135c-f6f3-4379-af91-792a2ec56e64_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e10e7618-81ca-4d33-ae02-8266d6166ec0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_0cc0dc2b-35f9-40cd-97ca-270f5f800d85_terseLabel_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod" xlink:href="moh-20210331.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsMaturityPeriod" xlink:to="lab_moh_InvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_219086c2-4c55-4529-a2c7-277b186a5768_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_c4d14cbb-75a9-4562-b7fe-1f6dbb09e59d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b631a30a-d2b0-4f7a-b8e5-01eee640541a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a13c9f7d-7a3c-4915-99ee-ab159c89824a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination_0f70cb57-1191-4433-a884-b715db59a289_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care acquisition opening balance</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Business Combination</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesBusinessCombination" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesBusinessCombination" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ccf15f5c-35d3-4ad7-9e33-7a31b116f99d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_f276835c-bae4-4cbf-8f24-9a0507ded179_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_32de3b7c-1b67-4d68-a965-f09a51518e76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3d4751d5-c869-4a6a-8342-dcff9f39ddd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aa190536-8681-47bf-98e9-eca5485b7fc4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7576c1b7-c553-4fd8-a0c3-f5a41efcd038_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements of senior notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8108147d-fffc-45e5-922b-2ada68b97404_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_09516945-8e99-4129-a80a-9b941d1d1ffc_terseLabel_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to:</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:href="moh-20210331.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_StructuredSecuritiesMember_47c56a7a-51a8-4e50-9798-5a4f31c9652a_terseLabel_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities</link:label>
    <link:label id="lab_moh_StructuredSecuritiesMember_label_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities [Member]</link:label>
    <link:label id="lab_moh_StructuredSecuritiesMember_documentation_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember" xlink:href="moh-20210331.xsd#moh_StructuredSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_StructuredSecuritiesMember" xlink:to="lab_moh_StructuredSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3dfd6036-cb6a-40d2-8238-15f15aa1b50e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3784873d-c2b3-4560-a20a-151e6ecb7231_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_11f28c82-0606-436d-a91d-4acb5a90fc29_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_260be0e1-3fe7-4128-bc90-df3224e44532_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_649fd0ec-2043-462a-ae3e-21cb170180bc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1974efe8-cb73-45ab-afd6-d40a6633b111_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c96d1406-e995-429f-9ff9-5cd7306acd75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_45e19385-19c2-4d10-8c3b-c37ebc0ed6c5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e21c84ee-20fc-4b85-8e38-27ba1f67d0ac_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ff877a52-53e8-4f90-b05c-6046e4cb87f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_af0fbdb5-38da-4aba-9c41-19e48d76ba0e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_be2dd8d0-623c-4f44-a181-a7d752920c17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_15d42cc8-2b3b-4391-a57b-49ac42a6ed91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_2d9412d6-68f9-46cd-9214-6d34c533208e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f27a3e0b-f4a6-4002-aa2e-a2d9886e388b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_57219f95-3ed9-48fa-bd6c-cfb6414cf81f_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fees reimbursed</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:to="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c6df668a-9f9c-47bb-bdc0-11be0bbc0322_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_c93fffd9-409e-407d-89ab-82f6bc9c426b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_40f70356-186d-4fe2-b6b6-1b33df5624b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_dcff72b7-643a-4fc1-947c-a1aa7a56889c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CapitationClaimsPayable_8f67a64c-7933-430e-82d1-97aca6bc8420_terseLabel_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_label_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_documentation_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable" xlink:href="moh-20210331.xsd#moh_CapitationClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CapitationClaimsPayable" xlink:to="lab_moh_CapitationClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_465ab009-140c-41bc-b1d4-499bf5f3c282_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_152abc98-b5e8-491e-91a3-208f48816516_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d90a1ae5-55a1-4ce1-96bd-9dcd9403a51f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_247182bb-f914-4999-8080-83403daf1ac9_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_10f9d047-5361-4977-973a-b390729ee77b_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_940c59bb-87f6-4721-a45e-1ae3848aff00_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_32cf17b7-cfc4-413f-969c-1a57cc5b3081_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_43c3b028-2ca8-4bcd-b79a-6d5f6e586f7a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares issued:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0019118d-cfd1-41de-b0a5-009d1c0cb093_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_469bf9a2-b6cc-4fe8-a77d-def15103ba5e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_db7a3f6a-d945-4115-a361-fbd7cc83bb94_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_13016cfe-19f8-4cb9-b47a-73a3fc64bd47_terseLabel_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas Acquisition - Medicaid and Medicare</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_6835792c-2c42-4630-8137-a350d49440e4_verboseLabel_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_label_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_documentation_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:href="moh-20210331.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:to="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_NumberOfMembersCovered_0164de27-4e80-431b-908a-e5910ce530d5_terseLabel_en-US" xlink:label="lab_moh_NumberOfMembersCovered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members covered</link:label>
    <link:label id="lab_moh_NumberOfMembersCovered_label_en-US" xlink:label="lab_moh_NumberOfMembersCovered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Members Covered</link:label>
    <link:label id="lab_moh_NumberOfMembersCovered_documentation_en-US" xlink:label="lab_moh_NumberOfMembersCovered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Members Covered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfMembersCovered" xlink:href="moh-20210331.xsd#moh_NumberOfMembersCovered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_NumberOfMembersCovered" xlink:to="lab_moh_NumberOfMembersCovered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_68e72136-2e7a-4a1d-99a3-057016eee4bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1662bfff-0f87-4d3d-b0c9-b73c47aaeb3c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_17b6d68a-5e04-4be4-ac9b-792e05c1dd39_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_11d4d84c-b34c-4b81-a49c-b06459c1df67_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_f8b949e1-56cf-4394-bda4-44ac0c8adb6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Health Care Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ce22ac94-ac85-439c-8071-c990a348715c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_89b825a2-0fad-4e00-b736-09f73493e25f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a63b8d2c-4067-46e8-910a-3e55d277ce9a_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e101d5d7-193d-4208-979c-85fd74370c53_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_78e9ad0b-3f1c-4fc9-86c8-8adb0cdc0b53_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_c38863b4-55fd-42b1-9b7d-fb12830fa750_terseLabel_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_label_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_documentation_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:href="moh-20210331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:to="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0c203d45-f181-454c-8a2a-643e3eed511e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_7d938db0-54cf-4d63-8cc9-c23ac3cbe802_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_9dd63c63-a304-45d4-815b-159be52dcad2_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_22b8dc5a-37f6-4583-8585-dbf382c4a1e1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthInsurerFeeReimbursementReceivablesMember_83423a13-f4c1-4152-a7ca-a9ad0fab5ece_terseLabel_en-US" xlink:label="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fee reimbursement receivables</link:label>
    <link:label id="lab_moh_HealthInsurerFeeReimbursementReceivablesMember_label_en-US" xlink:label="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurer Fee Reimbursement Receivables [Member]</link:label>
    <link:label id="lab_moh_HealthInsurerFeeReimbursementReceivablesMember_documentation_en-US" xlink:label="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurer Fee Reimbursement Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:href="moh-20210331.xsd#moh_HealthInsurerFeeReimbursementReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:to="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_1cbb4545-821a-4137-9a32-f416a0ee5dc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6fd084e2-8645-4a88-b15b-332f1945cde6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_097669ad-255b-4dc7-958f-9bd5397b115c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_6296a2e9-c663-499d-979f-02fa887896d0_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d922eee7-28e5-4df6-a4d7-ce89b7139545_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_9a6d396c-46b9-4d53-971e-b36db7472162_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_fb301e63-81d1-4bd6-ab87-4981887ff998_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5dd8cc2d-996a-43d4-bf10-464123158603_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at March&#160;31, 2021, and 59 million shares at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_8289ce24-f13f-4b6d-b000-d00d1600aca4_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HidalgoServiceAreaMember_8e9c6cf7-11fa-49da-a14c-b6ac2c88cc68_terseLabel_en-US" xlink:label="lab_moh_HidalgoServiceAreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hidalgo Service Area</link:label>
    <link:label id="lab_moh_HidalgoServiceAreaMember_label_en-US" xlink:label="lab_moh_HidalgoServiceAreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hidalgo Service Area [Member]</link:label>
    <link:label id="lab_moh_HidalgoServiceAreaMember_documentation_en-US" xlink:label="lab_moh_HidalgoServiceAreaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hidalgo Service Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HidalgoServiceAreaMember" xlink:href="moh-20210331.xsd#moh_HidalgoServiceAreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HidalgoServiceAreaMember" xlink:to="lab_moh_HidalgoServiceAreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c104a8bb-5155-4dda-9aec-cad428617bd9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_912e9f73-4bb4-4c00-9516-0438e7e590f1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_eb0aac83-5b36-46f0-8cd8-111f2a6a4e9d_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Premium Revenue By Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:href="moh-20210331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_5148df90-d70e-44d0-acdd-c805b98d533e_terseLabel_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation and Interim Financial Information</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="moh-20210331.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ca67da6c-d51d-45a8-8cb8-ba6988a6243e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8444bbf4-1e90-4d3c-b898-ef1473cd490c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf493a82-1c70-4ef4-9404-e3182da8da97_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a3b730d2-4f65-4702-b650-4f35630ce99d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of receivables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_429e3ba3-9b56-421c-8d66-4a4bede1e742_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_60487b3c-b789-42d8-a964-72afb9dabbfa_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e75bcb3-676f-46c7-a208-483e8fda400a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_7b9d6e4a-bb1e-4bb7-914c-ad3a5ffbba1d_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-risk and other provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable, Adjustments, Change In Provider</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable, Adjustments, Change in Provider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_7e376cdd-8540-41cc-a70c-8a6a372450da_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_a28197e0-a810-4d9f-914d-44bcc1c0beff_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:to="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_8eb89a3e-ff6e-42c0-ac62-e3948584852b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_279103a2-2eca-49b4-88c8-f1e460762060_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, and intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_75ff38db-b68f-4a57-bf29-eca897322f98_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_1fbc5352-cefe-45b3-b23f-37702e199c19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cc373915-1196-4dd7-9c70-60845d80bbab_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3b86443f-de09-4e2f-9566-e07d4c468b39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of denominators for the computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8043b00d-853e-4e4b-aa4e-82290574af3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_9bb490c7-5c10-45d9-b283-1301a222445a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_0d1f1449-0fb1-471c-bb89-ad94045831b3_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_da478f5b-88f3-46cd-a61e-1a3c51a9ef90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_277c7872-a084-4da2-9508-ddfb66404351_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6cf936b9-2daa-49f7-95d5-3658f7987942_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2da43796-7d0f-4d15-92bb-0925310fef5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_e642c4f6-bc0a-4d95-8d51-52c41a3ca874_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under letter of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d7fdc53-9836-4a3b-a790-40f0f2a56b86_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_c1535bae-5a17-4c1f-9937-d166328623ae_terseLabel_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:href="moh-20210331.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ff6a69e7-0a52-404a-8f76-c10fbd626c6b_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period claims, favorable development</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0eecc4f7-0dc7-4205-92f1-3798a8306414_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_36dd44a7-6253-4009-89a7-100863aec655_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_95250ce7-6c4d-4992-813b-47fb1645aae5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a2cf8179-17e9-44df-b9d5-58e308b31735_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_84ce7ffc-87be-498f-9759-07cbb66f1dc9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d0eb8f43-a72c-477b-bf4d-1e95b8597e2d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_d9ba3312-e828-4b0b-97b5-21d4e6ab4cd9_terseLabel_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod" xlink:href="moh-20210331.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsAverageMaturityPeriod" xlink:to="lab_moh_InvestmentsAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2de0c3e5-9733-4070-ab64-0e144b4bcf68_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2ac7f4ee-effd-4562-b545-16f90f6bc453_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_15d602c9-080f-45ae-a820-7bef14ab0d81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_7564035b-d8d5-47f6-8850-e1fcba05b685_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_3d6df929-2d89-4998-981f-0c327d2e4c7d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_07a36c91-553a-496d-987e-f7a3d3a1ee3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyClaimsPayable_5ffa52f5-d3e8-4f6a-a13d-e24a5bd7c985_terseLabel_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_label_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_documentation_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable" xlink:href="moh-20210331.xsd#moh_PharmacyClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyClaimsPayable" xlink:to="lab_moh_PharmacyClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_0d7c411c-7d95-43b3-b613-fd519efaeaa3_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized loss</link:label>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a67b99fd-fc40-4d06-a48e-e36dd70482a2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_ba92450d-59bc-4820-836b-7beea2b469bf_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c906e0c9-6d31-464b-94e3-7960a5f62745_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_296f9ba7-6df4-4cbe-923c-aac996e05ad0_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the change in medical claims and benefits payable</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_label_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_documentation_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:href="moh-20210331.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:to="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d96fd08d-7731-4a53-8d5a-c73d9a7a6231_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_8797b4e3-b8ea-43cc-a54d-5288c8f6a92d_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at fair value measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b3302069-9058-4708-88f7-f5a41dc5a933_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e3c81b0-4783-445f-af34-44e27b2395c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d33ce7dd-9248-45f7-89c9-7c76efa19ebc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8e7e72fa-860d-43e9-a6af-d620fb5f7e65_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1488855e-437c-46a0-80c7-b3a8029e4935_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4899138d-3c55-4f29-9eed-10aff803bccf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanContractTerm_45cc03a1-7949-4143-b4c7-8dcf3dcb7d78_terseLabel_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_label_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_documentation_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm" xlink:href="moh-20210331.xsd#moh_HealthPlanContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanContractTerm" xlink:to="lab_moh_HealthPlanContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d67a843-676e-4f25-ad4b-674ca6144c47_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9a933b73-3bbb-4670-a642-4f7d9ef4b4dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember_94142abd-c2bc-44a5-a999-01cce8ff1bf0_terseLabel_en-US" xlink:label="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hidalgo, Tarrant and Northeast Service Areas</link:label>
    <link:label id="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember_label_en-US" xlink:label="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hidalgo, Tarrant and Northeast Service Areas [Member]</link:label>
    <link:label id="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember_documentation_en-US" xlink:label="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hidalgo, Tarrant and Northeast Service Areas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HidalgoTarrantAndNortheastServiceAreasMember" xlink:href="moh-20210331.xsd#moh_HidalgoTarrantAndNortheastServiceAreasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HidalgoTarrantAndNortheastServiceAreasMember" xlink:to="lab_moh_HidalgoTarrantAndNortheastServiceAreasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b01b31a-a2f7-488d-b48e-8b53762add7f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8ac1cd76-37df-4044-b77a-ea26cb16f2ae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_5813cdaa-f75e-443b-94e0-f1e521c26509_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:to="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_4dc10a4c-ba14-44b7-bda6-c6240fdf32bc_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cf688db5-dc1a-4d56-be03-b08b9c29d9d9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicareMember_847ee527-18a2-4b58-b41f-45d0aee03753_terseLabel_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_moh_MedicareMember_label_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_moh_MedicareMember_documentation_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember" xlink:href="moh-20210331.xsd#moh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicareMember" xlink:to="lab_moh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ea471385-617d-4660-bd42-fbe2b298bce4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_GovernmentReceivablesMember_943ae05e-d809-4c0a-884b-6ddaa3db084c_terseLabel_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government receivables</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_label_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_documentation_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember" xlink:href="moh-20210331.xsd#moh_GovernmentReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_GovernmentReceivablesMember" xlink:to="lab_moh_GovernmentReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_67077123-bc5d-469c-bf56-b5aabf14c49a_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c812d75e-7577-4003-8b9b-f4cd0b9f1869_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average cost (USD per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PremiumTaxExpenses_4c8cf867-77b4-46c0-a787-406365f4132b_terseLabel_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_label_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Tax Expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_documentation_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An assessment levied by a state government on the net premium income collected.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses" xlink:href="moh-20210331.xsd#moh_PremiumTaxExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PremiumTaxExpenses" xlink:to="lab_moh_PremiumTaxExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28f5088e-6e23-4da5-bd49-8360f3597a16_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_09a2d91d-5978-413d-9236-77f9eaf3f23e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_65da1788-a3e2-4550-a871-1aa18205f03a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fcfc347b-5f6d-4492-b557-6df3577695e6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_888cfcdf-1a69-41c6-8ec1-28ab07e6a9a4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue Recognition and Premiums Receivable</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_89be3503-d2c6-4421-9490-16063f049792_terseLabel_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_label_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_documentation_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:href="moh-20210331.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:to="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_729c5d1f-1270-4bfe-be05-8af45a58990d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ed011331-8378-4d58-b905-91ba0f92ff6d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_df09f547-e7a4-4417-9bd5-48dbf545c60e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83c74b4c-7ac8-4020-91c4-76dec36f4910_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b0139747-cef0-40f2-be28-350b446f8063_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2cf101bc-9d69-4b03-948e-add14206b657_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_d71bc8ee-7d39-4325-95f7-544078b9c8a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_a5a21b3a-fbf0-417f-bab8-320ec3785885_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_c9fab667-b4fa-4f25-8a57-e056efee3f5a_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlansMember_e2f49806-e2ac-4cef-aac3-20ffad22aeff_terseLabel_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans</link:label>
    <link:label id="lab_moh_HealthPlansMember_5000859c-d8b6-4a7d-ad63-144538d6cb13_verboseLabel_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_moh_HealthPlansMember_label_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans [Member]</link:label>
    <link:label id="lab_moh_HealthPlansMember_documentation_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember" xlink:href="moh-20210331.xsd#moh_HealthPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlansMember" xlink:to="lab_moh_HealthPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_2c09844c-6c29-4f64-851b-c71cae72500d_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_0b4c8da3-213c-4c01-a547-e26380b0131d_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_789ef110-3b97-4105-83e9-6b29f89e67f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e8e433b1-5949-4700-b2b4-632100f02877_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a8a7ca08-04bf-4cfe-bdbf-83c66084a214_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4767a64a-5b38-4461-b692-91b20b3c9c67_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b6072ef1-576c-40df-95c9-d53364274a2b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c2fb4b9e-ebd8-4d47-8c0a-275eb53c67c1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_63fbc7df-9d01-45c3-a364-733ec90daa9b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ChangeInAcquiredBalances_830fed3b-8dd0-4802-bc24-d83057bc09f2_terseLabel_en-US" xlink:label="lab_moh_ChangeInAcquiredBalances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in acquired balances</link:label>
    <link:label id="lab_moh_ChangeInAcquiredBalances_label_en-US" xlink:label="lab_moh_ChangeInAcquiredBalances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Acquired Balances</link:label>
    <link:label id="lab_moh_ChangeInAcquiredBalances_documentation_en-US" xlink:label="lab_moh_ChangeInAcquiredBalances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Acquired Balances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ChangeInAcquiredBalances" xlink:href="moh-20210331.xsd#moh_ChangeInAcquiredBalances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ChangeInAcquiredBalances" xlink:to="lab_moh_ChangeInAcquiredBalances" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_c85b783a-f6cf-42ee-86ee-0a06775b3d7e_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:href="moh-20210331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_b7c9478e-7e41-436e-a84f-bcc4d64633de_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities held to maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_63bdc0f8-daf5-447f-87c3-9b3d8cb694a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a5788f8a-5658-4eb2-9be1-321a9e2e6967_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_48fadc68-558c-400f-b71f-d10d12cb1441_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_9d46b162-0561-47c5-8356-2fbc2f5d4511_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a12b665c-5254-4deb-8291-6553ceae08fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_99e063c7-12b1-4737-bc76-ea64e59fcfa9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ccc6ca1b-90ec-4a0c-80c6-1f7356392d90_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_876923db-ee11-4dac-a7df-b30398fb886e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_f02100e4-06e0-4774-bd0d-17d292698b20_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_971f0272-6c67-4eff-8558-7a897b2dbb7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3de2f6b0-c4ab-49ff-8f98-37bdd916bc08_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_12f752e4-c77a-4675-a9bf-359551dc5334_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_78683bef-6091-486b-be94-5167fb8b8502_verboseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6841f716-0373-4441-a6cc-ad9bb6f30c0a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3ce86023-a740-4b41-b66f-17b1c94ab4e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b276ed3-34b5-4626-83f2-17b7542f036d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d4329fa2-4fc1-4fbd-9754-57c8c13834a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_be3df0b2-4af9-4785-9ba6-fde6b989867b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8d06184-1b7b-4d03-a016-9ec4165f1515_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a507c3d3-0524-4cda-b086-46dc01fedf8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_4977c12f-343d-4d2b-bee9-b0f3b00e4253_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SeniorNotesDue2022Member_b95b5a03-9c68-4a1b-a2db-3f0a77a24222_terseLabel_en-US" xlink:label="lab_moh_SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Notes</link:label>
    <link:label id="lab_moh_SeniorNotesDue2022Member_label_en-US" xlink:label="lab_moh_SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 [Member]</link:label>
    <link:label id="lab_moh_SeniorNotesDue2022Member_documentation_en-US" xlink:label="lab_moh_SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SeniorNotesDue2022Member" xlink:to="lab_moh_SeniorNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CompleteCareReceivablesMember_5cb0f167-b2b9-456e-b854-9a83c3fde853_terseLabel_en-US" xlink:label="lab_moh_CompleteCareReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care acquisition opening balance</link:label>
    <link:label id="lab_moh_CompleteCareReceivablesMember_label_en-US" xlink:label="lab_moh_CompleteCareReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete Care Receivables [Member]</link:label>
    <link:label id="lab_moh_CompleteCareReceivablesMember_documentation_en-US" xlink:label="lab_moh_CompleteCareReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete Care Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CompleteCareReceivablesMember" xlink:href="moh-20210331.xsd#moh_CompleteCareReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CompleteCareReceivablesMember" xlink:to="lab_moh_CompleteCareReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_be6c7508-be26-4f61-80a5-aa2716b5d970_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c9551b16-b6f2-467f-9000-18e5c0b90cb3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_cfee0349-e12c-497b-8f79-0c5fef0e8d70_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_e6618de9-e47e-47db-80be-5140aa7f9a72_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b1f74609-5f48-41b4-a986-a6a8ef45aba4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a946cab0-93be-453e-a9b1-f5b68792a04d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_db639cb4-d614-4f97-8d1a-4bff225509de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contractual interest rate on notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_c8e86df6-9a48-4db2-9027-75c3840a2b28_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Due in one year or less</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherMedicareProgram_004361b2-87dc-4037-9967-0ce67a5939d9_terseLabel_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_label_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_documentation_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram" xlink:href="moh-20210331.xsd#moh_OtherMedicareProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherMedicareProgram" xlink:to="lab_moh_OtherMedicareProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_59f41b3b-59ab-43b5-a908-76b4310d7dd5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_608787a7-9ba2-4980-99eb-855d9c29c51f_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_44ea970b-334e-4c03-86ed-0c0bd528d207_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3801e338-c3c2-4548-a1f6-240389db830d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16a69c89-dfbe-46d8-b2e4-ad9853ff852a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_633f540a-b17c-420a-a2ba-ea273d959a42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number&#160;of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_67eda862-5864-4d0a-8ff1-36ed6ff8e0af_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_dbb8b7d9-239c-46a6-ba3a-50342531d89a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_6d171617-18a4-48f6-957f-68ab410d25a7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d1c9e62b-d014-4267-bb1f-578a64905ef3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_30f91dd9-7afc-47bd-9e67-e5361bb1638a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized investment loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A4375SeniorNotesMember_1de15b87-82b9-45a0-9ff5-4aa87f1f60c0_terseLabel_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_label_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A4375SeniorNotesMember" xlink:to="lab_moh_A4375SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_77cace6f-e744-4a69-9c5b-b5b12ec2899e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_c6f82325-6bdb-4197-80f4-0174b9e3e1b5_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_a6a191f0-a962-493e-8160-87988b1f41fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0ce8b51-2807-43b4-bbde-4889c06d7f53_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_cdcc1c84-48e7-4c5a-9dbd-4be2364ad118_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_3bdeb7d7-b24b-4862-a6ea-035f7e170fdd_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_44fc1c07-5f70-4e4b-a5cb-e0e5c09fdffd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_COVID19Member_5e5a3834-e623-44da-af7f-90eb0045bf10_terseLabel_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_moh_COVID19Member_label_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_moh_COVID19Member_documentation_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member" xlink:href="moh-20210331.xsd#moh_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_COVID19Member" xlink:to="lab_moh_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1ecbe128-0c55-4bb1-81da-44923a24deff_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dbbc1cfe-7f5a-4fc2-b9a1-dcbc51a0602a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_5799685b-924c-4f12-bbf1-f3fa5ad10352_terseLabel_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_label_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_documentation_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:href="moh-20210331.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:to="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dc81385a-038b-41a7-9234-d387c355423b_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_608d08c0-5765-41ec-9be1-77eebe6af0a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding equity interests</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_e2c67032-8296-4644-9864-ba50801b31ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in premiums</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Premiums Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_05ab56e0-d13f-4626-9854-a691e72879db_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_74045ee8-1155-465f-bfc9-7fec07c07128_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:href="moh-20210331.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_73dc4787-98e3-4146-963f-d9e9cbfa0f32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segment information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e166b0bc-fb18-4b1f-ae79-826e247afd15_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5d2cc14e-d243-4324-8409-470a82436c71_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5e31a5c3-e092-4117-bb7c-ebd872a33ee2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_86798fee-c96d-4009-82f8-2cacebccdaad_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_57695910-cc24-44c9-8f3d-52b90dc333e2_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_c2df0922-daec-499e-97dc-7604ee88f152_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_c138b26d-14b8-4eba-b519-c9554fef29a3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_67504831-b0f3-46a1-9b0b-a7eff1937362_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c825e094-843e-46c6-baf8-803edb67732d_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_741c20c5-208d-4ae9-9567-007cfbb8e3b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_50da9cb1-fa48-4e9b-93f4-1ba2214fd1ce_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs, approximately</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Members Eligible For The Health Care Programs</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:href="moh-20210331.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:to="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad6bc907-a04b-4308-b71a-b547e5e8b308_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14f6a241-6b6a-4123-93b0-7e98211683da_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2102ad78-7f14-49b3-b6e7-47a669dc143b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d7c40d5b-a7e8-44be-a7ac-1e52c2418147_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_660f0aff-de0b-40ed-bb36-85e6ffaef0cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_d4926efd-8327-491b-9f7a-6caad73083a9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual maturities of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7fbfc5f0-1818-4fb7-87fd-041266a2d332_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_d14ebe91-a540-49d3-9ae3-5e6e4ed54b7a_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable [Text Block]</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_52b69129-c247-419c-a4f2-dce9753e50d2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MarketplaceMember_71a2c917-db00-42fb-86f0-bf4c8ed35e81_terseLabel_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:label id="lab_moh_MarketplaceMember_label_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace [Member]</link:label>
    <link:label id="lab_moh_MarketplaceMember_documentation_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember" xlink:href="moh-20210331.xsd#moh_MarketplaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MarketplaceMember" xlink:to="lab_moh_MarketplaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c6e336b-03c2-43f0-a8b2-d80c4300ec38_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0124f5f8-1faa-4dab-8f83-5fe21b877e0c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_630bb369-a009-4201-8a0c-a8203b63d06d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c1610cec-5ccd-4660-ab4b-e24d9c16c9f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_a8b0caa6-5d38-4c5a-89cd-fc0068e9c934_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-risk provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_85eff49b-6f87-49da-af15-e8543e137b02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_87afaf59-3acf-4c9d-9cd4-7f4276794b72_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_9e140de5-4d3d-4575-a7ab-555113b35fe9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2b136e20-029b-4e1b-8928-d1429facfc5d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_1972e393-ac73-4c7a-8ce2-267d6442330d_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to:</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:href="moh-20210331.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:to="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_1c64b5be-2363-473f-a2a7-58414d3f2ea4_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_label_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_documentation_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:href="moh-20210331.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:to="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_451db23a-d4d0-4c4c-98e6-3863431fc3fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_c62ba932-ed47-4c3e-8aeb-1d31c2e61a6b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c436317a-8c7c-4cad-9dc8-fe5d5ceaeb57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d2015e55-011f-4150-b8a6-c21d4e1427b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b0409f5a-e585-4fdd-8a9c-4a6e8d0f7177_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MunicipalSecuritiesMember_d55e17f2-6969-4305-b3c0-30d59e341960_terseLabel_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_label_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Securities [Member]</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_documentation_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember" xlink:href="moh-20210331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MunicipalSecuritiesMember" xlink:to="lab_moh_MunicipalSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d2097340-2b7f-4ea3-9856-a6a5a5d3d0d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid to seller</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e2e9243c-003f-4d04-9e76-83fd78f75e04_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherReceivablesMember_ec43da54-813d-43bd-9af4-5b0d096e3fe8_terseLabel_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_label_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_documentation_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember" xlink:href="moh-20210331.xsd#moh_OtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherReceivablesMember" xlink:to="lab_moh_OtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_13cb0455-9116-4995-9246-1d63d854c237_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9fe65368-3880-4eec-ad5b-be7c58de2c22_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicaidMember_2c195c23-dd1f-4769-83bb-64ef87eb4982_terseLabel_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_moh_MedicaidMember_label_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_moh_MedicaidMember_documentation_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember" xlink:href="moh-20210331.xsd#moh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicaidMember" xlink:to="lab_moh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_933a3234-1891-4a8b-b570-4d8cbf3bf750_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_91810e4c-15f9-4212-84e3-1d38f0a98cae_terseLabel_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy rebate receivables</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_label_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_documentation_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember" xlink:href="moh-20210331.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyRebateReceivablesMember" xlink:to="lab_moh_PharmacyRebateReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a22980c7-78fe-4e9f-a95d-9118599fa5ae_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b0c23768-b90f-40b7-a334-8a5d1bbd91ba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1f4f94e9-1ade-428b-ae77-13a1f769ae6e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_b5b4b084-a7e2-4905-8c50-dcb63370071e_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_469169c2-70d9-4793-af87-c6dc80df9a3d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6b269f02-2953-41d6-b38b-770c3e31cf48_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bdb82a31-5de9-4455-9a8d-8fa343ca6dc1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_3a7d4cd3-1dc4-45b1-b9d6-66d4dd50f804_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d11967c0-7b72-40d7-b559-97095d5389d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2e869a0a-385a-4e88-86c4-59bc7b9e3892_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d2da0020-d6c5-44be-80bd-3a97aad7a3e1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_f5061edb-4d39-4eb4-8c29-7b87e4151c1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3452160e-1530-4464-919a-85b267dff6e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d47badab-9ac8-45cb-9504-c87e4fb52c78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_dca8b5a0-c500-4c88-82e3-99cfe2e4c838_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c06eeadf-9f93-4427-b0c1-55cbe53b598a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_012603ce-0b6f-436e-ab21-3eb0f0b428f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a2a6a514-7075-4c36-8a5a-d1027b17e044_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6ae72280-bec8-48b2-8fcc-fdc52303cc7a_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_30366e8b-f133-4def-92f1-be62f7b068bc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_751a7fbc-b43c-4db7-9f17-f20a4543e6d5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d9d765be-f005-4d70-87a9-45a38b0209ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9f9e32ff-1987-4578-b9db-e00a73afbfe9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_2ba3b655-c5a3-43de-bd23-6f24c462f5f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_7c2a00c9-a072-4aa5-86fa-df86d8860561_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_67926ca6-51a6-436f-8851-7d611dd0bfde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e53e7134-a809-4723-8add-b6fb95060641_terseLabel_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_label_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes [Member]</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_documentation_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:to="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_66369f91-f963-42f0-bf00-866d8f4fd434_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cf35c39a-a766-4957-ba8d-38ef30d634bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b64dc8ed-ef54-4344-8daf-d4c691a7de8a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d7138524-0906-4ce7-860d-3d254bbd43d9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96064a96-0269-43b9-9285-c6761d733185_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_b0a5fa7e-0a2d-4c7f-813f-9abea9e143e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of liability for unpaid claims and claims adjustment expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_fbd737ae-f6bd-4c7d-ab05-7b6a23ad383f_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:href="moh-20210331.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_45942729-e580-4c70-850c-e9e99b1d7f38_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_46bd17ac-53ca-4dae-85fc-15cd361069b9_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d5d19e79-590e-43b9-bb82-aa0e3953bc6c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_c5da98ee-a266-43ab-850e-3668ccd80129_negatedLabel_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_label_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_documentation_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:href="moh-20210331.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:to="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_06d30773-c80f-4448-b4d1-865a23919029_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_838b080f-9740-4ef7-8db9-67833147ddbd_verboseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable, current year</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_bb5598fb-76cd-4d28-856d-f7e59ee3cced_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2eb6f6ae-d937-4c13-a7ff-eb36f15c7bfc_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_64b08a6e-4883-4603-9191-c05cfef2f925_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5c443605-74a1-439c-9455-c3f57fbc7c5a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>moh-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1bf58a98-2aa7-4eef-bb6c-f5c42b4c24b2,g:53e813d1-18be-4855-aac7-c0269cc6b95f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9c457f2f-c048-4666-9bdc-08ee4626b6cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_DocumentType_9c457f2f-c048-4666-9bdc-08ee4626b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_54909d2d-0c51-4729-888e-cf32ce305a24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_DocumentQuarterlyReport_54909d2d-0c51-4729-888e-cf32ce305a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d28b4de4-7490-49fa-8873-223d1e5e1ec0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_DocumentPeriodEndDate_d28b4de4-7490-49fa-8873-223d1e5e1ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c6b919e8-ef00-4898-b48b-0eb38f2645a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_DocumentTransitionReport_c6b919e8-ef00-4898-b48b-0eb38f2645a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a641c868-b306-4b6a-8759-4cb992969893" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityFileNumber_a641c868-b306-4b6a-8759-4cb992969893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5567e1d3-d2e6-4640-87cb-66916e1f3431" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityRegistrantName_5567e1d3-d2e6-4640-87cb-66916e1f3431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9d0de377-9967-4105-aa56-405f7b580463" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9d0de377-9967-4105-aa56-405f7b580463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d6b2a4e1-300b-4338-b455-c03ced8afb37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityTaxIdentificationNumber_d6b2a4e1-300b-4338-b455-c03ced8afb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_852ae18f-2bc5-4f65-858e-3024c228a2f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityAddressAddressLine1_852ae18f-2bc5-4f65-858e-3024c228a2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d2514aef-0fe4-48f3-9570-8170361d043c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityAddressAddressLine2_d2514aef-0fe4-48f3-9570-8170361d043c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b6f38d3-901f-4990-94da-59d8be55cff8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityAddressCityOrTown_9b6f38d3-901f-4990-94da-59d8be55cff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_37061d8a-62a9-4331-bb6f-b82e3c643545" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityAddressStateOrProvince_37061d8a-62a9-4331-bb6f-b82e3c643545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_74ebc7c6-1b23-47af-a273-848b42dc24a2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityAddressPostalZipCode_74ebc7c6-1b23-47af-a273-848b42dc24a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f6d7102c-6f19-44d6-9701-3ae80d862256" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_CityAreaCode_f6d7102c-6f19-44d6-9701-3ae80d862256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c420849e-b55c-423e-8cd4-563866311edd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_LocalPhoneNumber_c420849e-b55c-423e-8cd4-563866311edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6ad4634d-40a3-4d3e-b512-809265ccebb3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_Security12bTitle_6ad4634d-40a3-4d3e-b512-809265ccebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a655bbe9-ef47-4618-8c23-318682ee4e1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_TradingSymbol_a655bbe9-ef47-4618-8c23-318682ee4e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8db96b0a-84fa-4b23-9781-a9c58eb3ec7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_SecurityExchangeName_8db96b0a-84fa-4b23-9781-a9c58eb3ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_58660a2e-fa8b-4eab-91ab-6d43a75e1363" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityCurrentReportingStatus_58660a2e-fa8b-4eab-91ab-6d43a75e1363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e12b33bc-6394-49dc-a0f3-75bb5673308b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityInteractiveDataCurrent_e12b33bc-6394-49dc-a0f3-75bb5673308b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b6ba349f-4410-4d57-a691-86e98d64cc4e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityFilerCategory_b6ba349f-4410-4d57-a691-86e98d64cc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_04eac79b-2425-459b-a0de-ddfef47064c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntitySmallBusiness_04eac79b-2425-459b-a0de-ddfef47064c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b79a21d5-62f0-485f-8bff-061e9983e14a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityEmergingGrowthCompany_b79a21d5-62f0-485f-8bff-061e9983e14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_87f75e41-2162-4a64-82a8-aaf511baccf2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityShellCompany_87f75e41-2162-4a64-82a8-aaf511baccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_55d23610-c999-4bb3-bf32-58ce565e4167" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_55d23610-c999-4bb3-bf32-58ce565e4167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_452369a9-e35e-44e1-b082-b4a79ce6671a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_EntityCentralIndexKey_452369a9-e35e-44e1-b082-b4a79ce6671a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_732bd8b4-7609-4c44-830f-64ab7fc48c0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_CurrentFiscalYearEndDate_732bd8b4-7609-4c44-830f-64ab7fc48c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_879a529b-d791-49f2-8c4d-b090bd368b5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_DocumentFiscalYearFocus_879a529b-d791-49f2-8c4d-b090bd368b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_de7f7af8-a213-4535-ba01-aa751a3e1065" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_de7f7af8-a213-4535-ba01-aa751a3e1065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5e34832c-0792-4d0f-9459-2ba29bbca58a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6180b7ac-bcc7-4b0e-9629-7edf549402b0" xlink:to="loc_dei_AmendmentFlag_5e34832c-0792-4d0f-9459-2ba29bbca58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_bb4cd034-550b-43e6-a53e-6fafa4b6f442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:to="loc_us-gaap_PremiumsEarnedNet_bb4cd034-550b-43e6-a53e-6fafa4b6f442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_6a5751f6-c0bb-476d-ba82-4f622001b58d" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_6a5751f6-c0bb-476d-ba82-4f622001b58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue_706b8a11-b609-4747-a017-a9148086357e" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeRevenue_706b8a11-b609-4747-a017-a9148086357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_997aceca-30ff-47ca-934b-16b7471787f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:to="loc_us-gaap_NetInvestmentIncome_997aceca-30ff-47ca-934b-16b7471787f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_35555878-d2c5-4ade-9c86-63bf0c195cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_35555878-d2c5-4ade-9c86-63bf0c195cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9407006d-6939-45b8-8608-4ac95d3c5d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ae9336b-dcae-4bbe-a343-927399a78d09" xlink:to="loc_us-gaap_Revenues_9407006d-6939-45b8-8608-4ac95d3c5d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d790b612-f5a0-4a3d-9e5a-15b186753268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d790b612-f5a0-4a3d-9e5a-15b186753268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e07307fa-b37c-4f53-b5b4-24ad55e6dbe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e07307fa-b37c-4f53-b5b4-24ad55e6dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_dd8d864d-c2e1-4981-93d3-5935ab4cfc03" xlink:href="moh-20210331.xsd#moh_PremiumTaxExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_moh_PremiumTaxExpenses_dd8d864d-c2e1-4981-93d3-5935ab4cfc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense_45b7f094-12d3-4410-ada5-27b128bdf3be" xlink:href="moh-20210331.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeExpense_45b7f094-12d3-4410-ada5-27b128bdf3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_0a217435-64f0-48a5-8f37-50b1bb802fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_us-gaap_DepreciationAndAmortization_0a217435-64f0-48a5-8f37-50b1bb802fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_3605db1a-4adf-4bf9-af44-803ecf344fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_3605db1a-4adf-4bf9-af44-803ecf344fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e068bcce-ec87-4687-a7e3-3ce4098ebee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_us-gaap_CostsAndExpenses_e068bcce-ec87-4687-a7e3-3ce4098ebee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fbeffb7d-42d7-4b05-b1b4-aae62d057a49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b335467-ef40-4f92-8eef-d963c2dcc9d4" xlink:to="loc_us-gaap_OperatingIncomeLoss_fbeffb7d-42d7-4b05-b1b4-aae62d057a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d2d610f3-add5-4347-9b67-90ce93453f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d2d610f3-add5-4347-9b67-90ce93453f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_298714e8-1371-44ca-b508-5d53243b2f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d2d610f3-add5-4347-9b67-90ce93453f12" xlink:to="loc_us-gaap_InterestExpense_298714e8-1371-44ca-b508-5d53243b2f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13ef09a2-a3c0-4641-9179-08ed067e3e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d2d610f3-add5-4347-9b67-90ce93453f12" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13ef09a2-a3c0-4641-9179-08ed067e3e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fddf59d7-1a4e-4a6b-aeb4-4806b706ccd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fddf59d7-1a4e-4a6b-aeb4-4806b706ccd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_396f7440-069e-4442-b120-67ab940e8ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_396f7440-069e-4442-b120-67ab940e8ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5aba376d-cfa9-4933-a7f9-270a1b208c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_NetIncomeLoss_5aba376d-cfa9-4933-a7f9-270a1b208c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d31c9b64-d6ac-4f34-bc96-d8a9659e1872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ea40795d-38e9-428d-ae2d-a0ee00c270dc" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d31c9b64-d6ac-4f34-bc96-d8a9659e1872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_854ab936-2611-49c1-a78a-d9c2c6fb8590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d31c9b64-d6ac-4f34-bc96-d8a9659e1872" xlink:to="loc_us-gaap_EarningsPerShareBasic_854ab936-2611-49c1-a78a-d9c2c6fb8590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b9a87564-56cb-4ff8-95a2-4f19c538f7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d31c9b64-d6ac-4f34-bc96-d8a9659e1872" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b9a87564-56cb-4ff8-95a2-4f19c538f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98b46dab-0cb9-4df0-b871-06d5cbd06a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76943e04-fed6-4a8a-ba2f-a8f039011853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98b46dab-0cb9-4df0-b871-06d5cbd06a73" xlink:to="loc_us-gaap_NetIncomeLoss_76943e04-fed6-4a8a-ba2f-a8f039011853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9e6a9ce3-cd9d-48fe-9e1d-b6b36d55cb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98b46dab-0cb9-4df0-b871-06d5cbd06a73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9e6a9ce3-cd9d-48fe-9e1d-b6b36d55cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_06233112-456d-4992-a9c7-cd97df245462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9e6a9ce3-cd9d-48fe-9e1d-b6b36d55cb7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_06233112-456d-4992-a9c7-cd97df245462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_80c1aa40-d342-4710-8c5f-e847e82e7e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9e6a9ce3-cd9d-48fe-9e1d-b6b36d55cb7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_80c1aa40-d342-4710-8c5f-e847e82e7e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6834ba49-23c2-47fb-a879-b491cc67da39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9e6a9ce3-cd9d-48fe-9e1d-b6b36d55cb7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6834ba49-23c2-47fb-a879-b491cc67da39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea879cd2-df0c-4272-a34d-77d7194bafbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_98b46dab-0cb9-4df0-b871-06d5cbd06a73" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea879cd2-df0c-4272-a34d-77d7194bafbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d34051e6-46b0-41e7-9c3b-9f37360be443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d34051e6-46b0-41e7-9c3b-9f37360be443" xlink:to="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6a2b485-895f-4569-8c11-83536007bfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6a2b485-895f-4569-8c11-83536007bfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_0d13e36f-9674-4548-9baa-156454b4ba56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_0d13e36f-9674-4548-9baa-156454b4ba56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_6b4e74af-3aa9-406c-88f3-f368fde3992c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:to="loc_us-gaap_ReceivablesNetCurrent_6b4e74af-3aa9-406c-88f3-f368fde3992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b21ff9e6-6724-4973-83a7-67b58c6c0ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b21ff9e6-6724-4973-83a7-67b58c6c0ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a6ad541a-77d8-4d7f-9ff1-cfcd18e573c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ba9eef41-8049-4e6a-aa55-033b60e38f6f" xlink:to="loc_us-gaap_AssetsCurrent_a6ad541a-77d8-4d7f-9ff1-cfcd18e573c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1a7e4128-aabd-4823-9ab4-3a3b2eb37a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1a7e4128-aabd-4823-9ab4-3a3b2eb37a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_3401a629-332c-4d14-a915-f17f6d1d3ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_3401a629-332c-4d14-a915-f17f6d1d3ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_3bb633bd-fb67-43d0-8289-5a1eded53f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_3bb633bd-fb67-43d0-8289-5a1eded53f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_909b6167-e1fb-4225-a360-31ab06504b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_909b6167-e1fb-4225-a360-31ab06504b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1d5be2e2-66a3-4e68-bd3f-bd30069b4d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1d5be2e2-66a3-4e68-bd3f-bd30069b4d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_90a6d14e-0cc0-46a2-a7d3-1ad71568d2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e97ea3a-c21a-4464-9856-e778479f82bf" xlink:to="loc_us-gaap_Assets_90a6d14e-0cc0-46a2-a7d3-1ad71568d2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d34051e6-46b0-41e7-9c3b-9f37360be443" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8934376d-c8aa-4c28-ae76-aec49d86b900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8934376d-c8aa-4c28-ae76-aec49d86b900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_aa5f10e7-64cc-45ee-a78c-0fd5dcfd169c" xlink:href="moh-20210331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_aa5f10e7-64cc-45ee-a78c-0fd5dcfd169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_97905a33-579a-42b8-8bf5-dcfb548dfc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_97905a33-579a-42b8-8bf5-dcfb548dfc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_639e4a2f-f63f-45f9-800d-71738a7c9f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_639e4a2f-f63f-45f9-800d-71738a7c9f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f198cf1-1370-4372-80a6-058a0813e328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a78c719c-3e4c-408f-bdc5-b03537e70d45" xlink:to="loc_us-gaap_LiabilitiesCurrent_6f198cf1-1370-4372-80a6-058a0813e328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_67ba19f2-e74a-4e08-a06e-eca866b33227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_67ba19f2-e74a-4e08-a06e-eca866b33227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9a39d7c0-94f3-4a80-b3aa-6792aa5deaeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9a39d7c0-94f3-4a80-b3aa-6792aa5deaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_996925bc-9a47-4985-bab6-fbe77b0f5f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_996925bc-9a47-4985-bab6-fbe77b0f5f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3c2d857d-cfbd-45c5-b423-6692f9b9983e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_Liabilities_3c2d857d-cfbd-45c5-b423-6692f9b9983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_3c844627-8b04-4182-875b-a4868752ec82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_3c844627-8b04-4182-875b-a4868752ec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_48990b66-2974-49e9-ae27-df171be4b9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:to="loc_us-gaap_PreferredStockValue_48990b66-2974-49e9-ae27-df171be4b9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_70723831-340d-4b2d-8c17-09d217cc8f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_70723831-340d-4b2d-8c17-09d217cc8f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3159ebcc-7741-4ca4-a52b-c95f3211bb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3159ebcc-7741-4ca4-a52b-c95f3211bb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29d03041-6b2f-4291-8751-8578b04ee561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29d03041-6b2f-4291-8751-8578b04ee561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa2d824e-05aa-4362-89d3-254215be78b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35158d8c-ce40-476e-930b-802c9f4140d3" xlink:to="loc_us-gaap_StockholdersEquity_fa2d824e-05aa-4362-89d3-254215be78b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f3cd7ebb-181f-4044-9de5-cde414b87adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4576e110-3253-42a2-a817-1a4115af8c3c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f3cd7ebb-181f-4044-9de5-cde414b87adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5fa2eb3d-17a9-4040-a1cd-4c71e3e7e861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5fa2eb3d-17a9-4040-a1cd-4c71e3e7e861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b1771bdb-4407-4eeb-ba0c-f3ed01fce214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b1771bdb-4407-4eeb-ba0c-f3ed01fce214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d32ea72c-9288-43db-8fe2-691b738ab896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d32ea72c-9288-43db-8fe2-691b738ab896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f6ef8174-15b2-40ed-ab4e-d07d12cc254a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f6ef8174-15b2-40ed-ab4e-d07d12cc254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a2e38125-bdf6-492c-8d5b-045b09f4f3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a2e38125-bdf6-492c-8d5b-045b09f4f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b4b7c791-20cd-4193-8e0e-963511d5170c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b4b7c791-20cd-4193-8e0e-963511d5170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5a90e2d4-7f3c-4c38-ac1e-5e4592942e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4273c81a-0ffa-4be9-99e3-386068519287" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5a90e2d4-7f3c-4c38-ac1e-5e4592942e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_23d13aa5-7cdc-4c43-a2ed-6423d0a369b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_23d13aa5-7cdc-4c43-a2ed-6423d0a369b2" xlink:to="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2bf05f4a-707b-48c3-9446-fc49a3e0fe74" xlink:to="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_382a62ef-f5f9-48c4-912f-1b88c371985b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_CommonStockMember_382a62ef-f5f9-48c4-912f-1b88c371985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6242a7c7-e674-40b1-aa11-16cf98d30bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6242a7c7-e674-40b1-aa11-16cf98d30bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5b24e48-b85e-4590-9273-6f9ee32d3517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d5b24e48-b85e-4590-9273-6f9ee32d3517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_70eb1b44-ed6d-4e76-b6ee-027356ebe774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ea52827b-1517-495c-9d97-c1266d1a950b" xlink:to="loc_us-gaap_RetainedEarningsMember_70eb1b44-ed6d-4e76-b6ee-027356ebe774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b07c0874-6dfe-4d57-b7c7-c0aa0c8f48e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5ec233e7-f3e5-4c42-86b0-e6b2fcb66b64" xlink:to="loc_us-gaap_StatementLineItems_b07c0874-6dfe-4d57-b7c7-c0aa0c8f48e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b07c0874-6dfe-4d57-b7c7-c0aa0c8f48e7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bc4d1281-ef16-497a-8892-e5391e2b6fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_SharesOutstanding_bc4d1281-ef16-497a-8892-e5391e2b6fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e62c4d6-f8b9-437c-8625-75bb579303b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e62c4d6-f8b9-437c-8625-75bb579303b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_697e2609-aa50-4669-ac10-060a6da786da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_NetIncomeLoss_697e2609-aa50-4669-ac10-060a6da786da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_798c31e8-20d1-439f-b5e4-2bdab96b20eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_798c31e8-20d1-439f-b5e4-2bdab96b20eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_19021abe-b337-468d-833f-3ccc5e7ccaa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_19021abe-b337-468d-833f-3ccc5e7ccaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0952a895-888c-4e71-b208-3dd796219764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0952a895-888c-4e71-b208-3dd796219764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee21610c-3361-4a44-b2ca-62eccf1218cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee21610c-3361-4a44-b2ca-62eccf1218cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_05e83ddb-621e-47ef-8c2e-d4070c3761c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_05e83ddb-621e-47ef-8c2e-d4070c3761c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0e1c3210-6070-4364-a0be-cf739aeee1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_SharesOutstanding_0e1c3210-6070-4364-a0be-cf739aeee1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d72ebe6d-29e2-42ef-a801-2ab40aba0d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c74ace92-21d5-4ada-bb10-2bfa93f72374" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d72ebe6d-29e2-42ef-a801-2ab40aba0d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20210331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc3ce7e4-c28c-45a8-9b0f-73d19ded1c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc3ce7e4-c28c-45a8-9b0f-73d19ded1c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e2a4753-34f0-4ea3-847c-ac53bc2e36e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc3ce7e4-c28c-45a8-9b0f-73d19ded1c3c" xlink:to="loc_us-gaap_NetIncomeLoss_5e2a4753-34f0-4ea3-847c-ac53bc2e36e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc3ce7e4-c28c-45a8-9b0f-73d19ded1c3c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_48554033-0555-4a20-acc9-93ad6cb55b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_48554033-0555-4a20-acc9-93ad6cb55b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_706baad9-bc9e-4565-a883-927f2e414f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_706baad9-bc9e-4565-a883-927f2e414f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_03e6068d-d665-41d5-821c-4f70cb839c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:to="loc_us-gaap_ShareBasedCompensation_03e6068d-d665-41d5-821c-4f70cb839c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5ea6f7b5-8b5c-471b-8b85-715f0d67de78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5ea6f7b5-8b5c-471b-8b85-715f0d67de78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0405a0a5-6dd8-46dc-b70d-9256b5855366" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_ffd4fc96-b381-458b-b135-36f6871cc951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_ffd4fc96-b381-458b-b135-36f6871cc951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cb6d2960-0905-454f-a55a-47a3bd6b35a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cb6d2960-0905-454f-a55a-47a3bd6b35a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_fcb5b014-b20d-4d92-8012-53e4b21e7084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_fcb5b014-b20d-4d92-8012-53e4b21e7084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_2cc37318-83fe-4546-9541-cb455728adeb" xlink:href="moh-20210331.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_2cc37318-83fe-4546-9541-cb455728adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4077a545-ffbb-48e1-a9f4-816b632fb8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4077a545-ffbb-48e1-a9f4-816b632fb8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_568985d6-f74c-4c99-8e7e-8378c3dce70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_568985d6-f74c-4c99-8e7e-8378c3dce70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f267456f-859e-4401-ae66-c1f17eb0bb89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12a737e9-7d3c-4081-9a61-5e035d640e0b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f267456f-859e-4401-ae66-c1f17eb0bb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d69cdc4-6dc6-4cfe-86d3-6a8ceba784a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc3ce7e4-c28c-45a8-9b0f-73d19ded1c3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d69cdc4-6dc6-4cfe-86d3-6a8ceba784a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0a4dfffb-4539-4316-8317-5b7778b5153e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0a4dfffb-4539-4316-8317-5b7778b5153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a1d8fe9c-9a12-421c-9fdc-2e4539299da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a1d8fe9c-9a12-421c-9fdc-2e4539299da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aac7ca84-9e18-4cd8-8d24-ecbc76a12425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aac7ca84-9e18-4cd8-8d24-ecbc76a12425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_73a99043-862b-4021-9c03-fa4f4e280b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_73a99043-862b-4021-9c03-fa4f4e280b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5de6e9b8-4aaf-4124-9de6-922e3332eb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_257913af-affb-4bf8-a0f8-038ea69e0f65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5de6e9b8-4aaf-4124-9de6-922e3332eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f8862e39-0b8c-414a-ac18-7026ef40093f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f8862e39-0b8c-414a-ac18-7026ef40093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_69926510-a0c8-41e7-8000-c521f46e3cfe" xlink:href="moh-20210331.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_69926510-a0c8-41e7-8000-c521f46e3cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c574eb95-1df1-4d96-9d26-96cb3ee806ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c574eb95-1df1-4d96-9d26-96cb3ee806ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_d464a0f9-bf47-44e9-9e4c-46a4af4fa108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_d464a0f9-bf47-44e9-9e4c-46a4af4fa108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_26577687-c211-4f1c-bb58-1f9a4934d0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_26577687-c211-4f1c-bb58-1f9a4934d0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_582e22ad-5318-4b07-bc22-ac2d2d419a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6025a177-010c-46e2-83eb-8771662ddac5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_582e22ad-5318-4b07-bc22-ac2d2d419a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d585c34e-4f63-40c5-a235-df5e96921acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d585c34e-4f63-40c5-a235-df5e96921acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52082712-a8f3-4288-b452-d5b1c329d39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52082712-a8f3-4288-b452-d5b1c329d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6b7a9d8-6ecf-445e-a2d5-45a4abb42fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bac3eedc-c55d-45bb-8e20-a758f26b97ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6b7a9d8-6ecf-445e-a2d5-45a4abb42fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa40ea7f-3bd1-44e8-b8c3-c28d074d81cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ac0ecc76-cebb-48d9-9946-bb7b972d2ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa40ea7f-3bd1-44e8-b8c3-c28d074d81cb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ac0ecc76-cebb-48d9-9946-bb7b972d2ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3be7bf6-5f4c-4f9f-8564-578bf1186320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3be7bf6-5f4c-4f9f-8564-578bf1186320" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a618e83-7ac2-4d9f-9aa7-60e6daaebb30" xlink:to="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c09b1c2-ff9d-4291-9566-c3b059a72eb6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:to="loc_srt_MinimumMember_1c09b1c2-ff9d-4291-9566-c3b059a72eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37689b3d-ec15-4e02-91cc-f4206221fb99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eda5e144-23f6-4c9f-9504-3c20e39c5d29" xlink:to="loc_srt_MaximumMember_37689b3d-ec15-4e02-91cc-f4206221fb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d1075ca-1df1-48bf-a308-f443d9af5a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fbdc5b34-82f6-4d3b-a0ae-5c528f403b74" xlink:to="loc_us-gaap_SegmentDomain_2d1075ca-1df1-48bf-a308-f443d9af5a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_493b3a36-b686-4ac2-b990-25fd47b364fd" xlink:href="moh-20210331.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2d1075ca-1df1-48bf-a308-f443d9af5a83" xlink:to="loc_moh_HealthPlansMember_493b3a36-b686-4ac2-b990-25fd47b364fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e15eca8-349a-4b69-8e39-07ce06b0a600" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_bee1295f-f3e6-48de-a62b-8ba652b73f5d" xlink:href="moh-20210331.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_bee1295f-f3e6-48de-a62b-8ba652b73f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanMember_0aeb89b2-13dd-470d-9244-9c1ef76948f0" xlink:href="moh-20210331.xsd#moh_AffinityHealthPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27aaf39f-aaf1-47b4-b2f5-792c969d44a3" xlink:to="loc_moh_AffinityHealthPlanMember_0aeb89b2-13dd-470d-9244-9c1ef76948f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7a5ebda-3305-4480-acc3-dcc40bc409cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d597e330-a705-4b71-b0a1-492decf8e0d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7a5ebda-3305-4480-acc3-dcc40bc409cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_be13c4f3-2169-471f-80fc-886c467e9511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7a5ebda-3305-4480-acc3-dcc40bc409cb" xlink:to="loc_us-gaap_SubsequentEventMember_be13c4f3-2169-471f-80fc-886c467e9511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_409b33d6-7911-4a1b-9e7c-25571f80f067" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a469b565-83e1-42b0-addb-1a01a3288a46" xlink:to="loc_dei_EntityDomain_409b33d6-7911-4a1b-9e7c-25571f80f067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_821917f4-fe9e-43ff-8129-8a24b398f26b" xlink:href="moh-20210331.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_409b33d6-7911-4a1b-9e7c-25571f80f067" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_821917f4-fe9e-43ff-8129-8a24b398f26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_91a4e8ac-05e1-4b42-80ad-f985e296d3a3" xlink:to="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HidalgoTarrantAndNortheastServiceAreasMember_6c23b148-091c-4cb9-abb0-4027280a0223" xlink:href="moh-20210331.xsd#moh_HidalgoTarrantAndNortheastServiceAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:to="loc_moh_HidalgoTarrantAndNortheastServiceAreasMember_6c23b148-091c-4cb9-abb0-4027280a0223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HidalgoServiceAreaMember_de81ce5e-d600-4e1b-9d1f-0129a28b6acc" xlink:href="moh-20210331.xsd#moh_HidalgoServiceAreaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_62adeada-07e3-4710-a448-f4ae03e4cdab" xlink:to="loc_moh_HidalgoServiceAreaMember_de81ce5e-d600-4e1b-9d1f-0129a28b6acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6ba842df-402d-4ad8-a40f-1e868c070d3b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_4b7d5631-dd93-494a-949d-563bf29385cc" xlink:href="moh-20210331.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_4b7d5631-dd93-494a-949d-563bf29385cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_e10dceef-89c8-4c2b-8c25-4d9de9c890b2" xlink:href="moh-20210331.xsd#moh_HealthPlanContractTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_moh_HealthPlanContractTerm_e10dceef-89c8-4c2b-8c25-4d9de9c890b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfMembersCovered_546a7cd4-e296-4c1c-b809-6de0faf74848" xlink:href="moh-20210331.xsd#moh_NumberOfMembersCovered"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_moh_NumberOfMembersCovered_546a7cd4-e296-4c1c-b809-6de0faf74848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_0c44542c-14f4-4ee5-a6d3-eef50cf02305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_PremiumsEarnedNet_0c44542c-14f4-4ee5-a6d3-eef50cf02305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_05c662fc-e5c5-454f-8ffa-48a2ae7df0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_05c662fc-e5c5-454f-8ffa-48a2ae7df0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5f8daf2b-9450-421b-8a9d-3552b932ff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_459ec84c-51ee-41d6-888f-65a343dabcdf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5f8daf2b-9450-421b-8a9d-3552b932ff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0d9c1c9-bb0d-4841-b65b-f61158fc3881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99d18bac-0524-47a5-8912-869beb6c2632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0d9c1c9-bb0d-4841-b65b-f61158fc3881" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99d18bac-0524-47a5-8912-869beb6c2632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_8274fe80-c74d-48ab-ad45-80b9d987c4d7" xlink:href="moh-20210331.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_8274fe80-c74d-48ab-ad45-80b9d987c4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_85a7e7c9-4405-42fc-8b5f-a2fa40ac45c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_UseOfEstimates_85a7e7c9-4405-42fc-8b5f-a2fa40ac45c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d380bc09-9b27-4b1a-804f-8105d3d6e1e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d380bc09-9b27-4b1a-804f-8105d3d6e1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_ff091e68-1ddd-4404-a38f-51f942503ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_ff091e68-1ddd-4404-a38f-51f942503ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5e41d2a4-cc97-4f2d-8611-d3ed76eaae89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5e41d2a4-cc97-4f2d-8611-d3ed76eaae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_15ed105b-e5a9-4b02-a912-5377f7b33323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_15ed105b-e5a9-4b02-a912-5377f7b33323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3dc92228-2b79-483d-8ccc-818044e04fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3dc92228-2b79-483d-8ccc-818044e04fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_90ec5f0b-b3c6-43ea-969a-f87f552a94a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5acb8d34-763d-4d6d-91eb-14c5ef318ebf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_90ec5f0b-b3c6-43ea-969a-f87f552a94a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_780bfaeb-21d4-476e-a39a-e29ab891a2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b1e33c3f-01f0-4086-806f-a7a41506cf81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_780bfaeb-21d4-476e-a39a-e29ab891a2f5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b1e33c3f-01f0-4086-806f-a7a41506cf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f0be62c5-5057-4d3e-a089-e56a4579ae5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_780bfaeb-21d4-476e-a39a-e29ab891a2f5" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f0be62c5-5057-4d3e-a089-e56a4579ae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_76052dc7-fffa-42e3-8a25-c48357bb23d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_780bfaeb-21d4-476e-a39a-e29ab891a2f5" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_76052dc7-fffa-42e3-8a25-c48357bb23d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_4966d095-f47a-4487-b8f2-2cba25b0c1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_780bfaeb-21d4-476e-a39a-e29ab891a2f5" xlink:to="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_4966d095-f47a-4487-b8f2-2cba25b0c1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_44d94f44-320a-4207-a2d3-35f597857693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36d5962e-47fa-447a-9ccb-2afb654a3436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_44d94f44-320a-4207-a2d3-35f597857693" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36d5962e-47fa-447a-9ccb-2afb654a3436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_76c75afc-e579-4c44-a6a7-94b95a9380e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_44d94f44-320a-4207-a2d3-35f597857693" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_76c75afc-e579-4c44-a6a7-94b95a9380e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d7d67d1-b573-481d-8928-4486bce1dbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_44d94f44-320a-4207-a2d3-35f597857693" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d7d67d1-b573-481d-8928-4486bce1dbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_01752238-d5af-4ad9-90bb-9af5bc51b6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01752238-d5af-4ad9-90bb-9af5bc51b6cf" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4f47fd52-d93a-4575-8cc9-feeffc048a93" xlink:to="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_95a95a8a-e144-40dc-a8f8-f3857b81b318" xlink:href="moh-20210331.xsd#moh_GovernmentReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_GovernmentReceivablesMember_95a95a8a-e144-40dc-a8f8-f3857b81b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_eea9ce67-7be3-4e82-a030-760791f8bd66" xlink:href="moh-20210331.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_PharmacyRebateReceivablesMember_eea9ce67-7be3-4e82-a030-760791f8bd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_3f55a151-d684-495a-b170-985310ce3b91" xlink:href="moh-20210331.xsd#moh_HealthInsurerFeeReimbursementReceivablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_3f55a151-d684-495a-b170-985310ce3b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_858b4971-c63e-4c12-bbf3-6cb341da0484" xlink:href="moh-20210331.xsd#moh_OtherReceivablesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_OtherReceivablesMember_858b4971-c63e-4c12-bbf3-6cb341da0484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CompleteCareReceivablesMember_ad39e7af-b4b6-46e0-a1b8-425dbceaa98b" xlink:href="moh-20210331.xsd#moh_CompleteCareReceivablesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_cb8dc321-ddec-49d0-aaea-1ba0b5c8cd75" xlink:to="loc_moh_CompleteCareReceivablesMember_ad39e7af-b4b6-46e0-a1b8-425dbceaa98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_40fcbbca-230d-4818-87c0-72318a3f568f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_137798bc-e65a-48df-a378-42958577aa97" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_40fcbbca-230d-4818-87c0-72318a3f568f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_b1d4a4ab-763b-4d6e-a199-758e9a714650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_40fcbbca-230d-4818-87c0-72318a3f568f" xlink:to="loc_us-gaap_ReceivablesNetCurrent_b1d4a4ab-763b-4d6e-a199-758e9a714650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b635f43-9429-49f3-b8bf-8a34578a7cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_fa6e5715-eef4-401c-9e1e-24d253a93f46" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b635f43-9429-49f3-b8bf-8a34578a7cf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_fa6e5715-eef4-401c-9e1e-24d253a93f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_86f4fde8-3214-4957-9f5e-3bd401d4eb6f" xlink:href="moh-20210331.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_fa6e5715-eef4-401c-9e1e-24d253a93f46" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_86f4fde8-3214-4957-9f5e-3bd401d4eb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_f47d529d-3086-4bc2-846a-9d4b8935a670" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_fa6e5715-eef4-401c-9e1e-24d253a93f46" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_f47d529d-3086-4bc2-846a-9d4b8935a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_87108825-ae85-497b-8c1d-d44c4596e823" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b635f43-9429-49f3-b8bf-8a34578a7cf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_87108825-ae85-497b-8c1d-d44c4596e823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_5964927f-92bc-4b03-9eb7-ce180d84a9ba" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_87108825-ae85-497b-8c1d-d44c4596e823" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_5964927f-92bc-4b03-9eb7-ce180d84a9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_372ed82d-b3c0-4163-9055-1e06f5816f1c" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_87108825-ae85-497b-8c1d-d44c4596e823" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_372ed82d-b3c0-4163-9055-1e06f5816f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_1837dfa0-9977-4d52-b514-93c610e33dc3" xlink:href="moh-20210331.xsd#moh_OtherMedicareProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_87108825-ae85-497b-8c1d-d44c4596e823" xlink:to="loc_moh_OtherMedicareProgram_1837dfa0-9977-4d52-b514-93c610e33dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_18c4f414-f471-4796-866b-53bdceb64f71" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b635f43-9429-49f3-b8bf-8a34578a7cf8" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_18c4f414-f471-4796-866b-53bdceb64f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_1d87ad92-f36c-4acb-b419-1d60dd7eb0a0" xlink:href="moh-20210331.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_18c4f414-f471-4796-866b-53bdceb64f71" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_1d87ad92-f36c-4acb-b419-1d60dd7eb0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_12554294-1613-4bc6-880e-2ebea50cb2da" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_18c4f414-f471-4796-866b-53bdceb64f71" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_12554294-1613-4bc6-880e-2ebea50cb2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_ac4ab485-595a-48a5-b4b0-7eb65eb0f3b1" xlink:href="moh-20210331.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_18c4f414-f471-4796-866b-53bdceb64f71" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_ac4ab485-595a-48a5-b4b0-7eb65eb0f3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesBusinessCombination_2a9c62ce-d17b-4e7e-a6e5-ef4f5cccff07" xlink:href="moh-20210331.xsd#moh_AmountsDueToGovernmentAgenciesBusinessCombination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_18c4f414-f471-4796-866b-53bdceb64f71" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesBusinessCombination_2a9c62ce-d17b-4e7e-a6e5-ef4f5cccff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_22cbe1f2-73ef-4de8-89de-cb1bd38c1cdb" xlink:href="moh-20210331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b635f43-9429-49f3-b8bf-8a34578a7cf8" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_22cbe1f2-73ef-4de8-89de-cb1bd38c1cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f4af0f28-2024-4fde-a41b-86299ecc9d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:href="moh-20210331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4af0f28-2024-4fde-a41b-86299ecc9d00" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_69f17e68-ad81-459e-ba73-a638194d58a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_c54feb4d-3171-43d7-a278-79bd221a8efe" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_69f17e68-ad81-459e-ba73-a638194d58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_77112f6f-bd4a-4af1-98d7-d0557affb25a" xlink:href="moh-20210331.xsd#moh_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_69f17e68-ad81-459e-ba73-a638194d58a4" xlink:to="loc_moh_COVID19Member_77112f6f-bd4a-4af1-98d7-d0557affb25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c220124-1405-4fe8-bc39-5dbdca8f039b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d18514b-1223-40e7-9812-cf116ebde17a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c220124-1405-4fe8-bc39-5dbdca8f039b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember_04ba98f3-3f1a-4cc3-a420-8e698359924c" xlink:href="moh-20210331.xsd#moh_StructuredSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c220124-1405-4fe8-bc39-5dbdca8f039b" xlink:to="loc_moh_StructuredSecuritiesMember_04ba98f3-3f1a-4cc3-a420-8e698359924c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:href="moh-20210331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23d7a3da-1f7c-419b-834b-c402c433687d" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc518592-7b07-4fd3-9616-47d7736b496c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc518592-7b07-4fd3-9616-47d7736b496c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_016fb336-8c89-40be-a2fb-e9c7a8f2f325" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_016fb336-8c89-40be-a2fb-e9c7a8f2f325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b54a633f-cb3f-45b6-be14-8ee2a2ee5b6b" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_b54a633f-cb3f-45b6-be14-8ee2a2ee5b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_ce995b64-468f-46d1-92fe-03b83fd47fd5" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_ce995b64-468f-46d1-92fe-03b83fd47fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_8e373a13-ae3a-4a9b-b53e-3d90c0a6483f" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_8e373a13-ae3a-4a9b-b53e-3d90c0a6483f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_54a65dfb-07c2-4854-a759-885965420099" xlink:href="moh-20210331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_54a65dfb-07c2-4854-a759-885965420099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_5e612d05-0550-4a98-814a-74c6e480218d" xlink:href="moh-20210331.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_InvestmentsMaturityPeriod_5e612d05-0550-4a98-814a-74c6e480218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_d06d09a6-42c1-4e29-8280-8139a46b8364" xlink:href="moh-20210331.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_252eef09-0736-40f7-8de0-b318fa29956f" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_d06d09a6-42c1-4e29-8280-8139a46b8364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShare"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fa84c9d3-d37d-4e54-8af3-f2da1a4a37a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_13c8dfdc-e970-45bc-9510-5b1ad590eeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa84c9d3-d37d-4e54-8af3-f2da1a4a37a6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_13c8dfdc-e970-45bc-9510-5b1ad590eeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShareTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_698210fc-4dac-470f-8f4f-063d00cc099f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5d4a5917-0003-43fc-94b0-977457a2c768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_698210fc-4dac-470f-8f4f-063d00cc099f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5d4a5917-0003-43fc-94b0-977457a2c768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#NetIncomeperShareDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6f1208b6-f35d-45bf-b7fe-9f234fb38ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2559ee9b-b261-4d9a-a83b-7e00db859fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f1208b6-f35d-45bf-b7fe-9f234fb38ac5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2559ee9b-b261-4d9a-a83b-7e00db859fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88da53fd-410b-4941-b874-a7c90f524158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2559ee9b-b261-4d9a-a83b-7e00db859fb8" xlink:to="loc_us-gaap_NetIncomeLoss_88da53fd-410b-4941-b874-a7c90f524158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5ee7830b-5289-4065-89d6-8253ae0b073b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f1208b6-f35d-45bf-b7fe-9f234fb38ac5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5ee7830b-5289-4065-89d6-8253ae0b073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e89323ee-2857-4201-ad8e-b5e318ecc15e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5ee7830b-5289-4065-89d6-8253ae0b073b" xlink:to="loc_us-gaap_SharesOutstanding_e89323ee-2857-4201-ad8e-b5e318ecc15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_00a81bb4-09a2-4761-8ed9-988520278433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5ee7830b-5289-4065-89d6-8253ae0b073b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_00a81bb4-09a2-4761-8ed9-988520278433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_99ed52ab-2a12-4644-80ca-4207792b154e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_00a81bb4-09a2-4761-8ed9-988520278433" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_99ed52ab-2a12-4644-80ca-4207792b154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_e5f2dedd-a4e1-48eb-9768-88eeeb3fc675" xlink:href="moh-20210331.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_00a81bb4-09a2-4761-8ed9-988520278433" xlink:to="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_e5f2dedd-a4e1-48eb-9768-88eeeb3fc675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d1cb086f-29f6-479f-8980-1c97c73602af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_00a81bb4-09a2-4761-8ed9-988520278433" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d1cb086f-29f6-479f-8980-1c97c73602af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_cc87d65d-03dd-40d3-abd8-84c3ecc673ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5ee7830b-5289-4065-89d6-8253ae0b073b" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_cc87d65d-03dd-40d3-abd8-84c3ecc673ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8ed1af6a-ce15-452e-b2d9-a9266b6960f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_cc87d65d-03dd-40d3-abd8-84c3ecc673ef" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8ed1af6a-ce15-452e-b2d9-a9266b6960f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9565d217-c365-43b3-9dbd-b40427e6b758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_cc87d65d-03dd-40d3-abd8-84c3ecc673ef" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9565d217-c365-43b3-9dbd-b40427e6b758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59998987-5182-4a55-9d27-c026d5ad9f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f1208b6-f35d-45bf-b7fe-9f234fb38ac5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59998987-5182-4a55-9d27-c026d5ad9f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f9c89383-a87d-48c9-9201-c8c4e5ef1b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f1208b6-f35d-45bf-b7fe-9f234fb38ac5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f9c89383-a87d-48c9-9201-c8c4e5ef1b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cde2b009-864e-485b-b7bc-e97fe4f2b6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f9c89383-a87d-48c9-9201-c8c4e5ef1b8c" xlink:to="loc_us-gaap_EarningsPerShareBasic_cde2b009-864e-485b-b7bc-e97fe4f2b6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_61085f1d-7224-495b-907c-050159326cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f9c89383-a87d-48c9-9201-c8c4e5ef1b8c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_61085f1d-7224-495b-907c-050159326cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20210331.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_841d1da6-4c17-4acb-a31f-228bccdcd451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_2e8d82d8-01a0-4b53-95ae-0ee10efbc272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_841d1da6-4c17-4acb-a31f-228bccdcd451" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_2e8d82d8-01a0-4b53-95ae-0ee10efbc272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_421ead07-505b-47fa-bec5-5999a638c4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_421ead07-505b-47fa-bec5-5999a638c4e5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6059f8a0-f1cd-45c8-89b9-a98760af6162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4c89c75a-ab0c-42be-b628-60ca5c02852f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6059f8a0-f1cd-45c8-89b9-a98760af6162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_708895b7-9c3e-4e8e-b3b8-b00c0dc12e3e" xlink:href="moh-20210331.xsd#moh_MagellanCompleteCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6059f8a0-f1cd-45c8-89b9-a98760af6162" xlink:to="loc_moh_MagellanCompleteCareMember_708895b7-9c3e-4e8e-b3b8-b00c0dc12e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ffe0884e-9bdc-44bc-85c2-8cdb9edf4239" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_10d03d22-6f1a-482c-8d29-a2b5be8d7e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_10d03d22-6f1a-482c-8d29-a2b5be8d7e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_61908a20-3788-498d-bf90-cdb52a19e038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_61908a20-3788-498d-bf90-cdb52a19e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_74d5598d-95f6-4c28-a148-c962a3aa3302" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_74d5598d-95f6-4c28-a148-c962a3aa3302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_f4287b43-6d82-481b-92fe-40bf44ee09b0" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_f4287b43-6d82-481b-92fe-40bf44ee09b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_0c1d7c74-c8d6-4647-bd6f-a19944846cc0" xlink:href="moh-20210331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_0c1d7c74-c8d6-4647-bd6f-a19944846cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b417884b-e5b2-456b-ab99-da2fa0efa89b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4c078a23-42fe-493d-880d-b9744e0b3b9d" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b417884b-e5b2-456b-ab99-da2fa0efa89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_daa0ec7c-b142-4c99-8cb4-2ba3cf174448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_20caf101-1f66-453f-b87a-cb7f3e2d2a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_daa0ec7c-b142-4c99-8cb4-2ba3cf174448" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_20caf101-1f66-453f-b87a-cb7f3e2d2a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1fd61bee-56d6-4bd6-bd74-7c0cb83a3362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c6a7b141-bc28-400a-829f-ef7d9eb01e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1fd61bee-56d6-4bd6-bd74-7c0cb83a3362" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c6a7b141-bc28-400a-829f-ef7d9eb01e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bd7182af-a6f7-4f96-8a7f-8dab3f540261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1fd61bee-56d6-4bd6-bd74-7c0cb83a3362" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bd7182af-a6f7-4f96-8a7f-8dab3f540261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f475a388-d94d-454a-b5a3-498ab8a1a7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f475a388-d94d-454a-b5a3-498ab8a1a7c1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6aa5c030-d686-433a-a50d-b332ac5582cd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b925d023-704c-4b40-ade9-3bdc64d5c52b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b925d023-704c-4b40-ade9-3bdc64d5c52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bfc1da9b-df30-4e01-987b-57ef39840e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bfc1da9b-df30-4e01-987b-57ef39840e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e30385f7-d36a-4041-9ee7-2ef8e699fa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_56aa5b3a-519c-44e5-bc15-2343f8ff8c3c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e30385f7-d36a-4041-9ee7-2ef8e699fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac62adc9-0a62-43f5-82ca-032e4cac12f8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5be1db28-ac3b-4b46-b9c0-999c220ecfed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5be1db28-ac3b-4b46-b9c0-999c220ecfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b5f8f32d-4dc5-484f-8210-862644f5528d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b5f8f32d-4dc5-484f-8210-862644f5528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_1a933831-77bb-4158-a007-0541fd82b566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_1a933831-77bb-4158-a007-0541fd82b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_d6270d61-775e-4fee-9adf-c1e98bbfdd81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_d6270d61-775e-4fee-9adf-c1e98bbfdd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_a49b3acb-9680-41c8-b108-a1b2192923fc" xlink:href="moh-20210331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb86b29f-acf4-4ffa-b070-c3f78a2ad00b" xlink:to="loc_moh_MunicipalSecuritiesMember_a49b3acb-9680-41c8-b108-a1b2192923fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_104c0690-cff9-4476-b7d9-ef3e02bc0719" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_651eac06-b695-4eb2-91ff-5bfec51f5d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_651eac06-b695-4eb2-91ff-5bfec51f5d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e48719cc-02c5-4e1d-9d51-e6d81bd81b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e48719cc-02c5-4e1d-9d51-e6d81bd81b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc53abca-a2ce-4284-935f-8cf05bda025c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_dc53abca-a2ce-4284-935f-8cf05bda025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_274abb13-f3d6-46e9-b38f-6ca1a4a00c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_476ffc59-e33b-46be-85ea-be77664b2b42" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_274abb13-f3d6-46e9-b38f-6ca1a4a00c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d30b2d97-e423-462a-8fca-3a741c0fa97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d30b2d97-e423-462a-8fca-3a741c0fa97a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eda56772-ee60-4ec8-b1ef-cf5aebf7d2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6ee7cec-d030-4281-8067-35bfe6e23a0b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eda56772-ee60-4ec8-b1ef-cf5aebf7d2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_29eba0fd-d3cf-4201-b8a3-2de9b8600f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eda56772-ee60-4ec8-b1ef-cf5aebf7d2da" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_29eba0fd-d3cf-4201-b8a3-2de9b8600f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_826f2942-e063-47b3-8b67-90786196990b" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ecefd01f-e292-41d9-bdd2-856f6c1fc266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ecefd01f-e292-41d9-bdd2-856f6c1fc266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_20142ff1-7d6e-4a6a-b5a7-3fbbbccd7da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_20142ff1-7d6e-4a6a-b5a7-3fbbbccd7da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_271b55f6-9c2a-4b03-9fa9-d450f686ad5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3cb04620-80d0-4a0d-ae82-57c5703c47d2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_271b55f6-9c2a-4b03-9fa9-d450f686ad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4c1ec0b5-153f-4551-beed-b5049bc45d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4c1ec0b5-153f-4551-beed-b5049bc45d61" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ee34bb68-e937-47cd-9d1d-c4cd298bacd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c70e31e5-600c-433a-b7c5-8dda83ec34ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ee34bb68-e937-47cd-9d1d-c4cd298bacd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fca96e69-71ff-4cc9-9c19-a853be17980f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ee34bb68-e937-47cd-9d1d-c4cd298bacd1" xlink:to="loc_us-gaap_SeniorNotesMember_fca96e69-71ff-4cc9-9c19-a853be17980f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1f1f34d-f8bd-4eed-b7f4-1cc248630b1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_d98df1a5-9213-4886-b599-a65b0374fa10" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:to="loc_moh_A4375SeniorNotesMember_d98df1a5-9213-4886-b599-a65b0374fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_cd894a90-3e03-4011-a378-d8bd68d24bea" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:to="loc_moh_SeniorNotesDue2022Member_cd894a90-3e03-4011-a378-d8bd68d24bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_62e7d270-1fdc-4208-a738-1f978911c326" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_102fdea7-1fa5-4142-b37d-efc571041028" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_62e7d270-1fdc-4208-a738-1f978911c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_f69b3f0e-76ca-4e61-82d7-fb021d716a35" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_982ded08-c689-44be-98ae-2c427761885c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_982ded08-c689-44be-98ae-2c427761885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e630406a-9657-4c25-99bf-61ecffa21341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e630406a-9657-4c25-99bf-61ecffa21341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9d42c418-931b-4d51-b793-87d2fc8bda8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_a1ab1f26-5088-4b54-83d4-f6fb7fbeb36f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9d42c418-931b-4d51-b793-87d2fc8bda8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6e892ee1-d824-4756-b171-c52cd96b25fd" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89c09cf6-5730-4c9c-8d6d-8b4f9784997e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89c09cf6-5730-4c9c-8d6d-8b4f9784997e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f7c776a5-db80-4f36-86e9-f770feaf228a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6a5ffc83-fd1f-4f19-99df-95974f78079d" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f7c776a5-db80-4f36-86e9-f770feaf228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20210331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eadf8de6-43c3-4884-8d4c-4be37175491c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_99647a60-439f-4bf5-ac31-9b0dd55e7f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eadf8de6-43c3-4884-8d4c-4be37175491c" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_99647a60-439f-4bf5-ac31-9b0dd55e7f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c08411f-1538-416c-bfd0-26d6b03b48dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9287aee7-7af6-4f97-86ac-c9edb8112a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c08411f-1538-416c-bfd0-26d6b03b48dd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9287aee7-7af6-4f97-86ac-c9edb8112a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c133858b-5737-4541-a6b5-2ac1e6e7c1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c08411f-1538-416c-bfd0-26d6b03b48dd" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c133858b-5737-4541-a6b5-2ac1e6e7c1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_adbe7b69-25a4-4cff-962c-79531318f31d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c08411f-1538-416c-bfd0-26d6b03b48dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_adbe7b69-25a4-4cff-962c-79531318f31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a32abb54-a949-4481-8626-eb7692976caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a32abb54-a949-4481-8626-eb7692976caf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8037cc2-72b3-4c9c-86fb-48811282c98e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_902a1d3c-66bd-4bdc-9e2f-8bb540a1c994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_902a1d3c-66bd-4bdc-9e2f-8bb540a1c994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_d8aeb19c-aba0-4190-8716-a446f9efdfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_d8aeb19c-aba0-4190-8716-a446f9efdfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ecae7ef7-050a-400a-9310-472e3a509ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ecae7ef7-050a-400a-9310-472e3a509ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_c778dd58-8e19-4e05-8c27-888fa8f5ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_c778dd58-8e19-4e05-8c27-888fa8f5ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_fec39517-d8c4-4b1f-9bb6-aa2687a42180" xlink:href="moh-20210331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b450a15-b7bd-4788-b99f-3dbceeed61ba" xlink:to="loc_moh_MunicipalSecuritiesMember_fec39517-d8c4-4b1f-9bb6-aa2687a42180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0cccab64-188d-42bd-b098-448c2a78876b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ace0bdec-4397-4353-9a15-90eba5cb4837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ace0bdec-4397-4353-9a15-90eba5cb4837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fbf39e3-999e-4911-8f7d-3f0d4403e735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fbf39e3-999e-4911-8f7d-3f0d4403e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_047daa87-776c-429a-b746-6e5aa7db674e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_047daa87-776c-429a-b746-6e5aa7db674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a6e3aa8-7fa9-4205-ad8e-ec845359084f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da189a8c-504a-4912-831e-68a50474ec88" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a6e3aa8-7fa9-4205-ad8e-ec845359084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7845c9d8-618f-4c8b-994c-2a47c0812abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7845c9d8-618f-4c8b-994c-2a47c0812abd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_19e041dc-bb2f-45ac-9c88-b4b7d6e5b5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_19e041dc-bb2f-45ac-9c88-b4b7d6e5b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0b4b40e9-1d2c-4108-bba7-46ea265f359d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0b4b40e9-1d2c-4108-bba7-46ea265f359d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_968f0d39-9a36-4bd5-aec0-4aa3aaf7d286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_968f0d39-9a36-4bd5-aec0-4aa3aaf7d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_8fd17c14-8dd0-42aa-af99-4e1aeed57230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_8fd17c14-8dd0-42aa-af99-4e1aeed57230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e7f61c0-43fb-4722-840d-ed72f58e34a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_88579fed-c1c3-4d30-b9d1-909defe98293" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e7f61c0-43fb-4722-840d-ed72f58e34a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7845c9d8-618f-4c8b-994c-2a47c0812abd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fdb384b8-29e1-4aa1-9e91-70da6ce04da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fdb384b8-29e1-4aa1-9e91-70da6ce04da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8f95136b-1553-4113-aba2-e7e07c895688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8f95136b-1553-4113-aba2-e7e07c895688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d3075509-4f8f-4372-83f2-aeac3c7b9bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d3075509-4f8f-4372-83f2-aeac3c7b9bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_3452ec50-80e5-49b8-923a-eaa2e46e4267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_3452ec50-80e5-49b8-923a-eaa2e46e4267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_99e64c74-d820-4efa-ad22-04f0b5cbdd27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_32ed6ca3-d777-430f-8268-35f642eaa3ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_99e64c74-d820-4efa-ad22-04f0b5cbdd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40b5b59b-0c09-4f1e-8fca-6495093b6273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_81b20da1-c4ff-4b60-8b91-418abf6e670d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40b5b59b-0c09-4f1e-8fca-6495093b6273" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_81b20da1-c4ff-4b60-8b91-418abf6e670d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_3922a0d9-a338-4b58-a4da-a72a1d10a7de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40b5b59b-0c09-4f1e-8fca-6495093b6273" xlink:to="loc_us-gaap_HeldToMaturitySecurities_3922a0d9-a338-4b58-a4da-a72a1d10a7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_1ee9a0e1-2951-45ea-ad0d-5a12a698e37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40b5b59b-0c09-4f1e-8fca-6495093b6273" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_1ee9a0e1-2951-45ea-ad0d-5a12a698e37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_a6005c55-6e54-41f5-b32b-7d438f553742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40b5b59b-0c09-4f1e-8fca-6495093b6273" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_a6005c55-6e54-41f5-b32b-7d438f553742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3ef6953-0735-4b6c-ada4-b4f1769fa4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3ef6953-0735-4b6c-ada4-b4f1769fa4e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:to="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_230f5ca9-c372-4e9b-ba35-d9648d01b2d7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_656e75a7-93e4-4d93-87ad-b75f3b6f177c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_656e75a7-93e4-4d93-87ad-b75f3b6f177c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_8b84c504-96eb-4b4c-a86d-3c51e06676f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_492cc7b7-c488-48bd-bb95-e8dba18d341b" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_8b84c504-96eb-4b4c-a86d-3c51e06676f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1faf45a9-2522-4503-ab0e-62690b03b4ec" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_670b3472-a898-4b0d-b57d-5cf90facb1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_670b3472-a898-4b0d-b57d-5cf90facb1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c7b81bc6-d2ae-4708-bd99-5df92596fc72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c7b81bc6-d2ae-4708-bd99-5df92596fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_ef3cc167-168c-46ba-951e-984d20a88f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_888cbf9c-a3da-43b2-8c7c-4c2f7a166e28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_ef3cc167-168c-46ba-951e-984d20a88f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_bab81453-34c0-44f0-9059-f1d8a2ed9b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_1105393c-5cc9-488b-a662-f1dd124d9709" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_bab81453-34c0-44f0-9059-f1d8a2ed9b5c" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_1105393c-5cc9-488b-a662-f1dd124d9709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_beade76c-b822-4538-9564-71893b09fb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_4bfc98b2-6f61-4b54-93c3-32d10eae4b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_beade76c-b822-4538-9564-71893b09fb53" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_4bfc98b2-6f61-4b54-93c3-32d10eae4b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_f8b50a8e-aa94-45fe-9e06-5f8b0b8ec000" xlink:href="moh-20210331.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_beade76c-b822-4538-9564-71893b09fb53" xlink:to="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_f8b50a8e-aa94-45fe-9e06-5f8b0b8ec000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_570f5e6e-6de3-4212-9a3c-f758f98ad01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_570f5e6e-6de3-4212-9a3c-f758f98ad01f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27b0af88-d828-43d9-8e64-4b9e5e2b4f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec71db64-f152-49ee-aeea-02c6de869b96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27b0af88-d828-43d9-8e64-4b9e5e2b4f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_3585c386-87eb-48ba-9b00-26e9e92c77db" xlink:href="moh-20210331.xsd#moh_MagellanCompleteCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27b0af88-d828-43d9-8e64-4b9e5e2b4f3e" xlink:to="loc_moh_MagellanCompleteCareMember_3585c386-87eb-48ba-9b00-26e9e92c77db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_9f5c9824-d757-4289-92f7-0559dd5585ae" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_73a52f79-0aa6-459f-8efb-3879111b5d9c" xlink:href="moh-20210331.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_73a52f79-0aa6-459f-8efb-3879111b5d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_d996bf58-468f-43a2-bfbf-b99e7078137c" xlink:href="moh-20210331.xsd#moh_PharmacyClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_PharmacyClaimsPayable_d996bf58-468f-43a2-bfbf-b99e7078137c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_f21da673-632c-44ae-8083-847969a18722" xlink:href="moh-20210331.xsd#moh_CapitationClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_CapitationClaimsPayable_f21da673-632c-44ae-8083-847969a18722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_8f96992d-365a-4b8d-8894-a70293a440ba" xlink:href="moh-20210331.xsd#moh_OtherClaimsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_moh_OtherClaimsPayable_8f96992d-365a-4b8d-8894-a70293a440ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2a87774d-3347-4bef-a835-4353e6ff6a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_5a0c5924-f0ff-4775-a877-66c205683e25" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2a87774d-3347-4bef-a835-4353e6ff6a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2aa4b0e4-a874-4298-b687-18cd9534b491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable_0aaa8d64-5934-4f7e-a2a9-7b8909a9f9f9" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2aa4b0e4-a874-4298-b687-18cd9534b491" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayable_0aaa8d64-5934-4f7e-a2a9-7b8909a9f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_7a27e04e-ef7c-469c-8f13-5ba3d43fd502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2aa4b0e4-a874-4298-b687-18cd9534b491" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_7a27e04e-ef7c-469c-8f13-5ba3d43fd502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7495e2c6-1d75-46fb-b379-bd7491ffa80d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7495e2c6-1d75-46fb-b379-bd7491ffa80d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1de7a25e-0503-4df6-a0c7-835df1da1dca" xlink:to="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_eeff9bf3-296d-4238-94ae-3d473095fc80" xlink:href="moh-20210331.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:to="loc_moh_MedicaidMember_eeff9bf3-296d-4238-94ae-3d473095fc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_ec288328-4c91-4c97-85c0-720fc4464ee2" xlink:href="moh-20210331.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:to="loc_moh_MedicareMember_ec288328-4c91-4c97-85c0-720fc4464ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_a0fc49ae-851e-4998-a284-20571ae8bf51" xlink:href="moh-20210331.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3a3ef1c1-c971-4c49-a127-c106530337ee" xlink:to="loc_moh_MarketplaceMember_a0fc49ae-851e-4998-a284-20571ae8bf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_8de661a9-77ba-44be-aa4d-9b14af4fcc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_89d91c4c-85a6-4a1c-b247-96fd70ca41f3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_8de661a9-77ba-44be-aa4d-9b14af4fcc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_8de661a9-77ba-44be-aa4d-9b14af4fcc00" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4f39f347-6fcd-4fee-825e-2203f41f3d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4f39f347-6fcd-4fee-825e-2203f41f3d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:href="moh-20210331.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2dc97ffb-7edf-4cca-a23a-295a55016bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2dc97ffb-7edf-4cca-a23a-295a55016bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_908c30dc-ff8e-4346-942f-2dbeacbc3a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_908c30dc-ff8e-4346-942f-2dbeacbc3a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_7152b5ef-ebd3-42aa-8ec9-ffda7b4a6aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0a275aab-6bbd-4c41-89eb-74996a9df0aa" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_7152b5ef-ebd3-42aa-8ec9-ffda7b4a6aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:href="moh-20210331.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1fc13136-79e6-45b4-9647-e75cf272ec7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1fc13136-79e6-45b4-9647-e75cf272ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_bcaff3d4-6327-4d7a-9629-bf04cdcbf209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_bcaff3d4-6327-4d7a-9629-bf04cdcbf209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_da08f452-92b8-4feb-8efc-396890f7b1fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_931fab09-4d8f-49ef-ac27-7d59d8a5bc95" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_da08f452-92b8-4feb-8efc-396890f7b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ChangeInAcquiredBalances_108cde1f-708d-4a50-909d-1833bcc4f68d" xlink:href="moh-20210331.xsd#moh_ChangeInAcquiredBalances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_ChangeInAcquiredBalances_108cde1f-708d-4a50-909d-1833bcc4f68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_cdb02eee-c3f7-484a-9218-c10bea3f4af3" xlink:href="moh-20210331.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_cdb02eee-c3f7-484a-9218-c10bea3f4af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_39d6e16a-f68c-4a72-9f7f-0e81436ddeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ade63ebe-b88d-449e-a59e-5e5f16ca4f60" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_39d6e16a-f68c-4a72-9f7f-0e81436ddeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20210331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ffff2c4a-b846-453d-ad58-405eab19d296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_7de4bbcb-7385-4088-bef6-b4515c5eef0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ffff2c4a-b846-453d-ad58-405eab19d296" xlink:to="loc_us-gaap_LongTermDebtTextBlock_7de4bbcb-7385-4088-bef6-b4515c5eef0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_976e7603-ff72-404b-ac36-75baa9ebd1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2a61e153-1b28-43f6-b3fd-02bd12ad0dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_976e7603-ff72-404b-ac36-75baa9ebd1a9" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2a61e153-1b28-43f6-b3fd-02bd12ad0dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1c05be4c-ced5-4681-99fd-ef4e3f761d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1c05be4c-ced5-4681-99fd-ef4e3f761d6d" xlink:to="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c8ae5cd1-c78b-4aef-97e7-369bd05cd7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_46e2e1f2-fb51-4a24-9c68-a5a0bc821f0e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c8ae5cd1-c78b-4aef-97e7-369bd05cd7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_15a90a03-81f1-45a5-9a99-ae44b296b164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c8ae5cd1-c78b-4aef-97e7-369bd05cd7c7" xlink:to="loc_us-gaap_SeniorNotesMember_15a90a03-81f1-45a5-9a99-ae44b296b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:to="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f24d62a-78d7-4bc2-bf74-057fd8bf2378" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_f9bb57c0-feb9-4388-aa77-5f363ab1e902" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:to="loc_moh_A4375SeniorNotesMember_f9bb57c0-feb9-4388-aa77-5f363ab1e902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_5a5f9149-976e-417c-acc7-accd35939b99" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:to="loc_moh_SeniorNotesDue2022Member_5a5f9149-976e-417c-acc7-accd35939b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f02f6ee3-dec6-42c9-857f-32f821238c0f" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3286affd-71b9-48dc-b4cc-8457fd26d1e0" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_f02f6ee3-dec6-42c9-857f-32f821238c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_089ac5dc-2668-4c14-88c3-c640388a9e03" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3c6d764-a141-4fa1-a748-1cf8bc8e7b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3c6d764-a141-4fa1-a748-1cf8bc8e7b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_fe15fca9-15db-4aa2-b34c-a8a94f221ae8" xlink:href="moh-20210331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_fe15fca9-15db-4aa2-b34c-a8a94f221ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8dcc8212-007d-43ef-9534-aa70349579b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8dcc8212-007d-43ef-9534-aa70349579b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_17bac1f7-10df-44be-9adc-b42f699fe224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1e088bfa-8411-42c4-9410-47b71a686b51" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_17bac1f7-10df-44be-9adc-b42f699fe224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2a6d586b-02b8-4ab5-a41a-d5191cdad229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2a6d586b-02b8-4ab5-a41a-d5191cdad229" xlink:to="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_314e9088-84fa-413b-ab30-986ce7bdc296" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_69bf5e54-962d-4bdc-aee8-be9060956b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:to="loc_us-gaap_LineOfCreditMember_69bf5e54-962d-4bdc-aee8-be9060956b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4c00124a-1be5-4d1e-b5c0-65aca50974a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b87bdf69-cc29-48a7-9580-397e8ab0907c" xlink:to="loc_us-gaap_SeniorNotesMember_4c00124a-1be5-4d1e-b5c0-65aca50974a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_98fb694e-faec-4781-88cb-5fdf818e26e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e1858ea6-c934-486b-a524-e1330f876898" xlink:to="loc_us-gaap_CreditFacilityDomain_98fb694e-faec-4781-88cb-5fdf818e26e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_64c90014-dbca-4121-a2de-ccfe89fee705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_98fb694e-faec-4781-88cb-5fdf818e26e4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_64c90014-dbca-4121-a2de-ccfe89fee705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_65d9e868-1f27-47b2-b60e-21c9774827a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_27a2f32c-0fe8-425e-b9e0-1c57555a75cd" xlink:href="moh-20210331.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:to="loc_moh_A4375SeniorNotesMember_27a2f32c-0fe8-425e-b9e0-1c57555a75cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_17383720-4625-4b0f-b7c3-b6b90f7022e5" xlink:href="moh-20210331.xsd#moh_SeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:to="loc_moh_SeniorNotesDue2022Member_17383720-4625-4b0f-b7c3-b6b90f7022e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_26b63ab3-28d0-4726-b61a-6f0b12c097cc" xlink:href="moh-20210331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_449610d9-b5bc-473a-8fae-07cadfb73948" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_26b63ab3-28d0-4726-b61a-6f0b12c097cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c59bdfc2-5c02-42c3-ac42-2e943e7c7993" xlink:to="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_92dec33d-765b-4845-94db-75dbb7bc9e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_92dec33d-765b-4845-94db-75dbb7bc9e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_44323a6f-35dc-45ce-8e3c-4b30d1c7a4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentTerm_44323a6f-35dc-45ce-8e3c-4b30d1c7a4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_58fed6cd-5da2-4a7e-9430-1d527cbf49d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_LineOfCredit_58fed6cd-5da2-4a7e-9430-1d527cbf49d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6586e0a1-49c9-44bb-a4e4-4a78f883fda2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6586e0a1-49c9-44bb-a4e4-4a78f883fda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cbc0b576-6a7a-4827-a3a3-5943e7302e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_73a0a5e5-b84b-44a0-a2c5-e61e53ca284b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cbc0b576-6a7a-4827-a3a3-5943e7302e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20210331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ea964a8d-1ce8-4f96-b71a-728fcf80d801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_411cf752-0763-4439-a2c8-b5dc891682d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ea964a8d-1ce8-4f96-b71a-728fcf80d801" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_411cf752-0763-4439-a2c8-b5dc891682d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d1dd9d94-5dcb-4208-ae83-f8f15ebb49bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d1dd9d94-5dcb-4208-ae83-f8f15ebb49bf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afc53e76-552b-441d-9622-a574a786581f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c4f9d98e-3aba-4394-b773-3b6450cd2774" xlink:to="loc_us-gaap_EquityComponentDomain_afc53e76-552b-441d-9622-a574a786581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f956e196-627a-4402-a2d5-eb419fc5005e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afc53e76-552b-441d-9622-a574a786581f" xlink:to="loc_us-gaap_CommonStockMember_f956e196-627a-4402-a2d5-eb419fc5005e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ee80aadf-b901-4816-9e99-ef65829faec1" xlink:to="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bd37e953-a1b4-42fe-9e07-cfa14dcdf11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bd37e953-a1b4-42fe-9e07-cfa14dcdf11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_59595789-7a65-4b03-90a4-766a2b984911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_59595789-7a65-4b03-90a4-766a2b984911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_18d6815e-2575-4078-875e-ce0a2eaafd56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_18d6815e-2575-4078-875e-ce0a2eaafd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20ee847c-e61c-42d7-a7eb-2292f7f60f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20ee847c-e61c-42d7-a7eb-2292f7f60f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_31b0d66d-34a8-4f16-9729-4636f52c57e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c5fbfffa-3060-40fe-a347-3cc98d11604e" xlink:to="loc_us-gaap_ShareBasedCompensation_31b0d66d-34a8-4f16-9729-4636f52c57e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20210331.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8d3ee4d2-678a-4a83-bd6a-7b86f23e0514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2edacb3a-4c38-4384-afba-62892ca07731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8d3ee4d2-678a-4a83-bd6a-7b86f23e0514" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_2edacb3a-4c38-4384-afba-62892ca07731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20210331.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4b193c4e-46e8-4689-8253-f68f065b0075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e061cd37-87c6-4022-85d6-7597d0162e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4b193c4e-46e8-4689-8253-f68f065b0075" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e061cd37-87c6-4022-85d6-7597d0162e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20210331.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cb6c7d32-5fb6-460c-beac-1879050c941f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cb6c7d32-5fb6-460c-beac-1879050c941f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:to="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9c35f704-5207-4a2b-b680-d9494b57a908" xlink:to="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e5c3f694-ceba-4e49-87e6-2ca5d0577d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:to="loc_us-gaap_OperatingSegmentsMember_e5c3f694-ceba-4e49-87e6-2ca5d0577d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_4204b19c-289c-468e-88b7-36f7dc0c8b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_522fffa1-7ee7-4323-ba25-9924932b41a8" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_4204b19c-289c-468e-88b7-36f7dc0c8b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83143910-7ea0-497c-b344-114b3c13476a" xlink:to="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_3717428e-b2c1-4a48-99f9-3a2f0b498673" xlink:href="moh-20210331.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_moh_HealthPlansMember_3717428e-b2c1-4a48-99f9-3a2f0b498673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_a42cbb9d-1c04-46fc-aeb5-1decf6a68450" xlink:href="moh-20210331.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_moh_MedicareMember_a42cbb9d-1c04-46fc-aeb5-1decf6a68450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_bcc23f90-ebd3-4467-830b-56600915e99f" xlink:href="moh-20210331.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_moh_MarketplaceMember_bcc23f90-ebd3-4467-830b-56600915e99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_71047fb6-fc29-4f9c-9328-1b5764d3f737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5405385-aec3-40c0-94ee-d3e30dcf0eaa" xlink:to="loc_us-gaap_AllOtherSegmentsMember_71047fb6-fc29-4f9c-9328-1b5764d3f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c90a1cbe-ef0b-4cbd-ab18-884f5b64c72f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad66b102-d487-4a03-989b-2fd47366e776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_Revenues_ad66b102-d487-4a03-989b-2fd47366e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b603c765-e2e1-461f-b3d0-22805c8eddd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_Goodwill_b603c765-e2e1-461f-b3d0-22805c8eddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a78183c4-d52e-4466-8f01-216941e3e006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a78183c4-d52e-4466-8f01-216941e3e006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_d0e3f295-e347-49d8-bccf-90b5317f88f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_d0e3f295-e347-49d8-bccf-90b5317f88f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8cfa4daf-fcb8-4207-abf7-3f6216fa13f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_GrossProfit_8cfa4daf-fcb8-4207-abf7-3f6216fa13f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f30ae921-9fc6-4fe5-865e-ba71daaaa2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_CostsAndExpenses_f30ae921-9fc6-4fe5-865e-ba71daaaa2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39ef5915-a5e0-4a3d-8dd2-8aa1018b4e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_OperatingIncomeLoss_39ef5915-a5e0-4a3d-8dd2-8aa1018b4e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_111a9201-8e2d-4c26-aa83-020b7a21a362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_111a9201-8e2d-4c26-aa83-020b7a21a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6bc66dd3-5917-488a-83a5-8d997210bb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e8a58d92-3132-4881-9154-2d5d46378584" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6bc66dd3-5917-488a-83a5-8d997210bb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_39bf75cc-c863-402d-9ed5-77fbe4d1a15e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_389fa3cf-ff5e-4453-bd56-ec2b5e812c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_39bf75cc-c863-402d-9ed5-77fbe4d1a15e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_389fa3cf-ff5e-4453-bd56-ec2b5e812c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>moh-20210331_g1.jpg
<TEXT>
begin 644 moh-20210331_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-H96EL82!(
M861E<G-B97)G97(   60 P "    %   $*R0!  "    %   $,"2D0 "
M S<R  "2D@ "     S<R  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@
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M7HK!0MJV?,2S[$<UXQ5OG_F?2MM=07D"S6DT<\3?=>-@P/XBI:^?/#WB2_\
M#E\)[&0F,G][ Q^20>X]??M7NVD:K;ZUI4%_9G,4RYP>JGH0?<&N*O0=)WZ'
MNX#,88Q-6M)=/\B[1117.>H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M??".%F\17LX^ZEKL/'=G4C_T$USXE)TG<]+*Y2CC(6_K0]<HHHKQ#[\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBHYKB&VC,EQ*D2#JTC!1^9H$VEJR2BH+>_M+S/V2Z@GQU\J0-C
M\JGHV!--704444#/"/&WAR3P]K\JI&19W#&2W;'&.Z_4=/IBN<KZ-U72;/6M
M/>SU&$2Q-SZ%3V(/8UYCJWPHU&"4MH]Q'=1=DE.QQ_0_7CZ5ZU#%1<;3=F?&
MX_**L*CG05XOIU1P%%=9#\-/$TLFV2SCA&?O23H1_P".DFNU\,?#2TTB=+O5
M9%O;E"&1 ,1H?7G[Q^N/I6L\33@M[G'0RO%5I6Y6EW>A/\-_#KZ+H;75VFRZ
MO2'*GJB#[H^O)/XCTKLJ**\><W.3DS[?#T8T*2I1V0C*'4JP!5A@@]Q7@/BS
MP]+X<UV6V96^SN2]O(>C)Z?4=#7O]9VM:'8Z_I[6FHQ;TZJP.&0^H/K6N'K>
MREKLSCS' _7*=EI);?Y'SM17=ZI\*=6MI6.ES0WD6?E#-Y;CZYX_6L^#X:>)
MII-LEG' /[TDZ$?^.DFO65>DU?F/CY9?BHRY73?W?J<H!DX%>W_#[PZ^@^']
MUTFR[NR))5/5!_"I^@R?J357PO\ #BST29+S49%O;Q3E!M_=QGU /4^Y_*NU
MKS\3B%-<D=CZ+*LLE0E[:M\71=@HHHKA/H0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$\5U;QSVTJ30RJ'CD1@RNI&001U%? M>P_!;XM'PU<Q>'?$4W_$GF?%O._\
MRZ.3W/\ <)//H>>F:!V/IVBD4AE!4@@C(([TM BIJU\=,T6]OUB,YM;>281
MXW[5)VYP<9QCI7E/A3X_P^*O%6G:);^')87O9=AE:[#!!@DG&SGI[5ZCK_\
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MQ.!6O9?"G6II@+R:VMHL_,VXNWX ?XBO2_#WARQ\-Z?]FL$)9N99G^](??\
MH*TK8F"BU%W9S8#*JTZJG55HKOU-:BBBO(/M KY^\7V:6'B_4K>( ()RR@=
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M4444 >D?!_\ X^]5_P!R/^;5ZE7EOP?_ ./O5?\ <C_FU>I5XN*_C,^[R?\
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M^UM7CN'MA*L3?9T#,I;.#@D<<8_&L+P?\7?#GC?7#I6BQWPN!"TQ,\*JNU2
M>0QYY%9WQ_B\SX1WC9QY=Q WU^<#^M>5_LU?\E)U#_L$R?\ HZ&@9]/UYWXD
M^-?ACPIXCN]$U:#41=VA4.8X496W(K@@[_1AUQ7HE8-WX'\+ZAJ<VHZAX?TZ
M\NYB#)-<VZREB %&=P/8"@1PW_#1O@K_ )Y:K_X#+_\ %T?\-&^"O^>6J_\
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MOUZI7-/\.?!CR!_^$7TI&!!!BM$3!'<;0,5TM @HHHH **** "BBB@ HHHH
M*^??%O\ R..J_P#7T_\ .OH*OGWQ;_R..J_]?3_SKOP7QL^=S[^##U_0QZ**
M*]0^0"BBB@#TCX/_ /'WJO\ N1_S:N9\>_\ (]:G_OK_ .@+73?!_P#X^]5_
MW(_YM7,^/?\ D>M3_P!]?_0%KCA_O,O3_(]RM_R*J7^)_J<[11178>&%%%%
M!7I'P?\ ^/O5?]R/^;5YO7I'P?\ ^/O5?]R/^;5SXG^"ST\J_P!]A\_R9S/C
MW_D>M3_WU_\ 0%KG:Z+Q[_R/6I_[Z_\ H"USM:TOX<?0Y<7_ +Q4]7^84445
M9S!1110!Z1\'_P#C[U7_ '(_YM7J5>6_!_\ X^]5_P!R/^;5ZE7BXK^,S[O)
M_P#<H?/\V?"FK^9_PEU]Y'^M^W2;/][S#CK7M\;_ +0Z-EHUD&/NL;#'Z$5X
MGJ+!/&EVSD*HU!R23@ >8:^Z*YCUSY<\?GXQ'PC<GQP,:+O3S@/LG7<-O^K^
M;[V.GXU)^S5_R4G4/^P3)_Z.AKUCX]_\D@U+_KM!_P"C5KR;]FQU7XE7H8X+
M:5(%]SYL1_H: Z'U!7P;HTMU!KMA+IL8EO([F-H(R,[I P*C'N<5]Y5\,>$/
M^1WT/_L(V_\ Z,6@$>W/XU^. C8_\(I".#RMF21]!OKUOP3>:QJ'@S3[KQ-
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M:>)O^?./_O\ I_C7M]%..+J122L9U,EPU2;FV[MWW7^1XA_PK3Q-_P ^<?\
MW_3_ !H_X5IXF_Y\X_\ O^G^->WT57UVIY$?V%A>[^]?Y'B'_"M/$W_/G'_W
M_3_&C_A6OB;_ )\X_P#O^G^->WT4?7:GD']A87N_O7^1PGPZ\,:IX>N+]]4@
M6(3*@3;(&S@G/3ZUW=%%<M2;J2YF>KA\/##4E2ALCY3U#X%>/KR^N[S^S[7,
MT[N$^UIDY.<]<=_6OJM22H)&TD<@]J6BH.@XGXM^'=5\5?#VYTG0H$GNIIHC
MM>0)\JL&)R3CM7GWP?\ A;XI\%^/3J.MVD*VCV<D7F17"MAB5(&.O\->[T4
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MM(J *N23DD5Y!X6^%'Q5\)7[ZCX>:SL+N6$PNS312'86!(PP8=54Y'-?3-%
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M]P))"/T-=K\-/"FL^&M)OIO%5^NH:UJ5SY]Q.KE\*% 5,D#I@].!G XKM**
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>moh-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:moh="http://www.molinahealthcare.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="moh-20210331.xsd" xlink:type="simple"/>
    <context id="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e071f24a77d46dfba2cb28cb63b9814_I20210423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-04-23</instant>
        </period>
    </context>
    <context id="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6dd146149d7f42a2af7252fcdc08ad86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4cb5b33923d44d48d6582373ff531da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3cf6223852e470887ad11579c175927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa001ce9f4904c2cb8455fe03b80f1a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3b15a9bdcdf4106965f1b2a88548c51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6cd7e619ba24682912dc1fadfbab673_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8589aefa8f474c159c7cbd51cc1dc98d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2976206aa3ad4285b3d0c9437c99451d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i031215c830df4ab98eaef20814b485e1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i32c24e92034d4912a1dc6ad0b7a49302_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b49845196634f1eb09dc0789aad5d88_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5bfeb6ebf43e495da6988002aa92c4e4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib3c912df2a854b3083036cd0dcf70baf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8b8ea1f43854547ba8cbbd4c725d620_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17551bd8c156404499e937e8c5664e40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i609e20519d204f7e8a1f149974d04ee8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0394e14e2ddb48f081b7cc6c9f6df17d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ba871cbc2264413b2e0bb8f269203ea_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i95adf552e2d049cbb4f27501f9a4dbad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i691ed4ca23c74d7e8b19e0fc8b00560c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i86edd17ebbb94db398c8c9bf6325ad1e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9fcdc345193e4adcb86cd7488aa5651e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5fb5b5c80f1a4b3988c0ec8e5cf119cc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id2edda39d39945aa83dab49b96ac9571_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7250e43387d044659d3061f2be2719fd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if6be335f460e4209851cdbd1a986fddb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib2f6d5bf02f946d797a178b2243023d2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3024a8346b4e4de8a8f90f83f027c364_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia27ea1622e334357a45a3002d5876949_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:HidalgoTarrantAndNortheastServiceAreasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e9ad87a1c5a48a78489b9938d8eae4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:HidalgoServiceAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf4236126773456e8b7ccaac00eaead1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba56960a4e954002902a215411511282_D20210422-20210422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-22</startDate>
            <endDate>2021-04-22</endDate>
        </period>
    </context>
    <context id="i85aa51d656a149329969f88cf738f0a2_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1bf57704a9f64502924a6c99e4e92834_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icb11d0cba77b4ec99ba52541a7506b5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1535abc2ae740d5bf9944b12b802296_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icdfa8c0b58cc4e4f8075fdbc4b67b24c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4eddaa9fd8a147b7949ef2c683c7f322_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if14923db8e82452ead1cb8577da709c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e3e8a05c22746188f8006f0cc466248_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i68770710aff54e859f753302935e9a33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i060bbae192754af18735ff173a812ff9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:CompleteCareReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i45f348898f464752bc2bb4d15a2e7e2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:CompleteCareReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if812ef76536b438e99d9bdfc430cff90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0497f33d5bf4e7187e8f9c8f6fb4d3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:StructuredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89e7332f8532480b940cc14c82d5a66c_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf47769cb2064e43baa8252d52471732_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2be9ab0685c342fdb10ce4970ddf28c6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a91a1b851c5460ea799477e1d8ffea0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d894df64afc4b708465d180e9e4d828_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i34971f76fea54413af66394067162aa4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia5ea329b6ce44f08b01706088442cd3d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia72442a16d054cf6b2add623661e1309_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c2c65749b7345faafdfba7c882cf15c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idffa9f6c7ef243a0945eb16b52a45524_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i89eff6b8e212434c80c97106458c80f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6e8486b4460641688370ab5c52704984_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6fffabe708ad4e94ba5b0636c6518d9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibbd148c06afc46d29d9896ffc0517005_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6e957ac778a7477899bb650c9835d5d2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i10c53b5850b44aea95b55cac2de8f94a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if96c7085c6d14448b5deab7fd704714d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if612cc865e074f888043131a4ddf811f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i367c629760754439af0a0d0519f9eccd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i90962768e25e4a079c9fa088d378e436_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i71e2bb0b925543119143aeb28e57dfb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i776889e2aac941f6b8777a276968f455_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c4d02fdb08d40358bf0167b7e447156_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2484837902cc473abe31b5f45b8b5d5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie81450857ab248f39dd4d14ca25f6884_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i624191553621462ab6d620e9fa29afe5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib66bdf91f7c54e64ae93432279b0c7d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacc3f4d81df942ecbe0f17b7684f3a38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i544ceef696034b4e8335a1bbb52a445a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8626edaea2f544f68b7eeffc9cdc5c74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ffff4e3ba0343a2861c235a54ba7686_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb78d77ebc514051a2802fae9ffa2745_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89766e1120fe4cfdbf2765441a571fcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4908d014efa1485e92e9f298580b4e47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8b9ad1f540c43b5b9d22ae02827f3b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bde201c232c4a07b85ad5ea4c855816_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i573d0b621da54b35beb8a4b399d05e90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54b1d89062504208983df2df1d02c5ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c9348c98a684882a89a1791746cd066_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i999e7c8caf5d4a449709bfcf9071b5d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5cfb1e5f1124f08a113456fed9b0aba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i96a3d683acc0407d9bc0027bd95e5c34_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifabcec5c78a74e89969fc2325fe4e83f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0d77563cade44be7befb74c969a2dd4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cd7f1592daf42cfa111ef9d3525f7dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i59b0cf8fcf28410b85ca7ccc1bd5028e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ed421117c6f422a9b4454963e89aaa4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4316903bcdcb421181b02d8d89f68ed1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47c23e80da0749b18fdf5572eeccf013_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d58211ae65042729ae93bc766bb2f03_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7598a3a1ef3e4c72915a1f6a9b3e0870_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie64eb88418e44ccdaa7c1b45b0e9c179_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie10b590b22514a43a3f12d61a7d8768a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if379c70eb4bc4cb89f39dd8542e38baa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1fea16fef42471dba019c040233981e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8074103f41e04c56b96df5ea82a9c412_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if451e23108a3485e917d50dbd51706d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1936ea8520f42d384dec241609293d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54983f52f1db4e76b731097292942bb3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iba24de5e17564671afe22ec89f5f3acf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i340f4a8c71a1410b99e342dbbe44f76c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia09ae954893b4c35919a0f83d0592f6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9981d0011a794884b2a7987b32480b6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iad67715684f94d79a4e970a446c35348_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6cd4b30c10a94ae093780ce38d46a370_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id3e72d808dd54b4097d93c8105045161_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i250ad4b68c834c7ab7f008a13f28fed5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03cf9b99099a418cbff01db407d511cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib0363d1d407c43858260eb498134562a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id9e8a21df22c49dea82dcb63e4eff8cb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i087cf67012d04ba0bbee3ed77b869dbd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if445e6aa2f2a404c9c2cae784a9d3c67_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4790b3dd8c914707b7598d0687f23cf3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf6b03e1fc3e49bdbe024dcf4fec7e6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25bb3713e7dc4ce8aff3b343553d1d5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee5537a3735a44efbf12ff851ff5fb61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iddefd20760394cda9704c051843be4a0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9d78eaf9f7854f45a976f7a9c34f0b2e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i33bc647cc4d341da839b637a42b74f25_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i05f1ddd5eada4525b9899833bd42aa9e_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ib7d95ca3899b4bbf91022aa523d90b4a_D20210101-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i9cdb8495a786463fb1d63d538dedadd6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74eb9bfff592416381c1931711db9989_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic3d574edc32f4858b10a9e95a7043b62_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4af07d6f77c412fa6fc30634723476c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i82a8212f4d97436f86b773388a97609f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica7f1fd63c014e4598191fc6de8562ec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i930068e669b4450986374f16ef76a5d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib75fd2e45f3d4d8982e9fdaef11c065a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idc1114f0eae5487fa865b3bccaf5b9bd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8e52755e7437453ea2f981a32951d999_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6918db6cf1846b8806408b26be49e6a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7187b436a3ea4d1da6a4704097325340_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d19f8b5724c4f88b4fa8f61f0b315f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4d1ddd3ae7e349248f4a8de4b08df629_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b1dad7a9e5040f9af2c8f17dc219501_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5586721f5cb7493dab355f7ba8acf352_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if1ce0ea0bd4a41f486cf13d1a3ecc8cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i304f43ebe4b34d7b9ce83118a0cac64b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9ac1d580f1145538873140cefeff994_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="member">
        <measure>moh:member</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>moh:position</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV8zLTEtMS0xLTA_295acb2a-0a88-429d-a79d-11bf039722ab">0001179929</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV80LTEtMS0xLTA_ef9a3e8d-a325-42db-82d7-63e73961c183">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV81LTEtMS0xLTA_8524025f-6260-417e-be91-792c0c6e9e26">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV82LTEtMS0xLTA_03b01ead-cf32-43ec-a102-57feb33db796">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80L2ZyYWc6NDU2YmU3YzljY2ExNDIyNzg3NzE4ZTNlODYxMTg4MmUvdGFibGU6YmEwMGM4MTVlMWIxNDA0OGE3MDc2MTVhMjAzZWU5NmEvdGFibGVyYW5nZTpiYTAwYzgxNWUxYjE0MDQ4YTcwNzYxNWEyMDNlZTk2YV83LTEtMS0xLTA_d4ca7b95-5a7a-44b8-9330-10874df273f3">false</dei:AmendmentFlag>
    <moh:HealthPlanContractTerm
      contextRef="ib2f6d5bf02f946d797a178b2243023d2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMyOA_8b240c5c-ac85-4fc4-b548-e90f16414f04">P3Y</moh:HealthPlanContractTerm>
    <dei:DocumentType
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE2_7bb23a00-d1c6-44f0-a977-d5cc6c21750f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6YmM1ZDM2NTViY2JkNGM5M2FkYTQ2MjVlZWMxMjgwZGYvdGFibGVyYW5nZTpiYzVkMzY1NWJjYmQ0YzkzYWRhNDYyNWVlYzEyODBkZl8wLTAtMS0xLTA_588c6492-deee-461c-b786-043f7fbc6a8e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8xNDA_1b7925e3-b311-4779-b7fc-50a92e72ad12">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6NmYyOGQ3YmYyMjAxNDBkN2IyYTA0MjZjNGQ0NTUxYTUvdGFibGVyYW5nZTo2ZjI4ZDdiZjIyMDE0MGQ3YjJhMDQyNmM0ZDQ1NTFhNV8wLTAtMS0xLTA_79c3279f-09ff-4ed9-8b98-8e178545a47b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTEy_e33fae4b-f483-4e49-b657-62074fb89133">001-31719</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE3_307ef2f4-ad84-4145-8cf3-4cca2d4bcd16">MOLINA HEALTHCARE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8wLTAtMS0xLTA_0bf576d5-b3b7-48c9-a9d2-40220910a241">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8wLTMtMS0xLTA_f72e494f-6012-4411-80c0-66d1eccaffe1">13-4204626</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDNhZjM3YjQ0MzU0ODJjOGExMWEzYTNmZTE3NjY1ZV84Nzk2MDkzMDIyMjQ5_200d38db-c73b-4fae-8f42-4a2f64df492a">200 Oceangate</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDNhZjM3YjQ0MzU0ODJjOGExMWEzYTNmZTE3NjY1ZV84Nzk2MDkzMDIyMjYx_6a83d136-917d-4408-8cec-b7b1ca5e6ba0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF80LTAtMS0xLTA_925c13d3-1102-42d6-9d6a-826582a05392">Long Beach,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF80LTEtMS0xLTA_b7d85eaf-e223-4a3a-8902-f68b9fb5bd6d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6N2M4YzZhYjA1OTViNDQ3ODgyYmJlNmEwY2UwNmMxZTQvdGFibGVyYW5nZTo3YzhjNmFiMDU5NWI0NDc4ODJiYmU2YTBjZTA2YzFlNF80LTMtMS0xLTA_5262c07b-c934-42fb-8a62-b4ec56c87d00">90802</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTEz_5231f563-b8a9-4802-b8e1-6750b8715166">562</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE4_773dcf3d-ef22-4e1f-8c4c-1bc1c7277245">435-3666</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6M2EzNmMzNzdjOTg2NGY0N2I4ZDM2YjM0NmRkZjExMDYvdGFibGVyYW5nZTozYTM2YzM3N2M5ODY0ZjQ3YjhkMzZiMzQ2ZGRmMTEwNl8xLTAtMS0xLTA_9a745e7e-33f8-47fa-b180-516185651f9b">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6M2EzNmMzNzdjOTg2NGY0N2I4ZDM2YjM0NmRkZjExMDYvdGFibGVyYW5nZTozYTM2YzM3N2M5ODY0ZjQ3YjhkMzZiMzQ2ZGRmMTEwNl8xLTEtMS0xLTA_cd9b3c30-004d-4b3c-8a68-28f45fc7230a">MOH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGFibGU6M2EzNmMzNzdjOTg2NGY0N2I4ZDM2YjM0NmRkZjExMDYvdGFibGVyYW5nZTozYTM2YzM3N2M5ODY0ZjQ3YjhkMzZiMzQ2ZGRmMTEwNl8xLTItMS0xLTA_372e4b06-aa63-4712-bc03-6ea950d25445">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE5_9a4e2efc-1749-4cd6-bb36-637b94909c76">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTIw_6f12a460-dc74-4dbd-b4dc-19f214e9a1c3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTIx_542f3484-3521-41f6-83f2-92f94778e1d3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTIy_1a56c6c8-4f5e-406e-b211-d188f781a51a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE0_54c9467a-681a-413d-a806-6402345f622e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTE1_349f2872-284f-4852-871a-1304f9602020">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4e071f24a77d46dfba2cb28cb63b9814_I20210423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xL2ZyYWc6ZWJlZThjODkzM2EwNDJiOTliM2Y3Nzk3OTMwZjY3MzAvdGV4dHJlZ2lvbjplYmVlOGM4OTMzYTA0MmI5OWIzZjc3OTc5MzBmNjczMF8yMTEw_526fb36b-38c9-4509-8909-4f0b21bbc2c1"
      unitRef="shares">58400000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PremiumsEarnedNet
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNS04LTEtMS0xODU2_344a384f-03f9-4e55-b12b-35614d6a0a15"
      unitRef="usd">6306000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNS0xMC0xLTEtMTg1OQ_a2eb8934-a643-42ba-878f-6f28ec0d95f3"
      unitRef="usd">4304000000</us-gaap:PremiumsEarnedNet>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNi04LTEtMS0xODU2_3e199a45-2150-4f7c-a3b3-27a1a50edb02"
      unitRef="usd">187000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNi0xMC0xLTEtMTg1OQ_dd253ca3-adc2-459d-a1f4-43d1fb1d0b3b"
      unitRef="usd">150000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNy04LTEtMS0xODU2_3fc23379-13ab-4207-8c27-cc8f00b5529f"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfNy0xMC0xLTEtMTg1OQ_22232187-bafa-46fc-abe8-cd03e9581aff"
      unitRef="usd">66000000</moh:HealthCareOrganizationInsurerFeeRevenue>
    <us-gaap:NetInvestmentIncome
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfOS04LTEtMS0xODU2_208eac34-e9a3-4d9e-b486-b572e0c3befb"
      unitRef="usd">9000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfOS0xMC0xLTEtMTg1OQ_ee43813e-e238-43ce-87a6-0ef098c2c134"
      unitRef="usd">25000000</us-gaap:NetInvestmentIncome>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTAtOC0xLTEtMTg1Ng_f0c2122a-e3cd-49c2-91fa-79a726d9f3c7"
      unitRef="usd">20000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTAtMTAtMS0xLTE4NTk_1dc6c42e-c5d3-4a84-8aa7-e07e989470ab"
      unitRef="usd">4000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:Revenues
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTEtOC0xLTEtMTg1Ng_58b59b68-01d2-4538-a654-a825dd6817b5"
      unitRef="usd">6522000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTEtMTAtMS0xLTE4NTk_7b87f64c-961e-4605-bc30-879e99a17e63"
      unitRef="usd">4549000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTMtOC0xLTEtMTg1Ng_b70550d1-7f5b-4b87-931d-d0408b955fc5"
      unitRef="usd">5474000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTMtMTAtMS0xLTE4NTk_6da693fd-7dc2-4b04-a6fd-63f6b82dfed4"
      unitRef="usd">3716000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTQtOC0xLTEtMTg1Ng_18d30fbb-29f4-471f-8f3a-06f73449b0e9"
      unitRef="usd">473000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTQtMTAtMS0xLTE4NTk_4e4246e7-33e1-4475-be53-94f33dc0041f"
      unitRef="usd">317000000</us-gaap:GeneralAndAdministrativeExpense>
    <moh:PremiumTaxExpenses
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTUtOC0xLTEtMTg1Ng_1011f82d-3012-4343-980e-5363d6eb9198"
      unitRef="usd">187000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTUtMTAtMS0xLTE4NTk_d270ac78-99fd-4da8-83a8-9b4461b8e257"
      unitRef="usd">150000000</moh:PremiumTaxExpenses>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTYtOC0xLTEtMTg1Ng_d29714c3-1288-42b5-81df-b416a36e647d"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeExpense>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTYtMTAtMS0xLTE4NTk_d1c1f9d5-96e7-4668-b9ef-4aeeeff41b81"
      unitRef="usd">68000000</moh:HealthCareOrganizationInsurerFeeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTctOC0xLTEtMTg1Ng_124f838f-aac7-470e-8577-02d8fb82cc45"
      unitRef="usd">33000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTctMTAtMS0xLTE4NTk_aedb9725-819e-46a8-9533-224879e9acde"
      unitRef="usd">20000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTgtOC0xLTEtMTg1Ng_26a601b5-4892-499b-8726-2de7deb82112"
      unitRef="usd">20000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTgtMTAtMS0xLTE4NTk_6cc13fe4-ba49-4f0d-b295-80cf2e377158"
      unitRef="usd">4000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTktOC0xLTEtMTg1Ng_77bf27fb-0596-4371-a069-b7efe871b63a"
      unitRef="usd">6187000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMTktMTAtMS0xLTE4NTk_1a2e16b2-8298-4f1e-8c03-e064df53a5ab"
      unitRef="usd">4275000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjAtOC0xLTEtMTg1Ng_172a45b6-43e7-4d44-9fba-9606b579f09c"
      unitRef="usd">335000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjAtMTAtMS0xLTE4NTk_43589c7e-ad99-47bf-8aa8-9f0813ae2f34"
      unitRef="usd">274000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjItOC0xLTEtMTg1Ng_6efadf1d-d2b7-42c5-9791-697899aa89d7"
      unitRef="usd">30000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjItMTAtMS0xLTE4NTk_710c87ba-39b7-48d2-80d8-4c032cc078e1"
      unitRef="usd">21000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjQtOC0xLTEtMTg1Ng_1cf75a0f-841b-4f9e-a075-5a63fe53accc"
      unitRef="usd">-30000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjQtMTAtMS0xLTE4NTk_51648753-c621-41e4-ac71-753ab2b53237"
      unitRef="usd">-21000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjUtOC0xLTEtMTg1Ng_63499ccc-7eca-40cc-8b8f-64f55c52d184"
      unitRef="usd">305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjUtMTAtMS0xLTE4NTk_d0a88908-1e16-449a-b1bd-80f058c28903"
      unitRef="usd">253000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjYtOC0xLTEtMTg1Ng_10699b6f-a2dd-449b-9fce-b2a88a9299fd"
      unitRef="usd">77000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjYtMTAtMS0xLTE4NTk_7dda60af-2242-40b7-a8fd-340af887c509"
      unitRef="usd">75000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjctOC0xLTEtMTg1Ng_ae4207af-c20a-4e9a-a1f6-a42f95fea351"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjctMTAtMS0xLTE4NTk_85d3ac97-61bb-4413-a09b-f808616fb4f3"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjktOC0xLTEtMTg2OQ_e54ce7ad-6164-427f-a3dc-d1b44f37337c"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMjktMTAtMS0xLTE4NzI_a628f128-a902-4e7c-8642-b3a9987ee657"
      unitRef="usdPerShare">2.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMzAtOC0xLTEtMTg2OQ_eb4e7516-b13b-4dea-aeda-8bc267d36f1a"
      unitRef="usdPerShare">3.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjM3N2U2MzdhMGU1YzQzZjRhNTQ0NGQ4ZTI1MDE3YzhhL3RhYmxlcmFuZ2U6Mzc3ZTYzN2EwZTVjNDNmNGE1NDQ0ZDhlMjUwMTdjOGFfMzAtMTAtMS0xLTE4NzI_a3b268cf-3c9e-479a-a6b9-1d4d368a83f1"
      unitRef="usdPerShare">2.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNC04LTEtMS0yOTcz_55fa31c4-d955-4425-af71-3191dae8a8fa"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNC0xMC0xLTEtMjk3Ng_d4af7f74-eff2-451c-a4b1-98c4879987c2"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNi04LTEtMS0yOTcz_6c0e37cc-5907-4ab0-b45f-23e4d8fc8a7e"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNi0xMC0xLTEtMjk3Ng_7001372b-73bf-4780-a5eb-5f1868aef889"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNy04LTEtMS0yOTcz_5732463d-2083-45db-a93f-b189434b4476"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfNy0xMC0xLTEtMjk3Ng_b4759254-c162-41bf-add2-4eef36fff157"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOC04LTEtMS0yOTcz_8d488d67-8e4d-4c16-a445-baa336de85bd"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOC0xMC0xLTEtMjk3Ng_46b089f8-5cc3-49fc-9c38-c166dec66a70"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOS04LTEtMS0yOTcz_fb85fbb3-5abf-4282-b0d8-d6944f2f0e51"
      unitRef="usd">217000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMy9mcmFnOmQ2YjhmZGM3YjQxMDQ5NTk4MDM5YjgxMWE1NjQ0MGQyL3RhYmxlOjk2YmFjOTZjY2ZhZDQ3OWZiMDJmYzhhOTkyNTQ1OTlkL3RhYmxlcmFuZ2U6OTZiYWM5NmNjZmFkNDc5ZmIwMmZjOGE5OTI1NDU5OWRfOS0xMC0xLTEtMjk3Ng_e6dde489-5260-4c75-8abe-ab23925187e0"
      unitRef="usd">159000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNi0xLTEtMS0w_10508d2e-8d77-4649-9c42-d482c8c85cbb"
      unitRef="usd">4431000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNi0zLTEtMS0w_a8445fea-96c8-40bf-8a83-9670597a7dec"
      unitRef="usd">4154000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNy0xLTEtMS0w_82cf7060-0872-49e2-b2d7-e1c6af8a32d1"
      unitRef="usd">1938000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfNy0zLTEtMS0w_5d5fa7be-b5f8-4078-a614-9646e877938c"
      unitRef="usd">1875000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOC0xLTEtMS0w_66f956ca-7bec-4a21-9bcf-c6828bff09f6"
      unitRef="usd">1776000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOC0zLTEtMS0w_54d9fc73-04e9-439b-818c-cd39e8d24086"
      unitRef="usd">1672000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOS0xLTEtMS0w_12bf418e-81a5-4934-83ac-f409d7fd350b"
      unitRef="usd">163000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfOS0zLTEtMS0w_0f2326b1-461f-4e99-a6a8-1b981c9966a5"
      unitRef="usd">175000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTAtMS0xLTEtMA_31aab5fd-1b4e-4805-a937-bfda236d7c4d"
      unitRef="usd">8308000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTAtMy0xLTEtMA_e60496d1-8ce4-4a61-b7ce-44c9eadd4df4"
      unitRef="usd">7876000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTEtMS0xLTEtMA_b071c9b2-a5c8-4f06-a9c1-791b9d0e1d12"
      unitRef="usd">378000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTEtMy0xLTEtMA_2b1e9796-0ba3-4868-b9ff-279bb78555cc"
      unitRef="usd">391000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTItMS0xLTEtMA_06b0a521-ac56-402c-90f3-fe0eccb59bda"
      unitRef="usd">923000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTItMy0xLTEtMA_b4478a75-0234-49df-82b4-24bf834724bf"
      unitRef="usd">941000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTMtMS0xLTEtMA_e4c01580-f913-4839-b8d2-84769be2191e"
      unitRef="usd">138000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTMtMy0xLTEtMA_a5aeb881-bb64-4f09-ac34-966f63101305"
      unitRef="usd">136000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTQtMS0xLTEtMA_7a3cd57b-f86c-4fa2-8654-1b3b24bf8341"
      unitRef="usd">66000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTQtMy0xLTEtMA_370a85a8-f978-4630-a299-a43b9f55d8fd"
      unitRef="usd">69000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTUtMS0xLTEtMA_6d9c1710-de60-44cf-a208-94f53f740da3"
      unitRef="usd">137000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTUtMy0xLTEtMA_950414f1-cba2-40ac-a2fd-32894d2d7d24"
      unitRef="usd">119000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTYtMS0xLTEtMA_5a9bfa69-cbbf-4f28-b404-e0bbfb2b1d68"
      unitRef="usd">9950000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMTYtMy0xLTEtMA_8c3aee7f-39fa-412a-b6f0-88aa99f9d366"
      unitRef="usd">9532000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjAtMS0xLTEtMA_a510deaf-e140-45f4-8484-29e7bb53ec52"
      unitRef="usd">2839000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjAtMy0xLTEtMA_5e10bbfd-fedc-4074-ab48-2b2325a50a60"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjEtMS0xLTEtMA_12c3b629-ad31-4cc5-a12a-5a9f5f755ae9"
      unitRef="usd">1718000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjEtMy0xLTEtMA_11f8a7ef-295e-4563-932c-438f40744bac"
      unitRef="usd">1253000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjItMS0xLTEtMA_6f6b7446-e5a3-416b-9159-d8f98615a54e"
      unitRef="usd">695000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjItMy0xLTEtMA_3048f089-92d9-432d-bc41-97cc688f2925"
      unitRef="usd">641000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjMtMS0xLTEtMA_600da553-1cb8-4cdd-ba8d-daf3b86d7999"
      unitRef="usd">71000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjMtMy0xLTEtMA_c9cee950-99ba-41f4-b330-b6b7b8b9421b"
      unitRef="usd">375000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjQtMS0xLTEtMA_5f6f02dd-90a7-46aa-8160-952475fffd3c"
      unitRef="usd">5323000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjQtMy0xLTEtMA_d3b1a926-683c-483a-8be5-a0eaf5c373e9"
      unitRef="usd">4965000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjUtMS0xLTEtMA_238147f8-25a9-42d7-a789-335d02412c7f"
      unitRef="usd">2128000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjUtMy0xLTEtMA_f291cc29-de7d-47c7-b52e-52933f1d95ab"
      unitRef="usd">2127000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjYtMS0xLTEtMA_8d2596fe-fa30-4f8a-86c1-e5c6f1a4b703"
      unitRef="usd">223000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjYtMy0xLTEtMA_e5e7edfd-9092-4ae2-9d25-cf971c487d6b"
      unitRef="usd">225000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjctMS0xLTEtMA_c57169ab-fe28-4eeb-ae62-58f11140fb7b"
      unitRef="usd">112000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjctMy0xLTEtMA_1290b5ba-9c6a-4a33-8a52-d33f5693106b"
      unitRef="usd">119000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjgtMS0xLTEtMA_de40d593-45ec-47cb-a988-3863376f9d36"
      unitRef="usd">7786000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMjgtMy0xLTEtMA_3317f1f1-ac30-487a-b799-16f4db65ebf3"
      unitRef="usd">7436000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzE5_24acdebb-27b2-4398-97cb-f81e6d264ecc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzE5_2b5ee931-3257-49a6-a749-9d7bbfaa67bb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzMz_5b5ed99f-42be-492f-9347-19ea5c8fdec2"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzMz_e62d7772-5157-41ce-b374-173ee0373507"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3XzY4_cf40f925-b62c-463d-9b64-94f59cef70e3"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmY4NjRmMmE2NDY5YzQ5YzQ4YzAyM2ZiNTVmNWUxMTM3Xzg5_0d316b69-a542-4913-ac1d-25f0d989d971"
      unitRef="shares">59000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMS0xLTEtMA_0cdfa854-696f-4949-8158-111b5c2b8837"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzAtMy0xLTEtMA_c418f3ce-ad5f-4413-8f9f-0e08247d331f"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzIy_02a278e6-5cc3-4764-8116-6bf290ee2ee3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzIy_296db74a-8fb1-4780-bbe9-075d049d006b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzM2_04c9bdca-8297-4db6-aeac-b8c6c2a3facf"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzM2_a3145584-c460-471f-a1c4-5322e2876c9f"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_5cd60690-a097-4cb8-a6dd-b0dd4fea049d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_7e4ca020-8b7d-4757-bc04-e6d81cf5ba01"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_c052085e-0a11-448a-b6ef-bb85b9c469a8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM4NGFlZDdlMWFlYTQ0NWY4Y2UwYTA5M2RlNmU4NTRjXzU4_e516fb3a-ce65-44d1-8597-6e340f2a8fbd"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMS0xLTEtMA_fb9e02dd-cdc3-40ed-82e4-3e8db73c91ef"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzEtMy0xLTEtMA_412d2960-c19d-4907-b236-c7979be499e0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzItMS0xLTEtMA_9ece06bd-6fdf-4090-a35c-6cbd3026c002"
      unitRef="usd">170000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzItMy0xLTEtMA_9c3399b1-c36a-4d65-9fe7-a65aa9f67bae"
      unitRef="usd">199000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzMtMS0xLTEtMA_53d89917-80c7-40e8-bcac-b961c6c6fab3"
      unitRef="usd">26000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzMtMy0xLTEtMA_3af6d45a-20fb-454d-a414-101cb132fb08"
      unitRef="usd">37000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzQtMS0xLTEtMA_8cd07697-d2bc-41d4-8f2e-c0ae5cfd5d8f"
      unitRef="usd">1968000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzQtMy0xLTEtMA_517f77b4-ee2f-4304-9ff8-f6c045bca7d1"
      unitRef="usd">1860000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzUtMS0xLTEtMA_f9b12bca-706e-487a-9a74-362e6ba9d8c2"
      unitRef="usd">2164000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzUtMy0xLTEtMA_5ad1b69c-c93f-42c2-8d8b-0290b10ede4d"
      unitRef="usd">2096000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzYtMS0xLTEtMA_5639d2d4-4ea7-4013-8352-ccb41d0df496"
      unitRef="usd">9950000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xOS9mcmFnOmE1ZTliNmY5ZTg2NDQzYzM4MTY3YWI1NTFmZGQwMWMwL3RhYmxlOmU3OGI1NDU1YWM1MTQyM2U5ZTc0MmIwNzcxYjhjMzM0L3RhYmxlcmFuZ2U6ZTc4YjU0NTVhYzUxNDIzZTllNzQyYjA3NzFiOGMzMzRfMzYtMy0xLTEtMA_2c4fe667-5044-470d-9839-0f0fe67da343"
      unitRef="usd">9532000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if4cb5b33923d44d48d6582373ff531da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS0xLTEtMS0w_7427341f-ed0b-47bf-b244-8ab82fc25afd"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4cb5b33923d44d48d6582373ff531da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS0zLTEtMS0w_8d592142-fa77-4afc-981c-ce9072120cee"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3cf6223852e470887ad11579c175927_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS01LTEtMS0w_f47d9e4b-7421-45af-b98e-d82af3ae9a8c"
      unitRef="usd">199000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa001ce9f4904c2cb8455fe03b80f1a3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS03LTEtMS0w_85ba4b1e-8c92-4235-b8cb-b8e7841b3b60"
      unitRef="usd">37000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3b15a9bdcdf4106965f1b2a88548c51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS05LTEtMS0w_c3ab30ac-6c23-407a-a38f-a2df991bf4ce"
      unitRef="usd">1860000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNS0xMS0xLTEtMA_fa11510c-0b75-4100-be19-8491dd26f6c6"
      unitRef="usd">2096000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib6cd7e619ba24682912dc1fadfbab673_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNi05LTEtMS0w_1aa2f16e-0b3b-4d2f-9d94-35be35d0168f"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNi0xMS0xLTEtMA_e012182b-9b3c-424e-b6e0-11fa1a6a0ac8"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8589aefa8f474c159c7cbd51cc1dc98d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy0xLTEtMS0w_f23c0172-b444-4a72-8399-d677bad20d6e"
      unitRef="shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2976206aa3ad4285b3d0c9437c99451d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy01LTEtMS0w_15eba16c-7ca3-4c86-81d3-cde51cf09f94"
      unitRef="usd">2000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib6cd7e619ba24682912dc1fadfbab673_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy05LTEtMS0w_f5e9b7b1-ef83-4804-8103-6f2f09009f78"
      unitRef="usd">120000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfNy0xMS0xLTEtMA_6cc58f56-71ca-4ac4-bd67-f0319972c671"
      unitRef="usd">122000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i031215c830df4ab98eaef20814b485e1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfOS03LTEtMS0w_4362feca-e811-497c-85c5-6f79edf5faf6"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfOS0xMS0xLTEtMA_b1d651ce-d902-47c7-a20f-6eef3aedffd0"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2976206aa3ad4285b3d0c9437c99451d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTAtNS0xLTEtMA_37568cc9-2dd6-4573-bb3c-79802d7993ed"
      unitRef="usd">-27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTAtMTEtMS0xLTA_a1907f08-5294-4e36-b0bf-d0443c46acb7"
      unitRef="usd">-27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i32c24e92034d4912a1dc6ad0b7a49302_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtMS0xLTEtMA_58bd3f6e-d127-426e-bcd8-98a4f0f43bf6"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32c24e92034d4912a1dc6ad0b7a49302_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtMy0xLTEtMA_5c955dfc-4136-4afc-b0fa-a841d1e0c77d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b49845196634f1eb09dc0789aad5d88_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtNS0xLTEtMA_447bcd6f-0953-4a72-ac2d-dec12e61fae5"
      unitRef="usd">170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bfeb6ebf43e495da6988002aa92c4e4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtNy0xLTEtMA_8d9f5b32-ef69-40af-907c-873c66f23d02"
      unitRef="usd">26000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3c912df2a854b3083036cd0dcf70baf_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtOS0xLTEtMA_8bce10e4-01e4-401a-9933-728b3f3e8ee7"
      unitRef="usd">1968000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3c912df2a854b3083036cd0dcf70baf_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtOS0xLTEtMA_e308bd13-f87f-411b-bdc4-30534d567029"
      unitRef="usd">1968000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjllZTFkOGZiNDM2OTRhNDBhZjdlM2Q4YjM1NmEwM2FkL3RhYmxlcmFuZ2U6OWVlMWQ4ZmI0MzY5NGE0MGFmN2UzZDhiMzU2YTAzYWRfMTEtMTEtMS0xLTA_f3c56ba1-b20a-4819-bf89-c7197dbffa89"
      unitRef="usd">2164000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ib8b8ea1f43854547ba8cbbd4c725d620_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS0xLTEtMS0w_6a6911c3-85d8-46f1-af16-5bab023d4f57"
      unitRef="shares">62000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8b8ea1f43854547ba8cbbd4c725d620_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS0zLTEtMS0w_d3e7d46f-290c-417e-899e-6947fc953576"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17551bd8c156404499e937e8c5664e40_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS01LTEtMS0w_691a7458-dd24-4691-a0f5-612616971312"
      unitRef="usd">175000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i609e20519d204f7e8a1f149974d04ee8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS03LTEtMS0w_98d8e194-ccf2-4b8f-9088-24baa531b12d"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0394e14e2ddb48f081b7cc6c9f6df17d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS05LTEtMS0w_7304b0fc-8b25-4026-80aa-e1a5460ce10b"
      unitRef="usd">1781000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNS0xMS0xLTEtMA_c40f0f42-f1a2-4382-84a6-3da50eb205a4"
      unitRef="usd">1960000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5ba871cbc2264413b2e0bb8f269203ea_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNi05LTEtMS0w_10f13df0-5d2b-4319-a406-bf3e4da2a54b"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNi0xMS0xLTEtMA_9fd7d40c-38b3-4584-a582-6ee90308364f"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i95adf552e2d049cbb4f27501f9a4dbad_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy0xLTEtMS0w_ba5f46c8-817a-42ac-885f-f15ae916727c"
      unitRef="shares">3000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy01LTEtMS0w_053edb65-f65d-4fd5-bbaf-fb000c80f098"
      unitRef="usd">9000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5ba871cbc2264413b2e0bb8f269203ea_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy05LTEtMS0w_62287dbe-a950-48d6-ba04-fd74ef9cf6c1"
      unitRef="usd">437000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfNy0xMS0xLTEtMA_fa628680-c830-40c6-81ce-5204e06f3387"
      unitRef="usd">446000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOC01LTEtMS0w_9c53b5ea-0bdf-4c81-8512-9880b7e623f0"
      unitRef="usd">-30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOC0xMS0xLTEtMA_9a00885e-529e-4223-b068-f667b87146a6"
      unitRef="usd">-30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i691ed4ca23c74d7e8b19e0fc8b00560c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOS03LTEtMS0w_e506a7ef-f4a9-427f-8533-a749fff31617"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfOS0xMS0xLTEtMA_52083204-2f0e-462a-892f-6a35271662ab"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ided3a711bab74acea7d9c98448bebb99_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTAtNS0xLTEtMA_25c3ec07-fb99-45ef-b162-e0746681822d"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTAtMTEtMS0xLTA_f6437097-b915-4adb-842f-907c4c8c1aa5"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i86edd17ebbb94db398c8c9bf6325ad1e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtMS0xLTEtMA_6df313cf-4c41-4423-bd68-0be62d8255f8"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86edd17ebbb94db398c8c9bf6325ad1e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtMy0xLTEtMA_10a8e8a7-31b1-4c3a-a2cf-ce1a5b560d53"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fcdc345193e4adcb86cd7488aa5651e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtNS0xLTEtMA_48bca466-6355-4a43-9668-cd1acab292e7"
      unitRef="usd">140000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fb5b5c80f1a4b3988c0ec8e5cf119cc_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtNy0xLTEtMA_939dcea5-d79a-4301-812f-f58f2c1b5b4e"
      unitRef="usd">-15000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2edda39d39945aa83dab49b96ac9571_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtOS0xLTEtMA_6487d581-02b2-4bb9-b8b7-cb378b71b784"
      unitRef="usd">1522000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yMi9mcmFnOmM0NDBmYWI2OTg1YTRhZmY4NThmN2IwOTEzOTNiZWI4L3RhYmxlOjZlMzc4NzM2ZTFkMzRiOTU5OTJiNTI2ZjJkOGRhYTM1L3RhYmxlcmFuZ2U6NmUzNzg3MzZlMWQzNGI5NTk5MmI1MjZmMmQ4ZGFhMzVfMTEtMTEtMS0xLTA_fd8c0e3c-b411-47db-8a8e-da67ca223f8f"
      unitRef="usd">1647000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNS0xLTEtMS0yNTA5_eccd8c5d-06c5-4a25-b876-3fccff5977b1"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNS0zLTEtMS0yNTA5_7ea02b7e-f748-46b0-8745-9d66ea7546e9"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNy0xLTEtMS0w_d20a1580-d533-4453-a119-03ccab6a8695"
      unitRef="usd">33000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNy0zLTEtMS0w_812ead68-8a84-44f8-9a49-696e2fb04983"
      unitRef="usd">20000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOC0xLTEtMS0w_3ee44193-668c-48ff-8110-9b1e6b1df82d"
      unitRef="usd">-6000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOC0zLTEtMS0w_d1a0c1ac-bec2-415a-83af-b037eb22a121"
      unitRef="usd">-14000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOS0xLTEtMS0w_d684e816-0173-4e8b-9f22-5faf2163fe5f"
      unitRef="usd">24000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfOS0zLTEtMS0w_c638b88e-e0f2-4345-8868-c091b332b8e4"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTQtMS0xLTEtMA_a9d4ccc3-6f0a-40e9-bf47-518a27ad38ce"
      unitRef="usd">12000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTQtMy0xLTEtMA_5c56dc67-3348-4974-b7e7-ee4553273664"
      unitRef="usd">-3000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTYtMS0xLTEtMA_53257c43-a00d-4c92-a011-d9a7247cad7b"
      unitRef="usd">98000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTYtMy0xLTEtMA_9ed8208b-fb35-4dc1-a44f-3ba0eb7f00bf"
      unitRef="usd">197000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTctMS0xLTEtMA_167c8cf8-5e80-4dde-a761-0f820139705b"
      unitRef="usd">15000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTctMy0xLTEtMA_2b5c8e57-a30b-4d9b-97f5-0d74e4355426"
      unitRef="usd">229000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTgtMS0xLTEtMA_a4132c26-cd8a-45f4-97fd-db3a1b30c39c"
      unitRef="usd">168000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTgtMy0xLTEtMA_3ae0d186-4ade-4cee-94b3-00f14bc13f83"
      unitRef="usd">127000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTktMS0xLTEtMA_8a230975-f776-4701-bb1e-4d93a00c69f3"
      unitRef="usd">432000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMTktMy0xLTEtMA_3314d588-f530-4541-9f58-a65a5f2014bf"
      unitRef="usd">113000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjAtMS0xLTEtMA_9c0d7784-b035-45c4-8a39-b5891624d37a"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjAtMy0xLTEtMA_767e6577-f45c-41a4-8ade-a561e223b666"
      unitRef="usd">254000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjEtMS0xLTEtMA_47f4804e-e4a0-40e2-85c4-f2ca83b24dfc"
      unitRef="usd">-304000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjEtMy0xLTEtMA_7c33ad79-c7cf-49ac-a30a-74ae9955e150"
      unitRef="usd">-206000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjItMS0xLTEtMA_7feed9ec-dc84-487a-8419-0770e96acacd"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjItMy0xLTEtMA_cd05056b-281b-4d38-a3a2-5f57851c8f04"
      unitRef="usd">60000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjMtMS0xLTEtMA_5b5442d5-a7ef-49a8-af2b-c7e244c535d0"
      unitRef="usd">568000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjMtMy0xLTEtMA_961710e3-2811-4219-b989-988aaf83d53b"
      unitRef="usd">143000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjUtMS0xLTEtMA_1f0416f1-c0cc-47d8-9f4e-a8503a797acb"
      unitRef="usd">388000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjUtMy0xLTEtMA_d1f8ba84-ca34-42f2-9746-a3aba4ba8fc0"
      unitRef="usd">578000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjYtMS0xLTEtMA_5f72d73b-abe8-490a-a88a-619d2143cb66"
      unitRef="usd">308000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjYtMy0xLTEtMA_af1cb2ba-3c62-402e-804c-e426e01f9792"
      unitRef="usd">493000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjgtMS0xLTEtMA_c2f839fd-0638-4caf-8bfd-ad7f42d95a3f"
      unitRef="usd">16000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjgtMy0xLTEtMA_b92c478c-b3b2-4d3c-bf77-d44d1600a3ca"
      unitRef="usd">21000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjktMS0xLTEtMA_d40a15ac-b893-4232-b745-c9178012451c"
      unitRef="usd">-9000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMjktMy0xLTEtMA_7b7ffca6-8a7c-47d9-9e56-2c9e1f937b6e"
      unitRef="usd">-3000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzAtMS0xLTEtMA_60b052fc-f58e-4ab3-9b48-56b0b8775d45"
      unitRef="usd">-87000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzAtMy0xLTEtMA_b9fae753-c082-423c-a3e1-64d6b81bb0fb"
      unitRef="usd">-103000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzQtMS0xLTEtMA_4825f70a-9f56-4f0e-a6ae-7cc4a9e2c96d"
      unitRef="usd">128000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzQtMy0xLTEtMA_1f184528-f103-47f6-95c1-e096fbc7df1c"
      unitRef="usd">453000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMS0xLTEtMTAyOTg_ab3c49ec-1661-4c21-8c99-9b12d5b947fe"
      unitRef="usd">51000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMy0xLTEtMTAyOTA_d268e4c2-afb2-499f-946c-31f4263eef7f"
      unitRef="usd">7000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMS0xLTEtODMzMA_9a26e309-2316-428d-ad5f-206b37f59fd5"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzItMy0xLTEtODMzMA_8c6469ff-cbab-4fa8-b709-a8584bdc03a1"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzUtMS0xLTEtMA_5de52ac4-e541-4b75-9d23-742703645d4a"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfMzUtMy0xLTEtMA_31f5d303-478b-46c6-b8b5-369005d97e20"
      unitRef="usd">380000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDAtMS0xLTEtMA_af24c385-8fde-4e52-b4c6-b820fc1aae77"
      unitRef="usd">-8000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDAtMy0xLTEtMA_dcb6fd1b-ad3d-42af-86c9-d2103fc34b2c"
      unitRef="usd">-45000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDEtMS0xLTEtMA_5b71beda-1439-4504-aa87-c978d3b55805"
      unitRef="usd">-207000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDEtMy0xLTEtMA_1d81e226-f7bd-4d36-9a3b-7ca067d87ef0"
      unitRef="usd">-125000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDItMS0xLTEtMA_bb511081-8c06-4914-a4b0-3c0d059d817f"
      unitRef="usd">274000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDItMy0xLTEtMA_545e0d22-9eb2-4afa-8527-6f3ac04b2957"
      unitRef="usd">-85000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDMtMS0xLTEtMA_e976ecf1-c896-424f-bf7f-56dcbc762a0e"
      unitRef="usd">4223000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDMtMy0xLTEtMA_6766e04a-9a53-4907-b853-e2c2877e98a8"
      unitRef="usd">2508000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDQtMS0xLTEtMA_b9639b88-bfd6-443d-b8a7-ee199292c678"
      unitRef="usd">4497000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8yNS9mcmFnOjU4YjUwZmNhZWJjNDRiMzFiY2JjMzYwNjk5NTdlZmNjL3RhYmxlOjFiODM1MGZmZWM3ZjRjZTRhNDk5MzZhNGRmZWZjY2ZhL3RhYmxlcmFuZ2U6MWI4MzUwZmZlYzdmNGNlNGE0OTkzNmE0ZGZlZmNjZmFfNDQtMy0xLTEtMA_130f0a98-de8a-461f-9506-7105037f9455"
      unitRef="usd">2423000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfNzMwMw_73f477cc-4398-4c72-a285-a143a5d3cf5d">Organization and Basis of Presentation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#x201c;Marketplace&#x201d;). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. For further information, refer to Note 10, &#x201c;Segments.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, we served approximately 4.6&#160;million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our state Medicaid contracts typically have terms of&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMyOA_8b240c5c-ac85-4fc4-b548-e90f16414f04"&gt;three&lt;/span&gt;&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#x201c;RFPs&#x201d;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#x201c;ABD&#x201d;); and regions or service areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Acquisition&#x2014;Medicaid and Medicare. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan (&#x201c;MMP&#x201d;) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as &#x201c;STAR+PLUS,&#x201d; in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0&#160;billion. The purchase price for the transaction is approximately $60&#160;million, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals and satisfaction of other customary closing conditions. We currently expect the transaction to close in the second half of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ohio Procurement&#x2014;Medicaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin in early 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio&#x2019;s Covered Family and Children, Expansion, and ABD programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York Acquisition&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close in the third quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the first quarter of 2021 are not necessarily indicative of the results for the entire year ending December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2020, audited consolidated financial statements have been omitted. These &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, &#x201c;Medical Claims and Benefits Payable,&#x201d; and Note 10, &#x201c;Segments,&#x201d; have been recast to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the three months ended March&#160;31, 2020, have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of medical claims and benefits payable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Settlements under risk- or savings-sharing programs;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Purchase price allocations relating to business combinations, including the determination of contingent consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The assessment of long-lived and intangible assets, and goodwill for impairment;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for potential absorption of claims unpaid by insolvent providers;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for the outcome of litigation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of valuation allowances for deferred tax assets;&#160;and&lt;/span&gt;&lt;/div&gt;&#x2022;The determination of unrecognized tax benefits.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="if6be335f460e4209851cdbd1a986fddb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMzI5ODUzNDg5NTA4Ng_906efdb3-4fdb-4172-bea6-932f5439d346"
      unitRef="member">4600000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <moh:HealthPlanContractTerm
      contextRef="i3024a8346b4e4de8a8f90f83f027c364_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMzMg_ea3e4e9c-0a96-4302-b5d9-39f7fef604a4">P5Y</moh:HealthPlanContractTerm>
    <moh:NumberOfMembersCovered
      contextRef="ia27ea1622e334357a45a3002d5876949_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI5MQ_b117deb7-0b0a-44e2-a055-a5f1ecd9a55f"
      unitRef="member">48000</moh:NumberOfMembersCovered>
    <moh:NumberOfMembersCovered
      contextRef="i5e9ad87a1c5a48a78489b9938d8eae4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI5OQ_ca4ea5c4-13b4-485e-8668-3f327f80a3ec"
      unitRef="member">2000</moh:NumberOfMembersCovered>
    <us-gaap:PremiumsEarnedNet
      contextRef="ibf4236126773456e8b7ccaac00eaead1_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI2NA_06c09f92-1f94-41f0-a007-12af64b4a995"
      unitRef="usd">1000000000.0</us-gaap:PremiumsEarnedNet>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="iba56960a4e954002902a215411511282_D20210422-20210422"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTY0OTI2NzQ1ODI3OA_57ddd305-3e8e-48e1-8baf-063c4d893a1d"
      unitRef="usd">60000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i85aa51d656a149329969f88cf738f0a2_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTk4Mg_26ccf6f9-6115-410b-a9d7-504b7a259463"
      unitRef="usd">380000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfNzMxMg_ffd4b328-0497-47a5-b69b-f96e45c2c997">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the first quarter of 2021 are not necessarily indicative of the results for the entire year ending December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2020, audited consolidated financial statements have been omitted. These &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, &#x201c;Medical Claims and Benefits Payable,&#x201d; and Note 10, &#x201c;Segments,&#x201d; have been recast to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the three months ended March&#160;31, 2020, have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfNzMyMQ_4bbaafbb-6f28-47aa-9ce2-d2c909e1a646">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of medical claims and benefits payable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Settlements under risk- or savings-sharing programs;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Purchase price allocations relating to business combinations, including the determination of contingent consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The assessment of long-lived and intangible assets, and goodwill for impairment;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for potential absorption of claims unpaid by insolvent providers;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for the outcome of litigation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of valuation allowances for deferred tax assets;&#160;and&lt;/span&gt;&lt;/div&gt;&#x2022;The determination of unrecognized tax benefits.</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2Njc_d3be8dea-3fbd-4ba8-8541-4ceb8ce370e5">Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health insurer fee reimbursement receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, &#x201c;Significant Accounting Policies,&#x201d; under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies,&#x201d; in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, through March 31, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the states&#x2019; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In the first quarter of 2021, we recognized approximately $110&#160;million related to such risk corridors, primarily in the Medicaid segment.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of March&#160;31, 2021, Marketplace risk adjustment payables amounted to $520 million and related receivables amounted to $20 million, for a net payable of $500 million, of which $211&#160;million related to 2021, and $289 million related primarily to 2020. As of December&#160;31, 2020, Marketplace risk adjustment payables amounted to $326 million and related receivables amounted to $20 million, for a net payable of $306 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;Various recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NDA_306f75c6-bb76-4bf5-bcf7-1796a3dd3805">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NzI_36dc6a26-4873-4856-b098-b3ad13c3fdb7">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2ODY_dc8782d7-3f04-4835-a85a-58c253559677">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNC0xLTEtMS0zODgx_8f147375-fa78-4946-9a80-5b94f6f81995"
      unitRef="usd">4431000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNC0zLTEtMS0zODg0_8005dc1d-6c71-43d5-8a9e-2f68febb8ee1"
      unitRef="usd">2365000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNS0xLTEtMS0zODgx_e50964f3-6f71-4d13-9b44-4f75100561ed"
      unitRef="usd">66000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNS0zLTEtMS0zODg0_bd760e44-d999-49f4-9f1d-1e98212da0bf"
      unitRef="usd">58000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNi0xLTEtMS0zODgx_f42889a3-9a32-4bd3-8b86-ad897486c8ef"
      unitRef="usd">4497000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmEyZjhmNTViOGFlYzRiOGJiZGNmZjc1YzIyYTdiZGJlL3RhYmxlcmFuZ2U6YTJmOGY1NWI4YWVjNGI4YmJkY2ZmNzVjMjJhN2JkYmVfNi0zLTEtMS0zODg0_8c4af0b8-9c23-4c4e-8f50-d53bbd5ccf2c"
      unitRef="usd">2423000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTA0NDUzNjA0OTQ2MzY_cb23a6a7-f4b8-4981-bb9c-f9178df2b29b">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTA0NDUzNjA0OTQ2Mzg_d49706e2-8dfb-44c1-a8f4-9138115ae8b3">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health insurer fee reimbursement receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i1bf57704a9f64502924a6c99e4e92834_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfMy0xLTEtMS0zODc1_029e9665-9c35-4edb-957e-d8ef79d7d25e"
      unitRef="usd">1332000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="icb11d0cba77b4ec99ba52541a7506b5d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfMy0zLTEtMS0zODc1_adcc9f77-49c7-49b6-8818-1fa2d385b9a7"
      unitRef="usd">969000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if1535abc2ae740d5bf9944b12b802296_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNC0xLTEtMS0zODc1_51abadc2-c795-49a9-9ede-cdf6e878c3f1"
      unitRef="usd">200000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="icdfa8c0b58cc4e4f8075fdbc4b67b24c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNC0zLTEtMS0zODc1_59698139-9ec8-4d37-822d-b19cef1f709f"
      unitRef="usd">178000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i4eddaa9fd8a147b7949ef2c683c7f322_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNS0xLTEtMS0zODc1_b045625e-a552-44f1-9705-0e92af00cdbd"
      unitRef="usd">54000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if14923db8e82452ead1cb8577da709c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNS0zLTEtMS0zODc1_a1b7b629-7c35-40af-97b6-2c9334ea0efe"
      unitRef="usd">104000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i2e3e8a05c22746188f8006f0cc466248_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNi0xLTEtMS0zODc1_b5d5324b-1595-4365-9ea1-c793f69633ac"
      unitRef="usd">190000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i68770710aff54e859f753302935e9a33_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNi0zLTEtMS0zODc1_ff5c7366-d036-4dc2-889c-8054eef64464"
      unitRef="usd">255000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i060bbae192754af18735ff173a812ff9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNy0xLTEtMS0zODc1_92fbf36e-f7cb-4cd4-8bdd-8bc7def02347"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i45f348898f464752bc2bb4d15a2e7e2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfNy0zLTEtMS0zODc1_5193a200-56a7-4b7c-9015-49386be7c214"
      unitRef="usd">166000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfOC0xLTEtMS0zODc1_16d32841-45f5-4c3b-b8b6-c7d6c0e622ce"
      unitRef="usd">1776000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOmE2NzcyMzlhNmUyYjQ0MGQ5OTBjODQ5MjkzMzM4YmI4L3RhYmxlcmFuZ2U6YTY3NzIzOWE2ZTJiNDQwZDk5MGM4NDkyOTMzMzhiYjhfOC0zLTEtMS0zODc1_e5a19c82-bfad-47ca-be17-89817a27b5b5"
      unitRef="usd">1672000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NjY_9f00f3dc-5c22-453c-a5a8-780ee31a363c">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, &#x201c;Significant Accounting Policies,&#x201d; under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions.&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, through March 31, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the states&#x2019; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In the first quarter of 2021, we recognized approximately $110&#160;million related to such risk corridors, primarily in the Medicaid segment.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace&lt;/span&gt;&lt;/div&gt;Risk Adjustment. Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReservesReportedToOtherAgenciesTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc3MTg_df7d3bc8-9ad5-4ff4-9b27-0f546d4edbec">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies,&#x201d; in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReservesReportedToOtherAgenciesTextBlock>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNC00LTEtMS0zOTA3_fcdbaa98-6e03-4522-b72e-3b6aa87c8fc5"
      unitRef="usd">735000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNC02LTEtMS0zOTA3_dc23afba-34d3-43ce-84fa-f0ce6ffb6eb2"
      unitRef="usd">513000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNS00LTEtMS0zOTA3_ffe612ce-639e-43bd-a8d8-34cb8370393e"
      unitRef="usd">167000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNS02LTEtMS0zOTA3_5db87c37-e0d9-487b-a93b-2a7c1722503e"
      unitRef="usd">76000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0xLTEtMS04Nzcz_4a2f5d98-32d5-42c2-8cd8-cd2353cef632"
      unitRef="usd">75000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0zLTEtMS04Nzcz_4e9a9fcd-79de-45e3-8bf2-c32753658972"
      unitRef="usd">45000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0xLTEtMS04Nzcz_3caf1608-de2b-4eb5-8060-12cf34f55cb7"
      unitRef="usd">105000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0zLTEtMS04Nzcz_28546cc9-0a35-4965-b36f-15bf88e61f58"
      unitRef="usd">62000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:OtherMedicareProgram
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0xLTEtMS04Nzcz_91c40b30-981e-498b-a9bd-a7f71d536c62"
      unitRef="usd">42000000</moh:OtherMedicareProgram>
    <moh:OtherMedicareProgram
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0zLTEtMS04Nzcz_be252afa-d434-43cc-86ea-58ad5b16b3fd"
      unitRef="usd">30000000</moh:OtherMedicareProgram>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0xLTEtMS03OTg2_df0385db-c274-43b2-8c8d-55c88a58e988"
      unitRef="usd">520000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfNy0zLTEtMS03OTg2_d66715e6-a64c-46d0-8b2d-e7354eb9a46d"
      unitRef="usd">326000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0xLTEtMS03OTg2_12a91bb1-4b62-487d-95ae-564b00862fd4"
      unitRef="usd">47000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOC0zLTEtMS03OTg2_caeebcda-99b5-4c5b-8a96-e81b2b6f3f1f"
      unitRef="usd">37000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0xLTEtMS03OTg2_4bb0403b-7a99-4deb-95ce-7936a326bda3"
      unitRef="usd">27000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfOS0zLTEtMS03OTg2_0457bf8c-73ad-4ec1-a862-ef1173593035"
      unitRef="usd">21000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:AmountsDueToGovernmentAgenciesBusinessCombination
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTQtNC0xLTEtMzkwNw_29099548-fe49-40e6-bad6-656768be9b7a"
      unitRef="usd">0</moh:AmountsDueToGovernmentAgenciesBusinessCombination>
    <moh:AmountsDueToGovernmentAgenciesBusinessCombination
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTQtNi0xLTEtMzkwNw_e6cdb9ef-f31b-4bdb-9c11-724dbbe3a50d"
      unitRef="usd">143000000</moh:AmountsDueToGovernmentAgenciesBusinessCombination>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTUtNC0xLTEtMzkwNw_e5db1d70-2ddf-48cc-8d45-731b864ab563"
      unitRef="usd">1718000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RhYmxlOjA1MjY5YTM0OWE3NDQwMDk5MzUxNTczYTgyYmQ0OWMxL3RhYmxlcmFuZ2U6MDUyNjlhMzQ5YTc0NDAwOTkzNTE1NzNhODJiZDQ5YzFfMTUtNi0xLTEtMzkwNw_eb405931-3061-4614-98e8-fec95863fa78"
      unitRef="usd">1253000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="if812ef76536b438e99d9bdfc430cff90_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfNTMzNw_973c2940-937e-4018-8e4f-6027f38fe4d9"
      unitRef="usd">-110000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODg5Ng_d13f0a3b-997e-4e97-bdc5-6198d270b0b2"
      unitRef="usd">520000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODkzNQ_de2fc4b5-4485-4055-ace3-1c23abaee89d"
      unitRef="usd">20000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODk2MA_6c61708c-a063-4f8c-a286-4ddd29cdc13e"
      unitRef="usd">500000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfODk5NA_c24cdbf3-2397-495b-acb6-8a301224494a"
      unitRef="usd">211000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTAzMQ_144bd3b4-2326-49f5-bfd3-d847c254a244"
      unitRef="usd">289000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTEzNg_b6488fdb-4305-4e7d-bb3e-3ed716104e2a"
      unitRef="usd">326000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTE3NQ_1bc87946-e6b5-4145-af35-d26219bcb6d2"
      unitRef="usd">20000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfOTIwMA_563e83e1-6f1a-4443-ba23-0a37882a4004"
      unitRef="usd">306000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2NjA_08cd9754-45d8-4fc4-80f8-e39f3b5af419">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <moh:InvestmentsMaturityPeriod
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTMwMTI_78586759-719e-4fa0-ad66-21d709e50640">P10Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsAverageMaturityPeriod
      contextRef="id0497f33d5bf4e7187e8f9c8f6fb4d3c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMjc0ODc3OTA5ODY5Mw_be2114a1-a005-4e57-bfb8-dbdb1e88c990">P10Y</moh:InvestmentsAverageMaturityPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc2MzA_40bc199d-ddf2-4066-bc94-2e1ddaa078f3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNy9mcmFnOjczN2Y0NTlmMDI3ZTQ4NzFhN2I0NDk5ZDFjNjc4YjQ5L3RleHRyZWdpb246NzM3ZjQ1OWYwMjdlNDg3MWE3YjQ0OTlkMWM2NzhiNDlfMTc3MDM_3695a9f5-e4db-4f24-bd90-3811827e9ae8">Recent Accounting PronouncementsVarious recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RleHRyZWdpb246YmFjMjFmNjBmNTNmNGY1YWJhNjAzYzg0NTkwNDg4NjhfNDQx_38de5bea-25fc-49de-8140-32ba7caa2138">Net Income per Share &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RleHRyZWdpb246YmFjMjFmNjBmNTNmNGY1YWJhNjAzYzg0NTkwNDg4NjhfNDI2_ad0fe6ef-6bf8-46ad-b5db-797f91e422cb">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNS0xLTEtMS00MDA3_730d58ae-7538-41d3-bb98-d529428c504d"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNS0zLTEtMS00MDEw_47339b01-7dda-430a-af0a-0ba71e665513"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNy0xLTEtMS00MDA3_31c7abd9-a939-458b-8c9f-9006dca9c76d"
      unitRef="shares">58000000.0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfNy0zLTEtMS00MDEw_10e49b83-fec3-44ff-8c65-9df78f24f47c"
      unitRef="shares">61900000</us-gaap:SharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfOS0xLTEtMS00MDA3_6b3acf50-45ce-4d2a-988a-4537b3bff9d2"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfOS0zLTEtMS00MDEw_77dc7b18-b9ab-40b6-a403-bfba16cf57de"
      unitRef="shares">1700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTAtMS0xLTEtNDAwNw_31db2d63-1011-4524-9f1b-76c23dfe5ffb"
      unitRef="shares">100000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTAtMy0xLTEtNDAxMA_4a8fe8eb-64fe-42a5-878d-6fe2c562867a"
      unitRef="shares">0</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTEtMS0xLTEtNDAwNw_0c16ba52-ea12-4ede-97fa-e1cade2d8924"
      unitRef="shares">57700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTEtMy0xLTEtNDAxMA_9b83259e-9ed4-4889-8737-be60287df550"
      unitRef="shares">60200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMS0xLTEtNzY2OQ_b7a71c8d-b838-4a46-8654-1743ecf2fc86"
      unitRef="shares">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMy0xLTEtNzY2OQ_19dc715f-28ee-4876-b820-116887bdeefc"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMS0xLTEtNDAwNw_f623e8e9-41e2-458a-872a-785d157145e3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTMtMy0xLTEtNDAxMA_a2ef19a5-f125-4ea7-a17a-b41035181ebf"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTUtMS0xLTEtNDAwNw_22872f44-32d7-451b-92ed-8b4c2c51616d"
      unitRef="shares">58600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTUtMy0xLTEtNDAxMA_9b58f356-6697-49bd-a034-4626b93a11d5"
      unitRef="shares">61000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTctMS0xLTEtMjU2Nw_3fffcf8b-aafe-4720-8140-765832a3ee55"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTctMy0xLTEtMjU2Nw_641257f4-7085-4867-bb11-32b22ae45e7f"
      unitRef="usdPerShare">2.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTgtMS0xLTEtMjU2Nw_b1e2fefc-c6ad-4a11-a683-04c341347e04"
      unitRef="usdPerShare">3.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80MC9mcmFnOmJhYzIxZjYwZjUzZjRmNWFiYTYwM2M4NDU5MDQ4ODY4L3RhYmxlOjY2MGI3MTNiOTZkNzQ0MjdiN2NlMzk5YWZjZjQxNmU0L3RhYmxlcmFuZ2U6NjYwYjcxM2I5NmQ3NDQyN2I3Y2UzOTlhZmNmNDE2ZTRfMTgtMy0xLTEtMjU2Nw_f2320684-c8d0-4109-b5dd-72e882f4ca5a"
      unitRef="usdPerShare">2.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMzIwNQ_cbd92b8f-cc5b-4ead-8d75-dae98f3f17bf">Business Combinations&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, we closed on our acquisition of 100% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc., for total purchase consideration of approximately $1,037&#160;million. In the first quarter of 2021, we recorded various measurement period adjustments, including an increase of $6&#160;million to &#x201c;Receivables,&#x201d; a decrease of $25&#160;million to &#x201c;Medical claims and benefits payable,&#x201d; and an increase of $33&#160;million to &#x201c;Amounts due government agencies.&#x201d; In the aggregate, we recorded a net decrease of $6&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 10, &#x201c;Segments&#x201d; for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA0NDUzNjA0NzE5Mzk_4a99d24d-5098-4522-9ad7-255d29c72d30"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i89e7332f8532480b940cc14c82d5a66c_D20201231-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMjc0ODc3OTA3NzM5MQ_2319b954-be3d-4d3b-9277-68513712ac02"
      unitRef="usd">1037000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables
      contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE1Nw_d8291174-ecc3-43c4-ae69-4c378ee52e41"
      unitRef="usd">6000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable
      contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE4Mg_dc2d9073-3bb1-48da-b48c-3bf1dae4adbf"
      unitRef="usd">25000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies
      contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE2OQ_9af3d4ca-32ce-4e9e-bee6-68297f9c44d7"
      unitRef="usd">33000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="ic33053c2ba4f4b76a00c7f0da541789a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80My9mcmFnOmI3MzZiMzE3NmVkNTRkMzQ4ZTJlOTlhZGY2NDk4ZGM4L3RleHRyZWdpb246YjczNmIzMTc2ZWQ1NGQzNDhlMmU5OWFkZjY0OThkYzhfMTA5OTUxMTYzODE5NQ_ecdc044b-1ccc-4e1e-8561-6748040808fe"
      unitRef="usd">6000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMjk4Mg_30866604-0492-493b-b445-a1bd3aeff99b">Fair Value Measurements We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2020 Annual Report on Form 10-K, Note 5, &#x201c;Fair Value Measurements.&#x201d;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net changes in fair value of Level 3 financial instruments are reported in &#x201c;Other&#x201d; operating expenses in our consolidated statements of income. In the first quarter of 2021, we recognized a loss of $8&#160;million for the increase in the fair value of the contingent consideration liabilities described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $31 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. In the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $23&#160;million, was paid to the seller. We expect to pay the remaining balance of the liabilities, reported in &#x201c;Accounts payable, accrued liabilities and other&#x201d; in the accompanying consolidated balance sheets, later in 2021 and in the first quarter of 2022. The portion of the contingent purchase consideration paid in the first quarter 2021 has been presented primarily in &#x201c;Financing activities&#x201d; in the accompanying consolidated statements of cash flows, with the balance reflected in &#x201c;Operating activities.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &#x2013; Disclosure Only&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMjk3MQ_da4e4a05-0270-498e-bcbf-cfe65d8315b0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC0xLTEtMS00MjA2_f9757bb7-a0d8-4bee-bd08-973e6b030941"
      unitRef="usd">1188000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2be9ab0685c342fdb10ce4970ddf28c6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC0zLTEtMS00MjA2_3abc9e1b-5bf3-4819-adea-81656b7717cc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a91a1b851c5460ea799477e1d8ffea0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC01LTEtMS00MjA2_70da7e6a-6a13-491f-9d43-6a64ee7de15e"
      unitRef="usd">1188000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d894df64afc4b708465d180e9e4d828_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNC03LTEtMS00MjA2_980b64eb-830c-4491-b48e-066ae3979065"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS0xLTEtMS00MjA2_d0b7d4b5-6903-45a1-a9cb-651d0b6ab7ee"
      unitRef="usd">429000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34971f76fea54413af66394067162aa4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS0zLTEtMS00MjA2_7e46c360-3332-410b-80cd-491d3362dbd0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5ea329b6ce44f08b01706088442cd3d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS01LTEtMS00MjA2_8e65b626-952e-4b95-9998-aa7c9f35e3ea"
      unitRef="usd">429000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia72442a16d054cf6b2add623661e1309_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNS03LTEtMS00MjA2_085d4a10-5e3b-4404-8c9b-c2ca444664d7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi0xLTEtMS00MjA2_c3516f95-6396-4b10-b138-0d67e945b8de"
      unitRef="usd">152000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idffa9f6c7ef243a0945eb16b52a45524_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi0zLTEtMS00MjA2_e6cb9f79-5d65-4144-be17-76527500e288"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89eff6b8e212434c80c97106458c80f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi01LTEtMS00MjA2_1102c18d-9d08-4144-97d1-3d8089d3af57"
      unitRef="usd">152000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e8486b4460641688370ab5c52704984_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNi03LTEtMS00MjA2_f4b298db-0588-4f93-839e-948b2ee2398b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy0xLTEtMS00MjA2_6a2e64c9-a3f4-4d10-80e1-ed16d0b101d3"
      unitRef="usd">97000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fffabe708ad4e94ba5b0636c6518d9f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy0zLTEtMS00MjA2_2ffd1aff-8104-424d-9f51-f06e9f073587"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbd148c06afc46d29d9896ffc0517005_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy01LTEtMS00MjA2_92308aa8-9f92-4e47-9b86-c3bcacc9ca0b"
      unitRef="usd">97000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e957ac778a7477899bb650c9835d5d2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfNy03LTEtMS00MjA2_68acfb80-bb65-499f-9185-845a27b2e25e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC0xLTEtMS00MjA2_cf0358be-617e-4734-90e3-fc405c7fa366"
      unitRef="usd">72000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10c53b5850b44aea95b55cac2de8f94a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC0zLTEtMS00MjA2_39a293ea-726f-4708-ae1c-d4769d6f3a6a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if96c7085c6d14448b5deab7fd704714d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC01LTEtMS00MjA2_f57970ca-fa90-4ab6-8053-11f5a00e99ae"
      unitRef="usd">72000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if612cc865e074f888043131a4ddf811f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfOC03LTEtMS00MjA2_de2da6b0-7d66-4afb-a6bc-71103c533ed0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItMS0xLTEtNDIwNg_33917e7f-c4dc-4adc-9025-b75183b8c36b"
      unitRef="usd">1938000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i367c629760754439af0a0d0519f9eccd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItMy0xLTEtNDIwNg_5024c619-b14a-4de2-ba55-719d1c5322bb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i90962768e25e4a079c9fa088d378e436_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItNS0xLTEtNDIwNg_8b414069-d46d-4a64-898a-99af4de61d2a"
      unitRef="usd">1938000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTItNy0xLTEtNDIwNg_1712f898-f7c2-484c-b556-7c058d14918e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtMS0xLTEtNDIyNA_34489ecc-67dd-4e6f-b39b-2e18f41fc70e"
      unitRef="usd">31000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i367c629760754439af0a0d0519f9eccd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtMy0xLTEtNDIyNA_825ed9f9-1c9a-4e3a-b56b-36a7eeabdac8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i90962768e25e4a079c9fa088d378e436_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtNS0xLTEtNDIyNA_b1ea61de-849e-41a3-9f5f-16e189ce5c55"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTQtNy0xLTEtNDIyNA_9bebb1c9-e29b-4063-b121-6da98092afe7"
      unitRef="usd">31000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtMS0xLTEtNDIyNA_d5de784c-fa0f-4931-84db-19bb17977be6"
      unitRef="usd">31000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i367c629760754439af0a0d0519f9eccd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtMy0xLTEtNDIyNA_e8637b47-0948-4b01-b80c-00610f274e2a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i90962768e25e4a079c9fa088d378e436_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtNS0xLTEtNDIyNA_859082a4-00ff-476f-92a9-5db736b50197"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjM0NGExZGVmOTU5NjQ1YzRhM2I3NWNmMjBjM2Y4NjU0L3RhYmxlcmFuZ2U6MzQ0YTFkZWY5NTk2NDVjNGEzYjc1Y2YyMGMzZjg2NTRfMTUtNy0xLTEtNDIyNA_7753e9f3-0344-44cf-85cc-d88141006673"
      unitRef="usd">31000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC0xLTEtMS0w_20c4c84f-041b-43b7-8736-9b7c88037f9e"
      unitRef="usd">1256000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i776889e2aac941f6b8777a276968f455_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC0zLTEtMS0w_99387a7f-fd2b-40b1-8776-3ba6aacebbb1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c4d02fdb08d40358bf0167b7e447156_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC01LTEtMS0w_89b322b3-4626-4574-84a8-625589f73a2a"
      unitRef="usd">1256000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2484837902cc473abe31b5f45b8b5d5c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNC03LTEtMS0w_fd32291f-05e2-43f3-af7f-18134794a923"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS0xLTEtMS0w_81846d72-0d4f-4aef-99f4-6fba01f456b3"
      unitRef="usd">392000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i624191553621462ab6d620e9fa29afe5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS0zLTEtMS0w_3194d0f0-8032-4c30-ad80-62eb6da2c7b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib66bdf91f7c54e64ae93432279b0c7d9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS01LTEtMS0w_84634cd5-b93a-42c2-848e-2f794abb91e8"
      unitRef="usd">392000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacc3f4d81df942ecbe0f17b7684f3a38_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNS03LTEtMS0w_7be492d0-9d7f-4d89-b718-2f56a300517f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0xLTEtMS00MDYx_ab302cda-9940-4dbc-aff4-d04d29671288"
      unitRef="usd">132000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8626edaea2f544f68b7eeffc9cdc5c74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0zLTEtMS00MDYx_2d3d8624-64c0-43a6-b900-9d00696a86fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ffff4e3ba0343a2861c235a54ba7686_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi01LTEtMS00MDYx_39301114-3ee3-460d-a435-114aea96bbb5"
      unitRef="usd">132000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb78d77ebc514051a2802fae9ffa2745_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi03LTEtMS00MDYx_4d5f6ba2-0d4b-4557-87e4-3c8958eaef61"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0xLTEtMS0w_202b24f8-bc28-4f37-932e-b266ce587caf"
      unitRef="usd">27000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4908d014efa1485e92e9f298580b4e47_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi0zLTEtMS0w_060a3aa8-ee91-4f4e-9b1a-813344afa408"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8b9ad1f540c43b5b9d22ae02827f3b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi01LTEtMS0w_7fb99cd8-6eb2-4bf9-a827-e4059425a026"
      unitRef="usd">27000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bde201c232c4a07b85ad5ea4c855816_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfNi03LTEtMS0w_56ccc375-76ce-4fdc-99eb-7d5f2745339c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC0xLTEtMS0w_01d169f6-6477-4db3-89c5-46d99be244b6"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54b1d89062504208983df2df1d02c5ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC0zLTEtMS0w_3db7d378-61cd-4ad0-9959-3b3b6400fcbf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c9348c98a684882a89a1791746cd066_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC01LTEtMS0w_34163192-51d3-4454-acaa-6a61fb87c818"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i999e7c8caf5d4a449709bfcf9071b5d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfOC03LTEtMS0w_e9dab5c0-1755-4e60-9b34-44c6c03fe72f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItMS0xLTEtNDExNw_eedb11e2-fcd1-4b64-b5e9-96eb4d4b346c"
      unitRef="usd">1875000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id5cfb1e5f1124f08a113456fed9b0aba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItMy0xLTEtNDExNw_45de794e-183e-4f20-a807-25fa2885c55e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItNS0xLTEtNDExNw_267f01e6-98e9-492f-bb1c-dbbe780ba28a"
      unitRef="usd">1875000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTItNy0xLTEtNDExNw_d7b1f20d-f3ad-4a36-bd62-47d1dbdba1cc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtMS0xLTEtMA_8b91b5b0-5837-40f6-8c01-9cb83d4e2a63"
      unitRef="usd">46000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id5cfb1e5f1124f08a113456fed9b0aba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtMy0xLTEtMA_85f91b29-4a94-440d-8fb3-73e544fe50b3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtNS0xLTEtMA_20b2d580-48e7-417c-a9d3-bd3849adc0be"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTYtNy0xLTEtMA_8c61bf79-bf8e-45fa-bf0e-fb1dc7b04cca"
      unitRef="usd">46000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctMS0xLTEtMA_e164e840-3e77-46db-875d-2bbe8a36ba1e"
      unitRef="usd">46000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id5cfb1e5f1124f08a113456fed9b0aba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctMy0xLTEtMA_78def395-28b5-4427-8ccd-5293621f7511"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if1ec5c1dcf7d4204be72315a18d2a77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctNS0xLTEtMA_db68b615-39c6-464e-a4d5-4933ae6e48a8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icf6917cee05f49fa99e3d38ecf7ed87a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOmY4MmNhMWFhNzBhZDRkYTJiMjQxMDcyNWZkZmYxM2VkL3RhYmxlcmFuZ2U6ZjgyY2ExYWE3MGFkNGRhMmIyNDEwNzI1ZmRmZjEzZWRfMTctNy0xLTEtMA_42558ba3-5dd1-434f-b123-08ede2e93aaf"
      unitRef="usd">46000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfNDM5ODA0NjUyNDY3Nw_9ed7d919-bd61-438c-b2b5-6f4310850cde"
      unitRef="usd">8000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i71e2bb0b925543119143aeb28e57dfb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfNDM5ODA0NjUyNDk1NQ_9bebb1c9-e29b-4063-b121-6da98092afe7"
      unitRef="usd">31000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMTA0NDUzNjA0Nzg0ODA_77a6e3d8-5c9b-47ae-86fe-1a57f04dd7c3"
      unitRef="usd">23000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RleHRyZWdpb246YWE3NmI1YzRkOWM0NGI2Njk4NmNiNTZkMmJjYTNiYzRfMjk5Mw_2f698cc4-7de9-4947-bec0-646766e38175">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy0wLTEtMS0xNjcvdGV4dHJlZ2lvbjo2ZjUyYjZlNmE5YWI0YTUwOGRjYzY5YTYyYTBkMzgwMl8yNzQ4Nzc5MDY5NDUz_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i96a3d683acc0407d9bc0027bd95e5c34_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy0xLTEtMS0xNjc_1d0c8cfd-f40f-40c9-b8b5-b0a6cc9f8d97"
      unitRef="usd">790000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ifabcec5c78a74e89969fc2325fe4e83f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy0zLTEtMS0xNjc_1cf4137c-1afb-4438-b083-744e2dbb4e4b"
      unitRef="usd">822000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0d77563cade44be7befb74c969a2dd4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy01LTEtMS0zOTk_a75a081c-8aad-4d43-b7a6-e6d88603bb04"
      unitRef="usd">789000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6cd7f1592daf42cfa111ef9d3525f7dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfMy03LTEtMS0zOTk_2abcb772-065a-47f4-9044-8b68ed4e9870"
      unitRef="usd">843000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC0wLTEtMS0xNjcvdGV4dHJlZ2lvbjpmM2I3ZjczOWFlYzQ0ZWQ0OWRkMGUxYzE1M2FkNzBiN18yNzQ4Nzc5MDY5NDU0_8a0c0854-4886-4d9b-8a59-f87640c3c730"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i59b0cf8fcf28410b85ca7ccc1bd5028e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC0xLTEtMS0xNjc_bb833d98-d6af-4cf8-a92d-8cc9c8cb51dc"
      unitRef="usd">697000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0ed421117c6f422a9b4454963e89aaa4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC0zLTEtMS0xNjc_6b6c7977-b1b5-4718-8fbd-bddb8b7d5c60"
      unitRef="usd">736000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i4316903bcdcb421181b02d8d89f68ed1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC01LTEtMS0xNjc_afc9a6fd-e312-4ff1-8e31-f6f433c3542d"
      unitRef="usd">697000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i47c23e80da0749b18fdf5572eeccf013_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNC03LTEtMS0xNjc_188373bb-11bb-48b0-95b8-d338e692c199"
      unitRef="usd">742000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS0wLTEtMS0xNjcvdGV4dHJlZ2lvbjo0ZmQ4NzgyZTRiYWM0MTg3ODhmOWZmOGQ2NmRjMmIxZV8yNzQ4Nzc5MDY5NDUz_e5b68285-40c8-462e-a4ec-2c6158818115"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7598a3a1ef3e4c72915a1f6a9b3e0870_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS0xLTEtMS0xNjc_8ab4c297-d3bd-494b-b9b1-d83f2060d1ee"
      unitRef="usd">641000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ie64eb88418e44ccdaa7c1b45b0e9c179_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS0zLTEtMS0xNjc_30ac6f47-5f81-42dd-9d88-b56a48bfcb57"
      unitRef="usd">665000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ie10b590b22514a43a3f12d61a7d8768a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS01LTEtMS00MDM_e2f95f09-dd81-42c1-9e80-9ba0bc3004cd"
      unitRef="usd">641000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if379c70eb4bc4cb89f39dd8542e38baa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfNS03LTEtMS00MDM_2a3f4340-e7f4-40ad-aab8-d83589aedc72"
      unitRef="usd">691000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id1fea16fef42471dba019c040233981e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS0xLTEtMS0xNjc_ed467274-4713-4447-8761-d0cf783c1018"
      unitRef="usd">2128000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8074103f41e04c56b96df5ea82a9c412_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS0zLTEtMS0xNjc_dc631186-5d3e-4e20-b58e-029042d07524"
      unitRef="usd">2223000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if451e23108a3485e917d50dbd51706d3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS01LTEtMS0xNjc_3e4df0fe-da27-46df-a660-456e9b2f5ad8"
      unitRef="usd">2127000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic1936ea8520f42d384dec241609293d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80Ni9mcmFnOmFhNzZiNWM0ZDljNDRiNjY5ODZjYjU2ZDJiY2EzYmM0L3RhYmxlOjczMzE4NzM5Yzc4ZTRhNGRiMDAzNDdhOTdmYzE4M2YwL3RhYmxlcmFuZ2U6NzMzMTg3MzljNzhlNGE0ZGIwMDM0N2E5N2ZjMTgzZjBfOS03LTEtMS0xNjc_2b58f165-6e2f-474c-9d54-bfb1821f64a6"
      unitRef="usd">2276000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMjY0Nw_1077ae8d-a8e3-4d60-915f-527a3738c392">Investments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our available-for-sale investments as of March&#160;31, 2021 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant in the three months ended March 31, 2021, and amounted to $5&#160;million in the three months ended March 31, 2020. Gross realized investment losses were insignificant in the three months ended March 31, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that unrealized losses at March&#160;31, 2021, and December&#160;31, 2020, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2021, and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Held-to-Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $138 million at March&#160;31, 2021, of which $122 million will mature in one year or less, and $16 million will mature in after one through five years.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMjY2Mg_8a22cd1f-0f7a-4b4b-9114-9d31968ec378">The following tables summarize our investments as of the dates indicated:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS0xLTEtMS0w_d7f1b885-e99a-44e7-8318-88e28ece7997"
      unitRef="usd">1162000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS0zLTEtMS0w_5ba8c950-8867-4044-88f5-5c0515ffbf16"
      unitRef="usd">27000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS01LTEtMS0w_babfa135-35fa-4c75-8cdb-89aa81abf5e4"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNS03LTEtMS0w_ecbebc86-e1b0-4989-b03d-dfb80391ba9f"
      unitRef="usd">1188000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi0xLTEtMS0w_d666669b-d061-4d71-8aaf-e23f2c8a148c"
      unitRef="usd">424000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi0zLTEtMS0w_1d11b662-290b-42fd-b214-a2f373298ba8"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi01LTEtMS0w_76b626d1-bdb0-4dfb-84a0-cb09844623dd"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNi03LTEtMS0w_8c0c5072-b35e-4f32-b9ed-92a6f24bd778"
      unitRef="usd">429000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy0xLTEtMS0w_a4c7b815-8a01-4766-94ae-3e4639d7fd98"
      unitRef="usd">150000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy0zLTEtMS0w_c741529e-44b1-450e-a86f-66833f5b5175"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy01LTEtMS0w_eda8ccde-f49c-430e-9b98-e658374a94f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c2c65749b7345faafdfba7c882cf15c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfNy03LTEtMS0w_22589246-806d-4173-8b22-1fe93df8f125"
      unitRef="usd">152000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC0xLTEtMS0w_cd3d7ca1-2171-4007-b3da-1744e9b46968"
      unitRef="usd">97000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC0zLTEtMS0w_7031d286-5bf9-456b-b58b-0bf4d66b1ee1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC01LTEtMS0w_36eb2ef9-82f9-451e-a68a-53b0057c2d75"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b5defbc615e4819b2c0c88d0eb25ba3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOC03LTEtMS0w_959b0ba4-f1d7-4887-b0ab-0302a66b06f4"
      unitRef="usd">97000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS0xLTEtMS00Mjgw_b7c09b1f-0dda-4de5-8766-c56486a12317"
      unitRef="usd">71000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS0zLTEtMS00Mjgw_752e2ad9-4186-449f-b890-c5511a472245"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS01LTEtMS00Mjgw_f7e83283-011f-44c0-b1af-ece39d25420b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c8be2d4f826466f8cbfc3927fcc5b6b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfOS03LTEtMS00Mjgw_fe7deb9c-03ec-4fbe-87c2-266d4a459418"
      unitRef="usd">72000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtMS0xLTEtMA_31261421-526f-4e89-9098-bfa013876bc4"
      unitRef="usd">1904000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtMy0xLTEtMA_fb94b009-f762-473d-906f-2e5ca7131da8"
      unitRef="usd">36000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtNS0xLTEtMA_10fcd9bb-2d4c-41ab-9c8a-67e808cd2363"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjg4NDEwN2NjNWY5MTQ1NjViZTUwZjBiYjcwYmQ4YTEwL3RhYmxlcmFuZ2U6ODg0MTA3Y2M1ZjkxNDU2NWJlNTBmMGJiNzBiZDhhMTBfMTMtNy0xLTEtMA_ef027950-735f-451f-b493-bd3d0e7128cc"
      unitRef="usd">1938000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS0xLTEtMS0w_53109880-beaf-4e33-9947-4a8d954d957d"
      unitRef="usd">1220000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS0zLTEtMS0w_e22e5d8f-78a5-46d2-a0bc-636f40e22588"
      unitRef="usd">36000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS01LTEtMS0w_a6e97feb-c935-4c5c-ac13-00a8afe9e55e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNS03LTEtMS0w_0934631c-e2a7-4bae-8649-57181827ce84"
      unitRef="usd">1256000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi0xLTEtMS0w_c8ce4b13-8008-4f90-b1f1-087de843a9e2"
      unitRef="usd">383000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi0zLTEtMS0w_37819a7e-7e3d-455d-861b-74d7f0a63353"
      unitRef="usd">10000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi01LTEtMS0w_294f4155-1ab0-41f5-b69e-c8e73ba17d4e"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNi03LTEtMS0w_8f176922-7e2d-4ba8-9e94-68c5d691f6b2"
      unitRef="usd">392000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy0xLTEtMS0w_300ca947-11ca-4e11-b4bc-7b31d9ef43b3"
      unitRef="usd">130000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy0zLTEtMS0w_954fc726-c604-465c-9878-f79da3c6a496"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy01LTEtMS0w_57e4a1c0-aa7f-4a1b-b98d-2be14ff42b96"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i544ceef696034b4e8335a1bbb52a445a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfNy03LTEtMS0w_ead956ee-7cf5-4c33-8ccb-3221dbafe912"
      unitRef="usd">132000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC0xLTEtMS0w_d2d2d673-2fb8-46cf-9db6-aa495efc9818"
      unitRef="usd">27000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC0zLTEtMS0w_587b043f-41ba-42b1-8b73-3bafc3d480b2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC01LTEtMS0w_0a61398b-2faa-49bb-9475-6b3e1b94f789"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89766e1120fe4cfdbf2765441a571fcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOC03LTEtMS0w_326d5ca6-66f3-4446-8b47-d81683c0747c"
      unitRef="usd">27000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS0xLTEtMS00Mjc1_2f0ba28f-f551-4698-9675-dcd929b4a0d5"
      unitRef="usd">66000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS0zLTEtMS00Mjc1_b9949f3e-915b-44ae-babd-eaaa8ddcd2c8"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS01LTEtMS00Mjc1_0872785d-f37f-454c-913b-57b38e49174a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i573d0b621da54b35beb8a4b399d05e90_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfOS03LTEtMS00Mjc1_ff7affa1-dd7e-406d-9b24-1674aa20012a"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtMS0xLTEtMA_6c4ce8b6-c91a-4093-8a8d-77c16343457d"
      unitRef="usd">1826000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtMy0xLTEtMA_4283b4bd-57a5-4398-ae77-d6a9ca8a1c44"
      unitRef="usd">50000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtNS0xLTEtMA_9ebd676b-7654-46e9-bb43-b58c2a5a4c37"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjdiMjMxODA2OTAxNDRhODM5YzU4YTNkNGUwNDNhMjAzL3RhYmxlcmFuZ2U6N2IyMzE4MDY5MDE0NGE4MzljNThhM2Q0ZTA0M2EyMDNfMTMtNy0xLTEtMA_a522a32b-0d42-44a7-b780-93085ab6391f"
      unitRef="usd">1875000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMjY0Ng_35ed7416-26fb-453e-b3e9-76091844d313">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our available-for-sale investments as of March&#160;31, 2021 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfMy0xLTEtMS0w_8c780853-1c1e-4a69-b7e7-0f756cee9c32"
      unitRef="usd">428000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfMy0zLTEtMS0w_06a4aeec-4026-4e3a-b949-d5b3605c12e3"
      unitRef="usd">429000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNC0xLTEtMS0w_20f4b78a-0f0d-4231-a044-2b13ca7dbef9"
      unitRef="usd">948000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNC0zLTEtMS0w_5e34a51d-cca5-48f7-932e-c5cf3e0dddbd"
      unitRef="usd">974000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNS0xLTEtMS0w_968d71c9-baad-4b5d-9dab-12b14d8bab17"
      unitRef="usd">167000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNS0zLTEtMS0w_6422285c-1037-4958-bdc8-1d7118d7c909"
      unitRef="usd">169000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNi0xLTEtMS0w_8f9c70da-2f95-4fed-b6c0-c0f90891705e"
      unitRef="usd">361000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNi0zLTEtMS0w_d0d43198-053c-4a7d-b4fe-f1cdf6740259"
      unitRef="usd">366000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNy0xLTEtMS0w_6c1d785a-a537-47f1-b8a0-74b8b664d517"
      unitRef="usd">1904000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RhYmxlOjQ1YTJjNzkzYTE0YjQwMmJiZTUxMmMyYjMyOWRjNDdmL3RhYmxlcmFuZ2U6NDVhMmM3OTNhMTRiNDAyYmJlNTEyYzJiMzI5ZGM0N2ZfNy0zLTEtMS0w_0510ca9b-78a8-498e-9335-9e882a26c939"
      unitRef="usd">1938000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF80OS9mcmFnOjU5ZTk1NmMxY2UxNzRkM2U4NjVlZGUwOWIxODY1ODEyL3RleHRyZWdpb246NTllOTU2YzFjZTE3NGQzZTg2NWVkZTA5YjE4NjU4MTJfMTY0OTI2NzQ0NDUwMw_136f0c9a-4d1c-41a1-802c-48c42d45c6de"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGV4dHJlZ2lvbjpkODQ0OTViMzNiZGE0ODRjODY4MmQxYTFkM2NjMjViMV8xMDQ0NTM2MDQ2NDE2Nw_cc05d83c-be5d-4e14-8266-dee8e6e7ba40">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2021, and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTEtMS0xLTU1NTc_c4670c4b-ac28-4925-9337-3c1ce2098f1c"
      unitRef="usd">175000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTMtMS0xLTU1NTc_434900c9-9749-448c-b229-3d8db5e9fdf0"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTMtMS0xLTU1NTc_72edbdf9-5f3a-4127-bc3f-dd63175a3c79"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="iaf47769cb2064e43baa8252d52471732_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTUtMS0xLTU1NTc_cd73002d-55a3-4f11-97e7-0eef369cf326"
      unitRef="position">78</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTctMS0xLTU1NTc_ba6e1bb4-86ff-448b-9f09-4ab8fff31935"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTktMS0xLTU1NTc_23a59682-a8c3-4e69-ace4-b4de6c801c9f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ibcc77b301d0e46a6884c3ae5dd73bfa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV80LTExLTEtMS01NTU3_fe0a08b1-39b6-4ba4-bce4-eb75b034da83"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTEtMS0xLTU1NTc_b71b540a-b7be-47fc-a88a-3abb16f52e07"
      unitRef="usd">101000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTMtMS0xLTU1NTc_455f0ed4-a4ba-4c42-a2dc-b47988e1697c"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTMtMS0xLTU1NTc_ea6fc609-9ae3-4419-bb5c-eac17e0117aa"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="id62eeb03b15e4bb6aaa44a5bfbeff8d6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTUtMS0xLTU1NTc_1e4e702c-e564-4462-8b53-bebf6d94ab92"
      unitRef="position">34</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTctMS0xLTU1NTc_413481cb-5d6a-43ce-8ba7-cae6b9b612fe"
      unitRef="usd">77000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTktMS0xLTU1NTc_81fa310f-1abf-4458-937e-1cc4ffdfc80f"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ie81450857ab248f39dd4d14ca25f6884_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV81LTExLTEtMS01NTU3_6adbd347-2d5d-471c-a52d-84e3161c53bf"
      unitRef="position">21</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0xLTEtMS01NTU3_befc5b35-9a0c-4153-a0f7-bd9308509fe0"
      unitRef="usd">276000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0zLTEtMS01NTc3_a7f430b8-2215-4ec1-9ce2-81d3ce70690c"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0zLTEtMS01NTc3_f406bf3c-65d6-418b-82d5-fdff53ae676f"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi01LTEtMS01NTc3_3be15ffb-7c93-4bdb-afa0-5a5b07e02dd1"
      unitRef="position">112</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi03LTEtMS01NTU3_18dedc86-1c12-459f-bb5d-b49bd3b5af3b"
      unitRef="usd">77000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi05LTEtMS01NTU3_181cce03-1249-4c7c-a063-cad4243f19ad"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTcyL2ZyYWc6ZDg0NDk1YjMzYmRhNDg0Yzg2ODJkMWExZDNjYzI1YjEvdGFibGU6MjYyNjJjMTBkYzcyNDNiMzlmOGU5OTQwMWQ1ODE3ZGUvdGFibGVyYW5nZToyNjI2MmMxMGRjNzI0M2IzOWY4ZTk5NDAxZDU4MTdkZV8xMi0xMS0xLTEtNTU1Nw_a80a02d1-ef86-4896-91b3-4575372256de"
      unitRef="position">21</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTY1L2ZyYWc6ZGE1ZDdhZmJmYWVkNGQ4Mzg5NGYwZjBhMWQ5ZWU3NTkvdGV4dHJlZ2lvbjpkYTVkN2FmYmZhZWQ0ZDgzODk0ZjBmMGExZDllZTc1OV8yNzQ4Nzc5MDcwNDMx_b0270c2e-ced0-4a43-8841-13707ce1dd9d"
      unitRef="usd">138000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTY1L2ZyYWc6ZGE1ZDdhZmJmYWVkNGQ4Mzg5NGYwZjBhMWQ5ZWU3NTkvdGV4dHJlZ2lvbjpkYTVkN2FmYmZhZWQ0ZDgzODk0ZjBmMGExZDllZTc1OV8yNzQ4Nzc5MDcwNDUy_3bdb01c5-e6f9-4e4a-b2ab-5f96848a3ec8"
      unitRef="usd">122000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8xMTY1L2ZyYWc6ZGE1ZDdhZmJmYWVkNGQ4Mzg5NGYwZjBhMWQ5ZWU3NTkvdGV4dHJlZ2lvbjpkYTVkN2FmYmZhZWQ0ZDgzODk0ZjBmMGExZDllZTc1OV8yNzQ4Nzc5MDcwNDkz_7c8dfb6f-099e-436e-9155-4f7499e6d408"
      unitRef="usd">16000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <moh:MedicalClaimsAndBenefitsPayableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTkwNA_a231f369-3f78-4fa3-8c28-d12794711063">Medical Claims and Benefits Payable &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fee-for-service claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other&#x201d; medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $222 million and $235 million as of March&#160;31, 2021, and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in acquired balances &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of medical claims and benefits payable recorded at December 31, 2020, and 2019 developed favorably by approximately $194 million and $101 million as of March&#160;31, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable prior period development recognized in the first quarter of 2021 was primarily due to lower than expected utilization of medical services by our Medicaid members and improved operating performance. Consequently, the ultimate costs recognized in 2021, as claims payments were processed, were lower than our original estimates in 2020.&lt;/span&gt;&lt;/div&gt;</moh:MedicalClaimsAndBenefitsPayableTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTkwNw_6944357d-5ad7-4c10-9f37-6813f54da3e9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fee-for-service claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfMy0xLTEtMS0w_44258058-d0f1-403a-b505-992bdd8dc6c9"
      unitRef="usd">2008000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfMy0zLTEtMS0w_3b03289e-c6d5-4501-b136-d29ace20ce44"
      unitRef="usd">1647000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:PharmacyClaimsPayable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNC0xLTEtMS0w_e9c87ff1-09e7-4f4e-8d3d-d4ef5b8e6898"
      unitRef="usd">217000000</moh:PharmacyClaimsPayable>
    <moh:PharmacyClaimsPayable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNC0zLTEtMS0w_9bd0b110-5d97-4898-95da-192d35019561"
      unitRef="usd">157000000</moh:PharmacyClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNS0xLTEtMS0w_0dd8cc5d-1468-493b-bdfe-de1be0127d5a"
      unitRef="usd">93000000</moh:CapitationClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNS0zLTEtMS0w_0a2cecf3-a859-4693-aa1c-71299ef2647f"
      unitRef="usd">70000000</moh:CapitationClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0xLTEtMS0xNjA5_2c93a9ac-c1e8-4b06-82b0-45e509393672"
      unitRef="usd">521000000</moh:OtherClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0zLTEtMS0xNjAx_6174cb1c-32ca-42f6-8693-9f90a35b7156"
      unitRef="usd">528000000</moh:OtherClaimsPayable>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i54983f52f1db4e76b731097292942bb3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0xLTEtMS0w_1ec6c78d-b22c-4b5b-b1a8-24512f861b9e"
      unitRef="usd">0</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNi0zLTEtMS0w_a40b7fa6-a18b-4512-9131-a1df6772ecb3"
      unitRef="usd">294000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNy0xLTEtMS0w_4ac4c686-66b9-4f32-95ff-beb017b39f2f"
      unitRef="usd">2839000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOmEwZWJmZDI0NGI3MTQxNWE5NzZhYzFjODY3Mzg0ZDRjL3RhYmxlcmFuZ2U6YTBlYmZkMjQ0YjcxNDE1YTk3NmFjMWM4NjczODRkNGNfNy0zLTEtMS0w_a5177061-5b9e-485a-b20b-4f6d0710ea94"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfNDQ1_f361a5ea-7d0a-4bd6-985f-015e0a1d81d6"
      unitRef="usd">222000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfNDUy_28992d97-6384-4205-af27-37bd769cc6fe"
      unitRef="usd">235000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTkxNw_e40f18c1-2354-4021-a01b-c0e235ca88cd">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in acquired balances &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iba24de5e17564671afe22ec89f5f3acf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC0xLTEtMS04MTYw_b661b8e3-7b36-477a-9954-48b6c49ddaeb"
      unitRef="usd">2129000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i340f4a8c71a1410b99e342dbbe44f76c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC0zLTEtMS04MTY0_7b3ee3ec-6b52-4158-a840-949a52c88c13"
      unitRef="usd">392000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia09ae954893b4c35919a0f83d0592f6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC01LTEtMS04MTY3_dd93118a-4fd3-458d-b4c2-b6b2e3d97f46"
      unitRef="usd">175000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNC0zLTEtMS0w_b29d8867-0d7d-4399-978d-e5a0da9a4ec4"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi0xLTEtMS04MTYw_d4c41124-49d9-4428-95c0-a2b9805f0805"
      unitRef="usd">4394000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi0zLTEtMS04MTY0_e4411fd8-dcb5-484c-b974-d3dc9244ebb2"
      unitRef="usd">738000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi01LTEtMS04MTY3_80f67d7a-da47-4248-83d3-379acd8fe5e8"
      unitRef="usd">536000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNi0zLTEtMS0w_e81eeb34-66dd-4b0f-b836-a7a7ec572333"
      unitRef="usd">5668000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy0xLTEtMS04MTYw_8e25e560-b094-4c6b-90e3-f766219465cc"
      unitRef="usd">-158000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy0zLTEtMS04MTY0_adb23702-0fc1-40e0-ac2d-3ed84b57a6d8"
      unitRef="usd">-16000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy01LTEtMS04MTY3_cf73c938-9f03-4b0b-b69b-160e3116f75b"
      unitRef="usd">-20000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfNy0zLTEtMS0w_0e7616c7-177d-40fc-81f0-ed4a0148ce99"
      unitRef="usd">-194000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC0xLTEtMS04MTYw_a7550f2d-3ae9-4094-ab1f-6908c6e08a12"
      unitRef="usd">4236000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC0zLTEtMS04MTY0_29e0d62e-77da-4984-bcfd-aac5e73b0e14"
      unitRef="usd">722000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC01LTEtMS04MTY3_c14f46ac-c170-47d0-8c9b-e2201b9f2b56"
      unitRef="usd">516000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfOC0zLTEtMS0w_4862753d-5de4-4f3a-81e3-eeea7186185d"
      unitRef="usd">5474000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTAtMS0xLTEtODE2MA_ca2b24a6-3abc-4a81-8077-9d818ce0dfa5"
      unitRef="usd">2790000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTAtMy0xLTEtODE2NA_25f00978-181a-4224-bf26-503e64dad157"
      unitRef="usd">410000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTAtNS0xLTEtODE2Nw_c01ac37c-543e-4363-b61d-c7e4ef334bcc"
      unitRef="usd">313000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtMy0xLTEtMA_2ae171b9-2b3b-480c-96ae-831b2269376e"
      unitRef="usd">3513000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtMS0xLTEtODE2MA_35c877fb-af27-4458-afbe-c653fa95cd92"
      unitRef="usd">1364000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtMy0xLTEtODE2NA_e835f019-3cdb-4afd-97ea-ff977b987b92"
      unitRef="usd">304000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTEtNS0xLTEtODE2Nw_1d0d8d9c-3d0d-4a31-9096-c272d876ce7c"
      unitRef="usd">113000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItMy0xLTEtMA_5277c884-4fed-44f2-bf2f-a6200baaf356"
      unitRef="usd">1781000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItMS0xLTEtODE2MA_ea6dcf40-c8a2-448a-9d59-af0b9ad03408"
      unitRef="usd">4154000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItMy0xLTEtODE2NA_46a23f6b-a6d6-404e-858d-ea82e20af33d"
      unitRef="usd">714000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTItNS0xLTEtODE2Nw_0cc42530-998a-46cd-872b-ae4ee1a42779"
      unitRef="usd">426000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTMtMy0xLTEtMA_1ab5bf4f-6ede-4d52-b6e2-c0992c5d2ad5"
      unitRef="usd">5294000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:ChangeInAcquiredBalances
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtMS0xLTEtODE2MA_131be792-6141-475b-bfec-1f7203f58052"
      unitRef="usd">8000000</moh:ChangeInAcquiredBalances>
    <moh:ChangeInAcquiredBalances
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtMy0xLTEtODE2NA_84c073bd-ef44-4752-a860-e3119d2092ff"
      unitRef="usd">-33000000</moh:ChangeInAcquiredBalances>
    <moh:ChangeInAcquiredBalances
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtNS0xLTEtODE2Nw_3e64472c-257c-49ce-89a6-c99baab47723"
      unitRef="usd">0</moh:ChangeInAcquiredBalances>
    <moh:ChangeInAcquiredBalances
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTMtMy0xLTEtMjE2NQ_3e9996e9-4bcc-47b2-9989-68917726adb4"
      unitRef="usd">-25000000</moh:ChangeInAcquiredBalances>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i89919ce69b2449b792ca722a43af1d2d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtMS0xLTEtODE2MA_42fbf646-7750-4aca-add3-fe675ce1d4c4"
      unitRef="usd">-11000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtMy0xLTEtODE2NA_8864e7bb-e55e-4329-b935-9df262aa6c3c"
      unitRef="usd">-1000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtNS0xLTEtODE2Nw_ea3025c5-1c78-4824-93be-771c95177a5f"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTUtMy0xLTEtOTY0_68359c31-db0d-4073-8ded-0f1b8c6e7792"
      unitRef="usd">-12000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9981d0011a794884b2a7987b32480b6b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTYtMS0xLTEtODE2MA_1a0decd4-370a-45b9-9506-60d09257e07a"
      unitRef="usd">2208000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iad67715684f94d79a4e970a446c35348_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTYtMy0xLTEtODE2NA_58294473-7378-4114-b7e4-2891dbc7e9fd"
      unitRef="usd">366000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6cd4b30c10a94ae093780ce38d46a370_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTYtNS0xLTEtODE2Nw_c9eb2680-c658-440e-bec5-e02c905aec01"
      unitRef="usd">265000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjFlZjhmNmVmZDI2NzRlMzJiOTYyM2I1OGYzNmJkNTFlL3RhYmxlcmFuZ2U6MWVmOGY2ZWZkMjY3NGUzMmI5NjIzYjU4ZjM2YmQ1MWVfMTQtMy0xLTEtMA_582cfd58-f688-4e4c-8cc3-9817b42bf88f"
      unitRef="usd">2839000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id3e72d808dd54b4097d93c8105045161_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC0xLTEtMS04MTc2_169f7b52-1fab-448e-9c2a-25998620708d"
      unitRef="usd">1465000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i250ad4b68c834c7ab7f008a13f28fed5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC0zLTEtMS04MTgz_fd714b2b-b60e-46d3-a0aa-1ec51ff36357"
      unitRef="usd">267000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i03cf9b99099a418cbff01db407d511cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC01LTEtMS04ODc0_a2ec5a67-23c8-4e6e-922b-236e5a701918"
      unitRef="usd">122000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNC03LTEtMS03ODc4_0b7f4ddf-8e9f-41a7-b9dc-5ed35de4ef5f"
      unitRef="usd">1854000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi0xLTEtMS04MTc2_4490956e-cf98-4120-8c82-5ee61dd126ad"
      unitRef="usd">2991000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi0zLTEtMS04MTgz_d3dcf832-689e-4750-b1c6-ae81099b095b"
      unitRef="usd">543000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi01LTEtMS04ODc0_144cd3a7-0b38-48ba-8be3-69bbfd8bf562"
      unitRef="usd">283000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNi03LTEtMS03ODc4_39d2dbd2-2f89-4faa-b903-e10c5b873b77"
      unitRef="usd">3817000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy0xLTEtMS04MTc2_fcb22a8f-c309-4901-98f3-823f56f672ca"
      unitRef="usd">-70000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy0zLTEtMS04MTgz_41c743f8-1394-4099-8da8-3ccf90bfba28"
      unitRef="usd">-26000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy01LTEtMS04ODc0_73ad1fd2-6fce-44a0-91ae-efbf87ca26bb"
      unitRef="usd">-5000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfNy03LTEtMS03ODc4_647c827f-060e-4f28-8113-c4821f96b4f2"
      unitRef="usd">-101000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC0xLTEtMS04MTc2_defc3632-d816-4ddf-af91-26b4aa3dbe96"
      unitRef="usd">2921000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC0zLTEtMS04MTgz_4be6da2a-bce1-4145-96cc-80ca99f531bf"
      unitRef="usd">517000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC01LTEtMS04ODc0_eb7291f8-e7d8-445d-9297-c500debd659c"
      unitRef="usd">278000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfOC03LTEtMS03ODc4_e717248e-db5f-48c2-91ec-4d182007d26e"
      unitRef="usd">3716000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtMS0xLTEtODE3Ng_4accca7b-50bc-4c70-b226-e23a000c5f1e"
      unitRef="usd">1786000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtMy0xLTEtODE4Mw_f8c75d3d-0c94-4501-b66b-c44ec31bb8f4"
      unitRef="usd">324000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtNS0xLTEtODg3NA_a863b114-5cc3-414d-be6d-fc5937c28935"
      unitRef="usd">164000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTAtNy0xLTEtNzg3OA_4a9a3f7b-15cd-4a3e-81f9-381c92ef2703"
      unitRef="usd">2274000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtMS0xLTEtODE3Ng_edf162cc-7ff0-4beb-81d0-cb5565ef64d8"
      unitRef="usd">1014000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtMy0xLTEtODE4Mw_8190fabe-7dd7-4072-9571-6e2757dfa487"
      unitRef="usd">205000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtNS0xLTEtODg3NA_f1d6d306-8c74-4794-90a6-b330add231c8"
      unitRef="usd">86000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTEtNy0xLTEtNzg3OA_c2257e3b-2915-4d18-b682-fa5b3ca8d2dc"
      unitRef="usd">1305000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItMS0xLTEtODE3Ng_568edc66-1b46-4d5b-8d5e-7ac11af0458b"
      unitRef="usd">2800000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItMy0xLTEtODE4Mw_7d789f36-0b35-4abc-b836-063bc86b073c"
      unitRef="usd">529000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItNS0xLTEtODg3NA_7408c968-5763-4189-b76c-f4843bf3c231"
      unitRef="usd">250000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTItNy0xLTEtNzg3OA_912ff859-38c9-4123-8c5e-ff4c220e083e"
      unitRef="usd">3579000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i862c90fdd196435ca2d0c332dad0ef16_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTMtMS0xLTEtODE4MA_7ad51c34-7a04-4d00-ad77-6ba71b7cbdaf"
      unitRef="usd">-10000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTMtMy0xLTEtODE4OQ_da7ad554-1f92-46f7-998e-243d7e62a51a"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTMtNS0xLTEtODg3NA_ddaafb7f-c483-47cc-b149-326da5c2dd82"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtNy0xLTEtNzg3OA_d7eda5b3-c0ea-4f71-94dd-03f3f0daa4e5"
      unitRef="usd">-10000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id9e8a21df22c49dea82dcb63e4eff8cb_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtMS0xLTEtODE4MA_3604afb1-0ceb-4119-a894-d11edb3f4299"
      unitRef="usd">1576000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i087cf67012d04ba0bbee3ed77b869dbd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtMy0xLTEtODE4OQ_ab872fb0-8cb3-47be-817c-12bd1b31941c"
      unitRef="usd">255000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if445e6aa2f2a404c9c2cae784a9d3c67_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTQtNS0xLTEtODg3NA_4c414610-3d4d-4de8-a5c8-2de2b7e84f30"
      unitRef="usd">150000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7250e43387d044659d3061f2be2719fd_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RhYmxlOjE0NzczYTJhOWYzYTQzNzZiOTUzMGJjYWM3YTU0NWY4L3RhYmxlcmFuZ2U6MTQ3NzNhMmE5ZjNhNDM3NmI5NTMwYmNhYzdhNTQ1ZjhfMTUtNy0xLTEtNzg3OA_5aa35098-8cfd-41a5-84c2-f7786142f052"
      unitRef="usd">1981000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTEwNg_0e7616c7-177d-40fc-81f0-ed4a0148ce99"
      unitRef="usd">-194000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81NS9mcmFnOmEwZmVlZGRiNTY0NTRmY2M4OGQ3ZjdhOGI0MGNlNjIwL3RleHRyZWdpb246YTBmZWVkZGI1NjQ1NGZjYzg4ZDdmN2E4YjQwY2U2MjBfMTExMw_647c827f-060e-4f28-8113-c4821f96b4f2"
      unitRef="usd">-101000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfNDI3MQ_2347fbb5-fb9d-4bf0-ae0d-be2c948ad349">Debt &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All long-term debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to a credit agreement (&#x201c;Credit Agreement&#x201d;) which includes a revolving credit facility (&#x201c;Credit Facility&#x201d;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains customary non-financial and financial covenants. As of March&#160;31, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of March&#160;31, 2021, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;High-Yield Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina Healthcare, and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare. In addition, each of the notes contain customary non-financial covenants and change of control provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;4.375% Notes due 2028.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $800 million aggregate principal amount of senior notes (the &#x201c;4.375% Notes&#x201d;) outstanding as of March&#160;31, 2021, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;5.375% Notes due 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $700 million aggregate principal amount of senior notes (the &#x201c;5.375% Notes&#x201d;) outstanding as of March&#160;31, 2021, which are due November&#160;15,&#160;2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. &lt;/span&gt;&lt;/div&gt;3.875% Notes due 2030. We had $650 million aggregate principal amount of senior notes (the &#x201c;3.875% Notes&#x201d;) outstanding as of March&#160;31, 2021, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15 of each year, commencing on May 15, 2021.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfNDI3Mw_3fc7cafd-3ef4-42e7-b2a9-85001c529516">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOC0wLTEtMS0wL3RleHRyZWdpb246YWVjMTE3NTkxM2YzNDg3Zjg1YWJiYWQ3NGY1YmI5MTZfMjc0ODc3OTA2OTQ2Mg_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOC0xLTEtMS0w_72d2b256-fe3d-4c57-9220-416e216beb5e"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i4790b3dd8c914707b7598d0687f23cf3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOC0zLTEtMS0w_0070dc7c-eef5-4d93-8758-a5b4a9110cfd"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOS0wLTEtMS0wL3RleHRyZWdpb246MTViZDFjZDdjNzJiNGZhMDkyMTQ2YWJhMGVkYzZmZjNfMjc0ODc3OTA2OTQ2Mg_8a0c0854-4886-4d9b-8a59-f87640c3c730"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOS0xLTEtMS0w_33c36253-cd7b-43e7-961b-bc4b881ef1db"
      unitRef="usd">700000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="icf6b03e1fc3e49bdbe024dcf4fec7e6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfOS0zLTEtMS0w_ed77be51-8921-406a-be78-ac2c548ae5f6"
      unitRef="usd">700000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTAtMC0xLTEtNDUzNS90ZXh0cmVnaW9uOjIwMDcxMWRiOTdhMjQyNDc5ZjhkMTAyZmQ1MzZjOTliXzI3NDg3NzkwNjk0NzI_e5b68285-40c8-462e-a4ec-2c6158818115"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTAtMS0xLTEtOTQ4_34351841-cce0-4c13-b5b4-d0749284e46c"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i25bb3713e7dc4ce8aff3b343553d1d5a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTAtMy0xLTEtOTQ4_7d6fc5ae-4e1f-41ab-8630-ffc9f6f563d3"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTItMS0xLTEtMA_e86d7a2d-4577-4271-9497-fc725dc3c706"
      unitRef="usd">22000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTItMy0xLTEtMA_6db37f94-a2e8-4247-829d-1ebb5457f64e"
      unitRef="usd">23000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTMtMS0xLTEtMA_6cf614f2-5b94-4125-ad79-2d7fc86f2ae1"
      unitRef="usd">2128000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RhYmxlOjk2OGQ0NjI4YTg1ZTRlMTZhZjAyZDc5M2UzNDA1MWFiL3RhYmxlcmFuZ2U6OTY4ZDQ2MjhhODVlNGUxNmFmMDJkNzkzZTM0MDUxYWJfMTMtMy0xLTEtMA_e90f64cc-ce9b-4a80-8b95-39b07122e846"
      unitRef="usd">2127000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iee5537a3735a44efbf12ff851ff5fb61_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfNzIw_d2359952-f53f-4e45-91d3-d5c283f45b41"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="iddefd20760394cda9704c051843be4a0_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMTMyNw_334c8ec2-a70e-4fcf-8773-5e224d5d23ad">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="iee5537a3735a44efbf12ff851ff5fb61_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMTk1OQ_c6df7de7-8b54-4687-9d0a-d9d2898e73c8"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjY3Ng_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0OQ_69e105d4-7b37-497a-b94f-bfc971818848"
      unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjgwMQ_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3497a8a249484c1aacdc7e16ef9f67e4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjk3OQ_f4a425d2-c587-4e89-8ca0-76f9d2acd1ee"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzM3Nw_8a0c0854-4886-4d9b-8a59-f87640c3c730"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzQwMw_ebfa4331-ed4c-4e6f-a5f6-29a0f1218cf4"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzQ1NQ_8a0c0854-4886-4d9b-8a59-f87640c3c730"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b95fdd56a99434dbbbdc32edd60c4bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMzU2OQ_8a0c0854-4886-4d9b-8a59-f87640c3c730"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU4MA_e5b68285-40c8-462e-a4ec-2c6158818115"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU5Mg_0247298a-d03a-4ec7-9e94-f26cf69ce455"
      unitRef="usd">650000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU4NA_e5b68285-40c8-462e-a4ec-2c6158818115"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6d58211ae65042729ae93bc766bb2f03_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF81OC9mcmFnOjdkNTBiY2JiYzM4ZTQ3ZDE5ZjVlZWE4Nzk5MzgyOWIyL3RleHRyZWdpb246N2Q1MGJjYmJjMzhlNDdkMTlmNWVlYTg3OTkzODI5YjJfMjc0ODc3OTA3NzU4OA_e5b68285-40c8-462e-a4ec-2c6158818115"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMjc0MQ_359ac18f-f0b5-4b51-b7b3-343abc7759b0">Stockholders' Equity In September 2020, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program is funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 577,000 shares for $122 million in January and February 2021 (average cost of $211.65). In the first quarter of 2021, we also paid $6 million to settle shares purchased in late December 2020.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i9d78eaf9f7854f45a976f7a9c34f0b2e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTEy_a9ea7490-3199-444c-8a56-769a62fc3280"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i33bc647cc4d341da839b637a42b74f25_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjA3Mg_b8c3781c-e319-4091-a852-d17ba1e2d05c"
      unitRef="shares">577000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i05f1ddd5eada4525b9899833bd42aa9e_D20210201-20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjA4OA_1c8d4af2-490c-4565-ae89-404d9aeff40e"
      unitRef="usd">122000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib7d95ca3899b4bbf91022aa523d90b4a_D20210101-20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjA5OQ_3b662e7c-cda5-4823-b7c1-d9a3855c436d"
      unitRef="usdPerShare">211.65</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8589aefa8f474c159c7cbd51cc1dc98d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82MS9mcmFnOjI0ZmYzMWQ2NzhjMjQyZDNiMmUyY2U3YThmODNmZDhjL3RleHRyZWdpb246MjRmZjMxZDY3OGMyNDJkM2IyZTJjZTdhOGY4M2ZkOGNfMTA5OTUxMTYzMjExMg_25a02c27-df92-4bf0-afc5-2f38e8cbcbdd"
      unitRef="usd">6000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RleHRyZWdpb246OThkMDczOWYxM2E5NGVjY2E3N2FiYjQwNjdiYzVkZDdfMTM0Mw_934a4892-ac35-45ef-8647-f706407ab3ee">Segments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December&#160;31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RleHRyZWdpb246OThkMDczOWYxM2E5NGVjY2E3N2FiYjQwNjdiYzVkZDdfMTMzNg_fe8b2609-d114-4a51-b1e2-53df5aa61cd7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December&#160;31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles assets, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="i9cdb8495a786463fb1d63d538dedadd6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNS0xLTEtMS01MTE1_c87251ec-ee79-461f-9a9c-f1e17569bb91"
      unitRef="usd">5020000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74eb9bfff592416381c1931711db9989_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNS0zLTEtMS01MTE3_68a83ccd-e4fc-4b62-bd57-071f6d3c051f"
      unitRef="usd">3517000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i003f6ce2c94c41bf8008f33ce6ed1f8b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0xLTEtMS04NjY1_4e64dbe5-9d2b-4d62-b8fb-404967731457"
      unitRef="usd">805000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0363d1d407c43858260eb498134562a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0zLTEtMS04NjY1_798f687c-fadf-44e9-80ba-ed2c8fc2545f"
      unitRef="usd">639000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8abe7f7274e342debe193a925fc2f195_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0xLTEtMS04MDQ0_ae50f322-d1c4-4b73-a786-a49b4e78c5fa"
      unitRef="usd">680000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd6734ad77bc4a02b0c10be4995a250b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfNi0zLTEtMS04MDQ0_93935404-67fa-4069-925b-e417f54e9d8e"
      unitRef="usd">393000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3d574edc32f4858b10a9e95a7043b62_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOC0xLTEtMS01MTE1_63dca098-1dc8-4b17-ab89-910181f74fde"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4af07d6f77c412fa6fc30634723476c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOC0zLTEtMS01MTE3_9a4ddd8c-c524-4330-88a4-833d8fd356f6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOS0xLTEtMS01MTE1_8ae2ef47-0db5-422e-97d2-46973269d08f"
      unitRef="usd">6522000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjIyZDhmNjQ2M2U0OTQ4YWZiYTYxMzFhNzQxMDRhMDUxL3RhYmxlcmFuZ2U6MjJkOGY2NDYzZTQ5NDhhZmJhNjEzMWE3NDEwNGEwNTFfOS0zLTEtMS01MTE3_9805032c-c3f4-4906-82eb-0aa481a3f605"
      unitRef="usd">4549000000</us-gaap:Revenues>
    <us-gaap:Goodwill
      contextRef="if6be335f460e4209851cdbd1a986fddb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNS0xLTEtMS02MzUz_095e00dd-bc2c-4468-a4b9-6af59a7ad8bd"
      unitRef="usd">372000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i82a8212f4d97436f86b773388a97609f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNS0zLTEtMS02MzUz_a4a62548-0332-42f8-a3b2-7c9a2c6b43b4"
      unitRef="usd">378000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iad67715684f94d79a4e970a446c35348_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNi0xLTEtMS02MzUz_5a07a4c6-4d74-49eb-9ec9-d9127356251b"
      unitRef="usd">247000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i340f4a8c71a1410b99e342dbbe44f76c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfNi0zLTEtMS02MzUz_de432a95-f930-48ff-8b30-11be97ab819b"
      unitRef="usd">247000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ica7f1fd63c014e4598191fc6de8562ec_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOC0xLTEtMS02MzUz_22c145e3-cf7d-4ec3-a369-7e652a24624c"
      unitRef="usd">67000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i930068e669b4450986374f16ef76a5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOC0zLTEtMS02MzUz_1469e309-e5b8-4eaf-b5f7-5ff6f8ba1e47"
      unitRef="usd">67000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if6be335f460e4209851cdbd1a986fddb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0xLTEtMS03NjEx_2a467dd8-0305-40fd-a2f6-5955d75b0e25"
      unitRef="usd">150000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i82a8212f4d97436f86b773388a97609f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0zLTEtMS03NjEz_a1cf8bc2-f7dd-4063-bccd-d734409d11d8"
      unitRef="usd">157000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iad67715684f94d79a4e970a446c35348_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTAtMS0xLTEtNzYxMQ_0302727b-d9da-45dc-b4bd-9ac897689ccf"
      unitRef="usd">72000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i340f4a8c71a1410b99e342dbbe44f76c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTAtMy0xLTEtNzYxMw_31e7d113-2ca3-4612-ba57-9457e830b847"
      unitRef="usd">76000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ica7f1fd63c014e4598191fc6de8562ec_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0xLTEtMS02MzUz_44fa4cb7-6d99-46f2-894e-c91496188d6c"
      unitRef="usd">15000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i930068e669b4450986374f16ef76a5d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfOS0zLTEtMS02MzUz_64b08208-36d2-44c4-aab4-52d5f9cb7ea6"
      unitRef="usd">16000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTItMS0xLTEtNzYxMQ_b666fc3b-95ee-4a31-b14a-c3c0c5ab5233"
      unitRef="usd">923000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6dd146149d7f42a2af7252fcdc08ad86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjNhY2RmMTU5YjI0OTRmMzNhZjM1ZDA5ZjU4NjVmODI3L3RhYmxlcmFuZ2U6M2FjZGYxNTliMjQ5NGYzM2FmMzVkMDlmNTg2NWY4MjdfMTItMy0xLTEtNzYxMw_723736b1-36c7-4b4c-abaa-e06e8db26a9b"
      unitRef="usd">941000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:GrossProfit
      contextRef="ib75fd2e45f3d4d8982e9fdaef11c065a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNS0xLTEtMS01MTM1_0643e52b-48b1-45f7-a451-a2bf9e6b9487"
      unitRef="usd">604000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="idc1114f0eae5487fa865b3bccaf5b9bd_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNS0zLTEtMS01MTM3_44e6c1e5-6ec7-477e-a5f8-76ac421c5785"
      unitRef="usd">365000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8e52755e7437453ea2f981a32951d999_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0xLTEtMS04NzA2_a841122e-e0c8-4609-a647-39bb1a1371ba"
      unitRef="usd">77000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id6918db6cf1846b8806408b26be49e6a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0zLTEtMS04NzA2_b64b5c3b-1b47-49c9-947a-96fbbdd52bef"
      unitRef="usd">117000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7187b436a3ea4d1da6a4704097325340_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0xLTEtMS04MDU0_85f5d69a-088e-4f84-be27-afd8d5818ae1"
      unitRef="usd">151000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4d19f8b5724c4f88b4fa8f61f0b315f6_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfNi0zLTEtMS04MDU0_9b6f5855-609a-4edf-bf9f-0eec24d5f3bd"
      unitRef="usd">106000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4d1ddd3ae7e349248f4a8de4b08df629_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOC0xLTEtMS01MTM1_4d34dedd-0e8d-4363-abcf-db4cc7feb9ce"
      unitRef="usd">4000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i5b1dad7a9e5040f9af2c8f17dc219501_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOC0zLTEtMS01MTM3_e5f8925c-c780-4406-bb0d-3d6c054af75a"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i5586721f5cb7493dab355f7ba8acf352_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOS0xLTEtMS01MTM1_acf55971-9845-4b1d-8042-f99d9f71b408"
      unitRef="usd">836000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if1ce0ea0bd4a41f486cf13d1a3ecc8cf_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfOS0zLTEtMS01MTM3_e4a6e314-5215-4244-946b-a1f3c336adea"
      unitRef="usd">588000000</us-gaap:GrossProfit>
    <us-gaap:Revenues
      contextRef="i304f43ebe4b34d7b9ce83118a0cac64b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTAtMS0xLTEtNTEzNQ_14cdb152-8c97-457c-8916-712e9a2463f5"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9ac1d580f1145538873140cefeff994_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTAtMy0xLTEtNTEzNw_54ce6053-6764-4049-96c8-c31e750e2062"
      unitRef="usd">245000000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="i304f43ebe4b34d7b9ce83118a0cac64b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTEtMS0xLTEtNTEzNQ_274c93b2-4fe6-4e65-a8d0-1553999701df"
      unitRef="usd">700000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib9ac1d580f1145538873140cefeff994_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTEtMy0xLTEtNTEzNw_08ebc383-360e-4c72-9ad6-e75d62452fce"
      unitRef="usd">559000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTItMS0xLTEtNTEzNQ_f7df9b1d-68bf-4545-a9d2-2b11b6359818"
      unitRef="usd">335000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTItMy0xLTEtNTEzNw_5bd9c79a-b412-4b79-88ca-6532a6450a9a"
      unitRef="usd">274000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTMtMS0xLTEtNTEzNQ_360e756d-6a9a-431d-a440-008a365042c4"
      unitRef="usd">-30000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTMtMy0xLTEtNTEzNw_292e54d6-7330-441d-ad37-b129b76f6fab"
      unitRef="usd">-21000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTQtMS0xLTEtNTEzNQ_7bc0164c-73bc-4ad3-aca8-d48663913fa5"
      unitRef="usd">305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF82Ny9mcmFnOjk4ZDA3MzlmMTNhOTRlY2NhNzdhYmI0MDY3YmM1ZGQ3L3RhYmxlOjQ4YmZkYjlmNmI2OTQ0Y2U4OTU2OWY2MWE2YWU3ZGY1L3RhYmxlcmFuZ2U6NDhiZmRiOWY2YjY5NDRjZTg5NTY5ZjYxYTZhZTdkZjVfMTQtMy0xLTEtNTEzNw_1fc28d62-614a-412e-84eb-79bcb716b46d"
      unitRef="usd">253000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF83MC9mcmFnOjU1NGViY2E0NGY2ZjQ4YzliMjcyNDk4OGFjOTY4OTMxL3RleHRyZWdpb246NTU0ZWJjYTQ0ZjZmNDhjOWIyNzI0OTg4YWM5Njg5MzFfMTI2MQ_a0029df7-a9b0-4fdc-9c3e-9e36ffd4002e">Commitments and Contingencies &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky RFP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the winning bidder health plans, including Molina Healthcare of Kentucky, Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the court issued a temporary injunction directing that open enrollment for 2021 proceed with six health plans, including both Molina Healthcare and Anthem. The new Medicaid contracts commenced on January 1, 2021. On March 2, 2021, the court heard oral argument on multiple motions for partial summary judgment filed by all parties in the consolidated action. On April 28, 2021, the court issued its Opinion and Order. Under the Order, the court granted Molina&#x2019;s motion for partial summary judgment, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina&#x2019;s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the court ordered a new RFP, with the status quo of six health plans to continue in the interim. This matter remains subject to potential additional legal proceedings, and no assurances can be given regarding the ultimate outcome. Under the court&#x2019;s April 28, 2021 Order, Molina Healthcare of Kentucky will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831887318264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLINA HEALTHCARE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4204626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Oceangate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Long Beach,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">435-3666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001179929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831894627704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">$ 4,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationPremiumTaxRevenue', window );">Premium tax revenue</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationInsurerFeeRevenue', window );">Health insurer fees reimbursed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Other revenue</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6,522<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Medical care costs</a></td>
<td class="nump">5,474<span></span>
</td>
<td class="nump">3,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PremiumTaxExpenses', window );">Premium tax expenses</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationInsurerFeeExpense', window );">Health insurer fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationInsurerFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Insurer Fee Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationInsurerFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationInsurerFeeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Insurer Fee Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationInsurerFeeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationPremiumTaxRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Premium Tax Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationPremiumTaxRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PremiumTaxExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An assessment levied by a state government on the net premium income collected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PremiumTaxExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884481784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment loss</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890638040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,431<span></span>
</td>
<td class="nump">$ 4,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,308<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill, and intangible assets, net</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,950<span></span>
</td>
<td class="nump">9,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Liability for Claims and Claims Adjustment Expense</a></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,323<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,128<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,786<span></span>
</td>
<td class="nump">7,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at March&#160;31, 2021, and 59 million shares at December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 9,950<span></span>
</td>
<td class="nump">$ 9,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831893748616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">58,000,000<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831887087592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">61.9<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,960<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(446)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Termination of warrants</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 2,164<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886972200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities', window );">Medical claims and benefits payable</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(304)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(388)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations', window );">Common Stock Withheld to Settle Employee Tax Obligations</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings under term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="nump">274<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,223<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,497<span></span>
</td>
<td class="nump">$ 2,423<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Withheld to Settle Employee Tax Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CommonStockWithheldToSettleEmployeeTaxObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in health care insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886032888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. For further information, refer to Note 10, &#8220;Segments.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we served approximately 4.6&#160;million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIzZWU0YjgxODJjYjRhOTdiMTZkN2E1N2IxM2E4ODY4L3NlYzpiM2VlNGI4MTgyY2I0YTk3YjE2ZDdhNTdiMTNhODg2OF8zNC9mcmFnOjQ4YmI5YzMwOTNmZDQyYWFhM2RlMmQ2ZjRkODMzZjdkL3RleHRyZWdpb246NDhiYjljMzA5M2ZkNDJhYWEzZGUyZDZmNGQ4MzNmN2RfMTA5OTUxMTYzOTMyOA_8b240c5c-ac85-4fc4-b548-e90f16414f04">three</span>&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as &#8220;STAR+PLUS,&#8221; in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0&#160;billion. The purchase price for the transaction is approximately $60&#160;million, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals and satisfaction of other customary closing conditions. We currently expect the transaction to close in the second half of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin in early 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio&#8217;s Covered Family and Children, Expansion, and ABD programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close in the third quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the first quarter of 2021 are not necessarily indicative of the results for the entire year ending December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2020, audited consolidated financial statements have been omitted. These </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; and Note 10, &#8220;Segments,&#8221; have been recast to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the three months ended March&#160;31, 2020, have been reclassified to conform to the current year presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets;&#160;and</span></div>&#8226;The determination of unrecognized tax benefits.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886107192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, through March 31, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In the first quarter of 2021, we recognized approximately $110&#160;million related to such risk corridors, primarily in the Medicaid segment.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of March&#160;31, 2021, Marketplace risk adjustment payables amounted to $520 million and related receivables amounted to $20 million, for a net payable of $500 million, of which $211&#160;million related to 2021, and $289 million related primarily to 2020. As of December&#160;31, 2020, Marketplace risk adjustment payables amounted to $326 million and related receivables amounted to $20 million, for a net payable of $306 million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div>Various recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886025400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income per Share</a></td>
<td class="text">Net Income per Share <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884667224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, we closed on our acquisition of 100% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc., for total purchase consideration of approximately $1,037&#160;million. In the first quarter of 2021, we recorded various measurement period adjustments, including an increase of $6&#160;million to &#8220;Receivables,&#8221; a decrease of $25&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $33&#160;million to &#8220;Amounts due government agencies.&#8221; In the aggregate, we recorded a net decrease of $6&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, &#8220;Segments&#8221; for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886304648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2020 Annual Report on Form 10-K, Note 5, &#8220;Fair Value Measurements.&#8221;<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2020, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the first quarter of 2021, we recognized a loss of $8&#160;million for the increase in the fair value of the contingent consideration liabilities described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $31 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. In the first quarter of 2021, the contingent purchase consideration relating to 2021 member enrollment was finalized and half the consideration due, or $23&#160;million, was paid to the seller. We expect to pay the remaining balance of the liabilities, reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets, later in 2021 and in the first quarter of 2022. The portion of the contingent purchase consideration paid in the first quarter 2021 has been presented primarily in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884687944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of March&#160;31, 2021 are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant in the three months ended March 31, 2021, and amounted to $5&#160;million in the three months ended March 31, 2020. Gross realized investment losses were insignificant in the three months ended March 31, 2021, and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at March&#160;31, 2021, and December&#160;31, 2020, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2021, and December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $138 million at March&#160;31, 2021, of which $122 million will mature in one year or less, and $16 million will mature in after one through five years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886118536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableTextBlock', window );">Medical Claims and Benefits Payable</a></td>
<td class="text">Medical Claims and Benefits Payable <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $222 million and $235 million as of March&#160;31, 2021, and December&#160;31, 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in acquired balances </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2020, and 2019 developed favorably by approximately $194 million and $101 million as of March&#160;31, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior period development recognized in the first quarter of 2021 was primarily due to lower than expected utilization of medical services by our Medicaid members and improved operating performance. Consequently, the ultimate costs recognized in 2021, as claims payments were processed, were lower than our original estimates in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical claims and benefits payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886181096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-term debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (&#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of March&#160;31, 2021, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of March&#160;31, 2021, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">High-Yield Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina Healthcare, and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.375% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $800 million aggregate principal amount of senior notes (the &#8220;4.375% Notes&#8221;) outstanding as of March&#160;31, 2021, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5.375% Notes due 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $700 million aggregate principal amount of senior notes (the &#8220;5.375% Notes&#8221;) outstanding as of March&#160;31, 2021, which are due November&#160;15,&#160;2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. </span></div>3.875% Notes due 2030. We had $650 million aggregate principal amount of senior notes (the &#8220;3.875% Notes&#8221;) outstanding as of March&#160;31, 2021, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15 of each year, commencing on May 15, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886011704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity In September 2020, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program is funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 577,000 shares for $122 million in January and February 2021 (average cost of $211.65). In the first quarter of 2021, we also paid $6 million to settle shares purchased in late December 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884585992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we now provide in Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December&#160;31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles assets, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886611320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will continue to be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the winning bidder health plans, including Molina Healthcare of Kentucky, Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the court issued a temporary injunction directing that open enrollment for 2021 proceed with six health plans, including both Molina Healthcare and Anthem. The new Medicaid contracts commenced on January 1, 2021. On March 2, 2021, the court heard oral argument on multiple motions for partial summary judgment filed by all parties in the consolidated action. On April 28, 2021, the court issued its Opinion and Order. Under the Order, the court granted Molina&#8217;s motion for partial summary judgment, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina&#8217;s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the court ordered a new RFP, with the status quo of six health plans to continue in the interim. This matter remains subject to potential additional legal proceedings, and no assurances can be given regarding the ultimate outcome. Under the court&#8217;s April 28, 2021 Order, Molina Healthcare of Kentucky will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886055960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock', window );">Consolidation and Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the first quarter of 2021 are not necessarily indicative of the results for the entire year ending December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2020, audited consolidated financial statements have been omitted. These </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; and Note 10, &#8220;Segments,&#8221; have been recast to conform to the current year presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the three months ended March&#160;31, 2020, have been reclassified to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets;&#160;and</span></div>&#8226;The determination of unrecognized tax benefits.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Premium Revenue Recognition and Premiums Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2020 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div>Many of our contracts contain provisions that may adjust or limit revenue or profit, which include those provisions with significant interim period balances described in further detail below. We recognize premium revenue as it is earned under such provisions.<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, through March 31, 2021, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized retroactive risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In the first quarter of 2021, we recognized approximately $110&#160;million related to such risk corridors, primarily in the Medicaid segment.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing risk corridors, and other states could implement some form of retroactive risk corridors in the future. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace</span></div>Risk Adjustment. Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting PronouncementsVarious recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidation And Interim Financial Information, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890125752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restricted cash and cash equivalents</a></td>
<td class="text">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of receivables</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock', window );">Amounts due to government agencies</a></td>
<td class="text">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. Categorized by segment, such amounts due government agencies included the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reserves reported to other federal agencies or authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReservesReportedToOtherAgenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884585992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of denominators for the computation of basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884578776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair value of assets measured on recurring basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2020, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value measurements of senior notes</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831889714632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Investments</a></td>
<td class="text">The following tables summarize our investments as of the dates indicated:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual maturities of investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of March&#160;31, 2021 are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Available-for-sale investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2021, and December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884571304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of liability for unpaid claims and claims adjustment expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock', window );">Components of the change in medical claims and benefits payable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated, with the prior period recast to conform to the current year presentation. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in acquired balances </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884622936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long term debt</a></td>
<td class="text">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886029000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating segment information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December&#160;31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles assets, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other operating expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886997832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> member in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>member</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>member</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">$ 4,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Hidalgo, Tarrant and Northeast Service Areas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_NumberOfMembersCovered', window );">Number of members covered | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Hidalgo Service Area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_NumberOfMembersCovered', window );">Number of members covered | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Purchase price</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanMember', window );">Affinity health plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members eligible for the health care programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Contract Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NumberOfMembersCovered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Members Covered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NumberOfMembersCovered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=moh_HidalgoTarrantAndNortheastServiceAreasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=moh_HidalgoTarrantAndNortheastServiceAreasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=moh_HidalgoServiceAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=moh_HidalgoServiceAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831881809672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,431<span></span>
</td>
<td class="nump">$ 4,154<span></span>
</td>
<td class="nump">$ 2,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</a></td>
<td class="nump">$ 4,497<span></span>
</td>
<td class="nump">$ 4,223<span></span>
</td>
<td class="nump">$ 2,423<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886980600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 1,776<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember', window );">Government receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,332<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember', window );">Pharmacy rebate receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember', window );">Health insurer fee reimbursement receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_CompleteCareReceivablesMember', window );">Magellan Complete Care acquisition opening balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_CompleteCareReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_CompleteCareReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831883309224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Amounts Due To Government Agencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract', window );"><strong>Medicaid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther', window );">Other</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract', window );"><strong>Medicare:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing', window );">Risk adjustment and Part D risk sharing</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_OtherMedicareProgram', window );">Other</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract', window );"><strong>Marketplace:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment', window );">Risk adjustment</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold', window );">Minimum MLR</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesOther', window );">Other</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesBusinessCombination', window );">Magellan Complete Care acquisition opening balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Medical Premium Liability Due To Agency</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies Medicare Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesRiskAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premiums Liability, Medical Care Costs Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherMedicareProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Medicare Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherMedicareProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831887557080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable', window );">Risk adjustment payable</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable', window );">Risk adjustment receivable</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable', window );">Risk adjustment, net payable</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear', window );">Risk adjustment, net payable, current year</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears', window );">Risk adjustment, net payable, prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_InvestmentsMaturityPeriod', window );">Maturity period (less than)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember', window );">Structured Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_InvestmentsAverageMaturityPeriod', window );">Average maturity period (less than)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPremiumsReceivable', window );">Reduction in premiums</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Average Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of premium revenue by health plan type.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPremiumsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the premium receivable balance on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPremiumsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831887082456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average number of shares issued:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Stock purchases (in shares)</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_WeightedAverageNumberofSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic net income per share (in shares)</a></td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net income per share (in shares)</a></td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_WeightedAverageNumberofSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_WeightedAverageNumberofSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890357112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details) - Magellan complete care - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Outstanding equity interests</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Purchase price</a></td>
<td class="nump">$ 1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable', window );">Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies', window );">Amounts due government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890819320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 1,938<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831902005544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Paid to seller</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890390360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 2,128<span></span>
</td>
<td class="nump">$ 2,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">2,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 790<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.875% Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.875% Notes | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 665<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831887052200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,904<span></span>
</td>
<td class="nump">$ 1,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890565128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contractual Maturities of Available-for-Sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">$ 1,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">$ 1,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831884754504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized investment gains</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities held to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Amortized Cost, Due in one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">Amortized Cost, Due one year through five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890135304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | position</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | position</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | position</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890119144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount', window );">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</a></td>
<td class="nump">$ 2,008<span></span>
</td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PharmacyClaimsPayable', window );">Pharmacy payable</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_CapitationClaimsPayable', window );">Capitation payable</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_OtherClaimsPayable', window );">Other</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember', window );">Magellan complete care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CapitationClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitation Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CapitationClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PharmacyClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PharmacyClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831882179448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayable', window );">Non-risk provider payables</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior period claims, favorable development</a></td>
<td class="num">$ (194)<span></span>
</td>
<td class="num">$ (101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831893206744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">5,668<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">5,474<span></span>
</td>
<td class="nump">3,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">3,513<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">5,294<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ChangeInAcquiredBalances', window );">Change in acquired balances</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">2,839<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">4,394<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">4,236<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">4,154<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ChangeInAcquiredBalances', window );">Change in acquired balances</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">2,208<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ChangeInAcquiredBalances', window );">Change in acquired balances</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ChangeInAcquiredBalances', window );">Change in acquired balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ChangeInAcquiredBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Acquired Balances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ChangeInAcquiredBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components of medical care costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable, Adjustments, Change in Provider</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for medical care costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890527656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred debt issuance costs</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">$ 2,128<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831886971592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under letter of credit</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">5.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 650,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831890538904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,000,000<span></span>
</td>
<td class="nump">$ 446,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased of common stock</a></td>
<td class="nump">$ 122,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average cost (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139831893017592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 6,522<span></span>
</td>
<td class="nump">$ 4,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total</a></td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">(6,187)<span></span>
</td>
<td class="num">(4,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5,020<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">$ (700)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .]8G5('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #O6)U2YJ.],NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NNG0$%&7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGJ"NJC5X8F,-&YB 15B(0C<6%48RW,<3WN*"#Y^QG6$6@5KRU'$"64H0>IH8
MCF/;P 4PP9BB3]\%L@MQKOZ)G3L@3LDQN24U#$,YK.9<WD'"V]/CR[QNX;K$
MID/*OY)3? RT$>?)KZN[^^V#T'55RZ*Z+NK;K92JNE%R_3ZY_O"["/O>NIW[
MQ\9G0=W K[O07U!+ P04    " #O6)U2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .]8G5)??6D,104  /@5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A=<ZLV$(:O3W^%QM.+=L8.2-A.<L;QC$.<QM-\.'%Z.FFG%S+(ACF 7"'B
MY-]W!38X*5Z8-A<Q7_ORL)+>E33:2O4]#830Y"V.DO2B$VB]^6I9J1>(F*<G
M<B,2N+.2*N8:3M7:2C=*<#\/BB.+V?;0BGF8=,:C_-I<C4<RTU&8B+DB:1;'
M7+U?BDAN+SJTL[_P%*X#;2Y8X]&&K\5"Z-\V<P5G5JGBA[%(TE F1(G516="
MO[J.8P+R)[Z%8IL>'!/S*4LIOYN3F7_1L0V1B(2GC02'GU?ABB@R2L#Q]TZT
M4[[3!!X>[]6O\X^'CUGR5+@R^CWT=7#1.>L07ZQX%NDGN;T1NP\:&#U/1FG^
MGVR+9_O]#O&R5,MX%PP$<9@4O_QMEXB# (<>"6"[ /8I@!Y[@[,+R#-G%63Y
M9UUQS<<C);=$F:=!S1SDN<FCX6O"Q#3C0BNX&T*<'KOR52@RAQ8C/9(&7(ET
M9&D0-K<M;R=R68BP(R(.N9.)#E(R37SA?XRW *BD8GNJ2X8*WG%U0AS:)<QF
MM(;'Q<,G&PAG3EWX!QRG3)*3ZSEHDOZ<+%.MH-_]A4CV2\E^+MD_(GDEO0Q&
M@R;/[QM1EW$\G-J]1X1B4%(,VE$\9EQIH:)W\B0V4NDZ(EQ*JTP@1,.2:-B.
M:"Y4*'W3HPAT[-H4X4K[/O3#ER\-W>"T9#MMV6:*@X_E-G0\7;C6BD<IEJ^S
MDND,U9DF.M3OY#J,!+G/XJ50=2RXAFW3GD-/Z3G"<U[RG+?A>1+KT P62-8]
MCVM;#]>Y>[B=W4_(S71R^WSC3IZF73*[=T\00FI7EF>W89PEGE30>MPT9)<L
M-'0S(A5Q999H]0Z_?BUX@_K5%(,\\&7:!O*9OY&9#YTN7(5>3HHT<X,D=7I]
M9O>';(@1LHJ0M2&<^#X4C;2[/R"W\!QY2.ISATO"Y(,\>((GZW\-^8^0E7-3
MY[]#/F]E+20NN<A"Z"C4MC' J@Y0W,D_ [KF#'KAL]PFM7"XW*U,UN12<"_H
M8GA5@:"XK7_&*T?)7,G7,/'J6QG7="<86E4I*&[PG]'F,M4\(G^$F^-#%U<\
MM\]LAK%5E8+B]IZWX@3FU<=1<('!$ 6IR@/%O?U6>I"3>2 3K#XTB/2=0<\9
M#E';J H$Q9W].=10J^2*4/;3\F>R$%ZF(%NU6+B2*^,8_'"AI?>]2WZT3Z"0
MP516D6\\0B<CK"H5##=SJ/1^""-J\1XO953'V"!P]W"#@53E@.'>O4\3F;YY
M ?BC.%I7&X3N7Q98@6*5_;-6]N]F2IDY43$1RG,%%I'5KB(:%%\^KST^DE6>
MSUIY_BR!&6VQ3#132+Y'K27#%1O(*K-GK<S>S-9@G@%.NI:JMN<WZ-QR!3U@
MXGFP'(;YB_ +28RQ<GS6RO$7,8\B<IFE<#NM;TU<IVF&RRJC9ZV,?AH+M38=
M[!=0T $X:[SA27WZ<,%&M,KG&6[3^V0% I*% ?V_U0"K_)ZU6@]\M,9%OJXG
M#YF&"ID80ZM=4Q?*@US9;/^\C@=G?=O\C:S7.JK*\UFK58$+HT]!.9HEOG@C
MOXKZ5.%20$/IZ?DYPU8K3F7P#N[/>_NZ#E-3*%\$E ]LS=D@U^M1!FLI#*VR
M? =WZG*Y><AV#1=K1V.#6--.2&7[#F[2GZEVZ_3C7+C<(TIUL$&#&_0$D/P"
M*^)UO?NR0>#H"+0.]M:, >5;CBGQS"*QV&8KKY;;FI-\,\^J'B_V1.^X\:^4
M1&(%H?;)*0PU56PS%B=:;O*=NJ746L;Y82"X+Y1Y .ZOI-3[$_."<K-W_ ]0
M2P,$%     @ [UB=4N&L2DFM!   UQ(  !@   !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6R5F&UOXC@0Q[^*A?;%KK37Q,X35!2IA>XMTE&JTMU[[28#1)O$
MG&V@=Y_^G 02&CMN]PWD83S^S<3^C^WQD?%?8@L@T6N>%>)FL)5R=^TX(MY"
M3L45VT&AWJP9SZE4MWSCB!T'FE2-\LPAKALZ.4V+P61</7ODDS';RRPMX)$C
ML<]SRO^]@XP=;P9X<'[PE&ZVLGS@3,8[NH$5R!^[1Z[NG,9+DN90B)05B,/Z
M9G"+KZ<D*AM4%C]3.(J+:U2&\L+8K_)FGMP,W)((,HAEZ8*JOP-,(<M*3XKC
MGY/30=-GV?#R^NS]6Q6\"N:%"IBR[.\TD=N;P7" $EC3?2:?V/$[G (*2G\Q
MRT3UBXZU;:",X[V0+#\U5@1Y6M3_]/64B(L&RH^Y 3DU(-T&?D\#[]3 JP*M
MR:JP9E32R9BS(^*EM?)67E2YJ5JK:-*B_(PKR=7;5+63D^GR8;7\:SZ[?;Z?
MH=6S^EO</SROT/(;FC],EXM[] ?ZL9JASY^^H$\H+= BS3*5?S%VI.J^=.+$
MIZ[NZJY(3U<>6K!";@6Z+Q)(WK9W%';#3L[L=\3J<$'Y%?+P5T1<@@T\TX\W
M=RTX7I-*K_+G]?A[@@,4>[BVN/(;5W[ERN]Q]<@A3_>YFB>52U.N:P=AY:"<
MJX=)Z+GAV#E<)D W\CW7;XS>L 4-6_ A-DE?;7RUD^"B:SR,.G@&F\ UTX4-
M76BE^PXTDULU4,6> T=K *$HT_QEST5WT-6@H0;A=C!UBS T4T8-962EG!<'
M$%*IH52D,<N-&8RT;D<=,-V"!&:P80,VM((MY59ES?)9AWJ7W73I)CTC;M1
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M7I^BU#>2[:J#B!<F)<NKRRW0!'AIH-ZO&9/GF[*#YBQK\C]02P,$%     @
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MHH9@7D-JV2AT 'U?<JX. YT@^Q/0^0=02P,$%     @ [UB=4OQBHZ#%!0
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M)<OKQPW!2GAEH'Y?,29?7JKKT>XZ?/8_4$L#!!0    ( .]8G5(&HW8LP@(
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M^G@"P@3H^W/.U=O$[(#5@2?\!U!+ P04    " #O6)U2&IF]]<@$  !)%
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M9=FY53;@=)^>LSQ0SFF4WNX(%DU9 L3_6TKYRT >W12GAY-_ 5!+ P04
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M]L(1HN?4:1MLK>;SK5S6SOD.((35U/6MLT0GH#JBQGD _VHZ B:? U4T>DI
MR>KAP >+7I6]!]\;WE[4V@VVOWY]T=L^!AH%05X&5X#S^Q!N 4^,!O69"_,9
M7$*YW-<F*ED4W%^>#R>SV6RH3"L@FEUX]JRO+](@>O4)".8HC#TVO#]]]_>+
M?WRXG/3@D 6\1&^MUWZBWNL ,$]L^AM/N*-17SM1E'+?56O.6L$9MS7+@G<D
M3,0QJZZNU8W1@:T>"C4@-UQGR#6[9_SU:#I32X$FAEW5=L T<#[L)=D$*70F
M@N"B%EH)%+\EY?ZLQ[<>Z3>&VX/C(ERA'^; Z5@IB$ C*>6\6X(!*1^IXW#S
M ?"T*2M=(U$8+@U:*\J0_"6@@,J@$O/A1M2Z0ICD9Z1&7&79D")H*@P3;%P5
MM8^4.\@Q@1_DSV_ ARX >A+L,M<MZW)+30(I;#5]/*(A";"I7O7-%B5560^V
MX2&-B^56 6[5W-'QWII+E4X,?2PIHTY+=9)AETS8( ^%[U-6D]E*;W0H#2L'
M,,P8VZ.'+H*/<8MI(-RQTU++.WREIS<,:,%\[@QREK*!Y2-4L2,6X=2E:5,N
MMEE?;&CK)(PU?V9:\!#&"VJ9@_WO*V(#F&$&P,>S>%R@>PF='9F!=*9RF!$X
M:<XDV.57U*NS6UC)@AH4=*:]@QF"[B"Q@1KAUTP+*I&6 UJ=DQ"<_X)ZYPT?
M=U[9ND1&3-3SZU;S;"9Z;&$#,N<-3/DWQK'OH"X3M-%?XBL$W1"1,M2C"5%_
M%VLI_@DQL]+LV!G25!@$Z>ETQ2)N,G]E?!4""]5'[VQG%1S=FR"5Z3 ?_Q0:
M'#_<@H.M@KY"$'R'Y>5'U* T*N1X+L,_A!P_4Z:ILDC<6ZQXNF<.>D7AL,W6
M_/-J9(GLFF+8@ZBMAF5Q')-ZWL%A*0K4M 3F&V.%)!2QD*&XF59E0N];1%-
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M10OP^\K#X_F!#A@^7#[]'U!+ P04    " #O6)U2F8"%9IP-  !\)0  &
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M#K<S158,3%&&?*<6NF++0@Y**3UJ=DV]6.ZT13UQ!Q<TM0M5#R"HDIQ\T5X
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MX&6SSBS@9?]')WR^R*TCKHPOSX0XF4.<A! GOYO*7X"!OS2\PP+;'&E*2[*
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MP%L%Q$;9]Q?L70=#!JE5K0OP 8YT6%9JGS15MX2"N%0@V[I21)*26:1!AI4
M 1]U+2_8C[IY3II'AP9G!^\A";>?<<X' GFKSWB:WT]XE??4H^H0^64/2(CI
M. )XVTK? ZK3Q2/;0UJ/DQ@.F*UN!MA^YB":/67IB_<+I8@D6XG(EY/]$OF
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MX'=*9 E?R&]$6N0JM8I5!6+]M39,I[%UIP.ZML[%LO-4@QQ<K)/O@IC!(\!
M%.Q#I-6L+\4NE;EF[+X85W&3' J-K&O/"-9%<V5QM4]547OI U8 .(5T/_I4
M557H- :)NE]H,R 4H,H0B(P#I+'SOW68V&T.:=*56B,A.&DCE<298;\+S-S9
MD@+FE%B,__N/C09N*LGQMUI+>4('SG'*;S6*BUVQ0HV6I0X1I3GSGB2FH%],
M7-^."(S3V*& !76N)7+D:/.4VCO&/<8W7<7FW;2H$&Z,:PDL!$;X!W"Q798Z
MY+$B=NWN>NIL/Y5O46MRMTMT^^(QMJO"&-<VXM^Y63?(@-Y@!A_]H84Y/['1
M*)B&']ZCK'+96\4]W^R9N"?Y0$>F3L_6%#:@5U)+#<EYWA)L-6OC&6P(^2W6
MC.>PH'U%;U@5(4^AT7254^8K(>? <B48.WE7$'DD/^+3(<WWV@<Y94Q@'>J-
M4\&K,=<N"!/M4ZEGU@$M%=8<^%AP.QW1;QJH9?;FR&V9[:VR3>[%=YHKLV"Q
M('H.[S(/R4BZR$B GA90=2:.)VSL2TX7@+/>'[5O6UMFH0S6D,P$8+I@24E=
MH8_7HK,5@1U@3YF51"8$ W"\SC2&H<Q"$[=V^EO(Y#Z-G=Z@T?* KSC5<[T9
MNUL<TQUM\/AH&\@4R55&SV2VM7,0 P0MLA!R>XQT=J X$(?M9-CVL!D+6SVB
M'N_R;IQ+5)&WQ].X"?JN32$G!C$7&OT%)*5W,ZF1AB8C0:N6BN?K4U8LV)JZ
M[,M[R9I)/9=:5M<%KS",,6.Z<3&>QHKIW@_&F!R/SOL-;"?_';;I_P';.Q1N
M&W,42'X<NNF_A.X6HZ)%;BN* 3WV3CO<^B8HV2WBEX\T%$!J/@^ZU>[CZJKY
MIMB(-U]FMW%\>BIX#M71X&3::QAL_1!L%;\P9C: )N)MC@]$=B* _;D%XNV#
M..@^.2__ 5!+ P04    " #O6)U22>-.9G0#   J!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6RE5=MNXT8,_15"#7H!7$N6XV2QM0TD>\%N@06"
MI-L^%'T8:6AIFI%&X8SBN%]?<B0K+M $*/J0>"[DX3DDAUKO'=W[&C' 4V-;
MOTGJ$+JW:>K+&AOEYZ[#EF]VCAH5>$M5ZCM"I:-38],\RR[21IDVV:[CV0UM
MUZX/UK1X0^#[IE%TN$;K]IMDD1P/;DU5!SE(M^M.57B'X6MW0[Q+)Q1M&FR]
M<2T0[C;)U>+M];G81X-?#>[]R1I$2>'<O6P^ZTV2"2&T6 9!4/SSB._06@%B
M&@\C9C*%%,?3]1']8]3.6@KE\9VSOQD=ZDWR)@&-.]7;<.OVGW#4LQ*\TED?
M_\-^L,TY8MG[X)K1F?>-:8=?]33FX<3A3?:"0SXZY)'W$"BR?*^"VJ[)[8'$
MFM%D$:5&;R9G6BG*72"^->P7MG?!E?>ULQK)?P<?'GH3#NLT,++<I^6(<CV@
MY"^@+.&+:T/MX4.K4?_3/V5&$ZW\2.LZ?Q7PBZ(Y+!<SR+-\\0K><I*YC'C+
M%_ &8?#[5>$#<2?\\0KF^81Y'C'/_V?J_CL*?&[A#KN 38$D*<AFX'IN/Z=(
M@]N!-L1=[<B#ZD/MR/R%&D*-T/54UMRD8M1W$!R<K;+LVV\6%]E/C;&6'\(,
M3!MM55415BK@3*P%OW1-PR_%"Z4Y_%(;#QVYBE0#O-SU4ESNSU!#J7P-;%JK
M5H/\X5/ 5GL&)M=7-;S'<F!_+*+@(9MQ\B$8[N0J^JG&]6T0 JH]\"N?!'!
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MCG=VC@@;B!U@8:KA,FH'4=H@@S91%6*!1])I">/=&3]Q^@7TQBG;E8!O*F=
M*@G0H)#.*]OA@#E2AX7<')FAK0P)%&QSX1HGV@Y)5_: %)(84^E5038] 2C/
M$WYL\1J10:*P 4V%NJ8F8#L-"D8NO9QE+FP*GK!,B2$^>$ V?0 [T-YAI OP
M$98+H'14WMDUP$.5=DDXGX0U4#*82WXN=C(0 *&1:9]Q*2L-(0:*$N0L36R[
M-(0B^)VA<LZ+%N+1-WH2W!-TH/,3"1^2#6RE;#!QP.Z(J#?")=!VT$?,"L=E
M^]JH&FWWP)@+DC00"K +T-VA7Q O.48]O?+AD"TP+*/MVA)DX (>A):9@$DJ
M>BK[@VA]C(9J#BTHZH$9ECE4CIV)M5,X33(*7_C46@*M5"IT6(HJ*:"?S$)R
MYQ0+/<GN0)E+:!]GC4[LI:SP8"MB6W#Y9PPCQ P=+Q94_A3E_K##Q"MDWD)A
M:HF61%@ER3.F)*[V+N \9!+$LK[-/:P7Q!XBFT:@DNKS^17/B$<P@9T U"'P
M(6'X7(@;U&:)M$3R"X8P+0TM1"#Q8"8($"8,8>5#ZH?09-PYED=;>KLE%8$=
M[C: X*TI<V<8E1VI,UE$LJOLTU2H?3CV%GCX,]!WZND@/MYMQ$(\./&HVY2[
MWP4/.ZLY' +.YKCV7CK0$>V>"G%C)4[[X-1"%-!7S)X,6@T>WX&33Q@<()R=
M0WIN35 =&AYNT4=DA9#%Q&$?[=^Q.SGG-R7"9V@"8H.WR#)J9WZZH7_*G/J1
M.P'OO9.-06H>==@9;LG<X2&L?9[1G!W%O3 EE6_N(:*%0R<5>8\X.]D;YA:#
M_</9V?4YW-H9*VZRV__P"X3NU>V'5ZO5F[/O.*X/*GF*ZOI\""M!4!P%$R,5
MC!2(/-HK*8-QGT IME:BFRH6TSQK@"YHT ':R-)$3M-0FD>:0>:C^?*L0UQ9
MWWK%X>949^8[Z,<]>JR2IN0A@*908F>#<Q6-9T[\)%U'</O!F#W%J(RJ7N<G
M4S>!)V!7H"(*59<%WXD&/#4M:KSQN;)8^ZB+8&'_D28^=665W34VZQTEDE?I
M4?-/BB)3D!'=M ')6;_]%E(?>0._'EH0S>>^^A! B(7X=9S2^,%T(SJ8HU-R
M&/_ZE[?KLS=_C[T++WHPAP37VN;.MY. 2ZK54Y+*4.XI3!#!;'N@;?3/;?P*
M@U08P+(,#&9I2LA:L,$E3W!F6NI$R(5XGV>\H?U!-90VU&.C\H&;><@#0C"Y
M\]=^#_D\B8NG0#&7B3YP9SZ.23Q8P>[GSA.2KQEZ,FKV">7)R# ?(;=9'Z%L
M])%_,MRU/B&R%&U9ENPY+K-<M\=),4?2>0I';I7CC%;!3_JXKV0H<Z5A^K6Y
MD0PM8,H'=G:,^"F_!K*\J!O?3N]9I?4+PV__U4!D55V@QO-M?4XG$L&'PO11
MN8?E^0,G+O[LFW(Y^8K'S%SQ;Q7<E5S*'_3CT_'GD)O\*\!Q>?XM!5)04:JL
MWF+K:O'F]4R$_/M$ODF^Y=\$($G)-WP)3L!+6H#W6X_,]C=TP/@CT?5_ %!+
M P04    " #O6)U2ZVV$JU$/  ";+   &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6RU6FUS&[<1_BL8M=-I9FCJQ?%;_#(CRT[B:=2HDI-\Z/0#> >2
ML.\.-( 3I?SZ/KL+X(X41<=Q^\6F[H#%ON^SBWNQ=OYC6!H3U4W;=.'EP3+&
MU7>'AZ%:FE:'J5N9#F_FSK<ZXD^_. PK;W3-F]KF\.3HZ/%AJVUW\.H%/[OP
MKUZX/C:V,Q=>A;YMM;]];1JW?GEP?) ?7-K%,M*#PU<O5GIAKDS\977A\==A
MH5+;UG3!NDYY,W]Y<'K\W>MCWL K?K5F'4:_%8DR<^XC_?&N?GEP1!R9QE21
M2&C\=VW.3-,0)?#Q*1$]*&?2QO'O3/U[%A["S'0P9Z[YS=9Q^?+@Z8&JS5SW
M3;QTZQ]-$N@1T:M<$_A?M9:UCTX.5-6'Z-JT&1RTMI/_]4U2Q&C#TZ-[-IRD
M#2?,MQS$7+[14;]ZX=U:>5H-:O2#1>7=8,YV9)6KZ/'68E]\=647G9W;2G=1
MG5:5Z[MHNX6Z<(VMK GJ[_G7-R\.(\ZC78=5HOU::)_<0_NA.G==7 ;UMJM-
MO;G_$'P69D\RLZ]/]A(\UWZJ'AY/U,G1R?$>>@^+\ ^9WL-[Z.T2^-^GLQ ]
MG.4_>P[XMASP+1_P[3T'G+DN@'"MQ0.[6KWKHO&V5=_;3G>5U0V>2&QAQ2X5
M_T\/4.^71E5ECZG5O"P+$0\0;S$HVU5-7QL5L5J+CH)R<Y@3YVOUH]%-7%;:
MFPF(5],)'VRQ)O2S8&NK/30YQ3NFX%:VH[-!H-4=0IT.P9ZF4;K^ !>70XDM
M6QL/ICI3F1"0)!0X5UK-M?4*22=@H<@!6D0:CQ!]0>F0GY!4S [MI <VZ6.%
M?UT=,AF<LM371LV,Z;*\]7,(4"WO<A4BD>](BPW.K'KOR6=&ZZ;J%.*$43#Q
MN95K5[J[1=YHH&5X%W$&[^J"YJ041DR8QB*^R2C3NV;*@H(-)&2O97.6<6X]
M6/S4:X\S:0W%AX)]P',LVK3-+;BJP1XEPFT59EJ0QF+CK=$>OVN2\PT(M#-0
MSJ$G#/:=[FM+W&VPFA6^T[,&<6&'E29C]T@.<K0.J TKMF]<ZJCZ8'PQ[%VR
M.$X+06.QPBNJ2@IB\#/X+:16T2G7PX=V<;J3PT&GH<*;K <LWU;#T90SIB<=
M-;<351D?4095C9V-"STT*W*L7=_4'!L1GH'S8(BZ7S5D"0FR\1:P2&18D\S[
MG7,G7R#.H'#7VIB=*_PYZX4E2S(SHFKPA[T?^DX*[!I6^'\J^])4#5R$ TS\
M_TR"$Z3D<")5+76W('<!CRL'B\P:HX)9R(&U"96W,QR@9^[:#$9;(3MX86!L
M#+SYIX.1GDS4W_[R].3DZ/FYH0AJU%FC;2L!_=IT9D[I[T+?TG$37GK\G%_R
M]N.CLO\JL5(6#19"9M&(8[@L-$<YFWZR3$@X)"2S-\Z#4W66^+< 560Y<*9;
M2=A#IK-=2>6<CRBH-XQ33$+1!B:6:@ZX-M@G+KTQJI5J+@9"+4:J'%QR0XQD
M)RS[$F'V%-Q'I> ^VEL/?PF<V-Z&:$D?85=%_3(*G.HD6972\T<J:!;;QEMQ
MSE^F5U.U@*MX3@"4GU:T7P\@!$X(2JN&<%=REQ].3R^2IWP#S7[J+;GE4$=)
MJZW^B!Q8&":O&U)IRD%Z/@<.3AF?XH).;DMEQWH396MC]<PV-G()']2@F^ ^
M1\6;:]/UB05S@\XAX(^ZYVHY;&)1N1Q3!HT]%U6I0A4GF-KB'*_FWK6T+8RD
MFZH+41(Y.K)02$K))_1BOD$;J;9_)_'W^#G;LS:(%:ZV&9BDJ*Z&J)[EJ%Y)
M5#\O%)!V&"$2XROOKFT8]-SJ6T6%/&9E4#@XP (^B?H'5+R5DX"L7!"T12'!
MI2NRLSD^%](U]O=2(;4**U-1]N,200P,+/T+O)"G@185\.M<>N!J"*">ZV!B
MY'=*CI5G[V'-"YMV7G+AIT2,RE6M/4 308G6C,Y#MQ:;Y.O"GK?AXP,2(>AK
M&",\"$OMQ:G=PNLV#)LO>J0.:(+\O3+,8\[HWC2:_0/\SOJ V SD%.TLV2I,
MDD&SO>]8DG2#EQ0:&5'RN^<;#D#^'D+.>(WK%@\::*T6) O%= M+A4/B0@#N
MPKEZ;0'S*"M:)%+KB<#S_9Y%"<Z3/6C7RE&QXB0]"\ZO"M/B=GT'HO \LB,2
MS#6QQPX&(<*7G,.PNX]0'$<#1?-BAQ;N$+G639]:"7(<P:Q$$'VN81^-^B8I
MA<O;GI3]N*3LQ_M;&"HWI%_^\1;!#"[(L7;E[C])2I4W7-S,Z,T(X%=Y$7".
MCP](-ZAK:.L;BFGL(=> BE-K( &&R)@YI'="1(2P0>\:<<3> T=RZF/GUMTX
M2Y9C!*<B941D2,0;(]U1H87>&_+_E"VXM<&:50H?0>%S1Y;B<&"H0U&._$@U
MA Z:W)%8G!GN$A%]#-/NU4W)\53 /@LB4I.C>!B1U(,JE.M^=)1N$IH/&IXI
MS=97H)6P"5=$(7](LN&T&0VFV(RY"R0&4O6]'&B-+)^1VQ=J9!^^>5*"Y<E>
M#P<&-A "AMX9'G]XLQK_SB& =-Q*FTA>A@IA8;ULGQHU@@OR KC9=YPZ@4$Z
M&II,U'II84LJ?C.RZ^P#PP0W2GC>1.]D!K?9.+\&ZJ6JO=D?T72 >@E?^"R<
MD*URM)4,Q@NZ[2Z+J<R9$"H>NA+G9?\@!.7B/B+@&?%,I(')R8]SG^Q$D:":
MH2P5[%&C#PB#!K]H*?$CR'=&;5:% *41)'/HN4'Q"WF?(!*T!]C,T;"9D2TA
MO=KL<YRGQ7&>[K7]13+G92KWER-40GI+[\>.L<O!ONZ0TZ2E-WCWP^!&I\F-
M,A,#)@D),#/.)N=C2R;T$P17<S:0D8^A8M^,W%)@>&>V&E1@^6@)0XJ6)8RE
ML;/U)/VBZ1911:/ST<15HRM3L,ST?E;)[<1I.0$0WL,9@+L 4-S0\D]*\ 7C
M7YQ?G \8GU$K4@U,8)$X.!WI^IK=,67//,NJ2(=#2[_:Y"E'2D)]);'*X8)6
MF2592'$*3%<GJ$@"J&69]"E"%T!KJ7RLLKLD[]YDD]9GQ#!55VR@K-ZB0YF%
M405+9LMJSRN2F(3+*90Y9PPR2C.0VU_*P*[+)6%+$<S/*"F-.JZMKHGYSA,"
MD)WWGB=+"$MM&ZD5:=HILQGJ?9$ .FH%+KE:DK7IO@ ]_X-_3*3]/QFZ__WC
M]C(4$$R=-HW[C8NAWWA/%CQ'RCT5U2!5_<2=1PX_/+C@7F)C()&(YH[A7>D8
MIGG55Y\W&/O<=K:%)<Y_NN3#+T=5((?0Z;@:W.<LG_4%TKO>J#((/ENFT @/
M@  N5;G^2"K8CN-N%&'TEU2V]0"6C80.5_[".<4_>)V5.D2MJ:.R=)M\C.9"
MXCEA2 O$P0SOBQ_F"$<S+']G_L  50MQX-09%JB?N)V982I-@??:+&S7T3/(
M(5,:X$O7+Y:;TQO\>XVZ[] F<C*E$8_FF ;,@D_3()[:.T29][:F&LKCM8"0
M"R;C.\1Z7V%/;=H\?\]==<X=(&_:EACB9'[V\Z_OWCPX?I;A ^-AF02D?")$
M<W="VLHD 50@'%LW4)>3C"N6WF)V;3@/#IY!I5?[QDHVYE1:-$07#H%?W](/
MDFQ6])C1*VN)PN7XR?/Q\#+1.7ZVI7S>1,"\WIK2'[$_)L%+HA[SNB6+#)2)
M)[ OHLQ,<3WQ,, );W:[D> 4\L%=#EJN;'9>*#"K(R[U"L?>,'T0^>OQ\9%J
MT1[+=6W#-1O<,:S9%&(R0II;Q3=/:L&)Q!1 %R,GECL/*)*7RK"(AQDT32 Z
M#73"D,_< -&2]K>/)@4Y3NJ;5-J5S#/$G7A@R5WUO99(G,][=&_0'&$:B00>
MKB=6!5-NF"+UY5NSKCR]A4H*T!D5I\"Q0)'!+0_/N)F%.0,A..U0JJ !MY(9
M<PHL.4G:3:[2J/G()S+,2VGHGIDF#,#X;;+["HKC9=R!C=#2'M3ZK*#69Y^[
MWJ3JE.^[</29@/%+V&(7/OT*<J,;4P#\Z/M1EU_:&)@G PD9JE5W2*9V(7G+
MCL[JWJYT,FXR)Z/6YV[//EHX53_#?./!!$,9Q9/6(7'>:8%YIL=S9)XXT=31
M!*KT;'4?Y_ &EU;0-9S8'!$EV*1V%6MH@QFUZ&UM2.V)K1V$6BZ],PYDJ<!T
M\\+)!*PAFR'V*%LBDW#R'.0:\AKU8L4U)2N[8#86FYO*&,+(*6=P9MBAK)TF
M&A8\ /RHJ?C/(F7P7MI$:24H2IH\OJ&G-&KC2T?$)_"?E(1)F>-L/%:(1@^-
MJ,;.I9*3SU643.K1273MM<OJ:6)!?YLZ7QRP?Q(:WC/XX6N(]Y0Q>Y3U\4$;
MT;'MR2PPE?Q-#!W&#3KR-8^^>:HB3;UT6[>4+T>*+KRF>IH[@*$KGY3N@&;#
MXS=ALP@/$(V.DGY%(?UT&]\B)._=VTD?'PV?S!SM32. S%0CWNN;W5.8+]B>
M;I<2QI;)LKR._-INC!1H(+Z@%)XK \VKN?>07,[81M\P(,ZY?^A*I=*$<JTB
MKI!U3^KLHR.H)X AAT,QY9S8,VA@9-#"0)VY%&-UCNX%^S3I*+<_,N0;XI Z
M-;P9/EB18IS8E-Q50UP;V!.O!U(RWKLKZ8ZQT[RA2$HY>73_Q'>.8*8S:^AY
M^"P&:I:,Q/TJ<3Q^2_1'-U_CN[4^I$E.QN^\X'Z;#)<7,/H':9R!S6@!6".X
MF.!":V]2)SM^ET%'ANOT[@/$"T!/PM"X8TE./]D]UM<+375NUVA_D@#],+U)
MC09U23X,8]R-)7.F4*[-1ABPP"%>D?-V\IL1F!E_LL.2CPDW>LV+-N65FK#F
MSV7(^<JMT53]-D*KNZ3<ONV4=JIT/!(NAG4U,W%-5]N"C3-,&&XSN=4L*8O5
MP$]2[=U]'GT"Y;"94VMGXJC$<GUC<B"5TG"EO;^E-+AWD'P\^O#O^+/3X*TI
MA'>=(UNU]UV_?"7)7Y/;>EFW<?,]7H=X#+W $M+G]Z=7K]7?A] A[WK;&FH
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M84D7,&IG0.N%H@)U$Q>@O])7/P!02P,$%     @ [UB=4HJL$:O. P  (@L
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M6!?D5JM[6: #T"-(:\ME90BKVFNH>Y*,(&Y.)&E[DG"WVPESBVID0S)6%)>
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M*E?!(H <"]$HNC7[C]CG,_-\F5&NG6'?V<;S ++&D:EZ,$=02=VMXJF_AP/
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M:V,)<TA]?9X#WS^C_ -L,<,J1=L*)U>:?Y]2WL,(IN-D/GL+GXUGR!OTC[6
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MK #UF_%9LLHR0<WPA+)"6+^T)D=P)2WJ'UH&K<2.&6)C^%;R#4\9[1 S8$(
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MVE38P$/96FE15&2CH*!\^T^>JD#L$8RC[82P(H1O)405(7*.;I4YMR9$D]%
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M/ABU,Z#]N5+V:>(<U)WUZ%]02P,$%     @ [UB=4G>CLR;N P  ] T  !D
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M2-PLE13-;)]H;76JQ79*L9U:L3/&4[ *:, (U%6R.B>RHK@Z9K>,V:V->?Z
M6Q007]0TN%=R]?Z+ ]<O]?3_2?/[)YT]:?ZIRTGSPZ.!F*%>^7O"D))<VF(V
MEM;R*KKQ$SC\Y5[<8S185ISJ(W!)T,95ETZ +NZ&8F/5QH_7A;(TK/UR3=<I
M:N= WY=*V</&!2@OZ-%/4$L#!!0    ( .]8G5)\-F&]!@0  ",5   9
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MEI(5Y=I /5\S)56YT.=DU;GHY%]02P,$%     @ [UB=4C;C8S.!!   ^18
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M7/2U>U'=^-5$\;6]-.=<Z2O8#C/]E03";-#/4\[5^\3<P^Z[:_(/4$L#!!0
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MH+]?":%>+NH!NG=Z9K\!4$L#!!0    ( .]8G5*W>M8)'P,  &4+   9
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M5#,0Q3*FTD#,KPCANXYT4);?XU]02P,$%     @ [UB=4F#L$>A(!0  \1H
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M^!)\*;@0X(X6JR0'DH,;G@N>)@LJV0+<YC'/&'@_9Y(FJ?B@6OCV. ?OWWT
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M[:BW/U+OE$^[F&X]US6^_Y%4Y_.S\?;ZR_*ZV6/G@G. GXCOOU!+ P04
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M4$L! A0#%     @ [UB=4HM49W+H @  $ @  !@              ("!:Q(
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( .]8G5+\8J.@
MQ04  !H7   8              " @8D5  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #O6)U2!J-V+,("  #\"   &
M@(&$&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ [UB=
M4AJ9O?7(!   210  !@              ("!?!X  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( .]8G5(QKK\,1@8  / 8   8
M      " @7HC  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #O6)U26;F*K"<+  #$'   &               @('V*0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ [UB=4IF A6:<#0  ?"4  !@
M             ("!4S4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( .]8G5([8&U^8 ,  *L'   9              " @25#  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ [UB=4G,8 VER P
ML <  !D              ("!O$8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #O6)U29;W7W1('  #?$P  &0              @(%E
M2@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .]8G5*N
M@*IE6 <  #P3   9              " @:Y1  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ [UB=4I"OF=JG!@  'Q$  !D
M     ("!/5D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .]8G5+K;82K40\  )LL   9              "
M@<]Y  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ [UB=
M4DXF#62P!   A \  !D              ("!5XD  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #O6)U2T*[K7(4#  #>!P  &0
M        @($^C@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( .]8G5**K!&KS@,  "(+   9              " @?J1  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ [UB=4F%8XF55!   ^@L
M !D              ("!_Y4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #O6)U2=2KCV($%   W#@  &0              @(&+F@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( .]8G5+/WYM9
MI (  (D%   9              " @4.@  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ [UB=4BR4-&.V!   -PL  !D
M ("!'J,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #O
M6)U2J=XHA3D$  "B$0  &0              @($+J   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .]8G5)7(-%#KP(  *D'   9
M          " @7NL  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ [UB=4ON8W#XS P  &@P  !D              ("!8:\  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #O6)U2S\:0"4L#  #8
M"@  &0              @('+L@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( .]8G5+4BP*&6@,  &4+   9              " @4VV
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ [UB=4G>C
MLR;N P  ] T  !D              ("!WKD  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " #O6)U25@(JLZ<"  #J!@  &0
M    @($#O@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M .]8G5(T+K6:)P8  &0Q   9              " @>'   !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ [UB=4O)GQ]F_ @  K <  !D
M             ("!/\<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #O6)U2?#9AO08$   C%0  &0              @($UR@  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( .]8G5(VXV,S@00
M /D6   9              " @7+.  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ [UB=4C&!SK?@ @  @PD  !D              ("!
M*M,  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #O6)U2
MW)VWH)X"  "5!@  &0              @(%!U@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .]8G5+S125(%0,  &T+   9
M      " @1;9  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ [UB=4M1"",@A P  V D  !D              ("!8MP  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #O6)U24@'50I<"  !8!@
M&0              @(&ZWP  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( .]8G5)VXNKB9@8  -\C   9              " @8CB  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ [UB=4K=ZU@D?
M P  90L  !D              ("!)>D  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " #O6)U2>#1:@4,#   V#   &0
M@(%[[   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( .]8
MG5*J\,<Y70,  (H+   9              " @?7O  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ [UB=4F#L$>A(!0  \1H  !D
M         ("!B?,  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " #O6)U2G*I])QH#  !J$0  #0              @ $(^0  >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( .]8G5*7BKL<P    !,"   +
M  "  4W\  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .]8G5(T_H14'P0  '(?
M   /              "  3;]  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #O6)U2N2/:-[(!  !4'   &@              @ &" 0$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #O6)U29>&9M;<!  !E'
M$P              @ %L P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..-P W /@.  !4!0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>166</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Net Income per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomeperShare</Role>
      <ShortName>Net Income per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Medical Claims and Benefits Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</Role>
      <ShortName>Medical Claims and Benefits Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Net Income per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomeperShareTables</Role>
      <ShortName>Net Income per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomeperShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Investments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables</Role>
      <ShortName>Medical Claims and Benefits Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Debt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Segments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails</Role>
      <ShortName>Significant Accounting Policies - Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails</Role>
      <ShortName>Significant Accounting Policies - Amounts Due To Government Agencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Net Income per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomeperShareDetails</Role>
      <ShortName>Net Income per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomeperShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails</Role>
      <ShortName>Fair Value Measurements - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Contractual Maturities of Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="moh-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails</Role>
      <ShortName>Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="moh-20210331.htm">moh-20210331.htm</File>
    <File>moh-20210331.xsd</File>
    <File>moh-20210331_cal.xml</File>
    <File>moh-20210331_def.xml</File>
    <File>moh-20210331_lab.xml</File>
    <File>moh-20210331_pre.xml</File>
    <File>moh1q21_ex311.htm</File>
    <File>moh1q21_ex312.htm</File>
    <File>moh1q21_ex321.htm</File>
    <File>moh1q21_ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moh-20210331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moh-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 166,
   "dts": {
    "calculationLink": {
     "local": [
      "moh-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "moh-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "moh-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moh-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moh-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "moh-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 380,
   "entityCount": 1,
   "hidden": {
    "http://www.molinahealthcare.com/20210331": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 6
   },
   "keyCustom": 41,
   "keyStandard": 263,
   "memberCustom": 20,
   "memberStandard": 22,
   "nsprefix": "moh",
   "nsuri": "http://www.molinahealthcare.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.molinahealthcare.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Net Income per Share",
     "role": "http://www.molinahealthcare.com/role/NetIncomeperShare",
     "shortName": "Net Income per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Business Combinations",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Fair Value Measurements",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Investments",
     "role": "http://www.molinahealthcare.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Medical Claims and Benefits Payable",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable",
     "shortName": "Medical Claims and Benefits Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Debt",
     "role": "http://www.molinahealthcare.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Stockholders' Equity",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Segments",
     "role": "http://www.molinahealthcare.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.molinahealthcare.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "moh:HealthCareOrganizationPremiumTaxRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Net Income per Share (Tables)",
     "role": "http://www.molinahealthcare.com/role/NetIncomeperShareTables",
     "shortName": "Net Income per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Investments (Tables)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables",
     "shortName": "Medical Claims and Benefits Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Debt (Tables)",
     "role": "http://www.molinahealthcare.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Segments (Tables)",
     "role": "http://www.molinahealthcare.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "ibf4236126773456e8b7ccaac00eaead1_D20200101-20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7250e43387d044659d3061f2be2719fd_I20200331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails",
     "shortName": "Significant Accounting Policies - Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i1bf57704a9f64502924a6c99e4e92834_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails",
     "shortName": "Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Net Income per Share (Details)",
     "role": "http://www.molinahealthcare.com/role/NetIncomeperShareDetails",
     "shortName": "Net Income per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Business Combinations - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i6d24fc64dd834ca1acb4cd31acc01c7e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "id1fea16fef42471dba019c040233981e_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
     "shortName": "Fair Value Measurements - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "id1fea16fef42471dba019c040233981e_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Investments - Summary of Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
     "shortName": "Investments - Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i99f8700af16d4c708ad35b0679de3fe2_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails",
     "shortName": "Medical Claims and Benefits Payable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i6dd146149d7f42a2af7252fcdc08ad86_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
     "shortName": "Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "iddefd20760394cda9704c051843be4a0_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "iddefd20760394cda9704c051843be4a0_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i9d78eaf9f7854f45a976f7a9c34f0b2e_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
     "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i9cdb8495a786463fb1d63d538dedadd6_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i950269ea6b5b4cc8adfdad5d1a0aa497_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "ia0f45adfaeb843a5a5c4a262462cb4fa_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "ib8b8ea1f43854547ba8cbbd4c725d620_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20210331.htm",
      "contextRef": "i7875ee5586204180b3db649fe9aedb5e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "moh_A4375SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Senior Notes",
        "label": "4.375% Senior Notes [Member]",
        "terseLabel": "4.375% Notes"
       }
      }
     },
     "localname": "A4375SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffinityHealthPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinity Health Plan",
        "label": "Affinity Health Plan [Member]",
        "terseLabel": "Affinity health plan"
       }
      }
     },
     "localname": "AffinityHealthPlanMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "terseLabel": "Risk adjustment, net payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years",
        "terseLabel": "Risk adjustment, net payable, prior year"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "terseLabel": "Risk adjustment payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "terseLabel": "Risk adjustment receivable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year",
        "verboseLabel": "Risk adjustment, net payable, current year"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesBusinessCombination": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 4.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Business Combination",
        "label": "Amounts Due to Government Agencies, Business Combination",
        "terseLabel": "Magellan Complete Care acquisition opening balance"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesBusinessCombination",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 6.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "label": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "terseLabel": "Minimum MLR"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "terseLabel": "Marketplace:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 3.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid, Other",
        "label": "Amounts Due To Government Agencies, Medicaid, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidOther",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "terseLabel": "Medicaid:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 9.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "label": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies Medicare Program",
        "label": "Amounts Due To Government Agencies Medicare Program [Abstract]",
        "terseLabel": "Medicare:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 5.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "label": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "terseLabel": "Risk adjustment and Part D risk sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 8.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Other",
        "label": "Amounts Due to Government Agencies, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesOther",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 1.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment",
        "label": "Amounts Due to Government Agencies, Risk Adjustment",
        "terseLabel": "Risk adjustment"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members eligible for the health care programs.",
        "label": "Business Combination, Number Of Members Eligible For The Health Care Programs",
        "terseLabel": "Number of members eligible for the health care programs, approximately"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "terseLabel": "Payable"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CapitationClaimsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitation Claims Payable",
        "label": "Capitation Claims Payable",
        "terseLabel": "Capitation payable"
       }
      }
     },
     "localname": "CapitationClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ChangeInAcquiredBalances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Acquired Balances",
        "label": "Change In Acquired Balances",
        "terseLabel": "Change in acquired balances"
       }
      }
     },
     "localname": "ChangeInAcquiredBalances",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan",
        "label": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]",
        "terseLabel": "Texas Acquisition - Medicaid and Medicare",
        "verboseLabel": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan"
       }
      }
     },
     "localname": "CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CommonStockWithheldToSettleEmployeeTaxObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Withheld to Settle Employee Tax Obligations",
        "label": "Common Stock Withheld to Settle Employee Tax Obligations",
        "negatedLabel": "Common Stock Withheld to Settle Employee Tax Obligations"
       }
      }
     },
     "localname": "CommonStockWithheldToSettleEmployeeTaxObligations",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CompleteCareReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete Care Receivables",
        "label": "Complete Care Receivables [Member]",
        "terseLabel": "Magellan Complete Care acquisition opening balance"
       }
      }
     },
     "localname": "CompleteCareReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "terseLabel": "Components of the change in medical claims and benefits payable"
       }
      }
     },
     "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ComponentsOfMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of medical care costs.",
        "label": "Components Of Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to:"
       }
      }
     },
     "localname": "ComponentsOfMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "label": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Interim Financial Information"
       }
      }
     },
     "localname": "ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_GovernmentReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Receivables [Member]",
        "label": "Government Receivables [Member]",
        "terseLabel": "Government receivables"
       }
      }
     },
     "localname": "GovernmentReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthCareOrganizationInsurerFeeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Insurer Fee Expense",
        "label": "Health Care Organization, Insurer Fee Expense",
        "terseLabel": "Health insurer fees"
       }
      }
     },
     "localname": "HealthCareOrganizationInsurerFeeExpense",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationInsurerFeeRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Insurer Fee Revenue",
        "label": "Health Care Organization, Insurer Fee Revenue",
        "terseLabel": "Health insurer fees reimbursed"
       }
      }
     },
     "localname": "HealthCareOrganizationInsurerFeeRevenue",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationPremiumTaxRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Premium Tax Revenue",
        "label": "Health Care Organization, Premium Tax Revenue",
        "terseLabel": "Premium tax revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationPremiumTaxRevenue",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthInsurerFeeReimbursementReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Insurer Fee Reimbursement Receivables [Member]",
        "label": "Health Insurer Fee Reimbursement Receivables [Member]",
        "terseLabel": "Health insurer fee reimbursement receivables"
       }
      }
     },
     "localname": "HealthInsurerFeeReimbursementReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthPlanContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Contract Term",
        "label": "Health Plan, Contract Term",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "HealthPlanContractTerm",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health plans.",
        "label": "Health Plans [Member]",
        "terseLabel": "Health Plans",
        "verboseLabel": "Medicaid"
       }
      }
     },
     "localname": "HealthPlansMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HidalgoServiceAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hidalgo Service Area",
        "label": "Hidalgo Service Area [Member]",
        "terseLabel": "Hidalgo Service Area"
       }
      }
     },
     "localname": "HidalgoServiceAreaMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HidalgoTarrantAndNortheastServiceAreasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hidalgo, Tarrant and Northeast Service Areas",
        "label": "Hidalgo, Tarrant and Northeast Service Areas [Member]",
        "terseLabel": "Hidalgo, Tarrant and Northeast Service Areas"
       }
      }
     },
     "localname": "HidalgoTarrantAndNortheastServiceAreasMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency",
        "label": "Increase (Decrease) In Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_InvestmentsAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Average Maturity Period",
        "label": "Investments, Average Maturity Period",
        "terseLabel": "Average maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsAverageMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_InvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Maturity Period",
        "label": "Investments, Maturity Period",
        "terseLabel": "Maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "terseLabel": "Fee-for-service claims incurred but not paid (\u201cIBNP\u201d)"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "terseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MagellanCompleteCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Magellan Complete Care [Member]",
        "label": "Magellan Complete Care [Member]",
        "terseLabel": "Magellan complete care"
       }
      }
     },
     "localname": "MagellanCompleteCareMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MarketplaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketplace",
        "label": "Marketplace [Member]",
        "terseLabel": "Marketplace"
       }
      }
     },
     "localname": "MarketplaceMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable",
        "label": "Medical Claims And Benefits Payable",
        "terseLabel": "Non-risk provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider",
        "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider",
        "terseLabel": "Change in non-risk and other provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical claims and benefits payable.",
        "label": "Medical Claims And Benefits Payable [Text Block]",
        "terseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_MedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premium Liability Due to Agency",
        "label": "Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies",
        "totalLabel": "Medical Premium Liability Due To Agency"
       }
      }
     },
     "localname": "MedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 7.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premiums Liability, Medical Care Costs Threshold",
        "label": "Medical Premiums Liability, Medical Care Costs Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MunicipalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities.",
        "label": "Municipal Securities [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_NumberOfMembersCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Members Covered",
        "label": "Number of Members Covered",
        "terseLabel": "Number of members covered"
       }
      }
     },
     "localname": "NumberOfMembersCovered",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_OtherClaimsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Claims Payable",
        "label": "Other Claims Payable",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherMedicareProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 2.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Medicare Program",
        "label": "Other Medicare Program",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMedicareProgram",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivables [Member]",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for medical care costs.",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_PharmacyClaimsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Claims Payable",
        "label": "Pharmacy Claims Payable",
        "terseLabel": "Pharmacy payable"
       }
      }
     },
     "localname": "PharmacyClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PharmacyRebateReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Rebate Receivables [Member]",
        "label": "Pharmacy Rebate Receivables [Member]",
        "terseLabel": "Pharmacy rebate receivables"
       }
      }
     },
     "localname": "PharmacyRebateReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PremiumTaxExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An assessment levied by a state government on the net premium income collected.",
        "label": "Premium Tax Expenses",
        "terseLabel": "Premium tax expenses"
       }
      }
     },
     "localname": "PremiumTaxExpenses",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Line Items]",
        "terseLabel": "Schedule of Premium Revenue by Health Plan Type [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeLineItems",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Table]",
        "terseLabel": "Schedule Of Premium Revenue By Health Plan Type [Table]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeTable",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2022 [Member]",
        "label": "Senior Notes Due 2022 [Member]",
        "terseLabel": "5.375% Notes"
       }
      }
     },
     "localname": "SeniorNotesDue2022Member",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_StructuredSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structured Securities [Member]",
        "label": "Structured Securities [Member]",
        "terseLabel": "Structured Securities"
       }
      }
     },
     "localname": "StructuredSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ThreePointEightSevenFivePercentSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Senior Notes",
        "label": "Three Point Eight Seven Five Percent Senior Notes [Member]",
        "terseLabel": "3.875% Notes"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentSeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_WeightedAverageNumberofSharesShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Share Based Compensation",
        "label": "Weighted Average Number of Shares, Share Based Compensation",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesShareBasedCompensation",
     "nsuri": "http://www.molinahealthcare.com/20210331",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r140",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r160",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r140",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r160",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r267",
      "r269",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r267",
      "r269",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r257",
      "r267",
      "r269",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r257",
      "r267",
      "r269",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r372",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r253",
      "r255",
      "r420",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r253",
      "r255",
      "r420",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r41",
      "r43",
      "r44",
      "r402",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r44",
      "r45",
      "r94",
      "r95",
      "r96",
      "r309",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Termination of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r136",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r192",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r87",
      "r148",
      "r155",
      "r162",
      "r199",
      "r306",
      "r310",
      "r325",
      "r377",
      "r400"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r36",
      "r87",
      "r199",
      "r306",
      "r310",
      "r325"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r179",
      "r206"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r183",
      "r186",
      "r394"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r183",
      "r185",
      "r393"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r183",
      "r187",
      "r395"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r183",
      "r184",
      "r392"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value",
        "totalLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r177",
      "r180",
      "r206",
      "r381"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r266",
      "r268",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Outstanding equity interests"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r294",
      "r295",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Paid to seller"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r293",
      "r296",
      "r298"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r23",
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r81",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r82"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r326"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r188",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities",
        "verboseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at March\u00a031, 2021, and 59 million shares at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r56",
      "r384",
      "r409"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r243",
      "r244",
      "r254"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r258",
      "r265",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r60",
      "r373"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Medical care costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedLabel": "Less: other operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r378",
      "r379",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Percentage of contractual interest rate on notes",
        "verboseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r31",
      "r89",
      "r234",
      "r237",
      "r238",
      "r239",
      "r335",
      "r336",
      "r338",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r195",
      "r209",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r195",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Total Number\u00a0of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized investment gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r194",
      "r208",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r24",
      "r337"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r278",
      "r279"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r78",
      "r219"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r143"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r110",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r385",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r385",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income per share - Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r125",
      "r200",
      "r233",
      "r240",
      "r272",
      "r273",
      "r274",
      "r285",
      "r286",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair value of assets measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r315",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r316",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r315",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r258",
      "r259",
      "r264",
      "r265",
      "r316",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r258",
      "r259",
      "r264",
      "r265",
      "r316",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r316",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r210",
      "r211",
      "r212",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.",
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "terseLabel": "Recognized loss"
       }
      }
     },
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r213",
      "r214",
      "r376"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r215",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r59",
      "r87",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r199",
      "r325"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Total margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r177",
      "r189",
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "terseLabel": "Debt securities held to maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r191",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Amortized Cost, Due one year through five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r190",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Amortized Cost, Due in one year or less"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r91",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r105",
      "r106",
      "r146",
      "r280",
      "r287",
      "r288",
      "r411"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r83",
      "r276",
      "r277",
      "r281",
      "r282",
      "r283",
      "r284",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in health care insurance liability balances during the period.",
        "label": "Increase (Decrease) in Health Care Insurance Liabilities",
        "terseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPremiumsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the premium receivable balance on the balance sheet.",
        "label": "Increase (Decrease) in Premiums Receivable",
        "negatedTerseLabel": "Reduction in premiums"
       }
      }
     },
     "localname": "IncreaseDecreaseInPremiumsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Warrants (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r111",
      "r112",
      "r114",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill, and intangible assets, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r142",
      "r334",
      "r337",
      "r387"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual maturities of investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r374",
      "r396",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r87",
      "r156",
      "r199",
      "r307",
      "r310",
      "r311",
      "r325"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r87",
      "r199",
      "r325",
      "r380",
      "r404"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r87",
      "r199",
      "r307",
      "r310",
      "r311",
      "r325"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r413",
      "r416"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical claims and benefits payable, ending balance",
        "periodStartLabel": "Medical claims and benefits payable, beginning balance",
        "terseLabel": "Total",
        "verboseLabel": "Liability for Claims and Claims Adjustment Expense"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Prior years"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Insurance Claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r10",
      "r379",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under letter of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r31",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r28"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other operating"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r46",
      "r49",
      "r55",
      "r79",
      "r87",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r115",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r199",
      "r325",
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other expenses, net",
        "negatedTotalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expenses, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r148",
      "r154",
      "r158",
      "r161",
      "r164"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r47",
      "r50",
      "r304",
      "r305",
      "r308"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net",
        "totalLabel": "Other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r38",
      "r41",
      "r197"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized investment loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r39",
      "r42"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Less: effect of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Contingent consideration liabilities settled"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r75",
      "r415"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r65",
      "r68",
      "r92"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Common stock purchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Net cash paid in business combinations"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and capitalized software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at fair value measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r382",
      "r406",
      "r412",
      "r428"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premium revenue"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r69",
      "r90"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from borrowings under term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r70",
      "r73",
      "r92"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r37",
      "r220",
      "r340"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, equipment, and capitalized software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r13",
      "r20",
      "r405",
      "r430"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "verboseLabel": "Total receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r172",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReservesReportedToOtherAgenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.",
        "label": "Reserves Reported to Other Agencies [Table Text Block]",
        "terseLabel": "Amounts due to government agencies"
       }
      }
     },
     "localname": "ReservesReportedToOtherAgenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r80",
      "r82",
      "r375",
      "r401"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "verboseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r240",
      "r275",
      "r403",
      "r425",
      "r427"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r200",
      "r272",
      "r273",
      "r274",
      "r285",
      "r286",
      "r422",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Premium Revenue Recognition and Premiums Receivable"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r54",
      "r87",
      "r139",
      "r140",
      "r153",
      "r159",
      "r160",
      "r166",
      "r167",
      "r170",
      "r199",
      "r325",
      "r388"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of receivables"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r31",
      "r89",
      "r234",
      "r237",
      "r238",
      "r239",
      "r335",
      "r336",
      "r338",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Long term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of denominators for the computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair value measurements of senior notes"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of liability for unpaid claims and claims adjustment expense"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r7",
      "r82",
      "r375",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r148",
      "r151",
      "r157",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r148",
      "r151",
      "r157",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Operating segment information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r33",
      "r85",
      "r126",
      "r127",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r136",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r148",
      "r152",
      "r158",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Shares outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r136",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r216",
      "r221",
      "r222",
      "r223",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r125",
      "r200",
      "r233",
      "r240",
      "r272",
      "r273",
      "r274",
      "r285",
      "r286",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r125",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r240",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r11",
      "r12",
      "r233",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Common stock purchases (in shares)",
        "terseLabel": "Repurchased of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r11",
      "r12",
      "r233",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Common stock purchases",
        "terseLabel": "Repurchased of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r17",
      "r18",
      "r87",
      "r173",
      "r199",
      "r325"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r87",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r199",
      "r200",
      "r240",
      "r272",
      "r273",
      "r274",
      "r285",
      "r286",
      "r302",
      "r303",
      "r312",
      "r325",
      "r327",
      "r328",
      "r332",
      "r423",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r240",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r333",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r333",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r333",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior years",
        "verboseLabel": "Prior period claims, favorable development"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average cost (USD per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Denominator for diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedTerseLabel": "Stock purchases (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted-average number of shares issued:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r445": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r446": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r447": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r448": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001179929-21-000086-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001179929-21-000086-xbrl.zip
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MUCMJ$09P1)R:@*R"'P1 &3.C*+5N80D#QA!E##5_OKD@S^F+=P1#</71<#&
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MH#$^#J[A\IGG+PZ*D ZD62MBE,4A,/A_+@Q:G8-V#@"*[_;Z6=CG:?OKHT&
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M@%O;PNI@V.K885Q/IY<\HB',FV+BH)20S-L0>>:C+B:GN ?]M#3/@2X5R:E
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MX44PJ35ZKW^_A7)/*2KXY:E7+>8JZY\:L_NIQLU )/XT#F8YA'X<#,:_\DX
MI'(NOW(N)^?HW*6$4@_75QI[._MU>+]/N'ZRA7,?K;]?/:I_63W9;C8Z.\U5
MUMC?)CN?-8?WH/7\?BMKQ_7]3^(KQ3@P'1SRBCG$DXU()PX^R](D>4C<4+NP
M!&?5UGVTW5W [,O.ZM7CCZI<51I:*<TS*<WVT5=I-0N$262("D!OL$;:QSP!
MS1%O193.XH6ES<,6.'B E:>:?58"]WT_]W*K'NGGJQ^S2V;+@;R%/]?[S=Z/
M;H4$OT("?#X;8*CPA 6&",& \S2 &0=ID:92:&JQ8(8N+.4-?&I_1>OW7I4K
M(5"6!-=8C8LH:+W_$<Z$:*?*;-U&EU=/==FIH$6T"45*(9BV#-38@%8GJ9U)
M3K@@P\+26] RD$^W91^@RG<(-YXE1ILM=/[8 P-H[[0.JG3M+97Z+'DDJ*0>
M*Z#DAG$ Z.20MI(BQZ,7TFL5,+ K@S6F]\@;$3*3XQ*W3#&,U2L/$A_T 3!;
M![9=BT?1'PY;W_/8<6KY.*A20S,E-("!6L:!:S(_MQQ293>,H3[=!(5'!,[,
M9)?[T986*A\TO^4$\(Z1)"1#3EN#., :_!4)DDI@IQ411,J%)2&OH-WOCYEX
M^- #@_FXU^N^V.F<_*M2+/C$ HJ)0J@028(XGWM$G"=>4:4H%PM+G G$I+QY
M$.,&VQXO@'QFPSZ;7_;?_]"4J#\&M6%LQX,L^?&TX5<U\#3MPPRR-0N&6O,7
MP.PV,ZFJN4;57*/'F&O$;C?7Z,G,:1.86+\U;,7!>!)?[,=0.SCL#P[S;+YA
MKP9G%"-!A/[F?L\\+B\]6/;#Q3O,YKL%@#S.["IR;X,CQCS27"5"'JOLS9W:
M?$.TP7]B<V.Q9+I]C1F-CV8AWVQC,SP<VFP-1[6]<A*MYMMV,+@%F9_S/NG;
MPHMN'G=<K_W;K0*U6_5(?_20N>NPQGA&=*%#\<COV>XN?-&M_=AKP3=G&'N;
MR/\6MGBC4YL7O7RB-:QG<<38(QX3Z@I$*&4<,4J&P7DGC4[]I'$2]M>;N[3Q
M?AM#>W@N?;&]7\>-SL:WG?W5H_K*Y3(7/8@WX)R3.FO0NH"VXYW]O#AU[UO]
M9*=5/_E$=]YO="#F^-%HZZ,+HQ56<1%51(PEC;A*%CD0 H*@D&@A!4G&C9;[
M@5$46RB_JOTG!J9(:A]MO_;9M@^O#%C7;H\ZE3U,VQ[&+F#D 2ICN(4QG UW
M^& <\PPCC'E '/[.F6&-J$Y<)(C(&;9Y)=#?]QCGF(K"E]\-/U.-@^S:KXX4
M3GS'ZMCQEW8%W%.;S-JIR; \$]=AB:R5#/P'H<AYS)",U@@<J. YA=6(/VK;
MO?ZWD0>I3?K[U\,KMPS3U<6@U=RY[-<M@_+K"].M=?/N6<-8<\<UOQ?A!3NY
M3-R/O5C,O,T!^+D5=[^1WT=##WMV4"R>#S7;;L,9N;1&#NO_?=C*03W$\BZ.
M3X ;C^/ZT:6$Y=FZHVH)XQ#_7&9@TKTY[,^'<[6$6H"C$!GD4P_ZT<<B3B"T
M5I08&M1^@_N!T=0&AT![!WN]O !P4J9@N&>'E]_BA[W8U*(*0''Q^$5^?U6S
MW5#[C9Y[6P?V!R>Y?7B7?%%Q?BK*A$]N5A3U+UI2M-0.AC6#:\$>#UZ/[G/U
MYZ./N;X][/>A6:/B)]FW#NWP<%!*H'A0PEH 6^21QN014=P@[H-$SC&))%/.
M<(.-5W)A:3L.+EOV!7F-K7RZU71N9ZJG]=KNWH0'/O=ZW6WT9JIG^-7RFK<"
M7#7+@)N1!T"GTQH. :MB&\"GW^MFOM,^KD7@/L>UM4R#K"_&N%?LT-9RF9'+
M4'QVC_/YUHU#.)-CD8%V(^X>MD<3\3=1\[$A=]2>4Q"-@]^?#R+/=6#NOS%B
MOCB(7/OQ529"+9<8!:\XXL$%Y'@ Q#2)$@Z=2CRK(+*"R)F"R-:@9FMM:&RL
M6>\!(OLVXUQ&E7[F<==^6P/E1=<>&'0 6^$I_0EC L3IP)L?O\JT%6X'-"]W
MS&YMM]_[,=R;''X-+#86;0LQM;I%K:QB+E(>.J;PFC>TL#A,_IB<]LL3;F[?
MY,1,7<<GW]#6R9FM[L@%$.H0G9#Q\PS\];WU91*YCY("3QS4/$DEK_Y;$-)N
MKW_\\CS%T5?!:6)<<\0$)8B3))%FB2)#D^%*Z4@"6R@ZOM4]C&$YIS,\<=0[
MR:BTE&M%C0!14$NHU%PEGR>6WQ14/T4RYU1SQJT><:%"M+]N>6'<R^=LM]"0
MXG7.WVZI]IB>X':O>#\?^05L.=OSX$'/KCVY0*_(I':O-DRU\_E+Z?P&.-E*
M ,\H@,V;R,+S"N'YR@*/W'?1+9,]=%^>^S[^2JR07GJ->!(1<2PC<I00%(C6
M26DX3.POR_K.N>VL7L^=7[;E3#KE?=$G;T==\N(L:!4# ?:&2V61!&L! LP"
MLAI+)#FFC(LD*8V_+HP]TU%X^DFTFZ<]7QNDM])U*<PB<0D$H-LK\HZ'@U&D
M#*H[VHSBFO+2$&SG9[6/\\-_M.#1V?BZ\4<.P_OQ>VM01,A=V_79OB!NSC7
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M.P&TD H0PAS$%&$K0@JK0C@'-#PW@5V%GI %=BD".],5 E;(6JR \\(!*JP
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M5/<2(XZ*EA[8D\JR)VBS2!RS69;9:3Y*9E[\U;QXS+Y 1Q W7 '-:#08%")
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M)EKKOGE%&S)$98CZA2G;&:)6X.V>K^:@HP&.H 70" ;B3@2!\4@!215R#O/
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MN*:#2C0]!UX/_9ZO?N_W)O2HC-*C1(V,.7? G,/=.=T@A7E0I C@7%I 90A
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M&,$,"H"P#IRF0SK%TN'8=15!3>4C*EVXTT:>D5<2+X7:'(H;:&]8\T0T$A[
M-9IQQ6$4 <6B(H$5Q!HC1A%B"&&):X.;8@PF+^X==W6%*W*AQ/U1>JC@!Q&?
MT/HZ'1<9BASN?&'".4<@ \2GWO;2(R"-#@!R8JF3BFCD-K;Y=?Q4^QPG!P@_
M?'GJT"LMHS".ORO]*P6F1UXYB?M9Q7H7>&S>8D[.P--1C5=182Y-_. 3(3OE
MAEA9:M%<279/?W!6<>CWR#/5QY'>PU!?.QF^I5ELQ\.HZ^LX.IW+)A4PLFIE
M$T8U\&,TVL:1-WJCR.+^[]-R+A>FF2S'^%4_@>*A3U>(S]0)DS.<K67'!ZS,
MY#@\:?>+5#1N/"AU]0L6Q];J;8QB:F0@<J614?I0DN5>SGW>AU,[C1.Q?^C4
M/B@=DB4U/C%(H7_H@?,E&:,M7Y2^Q*GQJ^T@>6IF+J*(D<.QKHR7A0/#R?EB
M:8_73IP20LOK5\X=EYC^O3\=U=8%G%@7M<>JG/F>/]6#46D@I<.@R8I',4D>
M&O]CYJ]H#VO>K#P/90YJ>HRXYT>VC5?&E<;X(PIEO%:8>8/*2=JDGL4YI^].
M'Z-R3MBX6.W2+W7QJ#-.*<UR:I[5.E[QNJ1T>;O=DW;'1=G9+%[]'=EC6.)!
M^F!.31X^7=$XB"3XU!]\^XE!_BML\/UYSJJX*HJ'3V>^9=F[TG%WDQF>)&44
MN;M=>;5*MJF\1Z5]G/[:">4ESNJC]M+TKL[:(Y%G?#0O?Y$E)XM6H7W/CQY=
MV9!,:X8<9UPCJ@A6BJL@I0V"R #UI/J"FE1?4 3>6]F85-0\ZN]4"SG1/OPP
MZJN'H8SSKCYQ:ZQL?*.MXR^86QMX4(!'M2]JK-  K9P #%(C-&:*<O*S&O93
M#6-.1_@>T:H_CMSBOL9MO3O)=:MW]CLI(_?9^4<G[8CP%^(WMBZ%$SU";%K5
M-7(Q%FT_B7R[.PU"VY^%1[R)X^Q9]7.-X]#^CFP8@J.&8 D@50)0H1DP7!D0
M%/>466R5$A>CN10)B 5EB!*<>AG-+AWA@P3!/8;&D(MQ:(WUC2^P3+DUUTQ3
M3+FFF&.;)I[A'%5'<?5CQ!TN3&<^G$9=3@]CRBW,VJ@I5IO8-=%BE9J2CF:F
M*F,*-9C$:?5/X\Y7&1&5MI=NLEEND_/(,VE<&2?5\^DD+2F>I298!-U.AWIS
M08CU_AK?&G<2:@TG[Z2G*J<SV1G;-8FJ@Z?AY#(I,"/%$QCO>Y/G=2_KHY^+
MLZJ"+'J)L.EP+R%=Z?V>C=LJ=N+CI+I#[:@&)D6WO&\Z8M2]L\+H3HISJRRK
M.4P<SDW"=]K5>6EMVRV0:?*@R1";!A1.G_'*2+CR##4=*TY6,RF:*;C$EBD5
M%Y=P<JWX-$FE*3U@$?33<T[\^HO!53<>:*U,$[V1X\<]/8Y&JG>+BSIAC2ME
M8$:8R#'1M(CC9_&.4:\;=T^K72W93^-A<B[6*WKYLO%VNKI@?78^\+H\3BS?
MT^6Y<=H>DQEVY4ROG.&,^DDUFE(L#K^28##R:)3E02)IYVQS>IKCIC'6]8'Z
MC_ZXXR[HM&Y<^A#JP_SYK]21!56-Z/0 5]]\\PX/-EOZ?K<]F@A$5!PN9$9<
MC$.^$'N<,XSNDF$DKL\PRLE"3RM9Z,H8_!MCZB_&X NE@Q'2)U<S8TPY9:/*
MC8S6RC.(-JZYSXW:7G.WBOML$\.3$BW+T!U=8F#\[M=QKS)YJF"G1T;UQNS#
M=P\UZ<2-M%28;I4@T0PNV:TTPN0"*LE;1K>5*0-%&6!W.9K?1?MFT#;)=6KZ
MW_ULZSV-*NF@(O'\EIH</RD,7TRC\"O_4*?8[>AVM](B_YB$0[W19^EVTQ/R
MZB3\ZBC^Z:#9%AO5V71B7@5T)=MEXJ*M[?EJ>O/*]Q-1_';K16YWDQLL7:_0
MW<J4F=D M2LB&3FEIEZ?:,QD="J9"7A+GT?H]'_,Q+3R>W?C;$Z&M9Q>WFDC
M(186O&;[RO]\SV6_K.T\;A[?AZ$_#*^&H]*I.%P_[\=9Z^T7:N+N%XP!/&"9
MO!\:*.LQ<-@JJ#S2G/*+^V@@"@<N+('04^V4#-:+--IQIKBQ3\;[$1D@R<"4
M!9X&"I0']*4!-W4<W,;_,9'*Y+$O4?[#UONMXCAB[J#R\4>;[;0\#*O<(PDW
M(IK'*YUV4@I;C;M_[NS,@NK2Z59[,,VIFQPB=/6W:!=.5K6*59J:E[5)ILN*
MPK6]GC:8=.?NU"]3'S.DKW;J'O2E ^;5[*HINNJ&J]0A+M5UD@^W-XQ_N''I
MZYA]J7S4TIF2#,K1N'2)5#X$6^I"KEV>F97-P$>EW39]NJWB3;5("8Q3;%:]
M*),[C"L>FZU&[9EY<2VSU94H0"H9](+PTPNM")!<,;^5U.8O5WV0]7)A'5#9
M@:%B?N<G@?@3'URM2]B9+C$-K3ZM=(GKL_SR<O]DN2=)*TDDR@3:X4R"4_A[
M<O"-II%D40_H'_>J<'JC4Y.M\6F_5R=+#"LO;-(%W"2_(EZR)%*9W7H^]4=%
M&_;4VZ1%3X^X,_WN1;^WD7 )\./")R_H]XE#K$I[&=>YPB75SGW56B2!> F
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MEU0([[DS-& )-Q[[:*FNYWVQX5ZSXFU_A;SM[7PAD ?!+ ?&"![E+3!@;!
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M>+^SPZ/XS?-4U_\DM,[F#QDM^A+IY!7G#"A+&*#1W >*"0^<]$$H)QQFT11
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M\'O' ]>[.A43WD?8U:F%]\$V<DKA]39&YX-%QKB< EHXI*V1*&KBJ).))9*
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M/949+YV)FZQ<1'A]1*"OE)<?^9(?E$,_< 14S:%_?N&]O0 .[237.@6'.,/
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M(\_$!*^(2(CJ&,&P4!(DFV)$B-1:N0"4Q&=Y7I8?H;8>5FM+>B?7"JCWGQ^
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M90P0I$B"3BE:7-.ARD(1F8$BT!M616F1M 2@R)"$3. ,_@2:&U6(1,2:#M5
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M."XJ/\30L,-& D!K?,N(U@ PM8U^SO+2AWXWG!VT!_F6K>CCL8O]4MX8>=4
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MPF(J:P6[@B)*7(@@@IXRZG->7:>%#2):[K40FMSR%$RM8)_&[C[;%])[SY1
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M6+HK[Y9OW&[W3FS7QPSER?W.%]L.<F_H6A=>:C"P_=.UVE\]^!#&:K,HU#H
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MEQR(FPZR;&R^!G(B\QN;3A$G.+;(*1=S"2 /AHJVB%GGB$R"1IQ+ .%2-+$
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MD2,<?!XJ@Q6>AJ!IH8,W3P<O6TFV4, S4L#V?)P#U'[(J13(XV@13XH@PT-
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M=[O<]AP@0Q9V/3L<=NTP'(0.#C:WACM&AD\V'G6\.(^J#4_MM2JV+#SUS,7
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M/ #:WYVF:9U740:2RJ\1PMS@,2*$P[._CM]V=5=[#W<#XMY??QCLX[&B3[S
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MCU)X _&"BK<(&R:(X1[1U2-L&\([],.@LH*/ TYFH'*B)Q4->[F?D.&%KS@
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M-J9"=)E,+\L6*M8$FAJ8S-@P5"AYJR(=4'Y'E#+5"H4M"P72N6<DD LL* P
MXN>5>C#ICT04F(T8$+A_(T1W3=O'#^:D0#K#A@-CP-0@R2\58J4U9D-Z(S(.
MS+N\*<T&#*,S#*T)')HI/X-P2W6!H?D469UVJ8PN\L4[6M1Y-'U")70*WS25
M=PC)P:=741(+[\(U5EH0"+.$4])$#=-*;[<V9H A'A]%DFT4SU<0L%4='S/B
M6JO!$P%6M,\0KH7/5Y8(HF(A8B=5$%5+/[%RA6(5C5XF])Q,ZJ40!P<$HV1F
MA2>PKE?JFV6IG/A!-P6F1/(L29!U5(1/TS-.,BHM\G>JU:PM+FV7;=1*UHI
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M%NZ6,;^,TK',OL!:HOJJD^@;$BUGR93RP<HNK[*(H@7P]@!,;;%\%2R1C>=
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MD]XD61TK=<BJGU?X=,E_*U3.3RP=P5(98$WK'GQ4NHW&N>B>1WZ*F[* ONR
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M'LTMQYVV$.BV0B#](49#.$8[&F+_JX?NR&BW,T/B[*^C\[^.CS[MAUA80G[
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MQB_.CT[??B!S]>/IX='YQ0%(AN,'IXXMT7/AR7\/!S@Z.3[<#Z(^2!?'(8J
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ME*= O&,PNM)QX:%3D2>1YH.B/9X2B:$#+<4D+ 13P7JNF \J)(A8T*HI$YX
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M)3GE\Z'#"2[A!MTW7.0\D5=GA@G^ZC7R66DYO8O";*0=1HF? T\ZQ H:?/"
M?B*,PRJ W$X1"!-W"YC"BZ57+B9!FUW'9(].R62F)$)8$WA8,I$1V;<8KHU\
MN4 1JU/[7@&^!;<EFGZADE"$F05R,?^KNH/Z"VL,@\K: LGUU#$E.(5M325(
MJOUCAGW*IG%"*@[L:5I$B<="WSMDXPC6GT:,['U@G !LT'($B*H;E'O[V/N
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M8X ',ID(>8<PZPK5N.A%09H4M;BE.X)[J:1HX,_)5XHLK1[Q$ZO24EF2^Q@
M4LJ=S(*+DTLF<I% BM7NG0!-^EW*J]LK-B4'J,"A7FEJW*["KM>:4?LDX:\U
M-6BU@@>"UUGR"^I.<;_69%M,D=NH>4@Q*9:0H$)5J$:+EK0E?15$)8*:A?(=
MR\P=H9I4J%!%]H7V+9IZR%=7P!M-JPY$*:]J:3A+4FZ*E@W*6/.E<:@:/0D?
M<M.;%Q?-[\LTOD67ADQHP9V!!5A(YO&-"-W4CK:TB;FT%'Y0?[YJXA0=^=:^
MYJ@AS-FY>Q(:_?WLD_;I2#OX\.'HPP?M_='YN[/SDX/3PSWIUO<)PV0)%:7E
M28D_94]?"H=(/1L(*$]$\P$AA5(Q:4H\?2.M4')=)TK#+KTEF#Y4K3%41F_)
M#':6U7WE-R"A,8@'/$EV,JSDEU1':JEF_ILP1Z%(U/P;G:9/7X[JZFF-<>T4
M@"VZ%]YM>#MRS81J2&7J)#EA;U!,UG<A V#%&W&\41E<V>S,U *NV*_8:H+8
MB WD5'+*W*TT3BZZRTQ(%L-^)IP!AM(9B\E+F&#-K\4NA>@HDV(B"4[XBF3!
M")O?5.HT,?5%F#9B%24@.@KZ%<A+OY=D^)44#ZV.06LB4(/3ESQ>0$)F"M8^
M(POZ/VAX97%3)( ./,U3NN=JJMSMT^EWBEN=%/ KH\JE+4OW#\+R!K0P)7R$
M6HA"JD%/4?%3KAIH"FVCWC.\DO_SO@22LBS1KA7E#I5D+IPJQQ^D7_FM!FP;
MNKLM=#=L0W=/*'2WDQJ@=*%H)T<G_SXZ__#[\?O]8*87E ^)/1TI[TG:LM3H
M$=L<HQ"JU.:5 SE1HY#<-:#<HZ+AQ:W-VE8=7&Y \2=LD="%"QBS6<I?J3^\
MQI&48W;S*IK2@>A'KT%_).>?9$^PIJ1,U^TYMHG$F27P3Z"6EW3;([K]-0OF
MO[/=GF$82[_N]_2EWZU:5M=[ W-XIV57?V>;[68'UO*OJ\O^2L@@$ (0"U'V
MOUZ8+TII0/UU7O4UG1!3K;?B46/V#1]^79&1J&[SI(F:@@ >ALR=VWR]?5GW
M*<J2"]J\_3A/X^15C\*S._QBL#\*YF-?JJ47L%BA%+?VF/?SP,UB[9ZQQFL7
M*.@H_[I&#S?=O#*6<J'/:3_KC<%C6T?C?8%AO[V7M>_E%N+'C/7+!$L*NW)W
MOL\YF UWO8X'.*][FR(K>)WT.RUE\L;MAY0*)Y(CG%$CBUW#_=:.W]<67 )9
MPS_^%LR.8[N89R7,X>9E/,P%X%=T$>M?P I"NQ7EEA+K?2"Z7T"UW6T M87K
MCX6KT7&'_1V&Z\:R(J3_[8NL2/B=9,6"0^XRDNG&X XHMAB26^4.C5?>B3OL
M&VQTNX7-KL*F_X-A\W0U]3(2?!]E?5\0258*WDW&[ZEZMB^P,76GA<VNPL:X
MA\VS0^HOO7LH0L4[QXLOXHR-[Z,&[[_+Q.H,[B/J=\-E\H *VE. :-\T6H@^
M(8B:':MO[2I$I9QHI&.9(I_AOF&(RM9A12V(<TR0J.U]@V#&4W@A7?>OE/.Q
M.D?8?*A4&@>GZZR12_//@O_=+1G&;$XZPKE&VYITM.[Q*@'(1WMK_1:&O8%!
M<X[J=>7U_M*=LGG/&D4'HL,MUCP'"PL0.I2/+&LLBI:4&:I-J<R!6EB)A@VA
ML!R$VM!$<2*[H-^_%\^2.L0?D>OV[OCTX/3P^."/^U<\N+N0]I9/L-SA.U4^
MK,S#[ZA$_&I"G&HJ( %=F0#U<X"):Z+?@:Q"3'_9)$UN42!Y&YER(&Q[?9''
MNFFJG-7OZ8;SX E=3D_7U\OGVC3Y[&ZKMGM].GLU'6MO]KJM>UV/8N^=,3:G
M[4GF=FO<\G&SZIK&R.+,F@OJIG$2T[31(S$#=BN)=KJ]2$G>RSNK9MJM9PLL
M/^8SN:_^(EQJ&)G./8W,)+Z>\R+L[,VME_<FAU21EMP<5+4MQ'N:-RFG,M!-
MGI!.VE[DW2[R\/R!4L^?X.6T]-K2ZZY=9(->%\M>W7@8#^_>/_IT$U66I)3?
M=K#[):?NQME?;N_0.QA?LCJ.M:M9N ^4(M(B[5-#VD'?>MHH^^P* IQAS_X1
M(-T-ZOUI'76U97O/G>V9'<,9/&W&UR+MDT/:P0]A[*VLWIZL=GIN*ZO;0L&-
M#KG+"#UT-\7GMA#M4> R;,&R@V!Q^SVS!<P. F9@;NH6:>'R&'#1]9:1[2)<
M'+WW P'S=(-'SZS*>; I$K55M(_"=6V]A<L.PF4XW%A]; 'S*)XZYXY1M18N
MVV5D_3LZ_5NX;)>1&3^2D3W;'@VWI=KM?1AHO8/M($$,.N9MK&H?&@RT"+:K
M".:8QLZAUP82;U\$FS/H.2OO>2]#=9N!KV4"N\H$+) RMQ@JK91I$>SN)[*=
MU=ROE3(/)656FT][*64V;XET]U#,0[<NVIV=_/!'VPN]0^NIQ0UN9+78 ]!C
MV>&&UGD594#S_NJR-F-A.=-.#Z8K1@8W>O%@+Z:$,^S7]%+OV+:E6NJHWDS+
M9LN/.([LGLQ84IU^O>CIOIBKJEZD7;-4F[!H.K[1@AR;/U5'X@%F7\-::IYQ
M!"_PL]M;4,'C,0UWK32C2E4C*GF2E/LQ/#=BX[#<V=$W;$5%78M&M596J1C;
M.[\UW#[SDSC%\;%7-&V9IC*+(<S5P^$(Z*D:Y L2AD]II*J<\_?^]R/9W*@X
M;66>>)JGL_+YRB[@NCF.%X^F8I*ZNL/#L[^.WW9U5UQV3!L;UR\=8)5%./<<
MA_"F/*-V2S10.HG2KSB /8F".(%S97PRP3NA>R]6W@],/X KX:F?1!Y<(_/@
M)A !Y!38BX1/ P&ICU,Y>3Z+>-I1PV>O<7ZO'U].X8WP\UIGM)>Z+JO:UJ,1
MU<)*(C%\WKAG/F4TEAF6::"2Q^'Z<-9R WD;E-7!KQ.>S@ 1" O$!/IK>"+/
MHG'TG64%!HF.6\7$>3%U>5^!?$&D61\^/*T-"0=&%U\F;%)E<(;I*O9&4[<'
M]D^=E3"\+YLK64"YBP8#%LBH!I*7#*!XUSP'*F<L$WJ+]FD$18;L(?>S"F[B
M?//]@2EU BQAB#WA JYN#O ;2[I^NHWL\"8PGWSE@WW" -WJ:Q[#V=:S.,+I
MT *&$T">*YHD767H+,N J^2B51QL1A!:-H(+XM]FG$BY0G:=)HW1[.QXXD4X
MWYV'(?R".AXR;1(#R\JT,:#$F,;V$C720+OZFIJ?(\\:BW'KQ#0 TR(L] ?6
MQ4@$SG&33BE@O)3+>>A,RVYF1#_A.(<?L#2>]JKSN'&=ZIO+.>^TW(S=B"GJ
M\.[+),K@>L9IK(7L*D[@@FXDU^-!@84+KW:13*KS3/S;%0,YF:>->UG"3:F)
M8./\:9-H=H<F[J1V5G+H?_3^UU [ 4=7J9VJF&<]J3I+(NPK66J/F^B)I7[7
MD5U(D3I'L&->F\R,&"X_;>[\_<G[DP6L?A$BUQ&TH_@(G._DY'VG*O[O)L.7
MZ&F:U@ZWO_-P>Z<=;O^$AML_$LKI]F*=%"V @@66BLQ+JVY'K%9"-S.V.PW;
MFDU+/E6JA)WE@K?RL%)1=T=8WJI %K>-JF,I9. BL,)D/=51[PW74!V=P4+5
ML2832E%5& )2J@01F)F9X-D%UOAQFDEMC41'"J0";)Z::@<Q-< .<P094,L8
M?RY\%CEJ7[ U-']*&=9;+@5V7<59D.O]HX^P6MB4&UZEZ!B.N8FB4Z?C<IT2
MQ(NIF!6<1K1+7Z2^G*&E7-EU5?59WH6=3>)\F@ERDG.XRC;Q"8=7@7E!]HZT
M5&$ALV]4GP/EY3\Y/H2;%JB>YA[HZ?(CL*1\SDDK0W2&):](\R\=(M(DN.$L
MD697H2#5W35VO9$]TB<0:]4 $?89E\:S,AI"T,I(72L5Q#1+8O@/_!*M:_0O
M@59#FT>NS+,(=2<D=Q^>[L!FLVS.,IRR+,?ER8JD'2=UXXP\A-C^-IX!J^#3
M)!Z3G2>]A(*_W ;:Q0Y('W9RR:ECNI>G@+\I/!1]ZPA94A41I;-18:<'1_^.
M&(*6>1;Q9%X:/+:4K6-NPPM4"EE["[[L9?9'16HVS @)I70)L2X4S^5N8'WR
M+>T'(VP"9TX(8Y[^6D(8\V#7$,) XZN$<)W UQ&]*;U0?!=-T46C*)462RZ%
MO39ATT+D5@]\R='I.!M%H#2M,,-V7 "?H1]I9S9_*\;1=HO!$7*X2*K,Y+JC
ME>"\T,\Z!@[?Q<A*:5\+Z32;Q0G\Q@?[')")S.3RD6L.:MDU2H:K*" 2_A2E
M^*@::T%>L6)/,N2 3H%93%@E9&I*RAWPAEC,N)!L13E".X5>2UA?Q3AY;$"W
M#[D_*I:[1L=@-$%1B)>,"R*NXLXPM43XSX@Z2-R#R$ED/&D1S:6%0QR/)*@/
M719('E<@:[<UAD6+@O]Z<;M1"/;TBX=#U'#H#S>Q?9M37A;3U!_'?WX\?GM\
M\5D[.'U;F?5R>'8*GQZ?G3XPO6UI6$UQC/U@#Y^X]%L+[&?I"-6Z*YYF1#2"
M1'TV0]:(6AYH=WDB8])<V%?I",B_2P^6+"+VQM&E)!@I!@K%ZGH4C3GI8$CJ
MJ#Z.H__D44 ^<HS41%,V]2/RO/-OD1>-X9N>]@E'Z(!D8FF&VV+CF^\RM#.)
MIQ%HI,41X'?Q=8J;Y%/RA<R2/!"L3YVLZ:V7[X2](+^3) [,(,0MJQ.4&X.;
M  YQN8"N'QUXXA:K5PA@N8Y%K"1]I>F_T%D2?IF+J,"(7'[:#+V_:%K KT!=
MX^EKP;O$XZA<P=60FC6]$?90N43U9R#2IYPX->K\40A<&']8@H%4B[D)1X $
MP(TC]7-AM/L<N"6(!(%3H$Q/0+WF"'5-Q31&A<.R(H;0?PY2H*>];QJ7J;22
M4"6]T5+XBXCN%->%"E%.>'Z#M@->LN+PM)\9Q5CFMD\)%;1R' )M"!SMP'WE
M8\R@  G(M"F_%,)0Q6I$ +;RZN/5:C=8,U% @@^-)+ALC#K!7^'0A-8!W,D-
M8B<)O=*&$9D9<'N(ST27*FY6GH..1B/%F)1SRG!4;G*X4K"V)I$OIHNA#@$D
M 4CCX29010!S;>HK_\LUQMG&X^9V4Q2Z<J-*<N;(0T ><_QSD@F=DZ)/J$MZ
M'-"FDI+PCA[7/A#L9&I"*HCR#W65^*ANJ$?Q:_G) TZ06T-;7$RF[^-,&/3:
M<1&T*R[YO;SDK6QTY;9Z,J5C/P35 ;"Z+W$B/7DR&8@#!H_XF$*:<8U#+6-R
MR!$4&F)4 ]820H\8%@=TNF+C4O)51"$((#2#V16+QD1]I+RFZ'R81)F,J[+9
M#'""OI9[$9E2M'HT)>=-FJH3*+DZY3PHA,QZ9RBY)C*^YI$ B*!L8R*/5&OK
M[!P_!2+.T>9$#[Q<K*)TSW+X4XHVVFH651$5!?=^.;3FO'CEAHH(Y.WG7,HA
M:B>\/[N0CRIZV!VK]%;#K@'6"9-)!J"XB$R,$L>DP;0&=L&3*>!M&L*"H)Y-
M0%Q@FD .&M8-H"IP>I#-(U@)+C/A4DTL78%A/A7_!<2:<HS25MZ4"G,2O9_X
M3.G#VP#1RL.5FBD\]](VZFBW]HEW*!"P$N*'"QE5DT^1_C>/&U77]$O+'-3O
M"M=X.; :A+O*TPT_4,-+:]\U#=^Z4W;%BO-9K\BXTA$CY0\8$N@W*5=9:VOH
M3NHGF#ZJL<O+!-4QOL -/AR2&YQ>E1+>OM0-HTR$8QFM@,[O2TX.$L(W0]=[
M QOYO_CI<AN_32JX+:G ;9,*VJ2"!W+.'I>\<#_X^@$B,WD>0:5)2"ZJF%C3
MC)9N2#3KD,%&E)J-S*[4!X4H$+_$C.K%1CN9;"*4*$SDXI7"G3/GQ$$70PSV
M9:+A5U4G41?X<: \,>1XE<:IEV%6=I[0+BE$*T*+]+XR ;]PR20<U+$I20P*
M]E1$6H*>CH!X>IJC?P$UV)@E09=X^16OBD!M!FS(QW<*)P.Z<9#98+)'J9^+
MQ/XQNQ82M**N[XL^@#Z91:<6N33HC1'B7OG>"\<#QN@X>D\*]5!!#X0B;$!F
M&0MX:*3!XUM0DI+-U=$$Y# QETVG"GG3C))64<&351,5%5%@'+Z7*@^$A^)F
M)A3S:(JN1?$<+"O 1N*_BK.HWHJ=S.-(>7KY4O&^N'9%J?#,H!L/XZ&90DWT
M!Z%91O%HO4^A\Y1\*O,?%WK . K)X"J]HD$%W=$5%8><[!5X&49(0MAA+/V.
M&# H2)DXLA;$/MT +',)8.)C\CQ6G+,U@D#;DU:5]E#A^JQHAL)KM^#5DQQ5
M&(_\AM(]!N<0E 2;E1ZWE(/^0P46Y7NOR0DDHD$IQA3E6'LR:.,&U2KVHF(Z
MPB.Y+]3U"5V/XPCV+%");(DH_9JN\).)Z.B-=%8J';;N3T=6AF85&]<KD20R
M2%B64 /Z@<M+58H%:?LI!5P#[>! P+A)!S> Z*F,XX)^240%)/HEGXIP;85&
M*[B&3GW<&7( <5)\&0B&.,T3L<A5C#R2O/?(Z &8!T% *"#25>+%" =L [B#
MEM,:4W9%4D66E '%D*$BET8'CW*_2^-.O6L_\$9XR@%:D<Q=KHNQ@I4"T4W]
M:"9E]DHOU,?>!\ 5M*!R=&(73(:JL8BEB=H%<7L QE$\#H3G=<E.P!2,"A8(
M1MK!>*PP+Y^NV+T_1E"&$8F" G1"*BPB['7#D^8#AB<?2\]$<UQ[A\ZG@T(7
MVQ\4K6B6%$O))YBT\UT %L@7OWEUY^/,C]G$2GRI=U4KK.&@8S9+^2OUA]=!
ME,[&[.95-*6-TX^:_0;@+=*H<]V>8YMHU\FN;'+YV\?1VV[/,(P'GW*/3@%S
M>*=E5W]GF^UF!];RKZO+WK=-WUHCW^\P9617)LY>@.7/M1-X;I1J1Y1322X:
MS=0[#SIIY3[M&O9]K"]ZN>XT8FZ3\S_S"^ZW%[S%"SZDC()=Z+3SPT#8;G+I
M)ELANYIZ?CZ>JAA2^LO]I.J^#*$XY=+Q+%V.(C%C@<_Z/KV;][$MWUKGVL%V
M<?;@EJY\>] %O<6MW<0MW=K_B10M;NTF;EG&'>??[M"0@-U#DT*\Y[)KG' /
MKQ;M"YJE[OT,LY^=X2]K8U8[5NY10*+WS18FNP43?=,1.NV@OSLPX;)TZ9Y,
M>,\F ?UL]#?@PKNG.SY)F.B&W<)DQV#B&#\$)(^M!E?"TW*)+C[_2K<K@[:B
M*1:"ONJZ#Q5R7Y]I%TT7?E;I\+_<EOA1R<2@!T0Q;OW)1@[NFB)V[=#$D[!:
M-S[T#I*Q,;SCG/%-HE"[,)NE1=FG@K(_.QLH RVVMMCZ8R?QVNZ.,MC-@^X/
M,NJDNOW'&O2R4^^\Q_R5QTWI7%5F=E:$7_<M3?435RW8R^8@,BF<LMAEA_44
M^[]D(TP_QY*4X(K)#N[%]UBE4?0Q&[-HDK[61O$UMC/L:)>8@#\5N?/L!OND
M4QEU\ 6+)#+84%*T<D_]$0_R,99<B<H'K'#5J,Y9=/HHNKJK]HP)QVSX-0NY
M:/O3&^V2NA*JIH;O8BS.8MBE>]EFJ;V&:@=)_3W4T:F(A4H2\#GX%KZ0G0(P
MPQ??3Y='!?'#UVES@3W)N5^5=X#%:VK0R)(9%BS57MH#IZSXK?<Z?*E;YCJ=
M$N6 BY>646VL6/8N+'! C+XHFR/*9J!8C5/N676]Q(K[2K-_T=0EB,*0)YRZ
MK\#/*F@AZ 195JK&$-!?]@*2J_C8<1%KFN=CCX=I>U*\M%:D3B"^,URS"VB3
M*/KK$46GV<*S) .LHM<':A75?W9)@VA!+F6/<%7>+PL(RSJ55:?8C^*S563P
MKO#VKQ#G/Q35%L4C!*H9_;OBFK%6JUK$M5H#X#JJ.4:):JN[1Y1'$&74>29$
MMVQ325V-06["!<?^USHFPEXK@N2EK1<;1R%4^QV>C;H78<<5GF6@CG(0\_$-
M!U1GWZKEU\(="!=8K$9M?\H?8E,4V*_LCT*%Y$))&D>B+DR4QHYEW9TH3/P?
M>#SWO]YH[UF:HJ)2G?^!]R>$VHJ[@AN?%K(7=Z0D[9(+JG<AL<WRIA;U_@5I
M[JO62"]-ISP\Z/(@,G'R#Y7.4BTQ%JR/8\#ZD/FB8^ 2LEC62K-N7;7-.I8U
MZS#[#9=SO?G#VC5_@Z+FKVWQ\31:?&RII>KV>\%NSX"ME9 71?H)%YTH@:\+
M5B9$#2CYU,"S:#%7LK=#$(91IAU<)EPV+:U.[%(]TAZL%UHQ[E$TEP)*I +O
MHM=G0&V^4M'QT</RT3#$]@NB,X=L"2WZ?!0634?UV, ^8O7N8=0KA(Q3.ENU
M[TBU_RSV*)G"GG/5IXGA2#@F['001-\R33>$0;LW;0;.L(M&K>LTM6NGKE,+
M^V3AI5['R5>),G0QI%V9O;[F+;%@C9ZKOL.%%W?NZFD'*]Y9!"!K->%5>3[H
MV4LW,.@9ZVQ@VYHLK;-^B?=YB;"'\JJI\9EL/JB=R_@L8>I^X-L1\T=SK2:Q
M'6],NM?UM-DIB)J%%&V&6=$34( >ERJ[ RI\5!-XY;!!^IZC*ZK698?ZL<LO
M2^XP1_6U+C+4WE"%Q2MM;CN%DXY:HQ1[*_M$EB.0@6^*!H*"*Z'2F.+FI.M0
MMJI!AYG'"ST[3]7L Z!4+A1;;+/ $[!;XW(^2;:@;PW>(-(#7+#JII\V&H06
M/CILGUNT=%C8"9N\1@GL.82S"#9,^^MI_R;#.)^),9C4FD%=;[/'D1S>+&'I
M5Y [S9/9.$^KUZZT^I37#X9L![T*$]62'^ZK.1&X-ZS2_4+NTC3V2C:RBE6@
MJZWLZK?H!!++EZ,V[K_9E#6=OY4Z M*#0,LC#=GUWLB9CZ1*S/>GG1?&U$MD
M 0'-485LNKOB?@&>8#O/]1>ZJ;Z<Y?"0;,1T2WO(!FZ9_:93H, '@1YSW:/0
M^UT>")VF\+-(B3'1YSJF2;;4DJW8,3;<!8J337XK744;!]@+)^N+-X)/R';D
M"^6ZQ\:"%:Z 2*6#OM1R)8Y$65II.[<</41G(^V:@PXI:4TT(*&N0VCYR_A+
MY;(5;591ED8#--O@"(\)?8J^"-&AN6R&!E\7C8NJ/7)Y13S6^M;"14PY\@GL
M(T^3!; IDF#K$46<BJ9*=5FXA*?N$*YLJ!2]167]G!Q)>Q)(K.H\...H>Q.A
MVRWE4^1+('%%3VUAV$C3Z=__[BH;"$C^0P9@9 E\RR:SU]K[.$Y4R$P@FOK5
M_]_>DS8GCB3[5Q03^^)UQV+: GRU=S<"8]S-M ^&8V-FOVP(4=C:EB560F/[
M_?I7F5E5*@D$&',(6Q,Q,[9U567E?5I5[:D;WQ^^J- :!3#X![LTMT"X6^K&
MD-,&]E"4(]HI,AB*:0)<+6%!R) KP;PE&J8QPVQ$&I9CRI+WP%"?'$FJ5V+<
ME5*#&IQG\Y_WI;-G;Y;E#JY:[.C&C7>^1N GGN\=Q+I><@:*+;>L-]FVT.WJ
M,M&+$"ULTGP],M>Q!:BO7Q;Z-OXLFGEQWA515T>NL8^DNBZ]J7&CN]0.%B/2
M+F#=\A1++XF1<Y#JB[X"BH]B9U6-%7#5!.8JJ@G7L]B"."S##OPP/.!0LF!2
M!@J1$"T5E'@ 36Y2W-^S0"K@\E8.T(BLBW@@6D(*^A3TA]4.^&'@A)RI20%"
M'X.^VM1]32H\L3ZGMLM9RAPUBHG)5]Z4Z((FA$DD3**E0L2Y;BEE9<6S@&!C
MKW7&+^M$/ENJ<=Q6)T!=]7O]3M/HWO4[C687IUGUN_R'NRLC>SC4CAELPOFW
M'[RUF$BT@8E$N3GZ3 3>KQ$[1O-9B>PXM!JJPV+/G'LB.K8C%G"SHN/8?DFU
M]>0"#0;C,BO0QO5Z[$G-/8RG!CO QU43-Q&;Q<&M3S)T.^"GCV,Q*"L-3A_E
M)$),B9JQ@!9:57'X@N.M-K<UD:21G-J +K*(2RI/SFKA,D+X [5T++4#_H5[
M?<8;-2+7KL=S?B>^B'/3EP:<3D<2?LH!)[\*?VA_;XH\NGB*L#;:<FQ%H"HG
M)M*F%PNZ1.!']S0#$YR^XMT<)-P>F,HO@1T(EQCI!K!9U#HP+J&6Y81JGC%7
M[":"3A/Z.XPR/\ QSI)YJ#</P+5VI/P?>TNWE\FY0%U]*LL.DKMV..%IE:E.
MT*I7OFKU"4_UI4; R8[NPA,CC=,BC6+E- HS.XVB2(C8NX2(7.K(B4"9[ ^^
M_)PY<)<F/.9"O"=YC=2<GY A</D9V6)$@!I)JE2+Q%#1?15:4T;OA7*T-80S
M+G:1;.^PYUO]#]90DVPSW(>8NU@^I$=E_"VV]+D*XKM_XA.T?9EF)_%IVDLT
MY9&9 IQPQHMD#E!ID@/(0E@B&D <+P_4%VGZQ5\X<TO>[K*)T,7$&O6G<#H#
MQAHLD60,2P"OO\P<##4 <4PGSP=3XRL2"GPTQI2'H]022@;Z^2V G.MPK8'I
MP6CLR*]_+D0O"099TK/'9_CW'!J"SJ$'0\MI+(FE/'<XO"5ZS!R:*)2)6W1K
M\;4W]*_%'M8NR'D1"81[C=.2=&Z#XS]W0T-7\W1 %E3^MY#!?BBUMHNIM6V9
M6KL+CL,)O,O&$S2>A,5)<0>(E*#""@-(0%D4,=+_HY">2@B&FS(I*1W3+:DY
M-UINL2@:$%,!@40@(T+F$E#VML>9GR?#BA,1RR:;3B872)O9I, Q>P8?@C9
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M GA&G%!$APA1481-2DW\\6]2U"<WO*\HOK?+5U%OM<5_=)N6POE :4\A.T$
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MBMD0*.55,N*^X'-TY?E?JUW*PK?IN_LX:1O>@#[)$<RNL+I7T5)7837;E$>
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M@R"F7/*@$%A);A E4/)..P\Y-^GIN"Z!?8IOZ^#GKF?61%75@H4;W;=7,9Y
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M=/K'N$.]%@)^\\/QKY GY0;ZR\!GZY.VBHBL<$<W3*%KKA1AT5(?0\GMWDN
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M3_%MH<I]A?H:9P1[?(XOQ]/IP 9''@</#,!PIJVEKQ+9@UL.-H/S]$<+O=U
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ME,;]2TI;4]0@XV(=K,5RUE7%T X 6V;_W(OP."D]O?#902/[DW$4U5AN0O'
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M+,L2D+Q(3EYD#H&97((TP9;DFL1J37OU7=R'D$.C,B[]=>[U127M3;G\^71
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M5X!VM?RX5[/UO'OP!9B?+Y"8D$M,Y%^4('0@E\4BT\(E!BFY^D=6)J@00^A
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M'UA.RE8DW1%D[F#A!DM(MQ?9=>)<2 U,1'*/=!;(8CTL; TD,#PX#4U.A3V
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MZ)7<?3 \1JV20?)@A*6(%Q0('KP!I32$P3WXEPS4/R),\6]_^O]02P,$%
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MP0$EJB(3XO30*7>'IR8(;4I?"-N\'$P,>[H(=.;FU+'OB0C+2@9\4^;-E&L
M9L99;L*BX]BQFN/<96;"?E^^X&CFPNB;$"O65G]/WOV!UWU=N0M)G+(U2<^T
M^'1@]#;-&,OY?LSP5QL^+-L,5O@EUE.5"'3GITP1 :^4WMR5M\Y\B +GUT9<
M6D8T@@*)N^4T1<6V?'(Z]6CS^.61[_J/-1?"AH4]O+PS[=\$&49I0)KG4>PN
M$^?1T>>CMAS''-T^?J&B%>91_K%IDX\B AV5141@]#7ZB R5$D9[Y0*N,Z?X
M-.#R"N$L!!F(0-K=)AE:O+7.[E@+P8!K-NI_OZNWQ_E^IHOUI+#]N)%J]NI@
M_R<(W1X3!^Z1-#T48CSR=I+P%"0K[N?"1(..8X9PXX+G@SP^.%95^0H-5 ?Q
MU92Q)L-5J!"5,/9Y:)W][ G$*HKBP3+D^Q5&6#696/=A).Y^I5LCY &2%=YA
MW"R'/M&8) ^+$R "?8P:%5N[-//^Z)@^E\H'/)<DL]E3YY0"#PP\&9*%9_2Z
MV@65;5:<@44G@07;YFRQ..MGD]W YQKFDB:*%P;L+3>\A&*U#D;5^,FH"[FX
M=M0]]48J$H2U^^K48 F>E],V/<8_+\O:>R4SXU/3O<Z&0Z '[ ,X2?OL]>8T
M10M?<\4H._E S&'VO<JD?3)&C-[]UNL+RH"4=Y)F[]6\6!%2;F,#_M[(EM!G
MRI]2#K]%<:>P"B>)@INTSALNI!R:O1H="$P+.(K*3*M,DNB[5FO-Z<^^S-W>
MY%:UXM0OE9]QVD<P<]-_OX,3\B88^O"*29!PW^&-08EBL0\5['X'NEFC.K/6
MYPQL6],B3%Z49!J*VX>S+3*US-ZI3V_*<G4)K\N8F)# ?ZNJ#0/@,:CKF(-H
M"9A2P4G&%]H'RW>16WJA1""G1/S^O;PAZ_%OX5W%-]]EF3I_.#%P%<FKB]PD
M;PC#AF:80]%&E3' (Y\N:DV>Y?9U6\W12-P!0;?$\&2/Y(,SM1]M>6QT>YTZ
M0VC0D/[,3;;;-D78.1VV6V0VWS#MYBE&F$&+GM;%4KC$:7AX/&JIXXC,1LXF
M%1/4@;QSL_4^) F._6!E9?QZQGZT<^W2_?ET2U33"GB!_M(&S*Y(BX;NT?TN
M:JTJC_9U\XI^Z)_D5D]\S_YH$TTE>M[&)1#^XK8.N].E7Z;>0-+O10^I7=KW
M5?PA874NA0BH]8KC7X0"'R;J:F</(:[#NNY)WKB*X 3HBQ>%PRY@>.I0Z@U>
MWGJ-%?LH7'_H/M-CE86B9GUN;?6#CG=P;;>%IO=L,D8@/R%_5 $1<.'9*L.K
ME)<;[UB[TM#LF>H*[TU:,>$%0.8G&1L*Q9=\X?8*K>.-2W/?;[?/,BOU&Y;X
M9F<H,T5I7"0"CZ7;1P++&B9Y$+MN/5"64K 2GB)\1C/4;:.T]QJ.JN$S[NP"
M!'<-3\E>,?1J[Y3XF<'%[4[$-'J>2N.=,U6P#FSG6 _:^"W(:4Y<Z?!LZ_#R
MX'#'(?,)F21B/WV@?K!%90GUI$XU]+TK-?/=)@>[S#/JST-2PM6_P;HQM5=J
M<:E8#VO/N_P/SPR&-FRB'S=L3;>I?U*!^^OE,%W,IG7W$*JLNIIHGIF?SV@:
M\84:BPHY>2%-M<4R+K,8%W0+/F.'WK?81CP-0-OC<N<OU?O3.A"!AK%*PC?K
MT8W1H$6\)KI"F-Z[0(9_X],%B+8S^/*/5Z]B2B0=JZN\DK2?Z//NFH*$"*:8
M@[@Z7=_Y&?:9=;/'3VJ>/]>&#^?,F6%N48:Z8VVP&V%LT"?FG0PC3R00NF>9
M5H>Q4>2Z!3 0ILMMAF6AKAH1VI#"4B.0R/"27 9WVI( LC4W>QSV5?%=C5.,
M!T:I4U[&J4^LE(2PBJ=7J7X=C-5 ^R\P&ZXUNC%SFI_D>$3'F.J_0(E "B$[
M=?;6M_-UV&^@<I^V+_U#LT74 I&VIF%]_?EXT0"[%+X-B8;V)/Q3U/-"4; W
M5)@$9![G?^&^^<E[V=JR^'KB(ZWM*C!&P*T3[D($#JEP@81:0WQRC>?X\E(!
MSIC7?>#[OO-H]I32CKU5[R:$" C,,)+R*FEL\BVI@IZ]@P8DZ=JDY]$\LL/L
M"_N?V5L,I:3M(]@(<94^3$5O;A$!Y]'>O5WJ31TB(%MY4D\$-KD/"8^2#DY\
M2,B0""RFXQ"$+X/PU0LUL4L:(M?.XLSF+]S34SPMS;\ 'GED^*P<R; 6O)S^
MSO:'%]?"P,)=#],PS%4A#U"#3,IFKVLG*O#D1=!0G2[R<(%Z)[@(BYKCV)=/
MP2&;F>$M]9/^TZ_=B !_>VTAN#$$,:<Q31Z'I-"0"DW-P2"?_H1XZ2$,:WP)
M[_>?(@H.##VR9!"YQ;-T1Y!99&OOIMXLIO+I!\C@,XK2&OBA1XXW#W@KL1T]
M6G@A1*J$&:E3'Y-)*[EHI/NPB'T;V7AE&@LW4/7]S-7C/7AP0^Z(4+%'2E#X
M2 _X>AP1$+25".N%;]\A)7Z4/OI9#E/Q:MY+B=(O]-UR[W2YTP+MPW-\]'-T
M(PD##:+CGF]Q-N,$%Z9)J7!(DVQIY)YJHGH4R>TQ=1R%4-_F#*I2*%-*B65Y
MAR(1*#Y;1;T6Q1EJ^,:=5:D5E8!LNS?D">?<3#EDX2; +8Y "\)1]J,-9VQ:
MW>B>EE=P!'3E_XQI_YI/(*NR'V5C.(QKS!;TI,4M7!\!L?#5S=ZDAKY:(N%T
M6 H"9C89LR[ABOWH<(_NHS(%_QZ&+]0?<[F%"&"2\/)EB4[3_F_!I=W95;>W
MP<>S$<A;SE0!P071Y:$N^:&6-\KKH$\$@W+O./ U"B?=>>AWK"[U35)^4D]2
M<O!G,X4=2UBX]QV1'*U?F?8?[9;U2?'&XA@G;*[O!N/@9M+@7M%JCH&U^4Z6
MTSQUC#P]NFPM6(CES!*O7JM5<.3W,O2<)RFL^Z1F" 2%8(V*?(OU&I//2D7/
MO;<_*U_=:)XRZPU,^V0^8^@".:TE>!6W1TU5+Z'F/&S1;@+[[&C,%9GA73AE
M6W#(MX677"<"1Y231&"F[0V8 U5Y:L*ZFJ\Q*2IHFGUXS]4:(7YLS(4G NF'
M_&5V6$_#EX_6N&'[XP21,3WJ;4A/K8'TW<&]5W#(C=K$.=5--=00O^Z"K;)I
MB:I1[0#*:,LP*^<E$T,!JI2OO<+>F+2*;XQ3&D$6C,/ILL?(0[">V5\J4GU(
M4[: X6GGV]^C:"]J6'6HB"=6[2N3$MI9[!8>88$\)JTU1]+N<5S"G9<S628)
M-X2$^5Z=</7TZ["O@<^1D@; _@-,3006MDR)@ ]D>7AY[Z]\[U,"O;I:\<D^
M&-*9V8N +P8/D12W/2%SR_H0UX[>5G>%;Z$(X14](^7H:/#E= X"UGB88*?#
M9IKYA>0FZM<P,!% U)N==!"!5V9%9FGXO_)QL00YC2UADK#HWAVG7GCY)F$=
MQ>32%39OH!J_UVEJ>T)9/!QV9OP]F!8& >5]TG?XT'55BRE-N?=X>-:V7#%_
M?R86X<&HDY!Y:Z$OLY,$I"E#A6>/X9^@8.W/ I&,69[\M#TRW+'+ZKZ+AD_Y
M6>"4T.6#:W0SCI(K%C($$<N?.S.\10?&9F&GH=T$YEZPQ925?IEA+1&X6M<Y
M*\@/)I![A;W<0[F>Y*KQ*J"H+]2[\'O*1Z9/*$,Y\3,'G<TAI[Y7;.^!U%?V
M$["%&6ZV-&/74V/B7LT7%+,<E^,3%_9LK^T:1O(S\I_&P1\.MG\F D;D:RN"
ME#X:5_ <E46NAZ2#M6'4"G:E)<YSD^] \?-K:YNZ@H E*THC0ZM,AF"G@88O
M.;H=$-Z2AF_8.',!NP?,'>AX4>00-[RQN/<3[-[ \TS)IF^L83(RX'>QPR?Y
M[GAD+(L^$5#?77V]3IA$$;JM#)LG9S:(P%-^_JH>\K6+Q6 =)SKXKZJU1@1B
M PS@&%3+Q9QN^@OIH!,$*34[HN**MXKCH!]*'"NKK+$WHO@,_04IPOXH9\K>
M<])G;%<K[2HMNK25P>N":OEA8EHY>@=,X[%+EGI8RH_'V%Z&Z.RO[R'[QC;K
MMJ(P *L6S-$"^3C=(5@YG'=\2<*+(F<9TIO*OR&^-D$6Q79;$R%P\MIS9&9N
M^DV.YW=K5]KMHW?YI^'JZ"P8VJ;T6!-7 V&&?E<7Z](Z_R&QA,51^90<RW*8
MN>E1$4H#4QDM#;L[[Z;.<]/H0?4ST8<.5]$M*V,,&70:.3CZMPU(3%J;/M5(
M789E/%A[4G>9&=Q6S30!)V@U\!&!#X-$0(AT^MI=#Q74+Q]\G^Y8_UJ4X7*_
M"0!)A:;_6QT37 D^GC$D L_<*T^\#1?%9V/_S(I0F9-@,,LLN((#WS6S?T $
MRMU6CHY ^WE$X*4EX3L1V$^ $0$MO6-"U4Q<LH0M+4SS6R:/>UUPVBU(5H#I
M%_S#Y\T83YM[<JE1<.4_*IG\R0OXXOEYZ:-?A>J(J]\A(5F'(?YB5[, XMKA
MRKX=279Z#'H]'OQM?368JC<M3!9_P9-F^G-U3I/EE2P"M/U"?^</PMQ&B)]Z
MV1+-)F\LMM3,.-7QDL#1Z/>#@&>VX]]<@N@,/54X%Y^VF0[%,^O 4K%.<U'M
MX17(\KOBW;G3U<=J!4C1FL,;H;KV4R&1FH+#!#:\A2&[L[&SAL!+8XM'TX^-
MRN#M\U%J)&P$+ :NKR-43[+8P+%2>A0?D*)<?(R+*(E'0>X%B2%!W*+V]SI6
MQQP%<RG\%-:094A\*BUD@T^:\/@YV9YZ$+(=P0YO4L?\M!01F@PL+JW09#JG
M]N#R;GLW$0"A;J"2"4K0#$-V_(VTMH[RST<NQVPT=5LI$&704&7W5ODM<CP'
MUO,)C/V]*S<J9C'32OX<_6VV\QC:[I15Z.W#T5+()FA621NAL"[.P.Q.2V'"
M;;:Q-XLKGY1YI^.O/M^$=!;WT:Y[P?.16BMS>#P,P-'ID$E(Y2FOI7OV+AN0
MY6ZW?9 PLZCGOEP[%K2U_R#)JTTMJYJ_JC78;.-X'KEA",X2"U*<6&<Y-!>.
M$%O,Q8<Y$H$(N@IL\9Q-^FR6],TAO$I*G(NCL]253Y[-+,\%,4Q'9LEWI[_9
MA5).%[]8J4QR3&@W=52FWF%C.%Z.[<!\0%/'PD0+W.Z,T0>1UXHHCYUPP:DH
MPMA16F?_7 !_-5L-7"5!]Y09H0%Y.-IG.LLO=RM;?IB<"/0V@WLSMK[ 'AY.
M'>,N[ITP7!/)J[^\^.OM&],-'$3.<]B.P'ME-AC\ AZ]9(7Z<UY_BR-%/C@8
M=9Q$!!0_./TIQ[<S';P,AB?]- OL*H(_)12HZK"9V<W]VL*4P;I?B #N>!@^
MA3BL"*K_"^L[#W_4:RA&!$*C>[>=Y!9F#ODK( >C1$#38L4M[\]URK>B1'JN
MO6^IE0C4F>S][:!S\==!YZ\U:<UT"?U7?GX>'=];2\K^4[D[^'&L;DN)[K'9
MO&>,5*2'<:B0:Z@I8R/\//M^U'.PX\?*RD9^DVLO^*BHQ'N%<+2S02]?ITU@
M5P*E=A0&S]R_>5/W9L/P#].OP8N!S#K^[I+U7]V$Y,[JLSRY+,HI0&#'2B?"
M)*4C84Z%SI^2.RE>1O1B6Z9RCV9W?IX*K;="Q!&XH)YM1ZDE^[6><H8/LRW*
MC1Y^KRU[L@>L$([DR2(PPB3#8!*@5*K'A9]MUQ:M]).ZVHF Q.CV>?2LZ8_R
MF#ANL:NYMZ^RF]PC^W%=$_$*XE(8@"N[BCS>E\B"U)Z%'"M 6\NWW )/M=B&
M<9C9%BJS[\/C&WB=-52JRE_96D8KQJPS/[&.7!;(Q&Z((]-GF<(=;K$:UL2L
MO+-N@!LY\_7J5F9)E=ROBEDZK[D6&M.!TL"58CZ#P3^*?._W3Z[?B;UR&CV=
MJG+X,%36A\D>:6R]G&7/__+-Q)AF#]:BZ5F^GD^KJ28%TD;L&[D&RW!YJ'%S
M<-E=UY&4,9NF\8G9(O[X@JI=P=@#3X#0-V([CC6'KEYG;[DG,G0_OJ9#W5I7
MX#C<=U5\O +-N$H0*CN6JGT[.:.ML9IQ\1K85-WD.';'W7C?!Q.U4/;C@#LQ
M4W_N].US3%^^>.*#([*T<+6S"H^[8-==*KD:&2T)AVUPNAU(#*1<0LZ\^RV.
MW9%)8&+B>7'9/2+PUC6H]UB7<_>G)'C\2?/7#JQ"QXW=XW,K8.N9@<^[R/'>
MIC.R$AGQ1T]>:RT)/;\:C='D(<'^''D-SSXUU?=0U!W+4XP]EMWIRN[U;/"@
M%QCJ:E1Q& =>N@P7^J8\^9.U&X<8Y;<.L%AB+:LZQTR1VA'9J/,1?_K<,8M3
MWICEV"1B]M'%:HV"H>-LUQ,R+Q2IIKIR\-3)<'IHUISW)0)67O"L4#*K@C_\
MIOIWO\7^RV\B+%CK4';J3>G77YQX+S<?Q&/;V,). "&ZM04<:);MAB+2]VSO
M=[?*WE4=50*;</,O.-I+RCG)1 !KPC#_ >*R2Q]G2R=S:?T\X6+8(PVXRIYG
M=+8XLJV!H7)4RMV^W.VID&FLH@2;>"IO=D'LLL,)LH[JYUUW:4%JW)W-CQ"U
MC$TU\;D0,#4T3!*L[Y(Q(OS 4#WRXI3/54V^;\"OTGA6)3KZW/2S4BO%J=W.
MFW##@3KNAGYL=+,A$V[Y:&+=]GITB/-7[YBW8Q=O!C6^YVH H'2F3>;3VJ%&
MFYTG^CE2P?P9\]9B_4,_[T31:.04DH+P1"D5DWBH?++90MM^/$L$KNU:7G<H
M*WLRP7OHU5;Z82$E_*+<X1W#6/SY-[A>76LYJ[LVPP_N?FZ]T&1.3F58($^#
MF1E/O,I-J.<\+G%G!1?:(Y;=5B<6ZX0Q@\T-=,/"#9A=)6;U%AN3F)UT(UE&
MKZ!>_OIO_N6 Z2E/G8]8Q@3?-VLCZ]XN/E%"5T]HU&/4(L>&CT1 \S,QV61H
M#'7,1-N*WXBOX\;/TI:BU5!.)XHP=9H/J'V2,Y-SA4\BWY"P>')# M;L<3F"
MR[G@QJC[US[/TX*B$]B//PM*VW3[,MHQZ"8T U35@C#4Y_[S;/7V#6'8QEJ7
MGM#LP>PMU?2PL]!<&'C66M=LB@+;OC0)PAM5TK?#6%,V3L%Z,69:GJ=A=SZ&
MA#O&ME3L?IU:+)@6)E"9[:'>XJUG$X3;]D<^3QQ,\$],7!9K9GO#/LE)6=H+
M$O#1P+[[SHSSG)L!S5A/.S,;\*8[%Q(>OMDO%)IU2AK=92,;_O5+\E+#>6@@
MX30B.KCAQ=.&@/!N@ _6<OB<J8@3[S;_[OBH;KB!#'?F>K7'A;*:9UT;2QH#
M7?G"E\B\P^4B-/O;"-^R):89<^<L"Y8@ YNR(;RT;&&J-]4GZK>K)%EG1Z/4
ME.?IW9UTKD]:%CM-O?*X+D4C4$2M3''Z5& YS;^_<A1OK",=OP4_%!$!Z]YM
M]JV*G8.XIQHRPSZ^A.<G814SCW#C.^,'F+/K1YQ#MW6"H]M_E1[^) R<H+%G
M>R!(<+?J_5\K9'>(0)*I-!8RM.*<%[NA=I&$X0"4WI\?0RG]E?\ ,\3<_;%D
MN_7QD'!C&19"6NY( >&("*S26VWZV:B3)EPW)E4Z^"[EAX"*-_A+1[Q5Z(/8
M;-0.G4C>^^5?K^35!4GAC0]=0__4Q4_47ZNK_"MK989]>1 $.7ZN 7^E]M9V
M0OC+LPYL'?>'72%FR<%"TBX??9<[%1&;*N1$78B*JH#6$0$.VRLWU;I_<&B\
M?!9[_*X:8=6,]8R3)P*4JY+%:S]4+27BN+:9Y<BG+PEYF_.SX-!S,]SKS?K]
M=NACW><#:1GLIJ963L+>>WSOTMO1AT+<Z2<!D:3S3TF0\,8,2\J\>S<((7TC
M%8'>$@2/A&L@L^T\/86^OF^2ES -SF3 9FR_.<FO8^NBC;QCI#NMV)ETJ!Y<
MWD^;DWRAP\SH=6+5N09.3)V,%0ZM^VA>(4W4,T=7EXOAK0X%R]3]<-T!.*8_
MFXX(9%N@""!IDB8VD7,(EKNXLN:TFN\O4LZ7C)!JX\U<VR6? @'6:<.PU&NV
MT=FG7FIZTJTV@I#);0H$[<_R]5+M.H/Y'P=*[,O+8TH3.=/I:E^4-FYV"F-S
M=&J6U *Q'%=Q(6Y.BA5\0VW8<<'887;D$I?D$T=.+A#*V]H:EHZM;9'%Y<^?
MWY[P3&O6N>W*I27VGH>Q?5#JVDI#OR;X-@YN58Z5CGY?D25?^KDN1B^BD:'A
MG7?2,Q^FJA)N#!$8+VLA9?B^/:934QH.9?#RR4?PI5>8QA"J%0*US9PFIXTT
MU@,Y6T)_;&F6.+?YN)@U- LDF];#2,OKC6C[6 ?&!C9G*XTRIN:UPZ0H)&7D
MFM[5FH0',00MW@ELQ]7U/@Y,R P*9%8:70$=C:82OMEN&_DS'5.0T$Y^;H[3
MX-Y*F!!N= Y!!TW<NC*<,Z0SG7MK^=+MU,IS50);NW:C[*NID8&S</HU[LR)
MQ-RY$Y7MG_<94JPFW[^)(;L:"!JCH_":P?0W_-D+NGAYST?HE;1B(A!.@N"M
MHXEXWT$)><33,HL?=Q1'%.='+C!/:I?F"/%FBI#7(^?,(F%R[_"B_1[^TDPN
M@6:L5P@..W?;!B!;G#XM3CF@$I JB@Z7UMM*X/D\LMNQDCBR6!5O)6*F:I5[
MB>+ ^'NU+2O>%8-^C-</S',M=:5:&WVPPT#7$7BNZLN4ZL5-ZX;T-^:K&<'F
M+HJE$Q97S5_+,(AYW&\'50J1*IH1;A? ?2F:!6[<8MTZ?I/#5*2F,$]OR(8+
M&+483';X7,-@?_<Y5>/]:H'3JDXEED.>>8/RM<7'X=_8WTO+/>:Z_^YU9LBL
MF20F5B%N3CIZV#?2O19I]-5PYT.<[4JS139\9<#V!.@3C!@,TX#JWAE^OSLI
MHG"UJBY;%1JI&7XF@$XV$"/K-E@\;QM]F[;A L[=?/;4S>FJ_6?@'[;NMQ1U
M_/T]'=W.?UO$3GXYG99\UTHLAZ]3C<S&KH30UW!J8-GY8=CXNYI,CL\Q$D%$
M(*BC=XA<O#-,$7^Y!JL;^T'>371</D'1F#G!/$+MG5?/]RIET&3VWAJ:JN&,
MRP1U=(G"]/T!U:S[^PHO&=YQ6N1RW<K9?7@O930S5%-4]UAOM;\#/<'//^R^
MX)&H* .)$#P<S8->;K=@2GRX7(4Y&;R^[Y,'?1V?WV)YJ4.C2BT^4=SIUN#[
M/4M1B3U5<X_--YS0MYI=<) 5$7BD1OD6Q\AWC>_LHK/GA[J]N\HR4GWD3D7
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MU!QD!3:O($6433Q6TC >DB+U"S\Y-=74WO [$K-!:<*([1U?<A)4-T8* ]7
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M$FQJ?-_(5I7@[6\R7[14_E;T6 LPJF%=*^5D7U]M_\DJ=[7-L:Y*[0YC;8<
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M(JC.)<Q9(B"F*(64*@491VG5@C7&7OQ\?LJI,?!68J :D?U8U %C-YX,B]S
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M&.0)C?*8*I7GGC%F7=--DL7![H+*-]2L$UDW>S <7@.S]U=U5U%'2]"ZU/$
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M3#HU=MG7TMS6T*Q#"'JYWYU0=^.:T%@.[2[O"6/_@J,.N Q29+1KWM<I+.J
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M36+  DODE[M/-^#*:<&W\K2@-:JUV66-JOKP^@:PTKI6W'2Y;Z*M]1QL&')
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M&YW*7F/A\N'LU4_VW$4\2D"YST)D.OQUE^7P]LD$\/U3"B-\NW4:QPFC19I
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MK1WZ;AXV.MH+>=:6]EMX_@$?L;QEJ-WF]F7[N%J;E><,LP07*DI@4F0I1+'
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M*)D.0@T(@7NOWPH-HG\T'"+53H#Q'A?3>7X]RZ]HKYYDX:+*J, 2)Z!\"<2
ME2 $[:RHD6,:PJQM?/E6H)#]@V)_B78"B4^+,%M.J^ O85V=)^[1 19&/#CR
MQ:)R$1A&Z8HP2@<SY'YQ[_U; 4/U#XR#Y#HR-E[/5M/5MY^GI_CK^5G$Q208
MQ9,S1+%DAH1A"-=6>U I>B^\\<[+ 3!Q_[U;84'WBX6#Y-@%!C[@R;0*8;;Z
M-9SA1&MCD6<)62#1;Q0C^E,$8SPWR(M4D@^&@[OOW@H+IG<L'"#/+O#P9I;F
M"S)G:\%_)/GCR_GY;+7X]G*>R57.+*.T%KPW)!O.:E2NB3&FBXW:,66&,Q-/
MDK(56FSO:!E.VEV YU/X_4TF\4W+]"+9<6D5LXDB*"0=,Q9!25EW1JTIX)()
MLPLE2CL8;!XA8BO N-X!,X2$NX#*BYQ)!<O+/]Y.9\@G3HN W!40,6E0Q6AP
MFN(MR81*0K@@RG";SP8"MH*([QTBATJV4W@(BKTT5P$+L$(!F')%@M>6-E1N
MF30\,R530WB([9)>[/O#QVZB[0D?+^G;=XM/\]]F$Q]-D8X\+<]XH<B<PG.O
M<@#MLXNH=2K%#8V.F]=OAXV.,Z)#B+4G9*R=J7>+]XOYU^DLX41:1CAV 8P(
MOFZ0O!X[%8A.H$Q&2:WTT/"X1\-V&.DX3SJ8@'L"ROOY<A5._[_IE[7+;17&
M9),!'H4$94.!(*P$IUQ4(B>A@A@:)G<HV XD'>=-!Q+NR!"I%O#% L.:[F*R
MY4PD,(43M%4VX&U5:$#'LC-"Z"$2IK??N1T,.LZ2[BW D15?C^E/WW^>SZXR
M>DD)YI1'B+39@1(2P:6L0!OIC)&<8\X#*/_^>[<#0,>IT8,$.3((/F(Z7Q"
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M1172C8QN90\,TSGR4!,'A<+.XB&46N7%)*8BE2JY213^%%'C1N9-X#28#CK
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MB]J*NL./C2Y?\JG>CYMH3$)*M#4JUI57 :ZV/L!Z"):B,=$T25G<):.;--A
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M@<_#21_7^QP*1)ONT1U/H]\+AE^&T]-W7ZINZ_WMO]:><955KTG,@EM(D@R
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M$Y4!@SH$FZ,AR?>$[SO4CQNR]X_O_57=(;X?'1)N@T%)C(&M_<V5H$ P9(=
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M$*K48!/J8G0M5G0I#3G6 B>?D;(/X">-DND/*W_C'+S/]5G<Y/K,YF.EM!Q
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M4CX4_9&!>*%Z;\N4$+A JCV0S@U'=\CL\<.<3))L8=>^LRJB:E%F3)):'+'
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M53XYH11;U,B'P'I58WP%UPVZ^V+"_-I$;<M(L%3?UD$IN,>:F[8S'IJ6WJ[
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M,S$N:'1M4$L! A0#%     @ [UB=4LH,G'?4#@  SY\  !
M ( !GK<! &UO:"TR,#(Q,#,S,2YX<V102P$"% ,4    " #O6)U2LCT.E! B
M  ">60$ %               @ &@Q@$ ;6]H+3(P,C$P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    " #O6)U2A#DXVR4^  #UC@( %               @ 'BZ $
M;6]H+3(P,C$P,S,Q7V1E9BYX;6Q02P$"% ,4    " #O6)U28L@D&D\W   W
M5P  $P              @ $Y)P( ;6]H+3(P,C$P,S,Q7V<Q+FIP9U!+ 0(4
M Q0    ( .]8G5)BM"&,#+$  '!<!P 4              "  ;E> @!M;V@M
M,C R,3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( .]8G5)4\81G[6H  "O(!  4
M              "  ?</ P!M;V@M,C R,3 S,S%?<')E+GAM;%!+ 0(4 Q0
M   ( .]8G5((M8M 7 @  %(E   1              "  19[ P!M;V@Q<3(Q
M7V5X,S$Q+FAT;5!+ 0(4 Q0    ( .]8G5($6K,-.P@  *4D   1
M      "  :&# P!M;V@Q<3(Q7V5X,S$R+FAT;5!+ 0(4 Q0    ( .]8G5(@
MOBY4H@0  #\1   1              "  0N, P!M;V@Q<3(Q7V5X,S(Q+FAT
M;5!+ 0(4 Q0    ( .]8G5(-DDI4JP0  (\4   1              "  =R0
I P!M;V@Q<3(Q7V5X,S(R+FAT;5!+!08     "P + ,$"  "VE0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
